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Exploring the Importance of PREX Proteins in Glucose 
Homeostasis and Insulin Signalling 
Elpida Tsonou, Babraham Institute  
PREX protein family (PREX1 and PREX2) guanine-nucleotide exchange factors 
(GEFs) activate the small G protein Rac. They are important in many physiological 
and pathophysiological processes, including inflammation, neuronal plasticity, 
cancer progression and metastasis, with an exciting new role in metabolic 
processes currently emerging. PREX1 was shown to regulate the thermogenic 
capacity and insulin-stimulated glucose uptake in adipocytes, whereas PREX2 was 
reported to mediate glucose tolerance, possibly through its adaptor function as an 
inhibitor of the tumour suppressor PTEN.  
The aims of this project were to explore the importance of PREX proteins in 
glucose homeostasis and insulin signalling, and to assess the significance of PREX 
Rac-GEF activity in these processes.  
Western blotting showed that both Prex proteins are expressed in brain, liver 
and brown adipose tissue, whereas Prex1 is also expressed white adipose tissue. 
Prex1 deficient mice had small livers, with reduced glycogen storage, eosinophilia 
in brown adipose tissue and reduced fasting plasma levels of adiponectin. 
Surprisingly, Prex1 deficiency lowered fasting blood glucose levels and protected 
mice from age-related glucose intolerance, in a diet- and sex-dependent manner. 
Bone marrow transplantation revealed that hematopoietic Prex1 deficiency was 
sufficient for the improved glucose tolerance. In contrast, Prex2 deficiency only 
affected glucose homeostasis in mice on high-fat diet, causing glucose intolerance 
and insulin resistance in old age. The phenotype of Prex1/Prex2 double-deficient 
mice suggested limited sex- and diet-dependent redundancy between both Prex 
proteins, as well as compensation by other regulators of glucose homeostasis. 
Overexpression of wild type or catalytically-inactive PREX1 and PREX2 in 
HepG2 cells caused increased insulin-stimulated Akt activity, suggesting that both 
PREX proteins can mediate insulin signalling at least in part through adaptor 
functions. Therefore, catalytically-inactive Prex1 and Prex2 mouse strains were 
generated and the metabolic phenotype of the catalytically-inactive Prex2 strain was 
assessed. In contrast to the Prex2 KO mice, catalytically-inactive Prex2 mice had 
reduced fasting blood glucose levels and improved glucose tolerance, both on chow 
and high fat diet. 
Taken together, these finding indicate that Prex1 and Prex2 have 
unexpected, important and divergent physiological roles in the regulation of glucose 
homeostasis, and that some of these roles are through adaptor functions. My work 
suggests that the development of therapeutics to target PREX activity may be a new 
avenue for the treatment of metabolic syndrome. 
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Summary 
The PREX protein family (PREX1 and PREX2) are guanine-nucleotide exchange 
factors (GEFs) that activate the small G protein Rac. They are important in many 
physiological and pathophysiological processes, including inflammation, neuronal 
plasticity, cancer progression and metastasis. However, an exciting new role in 
metabolic processes is currently emerging. PREX1 was shown to regulate the 
thermogenic capacity of adipocytes, as well as insulin-stimulated glucose uptake, 
whereas PREX2 was reported to mediate glucose tolerance, possibly through its 
adaptor function as an inhibitor of the tumour suppressor PTEN.  
The aims of this project were to explore the importance of PREX proteins in 
glucose homeostasis and insulin signalling and to assess the significance of PREX 
Rac-GEF activity in these processes.  
Western blot analysis of insulin-sensitive mouse tissues confirmed that both 
Prex proteins are expressed in brain, liver and brown adipose tissue, whereas Prex1 
is also expressed white adipose tissue. Prex1 KO mice had small livers, reduced 
glycogen storage in the liver, and eosinophilia in brown adipose tissue. Moreover, 
Prex1 KO mice had reduced fasting plasma levels of adiponectin. However, Prex1 
deficiency did not obviously affect insulin signalling pathway activity in liver, skeletal 
muscle or inguinal white adipose tissue.  
Unexpectedly, Prex1 deficiency resulted in lower fasting blood glucose levels 
and improved glucose homeostasis during glucose tolerance tests throughout 
ageing. In addition, Prex1-deficient mice showed an altered response to insulin 
challenge. This phenotype was diet-dependent, as Prex1 KO males on high fat diet 
(HFD) became glucose intolerant similarly to wild type mice. It was also sex-
dependent, as Prex1 KO females showed improved glucose homeostasis only on 
HFD. Importantly, bone marrow transplantation revealed that Prex1-deficiency in 
hematopoietic cells was sufficient to recapitulate the metabolic phenotype of Prex1-
deficient mice, as wild type mice with a Prex1 KO hematopoietic system exhibited 
improved glucose tolerance. Taken together, these findings indicate that Prex1 has 
an important role in glucose homeostasis. Prex1 deficiency helps maintain low blood 
glucose levels and protects from age-related glucose intolerance. Although the 
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mechanisms through which Prex1 contributes to glucose regulation in vivo are still 
unclear, the bone marrow transplant experiments indicated that this could be 
through the regulation of inflammation. 
To evaluate the importance of PREX Rac-GEF activity in insulin signalling, 
wild type PREX1 or PREX2 and catalytically-inactive mutants were overexpressed 
in HepG2 cells. All were found to cause increased Akt activity upon insulin 
stimulation, suggesting that both PREX proteins mediate insulin signalling at least 
in part through adaptor functions. Therefore, I generated mouse strains with 
catalytically-inactive Prex1 and Prex2, using CRISPR gene targeting to introduce 
point mutations into their catalytic DH domains. I succeeded in establishing the 
catalytically-inactive Prex2 mouse strain and compared its metabolic phenotype to 
Prex2 KO. Against expectations, Prex2 deficiency did not affect glucose 
homeostasis, except when mice were on HFD, where it caused glucose intolerance 
and insulin resistance in old age. In contrast, catalytically-inactive Prex2 mice had 
low fasting blood glucose levels and improved glucose tolerance, both on chow and 
HFD. These data suggest that Prex2 regulates glucose homeostasis both through 
its Rac-GEF activity and through adaptor functions. 
Prex1/Prex2 double deficient mice had a metabolic phenotype which 
suggested that there was limited redundancy between the Prex proteins only under 
some sex- and diet-dependent conditions, and that other regulators of glucose 
homeostasis compensate for the loss of both Prex proteins.  
In summary, this project has uncovered unexpected, important and distinct 
physiological roles of Prex1 and Prex2 in the regulation of glucose homeostasis that 
are in part due to their roles as Rac-GEFs and in part through adaptor functions. My 
work suggests that the development of therapeutics to target PREX Rac-GEF 
activity may be a new avenue for the treatment of metabolic syndrome. 
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Chapter 1 - Introduction 
 
1.1 Guanine-nucleotide Binding Proteins 
Guanine-nucleotide binding proteins (G Proteins) are binary molecular switches 
involved in cell signal transduction. There are two classes of G proteins, the 
heterotrimeric G protein complexes (‘large’ G proteins) and the monomeric G 
proteins, also known as small GTPases (small G proteins). 
1.1.1 ‘Large’ G Proteins 
The heterotrimeric G protein complexes are composed of α, β, and γ subunits. They 
are mainly located in the plasma membrane and are activated by G protein coupled 
receptors (GPCRs). Upon activation, the receptors undergo a conformational 
change that enables the G protein to bind to the receptor and the Gα subunit to 
exchange GDP for GTP. GTP binding activates the G protein and promotes its 
dissociation into active Gα subunit and Gβγ dimer. The cycle is completed by the 
hydrolysis of Gα-bound GTP to GDP, which leads to the re-association of the Gα 
and Gβγ subunits and the formation of an inactive trimer (Figure 1.1.1). The Gα 
subunit has a weak intrinsic GTPase activity, which is often accelerated by GTPase 
activating proteins (GAPs) such as the Regulator of G protein Signalling proteins 
(RGS). Further regulation of G proteins is achieved by covalent modification that 
can affect the interaction with effector proteins, RGS proteins, and between the Gα 
subunit and Gβγ subunits (Chen and Manning, 2001; Oldham and Hamm, 2008). 
G proteins are identified by their Gα subunits, which are grouped into four 
families (Gαs, Gαi, Gαq, and Gα12) on the bases of their sequence and function. 
Moreover, 5 Gβ and 12 Gγ genes have been identified in mammals. Different Gβ 
and Gγ isoforms form dimers, which directly interact with specific GPCRs creating 
a complex system of signal transduction. Among the effectors of G proteins are the 
PREX proteins, the primary focus of this study, and an isoform of phosphoinositide 
3-kinase, PI3Kγ, which is an important regulator of PREX proteins. 
G protein-mediated signalling is involved in many cell processes such as 
regulation of cell proliferation, growth, differentiation and migration, and 
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physiological functions such as perception of sensory information, modulation of 
synaptic transmission, hormone release and actions, blood vessel formation, bone 
homeostasis. Finally, G protein malfunctions have been involved in many diseases, 
including metabolic conditions such as diabetes, cardiovascular defects, and cancer 
(Syrovatkina and Huang, 2019; Wettschureck and Offermanns, 2005; Worzfeld et 
al., 2008). 
 
 
 
Figure 1.1.1: Regulation of ‘Large’ G protein activity 
G protein-coupled receptors (GPCRs) are associated on the intracellular side with heterotrimeric 
G proteins. Ligand-binding to the extracellular side of the GPCRs results in conformational 
changes that enable the G protein to bind to the receptor and the Gα subunit to exchange GDP 
for GTP. GTP binding activates the G protein and promotes the dissociation of the Gα–GTP from 
the Gβγ subunit dimer and the initiation of downstream signalling events. The cycle is completed 
by the hydrolysis of Gα-bound GTP to GDP, which is facilitated by the intrinsic GTPase activity of 
the Gα subunit, but regulator of G protein signalling (RGS) proteins can enhance it. The GTP 
hydrolysis leads to the re-association of the Gα and Gβγ subunits and the formation of an inactive 
trimer. (Figure adapted from (Kamp et al., 2016)) 
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1.1.2 Small G Proteins 
The Ras family small G proteins were the first to be characterised, however many 
related proteins have subsequently been identified, forming the Ras superfamily of 
small G proteins. The human Ras superfamily consists of 166 members. Although 
most of them can be grouped into five different subfamilies (Ras, Rab, Arf, Ran and 
Rho) based upon their sequence and function, a few still remain unclassified.  
Just like the ‘Large’ G proteins, the Small G proteins exist in two 
interconvertible forms: the active GTP-bound and the inactive GDP-bound form. The 
guanine-nucleotide binding domain consists of a single polypeptide chain (20-25 
kDa) with six conserved motifs that are responsible for nucleotide binding and two 
flexible switch regions (Switch I and II), whose conformation is determined by the 
nucleotide state (GTP- or GDP-bound), and who are responsible for effector binding 
(Figure 1.1.2). Upon activation, small G proteins undergo conformational changes 
that enable them to interact with an array of downstream effector proteins and 
regulate a plethora of cellular events. The GDP/GTP cycling is tightly regulated by 
guanine-nucleotide-exchange factors (GEFs), which promote the release of the 
GDP to be replaced by the more abundant GTP, and by GAPs, which accelerate 
the weak intrinsic GTPase activity to promote formation of the inactive GDP-bound 
form (Figure 1.1.3) (Reiner and Lundquist, 2018; Wennerberg et al., 2005). 
 
 
Figure 1.1.2: Schematic diagram of the small G protein switch mechanism. 
At the GTP-bound state, two conserved residues, Thr35 (switch I) and Gly60 (switch II), form 
hydrogen bonds with the γ-phosphate of GTP, a mechanism known as ‘loaded spring’. This 
contact of GTP with the switches I and II pulls the rest of the switch residues into a conformation 
that enables the interaction with effector proteins. (Figure taken from (Vetter and Wittinghofer, 
2001)) 
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The small G proteins, when active, are largely membrane associated. Their 
subcellular localisation and interaction with distinct membrane compartments is 
regulated through post-translational modification by lipids. Most of the Ras and Rho 
family proteins carry a CAAX C-terminal motif (C = cysteine, A = aliphatic amino 
acid and X = any amino acids), which is recognised for covalent addition of a 
farnesyl or geranylgeranyl isoprenoid to the cysteine residue of the tetrapeptide 
sequence by the farnesyltransferase and geranylgeranyltransferase I, respectively; 
this process is known as prenylation. Rab family proteins also undergo 
geranylgeranylation, whereas some members of the Arf family are targeted to their 
membrane compartments through the addition of myristate fatty acids to their N-
terminus. No lipid modification has been described for Ran and it is not usually 
associated with cell membranes, instead it shuttles between nucleus and cytoplasm. 
Rho and Rab GTPases are also regulated by a third class of proteins, guanine 
nucleotide dissociation inhibitors (GDIs), which mask the prenyl modification and 
promote cytosolic localisation of these GTPases (Figure 1.1.3) (Reiner and 
Lundquist, 2018; Wennerberg et al., 2005). The localisation and regulation of small 
G proteins enables them to function as modulators in a plethora of cellular functions. 
 
Figure 1.1.3: Regulation of small G protein activity 
The activation of the small G protein is regulated by guanine-nucleotide-exchange factors (GEFs), 
which catalyse the exchange of GDP for GTP. On the other hand, the inactivation is mediated by 
GTPase-activating proteins (GAPs), which catalyse the hydrolysis of GTP to GDP. The active, GTP-
bound form of the small G protein adopts a conformation that allows it to interact with effectors to 
mediate downstream signalling. In addition to this, guanine nucleotide dissociation inhibitors (GDIs) 
can sequester inactive Rho-family small G proteins by promoting their cytosolic localisation and 
inhibiting nucleotide dissociation. They do so by masking the hydrophobic prenyl modification of the 
small G protein. 
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The Ras sarcoma (Ras) protein subfamily consists of 36 members and 
regulate gene expression, cell survival, proliferation and differentiation (Wennerberg 
et al., 2005). The Ras proteins, and especially K-ras, are often mutated in cancer. 
According to the Sanger Centre, 30% of all human tumours carry ras mutations 
(Fernández-Medarde and Santos, 2011).  
The Ras-like proteins in brain (Rab) family is the largest branch of the 
superfamily with more than 60 members. Rabs regulate intracellular vesicle 
formation and trafficking on actin and microtubule filaments, and membrane fusion. 
More recently, it has been shown that Rabs are also implicated in signal 
transduction and autophagy (Li and Marlin, 2015). 
The ADP-ribosylation factor (Arf) family is divided in three classes based 
mainly on sequence homology (Class I, II, and III). Arfs mainly regulate protein and 
lipid trafficking by modulating vesicle budding and un-coating within the Golgi 
system. However, they also have roles in actin cytoskeleton remodelling, trafficking 
of the ciliary membrane, lipid droplet metabolism and mitosis (Jackson and Bouvet, 
2014). 
The Ras-like nuclear protein (Ran) is the only member of the Ran subfamily 
but is the most abundant small G protein in the cell. During the G1, S, and G2 
phases of the cell cycle, Ran regulates nucleocytoplasmic transport, whereas during 
the M phase it is involved in the mitotic spindle assembly by regulating microtubule 
organisation, and in the nuclear envelope formation (Clarke and Zhang, 2008). 
Finally, the Ras homologous (Rho) protein family consists of 20 mammalian 
proteins, which can be broadly separated into five different groups based upon 
sequence identity and known function. Relatively little is known about three of these 
proteins (RhoH, RhoD and RIF); however, the others can be divided into the Rho-
like, Rac-like, Cdc42-like, Rnd or RhoBTB subfamilies. Overall, the Rho family is 
involved in actomyosin cytoskeletal reorganisation, gene expression, cell-cycle 
progression, and reactive oxygen species (ROS) production (Heasman and Ridley, 
2008; Sadok and Marshall, 2014). 
 
This thesis focuses on the role of PREX family Rac-GEFs in insulin signalling 
and glucose homeostasis. Therefore, the Rac subfamily is described in more detail 
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in the following section. 
1.1.2.1 The Rac-like Subfamily 
The Rac-like subfamily consists of four isoforms, Rac1, Rac2, Rac3 and RhoG. The 
Rac1, Rac2 and Rac3 isoforms share ≥89% amino acid identity, while RhoG is 72% 
identical to Rac1. There is also a splice variant of Rac1, Rac1b, which contains a 
19 amino acid insertion near the switch II region. The members of the Rac-like 
subfamily are regulated as described in Section 1.1.2 and demonstrate relatively 
high intrinsic GTPase activity (Wennerberg and Der, 2004). The only exception is 
Rac1b, which cannot bind to Rho-GDI and has reduced intrinsic GTPase activity, 
hence it is mainly bound to the plasma membrane and displays constitutive activity 
(Fiegen et al., 2004; Matos et al., 2003). 
The Rac-like GTPases exhibit distinct tissue distribution. Rac1 and RhoG are 
both ubiquitously expressed, whereas Rac2 is restricted to haematopoietic cells 
(Wennerberg and Der, 2004) and Rac1b is preferentially expressed in breast and 
colon cancer (Jordan et al., 1999; Schnelzer et al., 2000). Rac3 is predominantly 
expressed in the nervous system with lower expression levels found in lung, liver, 
and pancreas, but it is absent from white blood cells (Haataja et al., 1997). 
 Although Rac proteins appear to have redundant functions when 
coexpressed, they also exhibit striking isoform specificity. For instance, genetic 
ablation of Rac1 results in embryonic lethality during gastrulation (Sugihara et al., 
1998). Instead, Rac2 deficiency allows normal embryonic development, but it has 
been associated with severe neutrophilic, phagocytic and lymphocytic defects 
(Kasper et al., 2000; Li et al., 2000; Roberts et al., 1999; Williams et al., 2000). In 
neutrophils, for example, Rac1 deficiency merely impairs the directionality of 
migration, whereas Rac2 deficiency blocks cell migration altogether (Pantarelli and 
Welch, 2018). Rac3 knockout mice are also viable and do not demonstrate any 
obvious physical abnormality, suggesting that Rac3 is not strictly required for the 
embryonic development; however it is important during the late maturation of 
specific populations of neurons (Corbetta et al., 2005; Pennucci et al., 2016). Finally, 
RhoG deficiency produces a mild phenotype in leukocytes, where it is highly 
expressed, indicating a functional redundancy of RhoG with other Rac proteins in 
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these cells (Vigorito et al., 2004). 
The Rac GTPases as intracellular signal transducers play a regulatory role 
in a wide variety of cellular functions. For instance, Racs are crucial for actin 
cytoskeleton rearrangements and they are fundamental in the regulation of cell 
adhesion and migration (Ridley et al., 1992). Moreover, the Rac-like subfamily are 
important for many cellular functions such as ROS production, cell proliferation and 
cell survival. To do so, they interact with a variety of downstream effector molecules 
in order to engage distinct signalling cascades (Bustelo et al., 2007; Mack et al., 
2011). However, their involvement in these processes is also dependent on their 
ability to bind GEFs. Racs can be regulated by a large number of GEFs which also 
display signalling pathway and cell type specificities, thus contributing further to the 
functional diversity of Racs. 
 
1.2 Guanine-nucleotide Exchange Factors (GEFs) 
GEFs are large multi-domain proteins that respond to a diverse array of cellular 
inputs to regulate the spatiotemporal activation of small G proteins (Bos et al., 2007). 
Upon activation, GEFs interact with the switch I and switch II domains of small G 
proteins, causing a series of structural rearrangements, which increase the rate of 
GDP release by several orders of magnitude. Subsequently, the nucleotide is 
replaced by the highly abundant cytosolic GTP (Bos et al., 2007; Cherfils and 
Zeghouf, 2013; Vetter and Wittinghofer, 2001). GEFs are primarily defined by their 
catalytic domain, which is normally able to regulate individual members of only one 
of the five small G protein families. For instance, GEFs that activate Ras contain 
CDC25 homology domains (CDC25-HD), which are usually found in combination 
with a Ras exchange motif (REM). Similarly, GEFs involved in the regulation of the 
Rab family contain Vps9, Sec2 or Mss4 catalytic domains. The Arf family is 
regulated by GEFs bearing a Sec7 domain, whereas Ran is stimulated by the β-
propeller GEF RCC1. Finally, GEFs that regulate members of the Rho family contain 
either a Dbl homology (DH) domain in tandem with a Pleckstrin homology (PH) 
domain, or a DOCK homology region 2 (DHR2) domain. These two domains are 
structurally unrelated and they are the basis of sorting the Rho GEFs into two 
8 | P a g e  
subtypes: the diffuse B-cell lymphoma (Dbl)-type Rho-GEFs and the dedicator of 
cytokinesis (DOCK)-type Rho-GEFs (Bos et al., 2007; Cherfils and Zeghouf, 2013). 
Despite GEFs being specific for one or more members of a single small G protein 
family, some can have catalytic domains for multiple small G proteins. Son of 
sevenless (Sos-1) for example carries catalytic domains for both the Ras and Rho 
family (Innocenti et al., 2002). 
Apart from their catalytic domain, GEFs have multiple other domains, which 
are involved in the modulation of their localisation, activity or interaction with binding 
partners and effector proteins. This regulation includes intramolecular interactions, 
post-translational modifications, and/or control of subcellular localisation via protein-
protein, protein-lipid, and/or protein-second messenger molecule (Bos et al., 2007; 
Cherfils and Zeghouf, 2013). 
1.2.1 Rho-GEFs 
The Rho-GEF family in humans comprises more than 80 members, of which over 
70 are Dbl-type and 11 are DOCK-type GEFs. This vastly outnumbers the small G 
proteins upon which they act (20 Rho family members in humans) with individual 
small G proteins often being regulated by multiple GEFs. In addition, some GEFs 
will act on multiple Rho-subfamily members, all be it with different efficiencies, whilst 
some are specific for just one (Cook et al., 2014). Although GEF expression displays 
tissue specificity, in any given cell type there are multiple GEFs for each Rho family 
member. It is generally assumed that this allows the coupling of small G proteins to 
different upstream pathways as well as providing functional redundancy (Cook et 
al., 2014). 
1.2.1.1 Dbl-Type Rho-GEFs 
The Dbl-type Rho-GEF family owes its naming to the Dbl protein, the first identified 
Rho-GEF originally found as a transforming factor in diffuse B-cell lymphoma (Eva 
et al., 1988). Dbl is now known to be a GEF for the Rho-family small G protein Cdc42 
(Hart et al., 1991). Dbl family Rho-GEFs share a catalytic DH domain, which 
stimulates the guanine nucleotide exchange and is usually in tandem with a PH 
domain. The PH domain often interacts with phosphoinositide lipids, contributing to 
the membrane localisation of the Rho-GEFs. Although the DH domain is sometimes 
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sufficient for GEF activity, in some Dbl-type GEFs the PH domain is also required 
for full catalytic activity through allosteric mechanisms (Rossman et al., 2005). 
Crystal or NMR structures have been solved for the DH domains of several 
Dbl-type GEFs including Vav1, ITSN1, Sos1, Trio, Tiam1, LARG, Dbs, Asef, β-Pix, 
p115-RhoGEF and PREX1 (Aghazadeh et al., 1998; Ahmad and Lim, 2010; Cash 
et al., 2016; Chrencik et al., 2008; Kristelly et al., 2003; Liu et al., 1998; Lucato et 
al., 2015; Murayama et al., 2007; Rossman et al., 2002; Soisson et al., 1998; 
Worthylake et al., 2000). These studies have revealed that despite the low primary 
sequence homology among the members of the Dbl-type Rho-GEFs, their DH 
domains fold into similar 3D structures (Figure 1.2.1). They usually comprise of 6-
15 α-helices and 310-helices, arranged along six main axes, forming an oblong 
helical bundle (Rossman et al., 2005). The core of the DH domain consists of three 
highly conserved regions (CR1, CR2 and CR3). Among these, the CR1 and CR3 
interact with the switch I region of the small G protein, whereas the CR3 region and 
elements of the C-terminal helix interact with the switch II region (Rossman et al., 
2005). Interactions with the conserved regions of the DH domain are thought to 
induce structural changes in small G proteins’ switch I and II that obstruct the binding 
of the GDP and its essential cofactor Mg2+, thus facilitating nucleotide exchange on 
the small G proteins (Rossman et al., 2005). Specifically for PREX1, the CR1 
residues Glu56 and Gln197 were found to interact with the switch I region of Rac1, 
while the CR3 residues Lys201, Asn238, and Arg242 were found to mediate 
interactions with the  switch II region of Rac1 (Lucato et al., 2015) (Figure 1.2.1). 
Importantly, mutation of these residues resulted in decreased GEF activity of the 
PREX1 DH/PH tandem in vitro, highlighting their importance not only in Rac1 
binding but also in its activation (Lucato et al., 2015). The less well-conserved 
regions of the DH domain are considered essential for GEF selectivity, and they 
have been found to interact with contiguous patches within the GTPase interface 
that are also poorly conserved, indicating that both sets of proteins co-evolved such 
as to enable pairing specificity. 
The DH domain is most commonly found with a PH domain immediately 
adjacent to the C-terminal side. However, there are cases like the Rho-GEF DEF6 
where this domain motif is inverted with the PH domain on the N-terminal side of the 
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DH domain (Mavrakis et al., 2004), or the Cdc42-GEF Tuba in where the DH domain 
is adjacent to a BAR domain and there is no PH domain (Cestra et al., 2005). The 
PH domain was shown in several cases to contribute in the interaction of the GEF 
with the small G protein and participate in the nucleotide exchange. For example, 
the PH domain of Dbs is required for efficient activation of Rho family proteins 
(Rossman et al., 2003). In contrast, the PH domains of other Rho-GEFs, such as 
PREX1 and Tiam, do not contact the small G proteins and thereby are not involved 
in their activation (Lucato et al., 2015; Worthylake et al., 2000). The PH domain is 
not specific to Rho-GEFs, instead it is found in many intracellular signalling proteins 
where they promote plasma membrane localisation by binding phospholipids 
(Lemmon et al., 1995). However, the affinity of Dbl-like family PH domains for 
phosphoinositides is low and in most cases insufficient for the effective translocation 
of Rho-GEFs to the plasma membrane (Baumeister et al., 2006; Snyder et al., 
2001). One such example is PREX1, where binding of the phosphoinositide 3-
kinase (PI3K)-derived lipid second messenger phosphatidylinositol-3,4,5-
trisphosphate (PtdIns(3,4,5)P3, PIP3) to the PH domain can only confer robust 
membrane translocation if membrane-bound Gβγ subunits of heterotrimeric G 
proteins are also present (Barber et al., 2007). Instead, phospholipid binding can 
modulate GEF-activity. Phosphoinositide binding to the PH domain of Vav1 was the 
first reported to promote GEF activity through weakening of the interaction between 
the DH and PH domains in vitro (Das et al., 2000), although this was a relatively 
weak effect that was not observed in some other studies. Other Rac-GEFs that are 
strongly activated by PIP3 include PREX1 and Swap70 (Welch et al., 2002; Welch 
et al., 2003). In contrast, PIP2 and PIP3 binding to the PH domain of Dbl inhibited its 
GEF-activity towards Cdc42 (Russo et al., 2001).Therefore, the role of the PH 
domain in the DH/PH tandem is variable between GEF proteins. 
Apart from the DH/PH tandem, Rho-GEFs usually contain several other 
domains with diverse functions. The roles of these domains can be broadly divided 
into the following three categories: protein interaction-mediating domains, such as 
the Src Homology 3 (SH3) domain, the Postsynaptic-density protein, Discs large, 
Zona occludens-1 (PDZ) domain, the Dishevelled, Egl-10 and Pleckstrin (DEP) 
domain and the Ras Binding Domain (RBD); second messenger-interacting 
domains, like the phorbol ester-/diacylglycerol-binding C1 domain; and subcellular 
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localisation-modulating domains, such as the Src Homology 2 (SH2) domain and 
the Calponin Homology actin binding (CH) domain. As previously outlined, these 
protein domains can modulate the GEF activity, localisation and effector interactions 
with different combinations of domains defining each GEF, giving it diverse roles 
and functions within the cell (Cook et al., 2014). 
 
 
Figure 1.2.1: Structure of the PREX1:Rac1 complex. 
Ribbon view of crystal structure of the DH (yellow) and PH (purple) domains of PREX1 in complex 
with Rac1 (teal). Interactions between the DH domain of PREX1 and Rac1 stabilise the two switch 
regions in a nucleotide-free conformation. Shown are the switch I and switch II regions (blue) of 
Rac1 which interact with the CR1 and CR3 regions of the PREX1 Dbl-type GEF. (Figure taken 
from (Lucato et al., 2015)) 
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1.2.1.2 DOCK-Type Rho-GEFs 
The DOCK-type GEFs are structurally unrelated to Dbl-type GEFs, yet capable of 
catalysing nucleotide exchange on Rho family small G proteins. The members of 
the DOCK family contain a catalytic DHR2 domain that is preceded by a regulatory 
DOCK homology region 1 (DHR1) domain, and they can subdivided into four groups 
according to sequence similarity. The DOCK-A subfamily (DOCK1, DOCK2, and 
DOCK5), as well as the DOCK-B subfamily (DOCK3 and DOCK4) are GEFs for 
Rac1 small G proteins. From the DOCK-C subfamily (DOCK6, DOCK7 and 
DOCK8), DOCK8 is capable of activating Cdc42, whilst DOCK6 and DOCK 7 can 
activate both. Finally, the DOCK-D subfamily (DOCK9, DOCK10, and DOCK11) are 
specific for Cdc42 (Gadea and Blangy, 2014; Laurin and Côté, 2014).  
 The DHR2 domain is responsible for the GEF activity of DOCK proteins. The 
crystal structures of the DHR2 domain of DOCK2, DOCK7, DOCK8 and DOCK9 
have been solved in complex with their substrate GTPases and provided insight into 
the mechanism of DOCK-mediated nucleotide exchange and specificity for certain 
substrates (Hanawa-Suetsugu et al., 2012; Harada et al., 2012; Kukimoto-Niino et 
al., 2019; Kulkarni et al., 2011; Yang et al., 2009). The DHR2 domain is organised 
into three lobes (lobes A, B and C), with catalytic activity being conferred from lobes 
B and C. Lobe A shares multiple contacts with lobe B to stabilise the DHR2 domain 
and lobe C contains the most conserved region of DH2 domains that is interrupted 
by the loop known as the 'nucleotide sensor’. In DOCK9, it was shown that contrary 
to the DH domains interacting with both switches I and II of small G proteins, the 
DHR2 domain catalyses nucleotide exchange by interacting with only the switch I 
region of Cdc42. The ‘nucleotide sensor’ region within the DHR2 domain has been 
shown to maintain the switch I region of the small G protein in an open conformation. 
Subsequently, a conserved valine residue from the GEF, occludes the Mg2+ cofactor 
from the nucleotide-binding site, resulting in the release of GDP and Mg2+ from the 
small G protein and facilitating its replacement with GTP (Yang et al., 2009). 
Moreover, mutational analysis of DOCK proteins revealed that DHR2 domains 
specifically recognise the residue at position 56 of Rac1 or Cdc42 (Kulkarni et al., 
2011; Zhou et al., 2013) and the rotation of lobe B relative to lobe C is important for 
dual substrate specificity (Kukimoto-Niino et al., 2019). 
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The DHR1 domain was shown to share weak sequence homology with C2 
lipid binding domains and bind phosphoinositides, thus controlling the membrane 
localisation of DOCK proteins (Premkumar et al., 2010; Zhang and Aravind, 2010). 
DOCK1, DOCK4 and DOCK5 demonstrated specificity towards PIP3 (Côté et al., 
2005; Jungmichel et al., 2014), whereas DOCK6, DOCK7 and DOCK8 preferentially 
bind to PIP2 (Jungmichel et al., 2014). In addition to the DHR2 and DHR1 domains, 
members of the DOCK-A and DOCK-B subfamily contain an N-terminal SH3 protein 
binding domain, which can interact with the adaptor protein Engulment and Motility 
(ELMO) that promotes the GEF activity of DOCK, and a proline rich (P-rich) region 
at the C-terminus, which binds Crk proteins. Instead, the DOCK-D subfamily 
proteins have an N-terminal PH lipid binding domain involved in membrane 
translocation (Gadea and Blangy, 2014; Laurin and Côté, 2014).  
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1.3 PREX Family Rac-GEFs 
The PREX protein family consists of two members, the phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac exchange factor 1 (PREX1) and the 
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 
(PREX2). They are Dbl-type GEFs for the Rac subgroup of Rho family small GTP-
binding proteins, and they are synergistically activated by the lipid second 
messenger PIP3, which is generated by PI3K, and the Gβγ subunits of heterotrimeric 
G proteins (Donald et al., 2004; Welch et al., 2002) (Figure 1.4.1). The PREX 
proteins have been reported to play an important role in physiological functions such 
as inflammation (Herter et al., 2013; Welch et al., 2005), skin pigmentation (Lindsay 
et al., 2011) and neuronal development (Waters et al., 2008). However, numerous 
studies have also associated the PREX family with pathologies like cancer and there 
is an emerging role of the PREX proteins in metabolic disorders (Hornigold et al., 
2018; Pandiella and Montero, 2013; Tsonou et al., 2018; Welch, 2015). Currently 
we have limited molecular insight into whether both PREX1 and PREX2 are 
important in metabolic disorders or how they are involved in insulin signalling and 
glucose homeostasis. Herein, it is considered important to further investigate how 
and to which extent the PREX proteins are involved in these processes. 
 
1.4 PREX Genes and Proteins 
In humans, the PREX1 gene is located on chromosome 20 (20q13.13), near a 
region associated with type 2 diabetes (Bento et al., 2008). PREX1 encodes for the 
185 KDa cytoplasmic protein PREX1. The PREX2 is a 183 KDa protein encoded by 
the PREX2 gene, which is located in chromosome 8 (8q13.2) close to a region linked 
to aggressive cancer and metastasis (Fejzo et al., 1998). Alternative splicing 
generates the 112 KDa splice variant PREX2b, which lacks the C-terminal half. The 
PREX1 and PREX2 proteins are conserved throughout vertebrates, are 56% 
identical in their amino-acid sequence, and share a common domain structure 
(Donald et al., 2004; Welch et al., 2002). As is characteristic for Dbl-type Rho-GEFs, 
the PREX proteins consist of an N-terminal DH domain which confers their catalytic 
Rac-GEF activity in tandem with a PH domain (Rossman et al., 2005). Following the 
DH/PH domains there are two DEP and two PDZ protein interaction domains. 
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Finally, in their C-terminal half there is a large inositol polyphosphate 4-phosphatase 
(IP4P) homology domain. Although the IP4P domain contains the minimal residues 
required for phosphatase activity, no catalytic phosphatase activity of the PREX 
proteins has been reported to date (Welch et al., 2002) (Figure 1.4.1). 
Recently, the crystal structures of the PREX1 DH/PH domain tandem in 
complex with constitutively active Rac 1 (Lucato et al., 2015) or nucleotide-free Rac1 
(Cash et al., 2016) were solved, which demonstrated that only the DH domain 
makes multiple contacts with and activates Rac1. Furthermore, it was revealed that 
the DH domain interacts with both switch I and switch II of Rac1, through its highly 
conserved regions CR1 and CR3. Moreover, the PREX1 residues Glu56 and 
Asn238 were confirmed as essential for Rac1 binding and catalytic activity (Lucato 
et al., 2015). These residues had previously been predicted to be important 
facilitators of PREX1-Rac1 interaction, and their mutation was shown early on to 
render the protein catalytically inactive (Hill et al., 2005), and thereafter 
Glu56/Asn238 mutants are in widespread use as catalytically inactive forms of 
PREX1 (Hornigold et al., 2018). 
 
 
 
 
Figure 1.4.1: PREX domain structure and function.  
PREX1 and PREX2 are Dbl-type Rho-GEFs and share an identical domain structure (Donald et 
al., 2004; Welch et al., 2002). At their N-terminus, they have a DH domain, which confers Rac-
GEF activity, in tandem with the adjacent PH domain, which binds PIP3. This is followed by two 
DEP and two PDZ protein interaction domains. Finally, in their C-terminal half there is an inositol 
polyphosphate 4-phosphatase (IP4P) domain that harbours no phosphatase activity and has weak 
homology between the PREX proteins. PREX2b is a splice variant of PREX2 (Welch et al., 2002).  
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1.5 Tissue Distribution of PREX Proteins 
The PREX1 protein was initially purified from neutrophils, where it is strongly 
expressed and constitutes 0.1% of the cytosolic protein (Hill and Welch, 2006; 
Welch et al., 2002). Other cell types that highly express PREX1 include 
macrophages (Wang et al., 2008), platelets (Aslan et al., 2011; Qian et al., 2012), 
endothelial cells (Carretero-Ortega et al., 2010) and neurons (Yoshizawa et al., 
2005). Northern-blot and western-blot studies on mouse tissues have found Prex1 
to be most strongly expressed in brain, but it is also abundant in other tissues like 
bone marrow, thymus, spleen, lymph nodes and lung (Donald et al., 2008; Welch et 
al., 2002). 
PREX2 mRNA expression has been detected in many mouse tissues 
(Donald et al., 2004), but the protein is not as widely expressed. Western-blot 
studies showed that Prex2 is abundant in brain, especially in the Purkinje neurons 
of the cerebellum, and in the lungs. At lower levels, Prex2 has been detected in liver, 
adipose tissue, thymus and spleen (Donald et al., 2008; Hodakoski et al., 2014). 
Notably, Prex2 protein is not present in peripheral blood leukocytes (Damoulakis et 
al., 2014; Lawson et al., 2011; Welch et al., 2005). It is currently unknown which 
mechanisms restrict the distribution of Prex2 protein to a few tissues despite the 
wider expression of its mRNA. Little is also known about Prex2b’s expression. To 
date, Prex2b mRNA has been detected only in heart and endothelial cells, and the 
endogenous Prex2b protein has only be studied in the latter (Li et al., 2005; 
Rosenfeldt et al., 2004). 
 
1.6 Regulation of PREX Expression 
The molecular mechanisms underlying PREX proteins’ expression have so far only 
been studied in the context of their deregulation in cancer. Work in prostate cancer 
cell lines has shown that the suppression of PREX1 expression in normal prostate 
epithelial cells is due to histone deacetylation (Wong et al., 2011). Treatment of 
human prostate epithelial cells and prostate cancer cells with Histone deacetylase 
(HDAC) inhibitors or HDAC siRNAs results in the stimulation of PREX1 expression, 
while HDAC overexpression represses PREX1 gene expression. Dual luciferase 
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assay experiments identified a 92 bp region (-190/-98) upstream of PREX1 as its 
minimal promoter, and electrophoretic mobility shift assay (EMSA) identified Sp1 
transcription factor as an important regulator of PREX1 gene promoter activity. It 
was proposed that Sp1 mediates HDAC binding to the PREX1 promoter, which 
leads to histone deacetylation-mediated repression. In metastatic prostate cancer, 
the observed disassociation of HDACs from Sp1 might be a contributing reason for 
the aberrant PREX1 up-regulation (Wong et al., 2011). Alongside regulation by 
HDACs, hypermethylation of CpG islands in the promoter and transcriptional start 
regions of PREX1 has been reported as a major mechanism to suppress PREX1 
expression in normal breast epithelial cells (Barrio-Real et al., 2014). PREX1 
promoter methylation was found to be reduced in luminal breast tumours and was 
associated with ER-positive status. Moreover, hypomethylation was correlated with 
high PREX1 expression and with poor long-term survival of breast cancer patients 
(Barrio-Real et al., 2014). A further mechanism of PREX1 expression linked PREX1 
deregulation to drug resistance of prostate carcinoma cells. In drug resistant cells, 
the transcription factor Myc was upregulated and binding of Myc to a consensus site 
in the PREX1 promoter induced PREX1 transcription (Goel et al., 2016). 
The expression of PREX2 has been found to be post-transcriptionally 
repressed by the microRNA (miRNA) miR-338-3p, which binds to the 3’-UTR of the 
PREX2 gene at three sites and negatively regulates its expression (Chen et al., 
2013; Guo et al., 2014). In metastatic neuroblastoma and in gastric cancer, miR-
338-3p is significantly down-regulated. Work in human neuroblastoma cell lines 
demonstrated that downregulation of PREX2 by siRNA rescues miR-338-3p 
antisense oligonucleotide-induced cell growth and invasion (Chen et al., 2013). 
Comparably, miR-338-3p overexpression in a human gastric cell line (BGC-823) 
reduced PREX2 levels and inhibited cell proliferation, and PREX2 down-regulation 
had the same effect (Guo et al., 2014). In the same way, blockade of the miR-338 
promoter by the transcriptional suppressor MECP2, in gastric cancer cells, was 
sufficient to induce PREX2 expression, cell growth, and proliferation (Tong et al., 
2016). 
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1.7 Regulation of PREX Activity 
1.7.1 PIP3 and Gβγ 
On matters of activity regulation, Prex1 was initially purified from neutrophils on the 
basis of its PIP3-dependent activation (Welch et al., 2002). Work with recombinant 
human PREX1 demonstrated that its Rac-GEF activity can be directly stimulated by 
PIP3 more than 30-fold (Hill et al., 2005; Welch et al., 2002). Interestingly, when 
different phosphoinositides were evaluated for their ability to bind and activate 
PREX1, it was shown that PREX1 can also bind to PI(3,4)P2 (Cash et al., 2016; 
Welch et al., 2002), which however cannot activate its Rac-GEF activity in vitro 
(Welch et al., 2002). Furthermore, it was observed in neutrophils that the Gβγ 
subunits of heterotrimeric G proteins, which are released upon activation of GPCRs 
(see Section 1.1.1), can also promote Rac activity (Figure 1.7.1). Sf9 cell 
transduction with viruses encoding PREX1, p101/p110γ- PI3K, and Gβ1γ2 showed 
that Gβγ subunits can activate PREX1 and that PIP3 and Gβγ act synergistically on 
PREX1 (Welch et al., 2002). The study of a panel of deletion and truncation mutants 
of human PREX1 revealed that the PH domain of the protein is necessary for the 
PIP3 binding, and the DH/PH tandem is sufficient for the PIP3-dependent activation 
of PREX1 Rac-GEF activity (Figure 1.7.1). In contrast, the basal and Gβγ-
stimulated Rac-GEF activity of PREX1 appears to be mediated by its DH domain 
(Hill et al., 2005), although other PREX1 domains also contribute to Gβγ regulation 
at least in vivo (Urano et al., 2008). The DEP, PDZ and IP4P domains of the protein 
have been found to contribute to keeping the basal activity of PREX1 low, potentially 
through intramolecular interaction with the DH/PH tandem (Hill et al., 2005). 
Similarly, PREX2 and PREX2b are also directly and synergistically activated 
by PIP3 and Gβγ (Donald et al., 2004; Li et al., 2005; Rosenfeldt et al., 2004). 
Experiments in Sf9 cells expressing combinations of PREX2, p101/p110γ-PI3K 
and/or Gβ1γ2 subunits demonstrated that PI3K or Gβγ alone can activate PREX2 
Rac-GEF activity but their synergistic interaction is required for full activation 
(Donald et al., 2004). Notably however, work in HEK293 cells has shown that 
inhibition of PI3K negatively affects the Gβγ-mediated activation of PREX2b, 
suggesting that PIP3 might be required for the Gβγ/PREX2 interaction in a cellular 
context (Li et al., 2005). 
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Figure 1.7.1: Crystal structure of the catalytic core of PREX1 in complex with Rac1, 
showing the PIP3 binding site and predicted Gβγ binding site. 
Crystal structure of the DH/PH domain tandem of PREX1 (electrostatic surface view) in complex 
with Rac1, shown alongside modelling of Gβγ and PIP3 binding. The crystal structure confirmed 
that residues Glu56 and Asn238 in the PREX1 DH domain are crucial for Rac1 binding, and that 
the DH domain is sufficient for catalysis. Furthermore, the modelling suggested that PIP3 and Gβγ 
binding sites are likely situated away from the Rac1 binding site and that Gβγ might contact both 
the PRΕΧ1 DH and PH domains (Lucato et al., 2015). The PREX1 PH domain was also crystalized 
in complex with the soluble PIP3 analogue IP4, which revealed that Lys280, Arg289, and Lys368 
in the PH domain are required for PIP3 binding (Cash et al., 2016). (Figure taken from (Lucato et 
al., 2015)) 
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1.7.2 Regulatory Partners 
In addition to PIP3 and Gβγ. PREX protein activity can be further regulated by 
phosphorylation or protein-protein interactions (Figures 1.7.2 and 1.8.1) (Hornigold 
et al., 2018; Tsonou et al., 2018). 
1.7.2.1 PP1α 
Both PREX1 and PREX2 have been found to directly bind protein phosphatase 1α 
(PP1α) in vitro, through a RVxF motif in their IP4P domains. Experiments with 
recombinant proteins and in HEK-293 cells have shown that PP1α (and to a less 
extent PP1β) stimulates PREX1 directly by dephosphorylating several residues in 
the C-terminal half, with Ser1165 being the major target (Barber et al., 2012). Study 
of hippocampal neurons has shown that stimulation through the ionotropic 
glutamate receptor NMDAR increases the binding of PP1α to PREX1, thereby 
contributing to PREX1-mediated synaptic plasticity (Li et al., 2015).  
Likewise, PP1α (and to a less extent PP2A) can regulate the phosphorylation 
state of PREX2 by dephosphorylating Ser1107, although it remains to be 
investigated further how PP1a regulates the PREX2 activity (Barrows et al., 2015). 
Regarding the splice variant PREX2b, it is unlikely to be regulated by PP1a as it 
does not contain the consensus RVxF motif required for PP1a binding.  
1.7.2.2 PAK 
In contrast to PP1, the p21-activated protein kinases (PAKs) were identified to be 
negative regulators of PREX proteins. PAKs were shown to phosphorylate PREX1 
in response to stimulation of receptor tyrosine kinases (RTKs); PAK2 could 
phosphorylate PREX1 directly in vitro, and phosphorylation by PAK1 reduced the 
PIP3-stimulated Rac-GEF activity of PREX1 in a broken-cell assay (Barrows et al., 
2016). As PAKs are activated by Rac1-GTP, a negative feedback loop to limit 
PREX1 activity was proposed (Barrows et al., 2016). 
It has been shown in vitro that PAK2 can also phosphorylate PREX2 at 
Ser1107. Moreover, co-expression of PREX2 with wild type but not kinase-dead 
PAK1 inhibited its Rac-GEF activity in broken-cell assays (Barrows et al., 2015). 
Knowing that phosphorylation of Ser1107 depends on PIP3 binding to PREX2, and 
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on its Rac-GEF activity, it was concluded that PREX2, similarly to PREX1, can 
catalyse its own inactivation through a Rac1/PAK-dependent negative feedback 
loop (Barrows et al., 2015). However, it is still unclear if phosphorylation of Ser1107 
by PAK is sufficient to inhibit PREX2. Interestingly, phosphorylation of the equivalent 
residue in PREX1 (Ser1169) by unknown kinases is associated with increased Rac-
GEF activity (Montero et al., 2013). It also remains to be seen whether other 
pathways affect the PAK-dependent inhibition of P-Rex2 during PI3K signalling. 
1.7.2.3 PKC 
Phosphorylation of PREX1 at Ser313 was found to limit its Rac-GEF activity 
(Montero et al., 2010). Interestingly, the crystal structure of the PREX1 DH/PH 
domain revealed that Ser313 lies within the β3/β4 loop of the PH domain, which is 
considered to be highly mobile. On this basis, Lucato et al suggested that 
phosphorylation of Ser313 may enable the β3/β4 loop to interact with the DH domain 
to sterically inhibit Rac1 binding (Lucato et al., 2015). More recently, the Pandiella 
lab showed that the PREX1 Ser313 could be directly phosphorylated by the protein 
kinase Cδ (PKCδ) isoform. Functional studies using overexpression of either wild 
type PREX1 or PREX1 S313A in several breast cancer cell lines with low intrinsic 
expression of PREX1 further confirmed that phosphorylation of PREX1 at Ser313 
restricts Rac-GEF activity (Montero et al., 2016). 
1.7.2.4 PKA 
The protein kinase A (PKA) is another known inhibitor of PREX1 which completely 
blocks PREX1 activation by either PIP3 or Gβγ (Mayeenuddin and Garrison, 2006; 
Urano et al., 2008). Work with HEK-293 cells has demonstrated that PKA can 
effectively inhibit PREX1, and that it does so by affecting the interaction between 
the second DEP/first PDZ domains and the IP4P domain of PREX1, which is 
important for Gβγ binding within cells (Urano et al., 2008). More recently, it was 
confirmed that the PKA regulatory subunit interacts with the PDZ1 domain of PREX1 
while the PKA catalytic domain phosphorylates Ser436 in the PREX1 DEP domain 
(Chavez-Vargas et al., 2016). Pull-down assays showed that PKA-mediated 
phosphorylation of DEP1 at Ser436 promotes its interaction with the DH/PH domain 
tandem, which probably results in an inhibitory intramolecular conformation 
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(Chavez-Vargas et al., 2016). Similarly, PKA was found to mediate the inhibition of 
the DH/PH domain by the C-terminal half of PREX1. However, this was independent 
of its interaction with the DEP/PDZ1 domains, suggesting that PKA might also target 
residues within the PREX1 C-terminus (Chavez-Vargas et al., 2016). Interestingly, 
another recent study showed that PKA, downstream of chemotactic Gs-coupled 
receptors, can also activate PREX1 independently of its kinase activity (Adame-
Garcia et al., 2019). It was proposed that upon cAMP production, the cAMP-bound 
regulatory subunits dissociate from the catalytic subunits of PKA and while the 
catalytic subunits phosphorylate and inhibit a fraction of the PREX1 protein pool, the 
regulatory subunits directly activate another fraction of PREX1 molecules. 
Eventually, the activity of the PKA catalytic subunits prevails and desensitises 
PREX1 signalling (Adame-Garcia et al., 2019). To this day, PKA has not been 
reported to regulate PREX2 phosphorylation. 
 
 
 
 
 
Figure 1.7.2: PREX1 regulation and binding partners. 
Depicted are direct interactions of PREX1 with its regulators, substrate, and binding proteins. 
Arrows denote activation, blunt ends show inhibition, and bobble-ends show direct binding.  
 P a g e  | 23 
In basal cells: PREX1 is largely cytosolic and has low basal Rac-GEF activity, due to 
intramolecular inhibition. In the cytosol, PREX1 binds constitutively to the serine phosphatase 
PP1a, the GPCR adaptor protein Norbin, the protein kinases PKA and mTOR and the gelsolin 
superfamily adaptor protein FLII. PP1a binds to the RVXF motif (residues 1146–1149) of PREX1 
and dephosphorylates Ser1165, which is sufficient to weakly stimulate PREX1 Rac-GEF activity. 
This interaction between PP1a and PREX1 in neurons increases upon NMDAR stimulation. Norbin 
binds to the PH domain, induces a robust membrane translocation of PREX1 and also weakly 
stimulates Rac-GEF activity. FLII binds PREX1 constitutively (at an unknown site), and PREX1 
mediates an interaction of FLII with Rac1-GTP that promotes cell migration and contraction. In 
addition, PREX1 binds constitutively to mTOR through its DEP domains and forms part of TORC1 
and TORC2. PREX1 affects mTOR responses (and likely also vice versa), but the underlying 
mechanisms remain to be elucidated. It also remains to be shown if the interactions of REX1 with 
Norbin, FLII and mTOR are affected by cell stimulation. 
Upon cell stimulation: Both the membrane association and the catalytic activity of REX1 are 
increased upon cell stimulation, through various mechanisms that cause release of intramolecular 
inhibition. PREX1 is directly activated by the lipid second messenger PIP3, which is generated by 
PI3K, and by the Gβγ subunits of heterotrimeric G proteins. PIP3 binds to the PH domain, and 
activation by Gβγ occurs through the DH domain, although further domains are involved in Gβγ 
binding in vivo. PIP3 and Gβγ can activate PREX1 independently, but also synergistically. This 
synergistic activation makes PREX1 a coincidence detector for the concomitant stimulation of 
PI3K-coupled receptors and GPCRs. As well as Rac-GEF activity, PIP3, and Gβγ also 
synergistically stimulate the membrane localization of PREX1. Other mechanisms of PREX1 
activation include Norbin binding and dephosphorylation by PP1a, as well as the phosphorylation 
of Ser1169 by unidentified serine kinases. Interestingly, the equivalent site in PREX2 (Ser1107) is 
phosphorylated by PAK, an inhibitor of PREX Rac-GEFs.  
Negative regulation: PKA binds to the PDZ1 domain and inactivates PREX1 by phosphorylating 
Ser436 in the DEP1 domain, which promotes an inhibitory intramolecular interaction with the 
catalytic core. In addition, PKA also regulates (possibly indirectly) an intramolecular interaction of 
the C-terminal half with the catalytic core. The Rac1 GTP-dependent kinase PAK can also 
phosphorylate PREX1 directly (at unknown sites) and inhibits PREX1 activity (possibly indirectly) 
within cells, which led to the proposal of a negative feedback loop involving PREX1, Rac1, and 
PAK to limit PREX1 signalling. 
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1.7.2.5 Norbin 
Norbin (Neurochondrin) is a leucine-rich cytoplasmic protein that is predominantly 
expressed in the nervous system where it is implicated in brain and neuron 
development, as well as the regulation of synaptic plasticity (Wang et al., 2010). 
Recently, our lab identified Norbin as a direct binding partner for PREX1, which 
promotes PREX1 membrane localisation and Rac-GEF activity (Pan et al., 2016). 
1.7.2.6 PTEN 
PREX2 binds directly to the tumour suppressor Phosphatase and Tensin Homolog 
Deleted from Chromosome 10 (PTEN) that blocks PI3K signalling by converting the 
PI3K product PIP3 back to PI(4,5)P2 (Fine et al., 2009). This interaction between 
PREX2 and PTEN is conferred by binding of the PREX2 PH domain to the catalytic 
and C2 domains of PTEN, and through additional contacts of the PREX2 IP4P 
domain with the C-terminal PDZ-binding domain of PTEN (Fine et al., 2009; 
Hodakoski et al., 2014). The interaction is specific to PREX2, as PREX1 does not 
bind PTEN. Importantly, PREX2 inhibits the phosphatase activity of PTEN, 
independently of its Rac-GEF activity. Consequently, PREX2 deficiency leads to 
increased PTEN activity and a suppression of PIP3 levels and PI3K pathway activity 
(Hodakoski et al., 2014). 
Intriguingly, PREX2 does not only inhibit PTEN, but inversely, PTEN also 
regulates PREX2 (Mense et al., 2015). PTEN attenuated the PREX2-dependent 
invasive migration of breast cancer cells, independently of its lipid- and protein-
phosphatase activities. This suggested that PTEN has an adaptor role, which blocks 
PREX2 function. Indeed, PTEN reduced the Rac1-GEF activity of PREX2, both in 
vitro and upon expression in HEK293 cells, independently of its own catalytic 
activity. Mutational analysis identified furthermore that the most C-terminal amino 
acids of PTEN are required for the inhibition of PREX2-dependent invasive cell 
migration (Mense et al., 2015). Importantly, PREX2 mutants that are frequently 
present in cancer were able to escape the inhibition by PTEN, both in vitro and in 
assays of invasive cell migration (Figure 1.7.2). The PREX2 V432M and P948S 
mutants (which are seen in melanoma and pancreatic cancer, respectively) showed 
normal binding to PTEN, but the ability of PTEN to inhibit their Rac-GEF activity was 
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reduced. In contrast, the melanoma-associated PREX2 G844D mutant evaded 
PTEN inhibition through reduced binding (Mense et al., 2015). It remains to be 
shown why PTEN could not inhibit the former two PREX2 mutants. However, it 
appears that these mutants retained their ability to inhibit PTEN, as PTEN was 
unable to suppress Akt phosphorylation in glioblastoma cells expressing the 
mutants (Mense et al., 2015). In summary, PTEN is a negative regulator of PREX2 
and loss of this inhibition in cancer cells promotes invasive migration. Future work 
will need to elucidate the effects of PTEN on physiological roles of PREX2. 
 
 
 
 
 
 
Figure 1.7.3: Cancer-associated PREX2 mutants escape negative regulation by 
PTEN.  
(A) Wild type PREX2: PREX2 binds to the tumour suppressor PTEN through its PH and IP4P 
domains and inhibits PTEN phosphatase activity, independently of its Rac-GEF activity. This leads 
to increased PI3K pathway activity. Inversely, PTEN also inhibits PREX2 Rac-GEF activity, thus 
limiting cell migration. It remains to be investigated under which physiological conditions PTEN 
can inhibit PREX2, and vice versa. (B) Cancer-associated PREX2 mutations V432M and 
P948S: The melanoma-associated PREX2 mutant V432M and the pancreatic cancer-associated 
mutant P948S escape inhibition by PTEN. These mutants bind PTEN normally, but their Rac-GEF 
activity is less sensitive to PTEN. It is likely that these PREX2 mutants retain their ability to inhibit 
PTEN, however. Cancer cells carrying these PREX2 mutations show increased invasive migration. 
(C) Cancer-associated PREX2 mutation G844D: The melanoma-associated PREX2 mutant 
G844D escapes inhibition by PTEN through reduced PTEN binding. Cancer cells carrying this 
PREX2 mutation show increased invasive migration. Due to the reduced interaction, this PREX2 
mutant should also not be able to inhibit PTEN. This may lead to a suppression of PI3K signalling 
in cells expressing PREX2 G844D, which requires further investigation. 
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1.8 PREX Binding Proteins 
Apart from Rac and the regulators described above, few binding proteins have been 
identified to bind PREX1 and/or PREX2 directly (Figures 1.7.2 and 1.8.1) (Hornigold 
et al., 2018; Tsonou et al., 2018). 
1.8.1 mTOR 
The serine kinase mammalian target of rapamycin (mTOR), a key regulator of cell 
growth and of a plethora of other cell responses, was found to bind PREX1 directly 
through the DEP domains. PREX1 interacts with both mTOR-containing protein 
complexes, mTORC1, which is central in cell growth, and mTORC2 (also known as 
PDK2), which controls cell morphology and migration (Hernandez-Negrete et al., 
2007). Although there is evidence suggesting that PREX1 can signal both upstream 
and downstream of mTOR (Hernandez-Negrete et al., 2007; Kim et al., 2011a), 
more research is required to elucidate whether PREX1 can regulate both TORC1- 
and TORC2-dependent cellular processes. Similarly, PREX2 and PREX2b also 
directly interact with the serine kinase mTOR (Hernandez-Negrete et al., 2007). 
However, it is unknown if PREX2 and PREX2b can modulate mTOR signalling or 
vice versa. 
1.8.2 FLII 
The Malliri lab performed a SILAC screen that identified proteins, which interact with 
Rac1 specifically in the presence of PREX1. This identified the actin remodelling 
protein flightless-1 homolog (FLII), a member of the gelsolin superfamily, as a 
PREX1 binding protein (Marei et al., 2016b). PREX1 bound directly to FLII, 
independently of its Rac-GEF activity. PREX1 interacted with the C-terminal GEL 
domain of FLII, whereas Rac1 bound to the N-terminal LRR domain of FLII. In 
addition, the actin capping protein TMOD3 was shown to bind Rac1 and FLII more 
strongly in the presence of PREX1 (Marei et al., 2016a). Importantly, PREX1 
enabled the interaction between Rac1 and FLII in fibroblasts preferentially when 
Rac1 was GTP-loaded, and the ability of PREX1 to induce cell migration and myosin 
contractility required FLII. Based on these findings, a model was proposed where 
PREX1 activates Rac1 and acts as a scaffold that enables FLII to interact with this 
active Rac1, thus inducing cell responses that require both Rac1-GTP and FLII 
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(Marei et al., 2016b).  
 
 
 
 
Figure 1.8.1: PREX2 regulation and interacting proteins. 
In basal cells: PREX2 is largely cytosolic and has low basal Rac-GEF activity, through 
intramolecular inhibition. In the cytosol, PREX2 constitutively interacts with the tumour suppressor 
PTEN, the serine phosphatase PP1a, and the serine kinase mTOR. PREX2 and PTEN can inhibit 
each other, independently of their respective catalytic activities. PP1a binds to the RVxF motif 
(residues 1084–1087) and dephosphorylates Ser1107 of PREX2, and possibly other residues. It 
is likely that PP1a activates PREX2, similar to PREX1. The consequences of the interaction with 
mTOR are unknown. 
Upon cell stimulation: PREX2 is activated by the lipid second messenger PIP3, which is 
generated by PI3K, and by the Gβγ subunits of heterotrimeric G proteins, which are released upon 
stimulation of GPCRs. PIP3 and Gβγ can activate PREX2 either individually or synergistically. The 
DH domain is sufficient for activation by Gβγ, whereas Lys254 and Arg263 in the PH domain are 
required for activation by PIP3. In order to activate Rac1, PΡΕΧ2 must be recruited to the cell 
membrane. By analogy with PREX1, it seems likely that PIP3 and Gβγ not only activate the Rac-
GEF, but also induce its membrane translocation in a synergistic manner.  
Negative regulation: One of the effector proteins of active Rac1 (Rac1-GTP) is the serine kinase 
PAK. Active PAK can phosphorylate PREX2 directly and inhibit PREX2 Rac-GEF activity in 
broken-cell assays. Thus, active PREX2 seems to be able to generate a negative feedback loop 
from PREX2/Rac1/PAK for PAK-mediated inhibition of its own Rac-GEF activity. PAK 
phosphorylates Ser1107 of PREX2, among other residues, but it is unknown if phosphorylation of 
Ser1107 is sufficient for inhibition. 
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1.9 Physiological and Pathophysiological Functions of 
PREX Proteins 
1.9.1 Leukocytes, Platelets, and Inflammation 
Work in neutrophils isolated from Prex1 knockout mice has demonstrated that Prex1 
acts downstream of GPCRs and is involved in Rac-dependent ROS production, 
actin polymerisation, polarisation and migration, whereas in vivo work has shown 
that Prex1 is important for neutrophil recruitment to inflammatory sites (Damoulakis 
et al., 2014; Welch et al., 2005). In addition to neutrophils, Prex1 is also expressed 
in platelets (Qian et al., 2012). Prex1 knockout mice show mild defects in 
haemostasis, and Prex1 deficient platelets show a partial impairment in GPCR-
dependant aggregation and dense granule secretion (Qian et al., 2012). However, 
in contrast to this minor role in haemostasis, Prex1/Vav expression in platelets was 
found to be important for the platelet-dependent vascular adhesion and tissue 
recruitment of neutrophils and eosinophils during inflammation (Pan et al., 2015). 
Prex1─/─;Vav1─/─ and Prex1─/─;Vav3─/─ platelets had low surface levels of the 
selectin ligand PSGL-1, and the mice showed a reduced occurrence of platelet-
neutrophil adhesion in the circulation, which is prerequisite for the extravasation of 
these leukocytes (Pan et al., 2015). Finally, Prex1 has been shown to be required 
for pulmonary fibrosis, a late phase of pulmonary inflammation, which can result in 
loss of lung function. Prex1 knockout mice exhibited reduced early leukocyte 
infiltration and fibrosis, which drastically increased survival in a bleomycin-induced 
model of pulmonary fibrosis (Liang et al., 2016). 
1.9.2 Neurons and Behaviour 
Another role of PREX proteins is regulation of neuronal development and behaviour. 
Prex1 was found to be localised in the leading processes and adjacent cytoplasmic 
regions of migrating neurons in the cortex (Yoshizawa et al., 2005). Activation of 
Prex1 in neuronal PC12 cells by stimulation with NGF resulted in increased Rac 
activity, lamellipodia formation, membrane ruffling, cell spreading and migration, 
whereas knockdown of endogenous Prex1 had the opposite effect (Yoshizawa et 
al., 2005). One study found single nucleotide polymorphisms (SNPs), copy number 
deletions and reduced mRNA levels of PREX1 in children with autism spectrum 
disorders (Li et al., 2015). Evaluation of Prex1─/─ mice in behavioural models of 
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autism revealed deficits in social recognition, reversal learning and fear extinction. 
Acute knockdown of Prex1 in the hippocampal CA1 region of young wild type mice 
resulted in similar behavioural defects as seen in Prex1─/─ mice, suggesting that 
Prex1 expression in the hippocampus is required for social interaction and flexible 
behaviours (Li et al., 2015). Furthermore, NMDAR-induced long-term depression 
(LTD) was shown to be impaired in the hippocampal CA1 region of Prex1─/─ mice. 
Remarkably, the impairments in NMDAR-dependent hippocampal LTD, social 
recognition and behavioural flexibility seen in Prex1─/─ mice could be rescued by the 
overexpression of Prex1 in pyramidal neurons of the CA1 region of the hippocampus 
(Li et al., 2015). More recently, a deep learning approach of analysing GWAS data 
from Taiwanese population identified the SNP rs4810894 adjacent to the PREX1 
gene as a putative modulator of the antidepressant treatment response (Lin et al., 
2018). However, the functional relevance of the effects of this SNP on the 
antidepressant treatment response is yet to be investigated. 
Prex2 is highly expressed in the cerebellum. Study of Prex2 knockout mice 
revealed that they have impaired Purkinje cell morphology, and they exhibit a mild 
motor coordination defect, which gets worse with ageing, especially in females 
(Donald et al., 2008). Prex1─/─;Prex2─/─ mice showed an exacerbated phenotype, 
with a more severe impairment of motor activity, as well as posture and gait defects. 
These impairments were consistent with cerebellar dysfunction and were evident in 
both males and females from a young age (Donald et al., 2008). Furthermore, patch 
clamp electrophysiology showed that Prex1─/─;Prex2─/─ Purkinje neurons 
compensate well for the dendrite morphology defect, as their passive membrane 
properties and basal synaptic transmission were normal. However, these neurons 
had impaired synaptic plasticity, as they were unable to maintain long-term 
potentiation, which is required for learned motor coordination skills (Jackson et al., 
2010).  
1.9.3 Endothelial Cells and Vascular Biology 
PREX proteins are also implicated in vascular biology. PREX1 deficiency in human 
microvascular endothelia cells (HMEC) inhibits stromal cell derived factor-1 (SDF1) 
stimulated Rac1 activity, chemotaxis and in vitro angiogenesis (Carretero-Ortega et 
al., 2010). Moreover, work in human lung microvascular endothelia cells (HLMVEC) 
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has demonstrated that PREX1 is involved in the tumour necrosis factor-α (TNF-α)-
induced endothelial barrier disruption, via Rac activation, ROS production, c-Src 
activation, and VE-cadherin phosphorylation (Naikawadi Ram et al., 2012). These 
findings were further confirmed in vivo, as Prex1 deficient mice showed significantly 
decreased vascular endothelial permeability and oedema formation. Finally, 
endothelial Prex1 has also been associated with the promotion of leukocyte 
transendothelial migration (Naikawadi Ram et al., 2012). In addition, PREX1 was 
also shown to mediate Weibel-Palade body secretion in primary human umbilical 
vein endothelial cells (HUVECs), a process required for the upregulation of P-
selectin on the endothelium and for the capture of leukocytes from the blood stream 
during inflammation (van Hooren et al., 2014). 
The PREX2 isoforms are also expressed in endothelia cells. Knockdown of 
PREX2b in HUVECs showed that it is required for the sphingosine 1-phosphate 
stimulated migration of endothelial cells (Li et al., 2005). Moreover, a study that 
employed an shRNA knockdown screen in HUVECs, identified PREX2 as a 
potential regulator of mechanical-force-induced orientation of endothelial cells, a 
response which is relevant in vivo for the integrity of blood vessel walls (Abiko et al., 
2015). 
1.9.4 Cancer 
Both PREX1 and PREX2 genes are located in genomic regions that are often 
amplified in cancer, and in particular melanoma, breast, prostate, and colorectal 
tumours (Berger et al., 2012; Pandiella and Montero, 2013). 
Deregulated PREX1 expression was shown to be sufficient to drive the 
growth and the metastasis of melanoma, breast, and prostate cancer. It was 
demonstrated that overexpression of PREX1 can occur through amplification of the 
PREX1 gene, as it is common in breast cancer (Sosa et al., 2010), or through the 
loss of epigenetic repression seen in prostate cancer (Wong et al., 2011) and in 
breast cancer subtypes (Barrio-Real et al., 2014). In contrast to overexpression, 
somatic mutations of PREX1 in cancer are rare. They have only be reported to occur 
in lung carcinomas, with a frequency of 5% (Suzuki et al., 2013), and in 3.65% of 
breast cancers (Dillon et al., 2014). It remains to be shown if such mutations affect 
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the function of the PREX1 in a manner that could promote the growth or spread of 
lung cancer. Finally, a SNP in the third intron of PREX1 (rs6066835) was identified 
in a GWAS study to be associated with multiple myeloma and with increased PREX1 
expression in multiple myeloma plasma cells (Mitchell et al., 2016). 
Apart from the mechanisms regulating PREX1 gene expression, additionally 
the PREX1 signalling pathway has been extensively studied in cancer cells, 
especially in the context of breast cancer and melanoma. In breast cancer cells, it 
has been shown that PREX1 is activated downstream of the RTK receptor ErbB and 
the GPCR receptor CXCR4. Signalling through the CXCR4 receptor has been 
associated with cell growth and migration, whereas signalling through the ErbB 
receptor promotes cell motility (Liu et al., 2016; Lopez-Haber et al., 2016; Sosa et 
al., 2010). Interestingly, it was also shown that ErbB can transactivate CXCR4, and 
it has been proposed that signalling pathways downstream of these two receptors 
intersect at PREX1 (Kazanietz et al., 2018; Sosa et al., 2010). Moreover, in breast 
cancer, PREX1 has been reported to promote PI3K/AKT signalling, while itself being 
modulated by PI3K at the transcriptional and posttranslational levels (Dillon et al., 
2014). Aberrant PREX1 signalling has been involved in the increased activation of 
the Raf/MEK/Erk pathway, in a Rac1 dependent way (Dillon et al., 2014; Liu et al., 
2016). It was also suggested that PREX1 is involved in breast cancer cell 
proliferation through PREX1-dependent regulation of the cell cycle regulators Cyclin 
D1 and p21Cip1 (Liu et al., 2016). However, a more recent study has argued that 
PREX1 is not required for the Erk-pathway dependent mitotic or survival responses 
of breast cancer cells (Barrio-Real et al., 2018).  
Prex1 was also implicated in the melanoblast migration during the normal 
development in mice. Prex1─/─ mice, on C57BL/6J genetic background, have white 
bellies, feet and tail tips. This migration defect becomes relevant in melanoma, 
where melanocytes are transformed into melanoma cells. Prex1 expression is 
deregulated in melanoma cells and is critical for melanoma metastasis, at least in 
part, in a Rac1 dependent way (Lindsay et al., 2011; Lindsay et al., 2015). PREX1 
was shown to regulate cell proliferation, invasion and migration of cutaneous 
melanoma cells via PREX1/RAC1/PAK1/p38/MMP-2 pathway. It was also found 
that PREX1 knockdown in melanoma cell lines inhibits cell cycle by reducing 
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survivin and cyclin D1 expression (Wang et al., 2017). Furthermore, comparison of 
PREX1 expression in human cutaneous melanoma specimens with disease 
outcome revealed lower distant metastasis-free survival among AJCC stage I/II/III 
patients with high PREX1 expression compared to patients with low PREX1 
expression (Wang et al., 2017). 
The PREX2 locus lies within a genomic region that is linked with aggressive 
cancers and metastasis (Berger et al., 2012). In melanoma, the locus also 
undergoes frequent chromosomal translocations and rearrangements (Berger et al., 
2012). Hence, multiple mechanisms seem to contribute to the deregulation of 
PREX2 expression in cancer. Furthermore, although it is very unusual for Rho-GEFs 
to be mutated, PREX2 mutations are frequently observed in cancer, particularly in 
melanoma, where the Rac-GEF is mutated in 14% of cases (Berger et al., 2012), 
and in pancreatic ductal adenocarcinomas (PDACs; 10%) (Waddell et al., 2015). 
Both the deregulated expression and mutations of PREX2 were shown to promote 
tumour growth.  
In a follow up study, Lissanu Deribe and colleagues generated a genetically 
engineered conditional knockout mouse harbouring the Prex2E824* mutation in an 
iNRAS background and observed that the Prex2E824* mutation accelerated 
melanoma development compared to control mice (Lissanu Deribe et al., 2016). 
Biochemical analysis revealed that Prex2E824* contributes to melanoma 
tumorigenesis both through increased Rac1 GEF activity and abolished PTEN 
binding (Lissanu Deribe et al., 2016). Interestingly, a replication study of the Berger 
et al. 2012 paper that repeated the tumour xenografts experiments, where TERT-
immortalised human melanocytes engineered to express NRAS(G12D) (PMEL-
NRAS*) and PREX2G844D or PREX2Q1430* isoforms were transplanted into 
immunodeficient mice, failed to observe the accelerated in vivo tumorigenesis that 
had been originally reported. This was largely attributed to different rates in tumour 
development in control mice between the two studies (Horrigan et al., 2017).  
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1.10 Glucose Homeostasis 
Recent evidence suggests a role of PREX proteins in metabolic conditions. To date, 
however, there has been no detailed investigation into the importance of PREX 
proteins in glucose homeostasis and insulin signalling, or into the molecular 
mechanism underlying their involvement in these processes. The purpose of this 
project was to investigate the metabolic effects of Prex deficiency in mice. 
Therefore, the rest of this introduction is focused on the mechanisms that control 
glucose homeostasis, and what is known about the roles of Rho-GEFs, and PREX 
Rac-GEFs in particular, in metabolism. 
 
1.11 Systems of Glucose Homeostasis 
Glucose is an essential source of metabolic energy, required by most cells in 
the body. The brain accounts for approximately 50% of all glucose utilisation, 
another 25% of glucose is being used by organs of the splanchnic area such as the 
liver and the gastrointestinal tissue, and the remaining 25% of glucose uptake 
occurs in insulin-dependent tissues, like muscle and adipose tissue (Cersosimo et 
al., 2000). Glucose is provided either through release from endogenous glycogen 
stores, mainly the liver and kidneys, or through intestinal absorption of exogenous 
dietary glucose. Low blood glucose levels (hypoglycaemia) can trigger dizziness, 
seizures, and loss of consciousness, while profound and prolonged hypoglycaemia 
can result in death. In contrast, increased blood glucose levels (hyperglycaemia) 
can cause, among others, headache, blurred vision, and dehydration. Moreover, 
long-term hyperglycaemia has been associated with cardiovascular diseases, loss 
of vision, renal failure, and neuropathy. Hence, it is crucial to maintain the blood 
glucose within a relatively narrow range (Szablewski, 2011). 
Glucose homeostasis is defined as the process of maintaining stable glucose 
levels in the blood. Glucose homeostasis is mainly achieved by the balanced actions 
of insulin and glucagon, two pancreas-released hormones with antagonistic effects. 
However, various other organs such as the brain, liver, kidneys, intestine, skeletal 
muscle and adipose tissue also contribute to the tight regulation of blood glucose 
levels by means of uptake, metabolism, storage, and excretion (Röder et al., 2016; 
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Triplitt, 2012) (Figure 1.11.1). 
The mechanisms orchestrating the regulation of glucose homeostasis are 
considerably complex both at cellular and at systemic levels. The tight regulation of 
circulating glucose is a diverse process that requires the sophisticated coordination 
of many organs, which respond to multiple hormonal and physiological signals. 
Here, I will focus on summarising how insulin and glucagon regulate glucose 
disposal and production in various organs while also creating a system of inter-
organ metabolic communication (Figures 1.11.1 and 1.11.4). 
 
 
 
 
Figure 1.11.1: Maintenance of glucose homeostasis by insulin and glucagon. 
Food consumption results in increased glucose levels in the blood stream that in turn promote 
insulin release from the pancreas. Insulin stimulates glucose uptake from the adipose tissue and 
skeletal muscle, as well as glycogenesis in the liver, which coordinate to return the blood glucose 
to normal levels. In contrast, low blood glucose levels promote glucagon release from the pancreas 
that increases blood glucose levels through glycogenolysis and gluconeogenesis in the liver. 
(Figure adapted from (Röder et al., 2016)) 
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1.11.1 Pancreas 
The pancreas is an exocrine and endocrine organ with a central role in glucose 
homeostasis. Its exocrine function involves the secretion of various digestive 
enzymes into the upper small intestine through the pancreatic ducts. In contrast, the 
pancreatic endocrine cells (α-, β-, γ-, δ-, and ε-cells) are clustered together in the 
islets of Langerhans and release hormones directly into the blood stream. As 
mentioned above, glucagon and insulin have key roles in glucose homeostasis. 
Glucagon is produced in the pancreatic α-cells and stimulates glucose production 
and release from the liver, when blood glucose levels are low during sleep or in 
between meals. On the other hand, insulin is produced in β-cells and is released 
when blood glucose levels are elevated, following a meal. Insulin promotes glucose 
uptake by adipose tissue and skeletal muscle, as well as glycogen formation in the 
liver (Röder et al., 2016; Triplitt, 2012). 
However, the pancreas is not involved in glucose homeostasis only by 
coordinating the metabolic status of other organs. The existence of an islet-acinar 
axis has been proposed which underlines the communication of the endocrine and 
exocrine parts of the pancreas (Barreto et al., 2010; Pierzynowski et al., 2018). One 
such example is the regulation of pancreatic amylase, a digestive enzyme released 
from the exocrine pancreas under feeding conditions to promote digestion. 
Postprandial increased glucose levels lead to insulin release, which was found to 
regulate the production of amylase (Kanno and Saito, 1976; Trimble et al., 1986). 
Inversely, intravenous amylase infusion in pig was found to decrease insulin levels 
during postprandial hyperglycaemia (Pierzynowska et al., 2018). Moreover, there 
are evidence suggesting an intra-islet communication. Work on α-cell-specific 
insulin receptor conditional knockout mouse has shown that insulin inhibits glucagon 
secretion in vivo (Kawamori et al., 2009). In contrast, glucagon was found to 
stimulate insulin secretion, thus preventing uncontrolled increase of glucose levels 
(Song et al., 2017) (Figure 1.11.4). 
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1.11.2 Liver 
Glycogen is a multibranched glucose polysaccharide that serves as a form of energy 
storage. Liver and skeletal muscle are the major sites for glycogen storage. 
However, while skeletal muscle mainly uses glycogen for energy purposes, the liver 
is able to accumulate glycogen or release glucose according to blood glucose 
availability. Hence, the liver is an important organ in systemic glucose homeostasis. 
In the case of reduced blood glucose levels, pancreatic-released glucagon 
binds to the glucagon receptor (GCGR), a GPCR on the surface of hepatocytes and 
activates the adenylate cyclase (AC) that in turn increases the amount of 
intracellular cyclic adenosine monophosphate (cAMP). The increased cAMP levels 
stimulate PKA to inhibit glycogen synthesis (glycolysis and glycogenesis) while 
promoting glycogen breakdown and glucose release 
(glycogenolysis/gluconeogenesis) (Röder et al., 2016) (Figure 1.11.2). 
 
 
 
Figure 1.11.2: Regulation of glycogen metabolism in the liver.  
When blood glucose levels are low, glucagon signals through GCGR to induce cAMP-dependent 
signalling cascades, which result in the activation of glycogen phosphorylase and therefore 
promote glycogenolysis. Through the same pathway, glucagon also inhibits glycogenesis. 
Conversely, high blood glucose levels trigger insulin-mediated signalling in the liver, resulting in 
the activation of the PI3K/Akt pathway and also PP1. In this way, insulin promotes increased 
glucose uptake into the liver cells and glycogen synthesis, while also inhibiting glycogen 
breakdown. (Figure adapted from (Han et al., 2016)) 
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During glycogenolysis, PKA activates the glycogen phosphorylase kinase 
(PhK) (Ramachandran et al., 1987), which afterwards activates the glycogen 
phosphorylase, an enzyme that causes phosphoroclastic cleavage into glycogen to 
produce glucose-1-phosphate (G1P). Finally, G1P is converted by 
phosphoglucomutase (PGM) to glucose-6-phosphate (G6P) which in turn is 
hydrolysed by the glucose-6-phosphatase (G6Pase) to a phosphate residue and 
free glucose. Meanwhile, PKA also inhibits the enzyme glycogen synthase by 
phosphorylating it, which catalyses the production of glycogen from G1P (Feher, 
2017; Koren and Palladino, 2016; Proud et al., 1977) (Figure 1.11.2). 
Upon depletion of glycogen stores, the liver turns to gluconeogenesis to meet 
glucose demands. Gluconeogenesis is the process of synthesis of new glucose from 
lactate, pyruvate and amino acids. PKA was found to promote gluconeogenesis at 
multiple levels. PKA stimulates the phosphatase activity of the bifunctional enzyme 
phosphofructokinase-2/fructose bisphosphatase-2 (PFK-2/FBPase-2) which in turn 
reduces the levels of fructose-2,6-bisphosphate (Fru-2,6-BP), resulting in the 
activation of fructose-1,6-bisphosphatase 1 (FBPase-1) and promotion of G6P 
production. In addition, the PKA-mediated activation of FBPase-2 suppresses 
glycolysis (Pilkis et al., 1982; Rider et al., 2004). PKA is also involved in 
gluconeogenesis at a transcriptional level by phosphorylating the cAMP response 
element binding protein (CREB). CREB induces the expression of the transcriptional 
PPARγ coactivator-1α (PGC1α) and together potentiate the expression of the rate-
limiting gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and 
G6Pase (Herzig et al., 2001). Finally, PKA promotes the nuclear localisation of 
another CREB coactivator, the cAMP-regulated transcriptional coactivator 2 
(CRTC2). PKA stimulates the nuclear translocation of CRTC2 by dephosphorylation 
through the inositol-1,4,5-trisphosphate receptor (IP3R)/calcium-calcineurin (CaN) 
pathway. Simultaneously, PKA further promotes the nuclear translocation of CRTC2 
by phosphorylation of the salt-inducible kinase (SIK2), a negative regulator of 
CRTC2 (Altarejos et al., 2011; Wang et al., 2012) (Figure 1.11.3). 
Under feeding conditions, blood glucose is taken up in the liver via the 
glucose transporter-2 (GLUT2), in an insulin-independent manner. The absorbed 
glucose is initially converted into glucose 6-phosphate, which in turn is mainly used 
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to either meet the energy needs of the liver or to produce glycogen (glycogenesis). 
Excess glucose 6-phosphate is utilised to form fatty acids, cholesterol, and bile salts 
(Berg JM, 2002). Insulin-dependent glycogenesis is promoted by the PI3K-Akt-
mediated inactivation of the glycogen synthase kinase-3 (GSK3). This results in the 
activation of glycogen synthase, an enzyme that catalyses the formation and 
storage of glycogen (Akpan et al., 1974; Miller and Larner, 1973). Moreover, insulin 
regulates glycogen metabolism by activating PP1. PP1 acts both to promote 
glycogen synthesis by activation of glycogen synthase and to inhibit glycogen 
breakdown by the inactivation of the glycogen phosphorylase kinase and glycogen 
phosphorylase (Bollen et al., 1983a; Bollen et al., 1983b; Ceulemans and Bollen, 
2004) (Figure 1.11.2). In addition, insulin was found to mediate the activation of the 
liver-type pyruvate kinase (L-PK), a rate-limiting enzyme in the glycolysis pathway 
that converts phosphoenolpyruvate (PEP) into pyruvate (Guo et al., 2012). Insulin 
and glucose, in an additive or synergistic manner, further promote glycolysis through 
PFK-2/FBPase-2 de-phosphorylation, which increases the kinase activity of PFK-2, 
leading to increased levels of fructose-2,6-bisphosphate (Fructose 2,6-BP) and 
elevated phosphofructo-1-kinase (PFK-1) activity (Guo et al., 2012). Finally, insulin 
signalling also leads to SIK2 kinase activation, thus promoting CRTC2 
phosphorylation and nuclear exclusion. At the same time, upon insulin stimulation, 
Akt directly phosphorylates critical residues of the transcription factor FoxO1, turning 
off the transcription of hepatic gluconeogenesis (Oh et al., 2013) (Figure 1.11.3). 
More recently, it was shown that the role of the liver in glucose homeostasis 
is not limited to the control of various pathways of glucose metabolism; it also 
contributes in the regulation of pancreas secretion. For instance, blocking of 
glucagon signalling to the liver results in elevated levels of circulating amino acids, 
especially L-glutamine, which in turn promote mouse and human pancreatic α-cell 
proliferation (Dean et al., 2017) (Figure 1.11.4). 
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Figure 1.11.3: Regulation of hepatic gluconeogenesis. 
Under fasting conditions, glucagon binding to GCGR promotes the activation of PKA, which in 
turn phosphorylates the serine 32 of the bifunctional enzyme PFK-2/FBPase-2, hence decreasing 
its kinase activity (PFK-2) and increasing its phosphatase activity (FBPase-2). Consequently, the 
levels of Fructose 2,6-BP are decreased, leading to reduction of PFK-1 activity and elevation of 
FBPase-1 activity. This results in a decrease in the rate of glycolysis and an increase in 
gluconeogenesis. At a transcriptional level, PKA also activates the transcription factor CREB. In 
addition, PKA promotes de-phosphorylation of CRTC2 by inactivating SIK2 kinase, leading to the 
nuclear localization and increased association of CRTC2 with chromatin-bound CREB. These 
events lead to the increased expression of gluconeogenic genes such as PEPCK and G6Pase, 
leading to the increases in hepatic gluconeogenesis during the early phase of fasting. At the same 
time, CREB/CRTC2 can enhance the expression of PGC1α, which is a key transcriptional 
regulators of hepatic gluconeogenesis during the later phase of fasting. 
Under feeding conditions, the increased glucose levels lead to increased insulin release from 
the pancreas and insulin signalling in the liver. Glucose is taken up by the liver cells through the 
glucose transporter GLUT2, largely in an insulin-independent manner. Glucose signalling 
activates PP2A, while insulin signalling activates the pyruvate kinase (PK). In an additive or 
synergistic manner, glucose and insulin promote the de-phosphorylation (serine 32) of 
PFK2/FBPase2, hence increasing the kinase activity of PFK-2 and decreasing the phosphatase 
activity of FBPase-2. Consequently, the levels of Fructose 2,6-BP increase, leading to the 
elevation of PFK-1 activity and reduction of FBPase-1 activity. This results in an increase in the 
rate of glycolysis and decrease in gluconeogenesis. Insulin signalling also leads to the activation 
of SIK2 kinase, via Akt, thus promoting increased phosphorylation of CRTC2. At the same time, 
Akt directly phosphorylates critical residues of the transcription factor FoxO1, turning off the 
transcription of hepatic gluconeogenesis. (Figure adapted from (Guo et al., 2012; Liu and Zhang, 
2018; Oh et al., 2013)) 
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1.11.3 Skeletal Muscle 
The skeletal muscle is another tissue with a central role in glucose homeostasis. In 
humans, it accounts for 85% of the total glucose uptake. As mentioned before, 
skeletal muscle, alongside liver, is a major site for glycogen storage. However, 
contrary to liver, insulin-stimulated glucose uptake in skeletal muscle is solely for 
local energy consumption. As skeletal muscle does not express the enzyme 
G6Pase, hence it cannot release glucose back into the blood stream. Instead, 
glycogen is readily converted into glucose 6-phosphate, which is used as a local 
energy source, especially during exercise (Berg JM, 2002; Carnagarin et al., 2015).  
Following glucose ingestion, insulin stimulates skeletal muscle glucose 
uptake by promoting the translocation of the glucose transporter-4 (GLUT4) from 
intracellular vesicles to the plasma membrane (Bryant et al., 2002). Furthermore, 
insulin enhances glucose storage as glycogen. Insulin has been shown to stimulate 
the activation of glycogen synthase via the PI3K-Akt-mediated inactivation of GSK3. 
Inhibition of GSK3 through phosphorylation results in the dephosphorylation of 
glycogen synthase, which increases the enzyme’s affinity for G6P and promotes full 
activation (Bouskila et al., 2010). 
Apart from insulin, physical activity can also stimulate the AMP-activated 
protein kinase (AMPK)-mediated translocation of GLUT4 to the cell surface (Richter 
and Hargreaves, 2013). Moreover, exercise increases skeletal muscle insulin 
sensitivity and enhances glycemic control (Kjøbsted et al., 2017; Sjøberg et al., 
2017). Correspondingly, physical inactivity has been shown to promote the 
development of insulin resistance, initially through reduced skeletal muscle insulin 
sensitivity (Hamburg et al., 2007; Krogh-Madsen et al., 2010). 
Secretion of cytokines from contracting skeletal muscle (myokines) has been 
found to affect the function and physiology of the skeletal muscle itself but also of 
other organs, contributing further to the systemic glucose homeostasis. For 
instance, skeletal muscle derived interleukin-6 (IL-6) has been associated with 
improved glucose homeostasis during exercise in humans (Febbraio et al., 2004). 
Through a mechanism that remains unclear, contracting skeletal muscle promotes 
hepatic glucose production via IL-6 stimulation. Moreover, IL-6 may also increase 
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whole body glucose disposal independently of glucose production (Febbraio et al., 
2004). Finally, exercise related IL-6 secretion has been involved in the activation of 
AMPK in the adipose tissue (Kelly et al., 2004). Taken together these findings show 
that skeletal muscle is able to modulate systemic glucose homeostasis and insulin 
sensitivity. 
1.11.4 Adipose Tissue  
Adipose tissue has a profound effect on energy balance and glucose homeostasis. 
Although it only accounts for 2-5% of total glucose uptake, adipose tissue regulates 
lipid metabolism and influences insulin sensitivity in the liver and skeletal muscle via 
hormone secretion. 
In the postprandial phase, insulin stimulation of adipocytes promotes GLUT4 
translocation from the cytoplasm to the cell surface. Despite the relatively small 
contribution of adipose tissue to glucose clearance, selective GLUT4 deletion in 
adipose tissue results in glucose intolerance and insulin resistance in mice (Abel et 
al., 2001). In contrast, overexpression of GLUT4 in adipose tissue can reverse 
fasting hyperglycemia and enhance whole body glucose clearance and insulin 
sensitivity in skeletal muscle GLUT4 knockout mice (Carvalho et al., 2005). These 
findings highlight the important role of GLUT4-mediated glucose uptake in 
adipocytes to systemic glucose homeostasis. 
Moreover, insulin can regulate lipolysis in adipocytes directly via PI3K-
dependent activation of the phosphodiesterase 3B (PDE3B), which in turn inhibits 
cAMP/PKA signalling via increased cAMP degradation. cAMP inactivation was 
shown to facilitate the inhibition of the adipose triglyceride lipase (ATGL), a rate-
limiting enzyme of lipolysis, and the hormone-sensitive lipase (HSL), a neutral lipase 
that in the lipid droplet acts mainly as a diglyceride lipase (Choi et al., 2010). In 
addition, insulin supresses lipolysis indirectly through the lactate/ G protein–coupled 
receptor GPR81-dependent inhibition of cAMP. Work in GPR81 deficient mice has 
revealed that insulin-induced glucose uptake results in the production and release 
of lactate from adipocytes. This lactate then activates the adipocyte specific receptor 
GPR81 that in turn inhibits adenylyl cyclase, the enzyme which catalyses the 
cyclisation of adenosine triphosphate (ATP) into cAMP (Ahmed et al., 2010). 
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The contribution of adipose tissue to glucose homeostasis is not limited to 
glucose uptake and energy storage. Adipocytes also have a considerable effect on 
glycaemic control by secreting various factors, such as adipokines, that enable the 
communication of adipose tissue with other organs. One such adipokine is 
adiponectin, the most abundant adipose derived hormone in the plasma. 
Adiponectin was found to mainly stimulate liver insulin sensitivity. Moreover, 
adiponectin has been implicated in the promotion of β-cell survival and function 
while also stimulating insulin gene expression and release (Holland et al., 2011; 
Wijesekara et al., 2010) (Figure 1.11.4). Likewise, insulin stimulates both leptin 
biosynthesis and secretion from adipose tissue (Barr et al., 1997). Leptin serves as 
a major regulator of systemic glucose homeostasis by repressing food intake and 
increasing energy expenditure (Schwartz et al., 2000). In addition, leptin improves 
peripheral insulin sensitivity and modulates pancreatic β-cell function (D'Souza et 
al., 2017; Kieffer and Habener, 2000) (Figure 1.11.4). Finally, omentin-1 and visfatin 
are two more adipokines known to be regulated by insulin and by glucose levels that 
act as modulators of insulin expression and function (Brown et al., 2010; Haider et 
al., 2006; Tan et al., 2008; Yang et al., 2006). However, many more adipocyte-
secreted proteins exist that demonstrate a variety of effects on glucose 
homeostasis. 
1.11.5 Intestine 
The gastrointestinal tract is an important player in the regulation of systemic glucose 
homeostasis in the postprandial phase. Starting from the stomach, the gastric 
emptying process ensures the steady delivery of nutrients and glucose into the 
duodenum. Afterwards, the digestion and absorption of nutrients from the small 
intestine stimulate the release of gastrointestinal peptide hormones (incretins) from 
the intestinal mucosa that can feed back to regulate subsequent gastric emptying 
as well as enhance hyperglycaemia-stimulated insulin release from the pancreas 
(Holst et al., 2016). Neatly, amylin, another pancreatic hormone that is co-secreted 
with insulin from β-cells, is involved in slowing down the rate of gastric emptying, 
while also regulating postprandial glucagon, and reducing food intake (Kiriyama and 
Nochi, 2018). 
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Among the best-characterised incretin hormones, glucose-dependent 
insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are most relevant 
to glucose homeostasis, through their involvement in the regulation of pancreatic 
hormone secretion. In response to nutrient absorption, K cells in the duodenum and 
proximal small intestine, as well as L cells in the jejunum, ileum, and colon produce 
and release GIP and GLP-1, respectively. Pancreatic β-cells have receptors for both 
GIP and GLP-1, which upon stimulation promote cAMP production and 
consequently PKA activation. Activation of this signalling pathway acts additively to 
signalling pathways stimulated by hyperglycaemia to facilitate insulin release 
(Nauck et al., 2002; Nauck and Meier, 2018; Parker et al., 2010) (Figure 1.11.4). 
Moreover, GLP-1 and GIP have been implicated in the regulation of glucagon and 
somatostatin release (Figure 1.11.4). Interestingly, in this context GLP-1 and GIP 
have opposing effects. GIP promotes glucagon secretion under basal glucose levels 
(Meier et al., 2003), while GLP-1 suppresses it during hyperglycaemia (Nauck et al., 
1993). GLP-1 is also responsible for the reduction in appetite and food intake 
(Turton et al., 1996), influencing therefore the size of adipose tissue stores. In 
addition, GLP-1 was shown to directly regulate adipogenesis, thus having an 
important role in peripheral insulin sensitivity (Challa et al., 2012; El Bekay et al., 
2016). Finally, insulin was found to promote GLP-1 secretion via Rho GTPase 
Cdc42-mediated activation of MEK/ERK1/2 pathway and actin remodelling (Lim et 
al., 2009). 
1.11.6 Central Nervous System 
The brain accounts for 60-70% of glucose utilisation in the resting state, since 
glucose is its only source of energy in the normal state. During prolonged starvation, 
only ketone bodies (not free fatty acids) can cross the blood-brain barrier and be 
partly used as an alternative fuel for the cells of the central nervous system. Despite 
its great need for energy, the brain does not store glucose and therefore relies on a 
continuous supply of glucose from the circulation (Berg JM, 2002). Consequently, 
glucose level monitoring and maintenance is of great importance for the brain. 
Specific subsets of hypothalamic neurons – as well as glial tanycytes and astrocytes 
– act as glucose sensors and are able to trigger counterregulatory responses during 
hypoglycaemia (Evans et al., 2004; Routh et al., 2014). The brain, similarly to the 
liver, does not require insulin for glucose uptake. It utilises the high affinity glucose 
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transporters GLUT1 and GLUT3 that allow efficient glucose uptake under normal 
glucose levels (Berg JM, 2002). 
Despite brain glucose uptake not being insulin dependent, insulin can cross 
the blood–brain barrier via insulin-receptor-mediated active transport, and insulin 
signalling has many important functions in the brain. Work on neural progenitor cells 
(NPCs) isolated from neonatal rat telencephalons showed that insulin induces 
neuronal differentiation via the PI3K-Akt-mTOR pathway (Han et al., 2008). 
Moreover, studies in mouse hippocampal slices demonstrated that insulin 
modulates basal synaptic transmission and synaptic plasticity in a dose-dependent 
manner (Zhao et al., 2019). In regards to glucose homeostasis, insulin has been 
identified as a major contributor to the regulation of food intake and systemic 
glucose homeostasis. Insulin signalling in orexigenic acting neuropeptide Y (NPY) 
neurons inhibits food intake and increases energy expenditure (Loh et al., 2017). 
Furthermore, through the PI3K signalling pathway, insulin suppresses the ability of 
ventromedial hypothalamus glucose‐excited neurons to sense physiological 
decreases in glucose (Cotero and Routh, 2009). Finally, insulin signalling in the 
hypothalamus has been associated, in mice and rats, with the inhibition of hepatic 
glucose production (Pocai et al., 2005), and with glucagon secretion from pancreatic 
α-cells (Paranjape et al., 2010) (Figure 1.11.4), as well as the promotion of 
lipogenesis in adipose tissue (Koch et al., 2008; Scherer et al., 2011) and glycogen 
synthesis in skeletal muscle (Perrin et al., 2004). 
Overall, these studies suggest that the brain, and especially the 
hypothalamus, modulates peripheral glucose metabolism via insulin signalling. 
However, insulin is not the only hormone that exerts its actions through the CNS in 
order to promote systemic glucose homeostasis. The brain receives a plethora of 
metabolic information from the peripheral organs and tissues through humoral and 
neuronal pathways, which enable it to orchestrate appropriate systemic responses. 
Pancreatic insulin and glucagon, adipose tissue-derived leptin, and intestinal GLP-
1 are only a few examples of hormones that exert CNS-dependent glucoregulatory 
effects. Glucagon, for instance, was found to signal through the mediobasal 
hypothalamus. Interestingly, central glucagon signalling inhibits hepatic glucose 
production, under glucagon-stimulated conditions, thus creating a self-regulatory 
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feedback loop that abates increased glucose production from raised peripheral 
glucagon concentrations (Mighiu et al., 2013). Moreover, the adipokine leptin binds 
receptors in the hypothalamus and stimulates multiple signalling cascades that 
modulate glucose homeostasis. For example, central leptin signalling has been 
associated with reduced food intake, improved hepatic metabolism and increased 
glucose uptake from the skeletal muscle (Friedman and Halaas, 1998; Fujikawa et 
al., 2013). Finally, the peptide hormone GLP-1 was shown to act through the vagal–
brainstem–hypothalamic pathway to suppress food intake (Abbott et al., 2005). 
Moreover, GLP-1 was found to increase glucose-stimulated insulin secretion and 
reduce hepatic glucose production probably via receptors in the arcuate nucleus of 
the hypothalamus (Sandoval et al., 2008). 
 
 
Figure 1.11.4: Neuronal and hormonal regulation of pancreatic hormone secretion. 
Glucose homeostasis requires the interaction of several organs. Neurotransmitters released from 
the brain play a central role in facilitating this inter-organ communication, for example by regulating 
the secretion of insulin and glucagon by the pancreas. Moreover, hormones secreted by the liver, 
intestine and adipose tissue are also important in modulating pancreatic function.  (Figure adapted 
from (Röder et al., 2016)) 
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1.11.7 Kidney 
The kidney is increasingly recognised as an important contributor to systemic 
glucose homeostasis. Similarly to the liver, the kidney expresses the enzyme 
G6Pase, mainly in the renal cortex cells, which enables it to release glucose into the 
blood stream. Although under normal conditions, kidney’s glucose release from the 
kidneys accounts only for a small portion of circulating glucose, during prolonged 
starvation, the contribution of the kidney may reach that of liver. This is due to the 
fact that all of the kidney-released glucose is the result of gluconeogenesis (Alsahli 
and Gerich, 2017). Gluconeogenesis was found to be suppressed, in the fed state, 
synergistically by activated insulin signalling on the basolateral side of the proximal 
tubules of the kidney and by increased glucose reabsorption through the sodium–
glucose cotransporter 2 (SGLT2) on the luminal side of the proximal tubules (Sasaki 
et al., 2017). 
Moreover, renal cells take up glucose to meet their own energy needs. 
Kidneys account for around 10% of the systemic glucose uptake, which is only in 
part directly insulin-dependent (Cersosimo et al., 1999; Meyer et al., 1998). 
However, targeted insulin receptor (IR) depletion from the proximal tubule, in mice, 
was found to result in increased fasting plasma glucose levels compared to wild type 
controls, suggesting that IR in proximal tubule has an important role in regulating 
systemic glucose levels (Tiwari et al., 2013). 
In addition, kidneys contribute to glucose homeostasis by reabsorbing 
glucose from glomerular filtrate or by excreting it into the urine when glucose levels 
exceed the tubular maximum glucose reabsorptive capacity (TmG). In healthy 
individuals, ∼180 g of D-glucose is filtered by the renal glomeruli per 24 h period. 
The ability of the proximal tubule to reabsorb glucose increases linearly with the 
increase in plasma glucose (Wilding, 2014). Interestingly, insulin receptor deficiency 
has been associated with renal glucosuria, in a mouse model of diet-induced 
obesity, hyperinsulinemia, and hyperaldosteronism through mineralocorticoid 
supplementation (Nizar et al., 2018). 
Finally, kidneys are an important site of insulin degradation, hence 
contributing to the regulation of its levels in the circulation (Tokarz et al., 2018). 
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Consequently, renal insulin degradation contributes to the regulation of systemic 
glucose homeostasis. 
 
1.12 Obesity, insulin resistance and Type 2 Diabetes 
Overweight and obesity are fast becoming leading risk factors of collective health 
worldwide. In Britain alone, 60% of adults are overweight and 26% are obese 
(Statistics, 2018). Obesity is closely linked with a large number of health conditions 
including type 2 diabetes mellitus (T2DM), heart disease, stroke and cancer (Pi-
Sunyer, 2009). Whereas type 1 diabetes (T1D)  is a metabolic disorder which is 
characterised by impaired insulin secretion and glucose metabolism (Atkinson et al., 
2014), T2DM develops in adulthood and starts from an insulin-resistant state which 
progresses to pancreatic β-cell failure (Muoio and Newgard, 2008). Long-term 
T2DM can cause heart and blood vessel disease, neuropathy, kidney and eye 
damage as well as Alzheimer’s disease.  
T2DM is a complex metabolic disease that results from the malfunction of 
many glucoseregulatory mechanisms, ultimately leading to hyperglycaemia. 
Aberrant insulin secretion and insulin resistance play a central role in the 
development of T2DM. One of the most prominent effects of insulin resistance is the 
decreased hepatic glucose uptake combined with increased hepatic glucose 
production. Moreover, adipose tissue insulin resistance promotes increased 
lipolysis that is subsequently associated with increased hepatic gluconeogenesis 
and impaired skeletal muscle insulin response. In addition, the excess of lipids in 
the bloodstream results in their accumulation in other organs, like pancreas, liver, 
and muscle, where they further augment the development of insulin resistance. As 
a response to the increasing systemic insulin resistance, pancreatic β-cells produce 
and secrete more insulin in order to compensate. Eventually insulin secretion 
reaches a maximum, β-cells become damaged and insulin secretion deteriorates 
leading to the development of T2DM. The defect of insulin secretion alongside α-
cell insulin resistance results in excessive glucagon secretion. Moreover, 
established T2DM has been associated with reduced responsiveness of insulin 
secretion to gastrointestinal hormones, further deteriorating glycaemic control. In 
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addition, T2DM was shown to result in hypothalamic insulin resistance and 
abolished central regulation of hepatic glucose production. Finally, diabetic patients 
were found to have increased renal release of glucose due to increased 
gluconeogenesis as well as enhanced glucose reabsorption from glomerular filtrate, 
which enables further the development and maintenance of hyperglycaemia (Alsahli 
and Gerich, 2017; Cersosimo et al., 2000; Esterson et al., 2016; Girard, 2017; Nauck 
and Meier, 2018; Petersen and Shulman, 2018) (Figure 1.12.1). 
 
 
 
 
 
 
Figure 1.12.1: Pathophysiology of hyperglycaemia in type 2 diabetes 
The main defects in T2DM include impaired insulin secretion by the pancreatic β-cells, and insulin 
resistance in muscle and liver, which leads decreased glucose uptake. Combination of decreased 
insulin secretion – due to β-cell resistance to the gastrointestinal hormone GLP-1 alongside β-cell 
failure – and increased glucagon levels result in excessive glucose production in the liver and the 
kidneys. Insulin resistance in adipose tissue enhances lipolysis and increases plasma FFA levels, 
both of which aggravate the insulin resistance in muscle and the liver and further deteriorate to β-
cell function. Hypothalamic insulin resistance abolishes central regulation of hepatic glucose 
production and contributes to weight gain, exacerbating the insulin resistance. Finally, enhanced 
renal glucose reabsorption alongside the increased gluconeogenesis further augment the 
development and maintenance of hyperglycaemia. 
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Low-grade systemic inflammation is another underlying characteristic of 
obesity that can contribute to the pathogenesis of obesity-related metabolic 
disorders, by promoting insulin resistance and β-cell death. Excess of nutrients has 
been identified as the main drive of systemic inflammation. Free fatty acids (FFAs), 
alongside the hyperglycaemia, lead to stimulation of oxidative pathways ultimately 
resulting in mitochondrial dysfunction, increased ROS formation, and oxidative 
stress. Nutrient excess also triggers endoplasmic reticulum (ER) stress and 
unfolded-protein response (UPR). Under these conditions, transcription factors such 
as the nuclear factor-kappa-B (NF-κB) are activated, leading to the production and 
secretion of pro-inflammatory cytokines like TNF-α and IL-6, finally resulting to the 
establishment of inflammation (Gerst et al., 2019; Hotamisligil and Erbay, 2008; van 
Greevenbroek et al., 2013). 
The increased adipose tissue mass observed in obesity is involved in the 
establishment of insulin resistance, by promoting a chronic activation of the innate 
immune system. Lean adipose tissue is populated by M2-anti-inflammatory 
macrophages and CD4+ regulatory T-cells which promote the production and 
secretion of anti-inflammatory adipokines such as adiponectin and interleukin 10 (IL-
10). As adipose tissue expands, poor vascularisation results in the generation of 
hypoxic signals, which induce angiogenesis and trigger inflammation. Adipose 
tissue hypoxia stimulates the transcription factor NF-κB that promote the secretion 
of pro-inflammatory cytokines, while also reducing the secretion of anti-inflammatory 
adipokines. Moreover, adipose tissue hypoxia promotes the infiltration of CD8+ 
cytotoxic T cells and the conversion of macrophages to an M1 pro-inflammatory 
phenotype, which also secrete pro-inflammatory cytokines hence promoting the 
infiltration of additional macrophages from the circulation (Keane et al., 2017; van 
Greevenbroek et al., 2013; Ye, 2009).  
Similarly, consumption of a high fat diet was shown to promote the conversion 
of hepatic macrophages, Kupffer cells, towards the M1 phenotype, which promotes 
the development of obesity-induced insulin resistance and fatty liver disease. TNF-
α production by M1 Kupffer cells in the liver increases blood glucose levels by 
promoting hepatic gluconeogenesis and glycogenolysis. Moreover, TNF-α signalling 
inhibits intracellular lipases and provides intracellular fatty acids for triacylglycerol 
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synthesis, which enhances lipid production and storage in the liver, thus promoting 
fatty liver disease (Esser et al., 2014; Keane et al., 2015). 
Overall, chronically elevated levels of IL-6 and TNF-α promote insulin 
resistance through the activation of serine kinases which suppress the IR mediated 
phosphorylation of insulin receptor substrate-1 (IRS1), an important effector in the 
insulin signalling pathway. TNF-α signalling leads to the activation of the inhibitor of 
nuclear factor κ-Β kinase-β (IKKβ) and c-Jun N-terminal protein kinase (JNK) both 
of which inhibit IRS1. Similarly, IL-6 activates the signal transducer and activator of 
transcription 3 (STAT3) transcription factor, which drives the expression of 
suppressor of cytokine signalling 3 (SOCS3), a negative regulator of IL-6 signalling 
that also inhibits IRS1 (Kern et al., 2018). 
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1.13 Insulin Signalling Pathway in Glucose 
Homeostasis 
As discussed above, insulin is a peptide hormone released from pancreatic β-cells 
in response to elevated glucose levels in the blood, following a meal, and controls 
critical energy functions such as glucose and lipid metabolism. 
1.13.1 Signal Initiation  
Insulin signals by activating the intrinsic tyrosine kinase of the IR, a tetrameric 
protein that consists of two α- and two β- subunits linked by disulphide bonds. The 
α-subunits are extracellular and contain the insulin-binding domain, whereas the β-
subunits are transmembrane and act as a tyrosine kinase. In the inactive state, the 
α-subunits inhibit the β-subunits’ kinase activity. Upon insulin binding, 
conformational changes in the extracellular domains promote the 
transphosphorylation of the β-subunits, allowing subsequent activation of the 
receptor’s tyrosine kinase activity. Following insulin stimulation, the tyrosine kinase 
subunits of the IR phosphorylate key tyrosine residues on at least nine intracellular 
substrates. Out of these identified IR substrates, four are members of the family of 
insulin/IGF-1 receptor substrate (IRS) proteins (IRS1 to IRS4) while the others are: 
Casitas B-lineage lymphoma (Cbl), adapter protein with a PH and SH2 domain 
(APS), Grb2-associated-binding protein (Gab-1), 60-kDa tyrosine phosphorylated 
protein (p60Dok), and isoforms of the SH2-domain containing proteins (Shc). Once 
phosphorylated the IRS proteins serve as recognition sites for proteins containing 
Src-homology 2 (SH2) domain such as PI3K and growth factor receptor-bound 
protein 2 (Grb2) (Saltiel and Kahn, 2001).  
1.13.2 PI3K Pathway 
Class IA PI3K consists of a p110 catalytic subunit in complex with a p85 regulatory 
subunit, which maintains the heterodimer in an inactive state in the cytosol. PI3Kα 
has mostly been implicated in insulin signalling and metabolic regulation. Upon 
recruitment to the plasma membrane and activation, PI3K produces the lipid second 
messenger PIP3 by phosphorylation of the phosphatidylinositide 4,5-bisphosphate 
(PtdIns(4,5)P2, PIP2). PIP3 recruits and activates a number of downstream effector 
proteins, by binding to their PH domain, including phosphoinositide-dependent 
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protein kinase 1 (PDK1). In turn, PDK1 phosphorylates serine/threonine protein 
kinase B (PKB/Akt) on T308 and PKCλ/ζ on T410. For the complete activation of 
Akt, phosphorylation of S473, mediated by mTORC2, is also required. Several 
substrates have been identified for Akt, implicating it in a plethora of cellular 
functions including cell survival, cell cycle progression, metabolism, transcription, 
protein synthesis, and apoptosis. There are three Akt isoforms (Akt1, 2, 3) of which 
Akt1 and Akt2 are ubiquitously expressed, but Akt2 shows an enrichment in insulin 
sensitive tissues such as liver, skeletal muscle and pancreas (Bilanges et al., 2019; 
Escribano et al., 2017; Saltiel, 2016) (Figure 1.13.1). 
 
 
 
 
Figure 1.13.1: PI3K/Akt pathway initiation 
Class PI3Ks are activated by cell surface receptors and phosphorylate the PtdIns(4,5)P2 (PIP2) to 
generate PtdIns(3,4,5)P3 (PIP3). PIP3 promotes the translocation of PDK1 and Akt to the plasma 
membrane, through their PH domains. At the membrane, PDK1 phosphorylates Akt on Thr308. 
Additional phosphorylation of Akt on Ser473 by mTORC2 leads to its full activation. In turn, 
activated Akt phosphorylates many downstream protein targets, hence modulating a plethora of 
signalling pathways involved in cell growth, proliferation, survival, autophagy, and metabolism. 
The inositol phosphatases SHIP2 and PTEN hydrolyse PIP3 back to PI(3,4)P2 (PIP2) or 
PtdIns(4,5)P2, respectively. Thus, they limit the cellular pool of second messenger PIP3 and tightly 
regulate the downstream pathways. 
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1.13.2.1 Metabolic Effects of the PI3K Pathway 
A central effect of insulin on glucose homeostasis is its ability to promote glucose 
uptake in skeletal muscle and in adipose tissue. Insulin-dependent Akt activation 
results in GLUT4 storage vesicle (GSV) exocytosis through the phosphorylation and 
inactivation of two GAP proteins, AS160 and the RAL GAP complex (RGC). In turn, 
these GAPs regulate small GTPases such as Rab8, Rab10, Rab14, and RalA, 
which are involved in the trafficking of the glucose transporter GLUT4 from 
intracellular GSVs to the plasma membrane, thus allowing glucose to be transported 
into the cell (Leto and Saltiel, 2012). In addition to stimulating glucose uptake, insulin 
enhances glycogenesis in the liver and in skeletal muscle, and inhibits 
gluconeogenesis in the liver and kidneys. Insulin achieves these effects by directly 
regulating the expression of key metabolic enzymes, as well as controlling their 
phosphorylation state and hence their activity. Activated Akt was found to 
phosphorylate GSK3 and, at least in part, to contribute to the dephosphorylation of 
the enzyme glycogen synthase, thus promoting glycogen accumulation (Cross et 
al., 1995). Moreover, Akt-mediated phosphorylation of the Forkhead box class O 1 
(FoxO1) transcription factor results in its nuclear exclusion, which subsequently 
decreases the transcription of the gluconeogenic enzymes G6Pase and PEPCK (Oh 
et al., 2013). Insulin also acts on the hypothalamus to suppress food intake. Akt 
signalling to FoxO1 suppresses food intake by transcriptional inhibition of the 
orexigenic peptides NPY and agouti-related peptide (AgRP) (Kim et al., 2006). 
Moreover, hypothalamic mTORC1 and p70 ribosomal S6 kinase (p70S6K) 
signalling also blocks NPY and AgRP production (Cota et al., 2006)(Figure 1.13.2). 
As mentioned above, in addition to the IRSs, insulin receptors also 
phosphorylate other substrates. One such substrate is the adapter protein APS. 
Upon phosphorylation, APS is recruiting to the IR a protein complex consisting of 
the Cbl protooncogene product and the adapter protein CAP, thus facilitating the 
phosphorylation of Cbl by the IR. Subsequently, the Cbl/CAP complex moves into 
lipid rafts on the cell surface, guided by the interaction of CAP with the caveolar 
protein flotillin. There, Cbl recruits the adaptor protein CrkII in complex with the GEF 
C3G, resulting in the activation of TC10, a lipid raft-associated Rho family small 
GTPase that has been implicated in both insulin-dependent and osmotic shock-
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induced GLUT4 translocation and glucose uptake (Baumann et al., 2000; Leto and 
Saltiel, 2012) (Figure 1.13.2). 
The small GTPase Rac1 was also implicated in the insulin-stimulated 
translocation of GLUT4 transporter to the plasma membrane of skeletal muscle. 
Cytoskeletal remodelling is an important step for the transport of GSVs within the 
cytoplasm and for their retention beneath the plasma membrane. Rac1, as major 
regulator of actin rearrangement, has been associated with the GLUT4 translocation 
downstream of insulin signalling in L6 myotubes (JeBailey et al., 2004; Khayat et 
al., 2000) and in skeletal muscle (Sylow et al., 2013; Sylow et al., 2014). The 
mechanism still remains unclear but is likely to include the activation of Rac1 
through Rac-GEFs that are known to signal within the insulin pathway, such as 
PREX1 and FLJ00068. Upon activation, Rac1 activates the WAVE protein, which in 
turn promotes the actin related protein-2/3 (Arp2/3) complex to generate branching 
networks of filaments and facilitate GSV movement to the plasma membrane (Chiu 
et al., 2010). Moreover, Rac1 stimulates the serine/threonine kinase PAK1, which 
inhibits the cofilin-mediated actin filament severing by promoting the function of LIM 
kinase (LIMK1/2) (Sylow et al., 2013; Tunduguru et al., 2014). More recently, it was 
also proposed that Rac1 can act as a downstream effector of Akt2 to regulate 
GLUT4 translocation through the small G protein RalA, a component of the GSV 
that interacts with the exocyst subunit Sec5 and the motor protein Myo1c (Takenaka 
et al., 2019). 
1.13.3 Ras-MAPK Pathway 
In addition to the PI3K pathway, insulin activation of the IR also stimulates the Ras-
MAPK pathway, through the interaction of phosphorylated IRSs or Shc with the 
adaptor protein Grb2. Subsequently Grb2 recruits to the plasma membrane and 
activates the GEF SOS, which leads to the activation of the small GTPase Ras. Full 
Ras activation also requires stimulation from the protein Src homology region 2 
domain-containing tyrosine phosphatase-2 (SHP2, also known as PTPN11), which 
also interacts with IRS proteins such as Gab-1 and IRS1/2. Upon activation, Ras 
triggers a signalling cascade that involves the stepwise activation of Raf, MEK1/2 
and ERK1/2. Activated MAPK/ERK proteins can translocate into the nucleus to 
modulate gene expression of various proteins that promote cell proliferation 
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(Escribano et al., 2017; Saltiel, 2016). Finally, Ras is also a direct activator of class 
1 PI3Ks, so this arm of the insulin pathway also feeds into PI3K signalling. 
1.13.4 Inactivation of Insulin Pathway 
Maintenance of glucose homeostasis requires the rapid activation and inactivation 
of the insulin pathway; therefore, the IR and its downstream effectors are subject to 
multiple regulatory controls. Once insulin dissociates from the receptor, the IR is 
dephosphorylated and inhibited by the protein tyrosine phosphatase 1B (PTP1B). 
Inversely, hydrogen peroxide produced through the IR signalling pathway inhibits 
PTP1B. Moreover, the activity of another IR inhibitor, the adaptor protein Grb10 that 
acts as a pseudo-substrate and obstructs IRS binding and activation, was shown to 
be enhanced through phosphorylation by mTORC1. Similarly, some members of the 
SOCS family attenuate insulin signalling by binding to the IR and obstructing its 
ability to bind and activate IRS. In addition to their inhibitory effect on the IR, SOCS 
proteins recruit a ubiquitin ligase, which targets IRS for proteasomal degradation. 
More recently, it has been proposed that the SHP2-MAPK pathway promotes IR 
endocytosis and thus creates a negative feedback regulation of insulin signalling 
(Choi et al., 2019). 
The insulin pathway undergoes regulation also at the IRS level. In response 
to insulin, a number of serine/threonine kinases have been found to phosphorylate 
serine residues of IRS proteins. This leads to the inhibition of IRS activity by 
decreasing their activating tyrosine phosphorylation. An example of such inhibitory 
feedback loop is the phosphorylation of IRS1 by mTORC1 and p70S6K. Other 
stimuli also activate serine kinases in insulin-sensitive cells. Pro-inflammatory 
cytokines and free fatty acids, for instance, activate JNK1 that also inhibits IRS1.  
Insulin signalling inhibition also extends to downstream effectors. For instance, 
PTEN and the Src homology 2 domain-containing inositol-5-phosphatase 2 (SHIP2) 
facilitate the degradation of PIP3 (Fukui et al., 2005; Ogg and Ruvkun, 1998). 
Furthermore, the putative protein kinase tribbles homolog 3 (TRB3) and protein 
phosphatase 2A (PP2A) inhibit insulin signalling by deactivation of Akt (Du et al., 
2003; Ugi et al., 2004).  
56 | P a g e  
 
 
Figure 1.13.2: Insulin signalling pathway in glucose homeostasis 
Schematic illustration of insulin signalling pathway involvement in glucose homeostasis. Insulin 
binding to the insulin receptor (IR) leads to conformational changes in the receptor that enable 
autophosphorylation, which in turn augments its intrinsic tyrosine kinase activity. Upon receptor 
activation, the next step in the signal transduction is the phosphorylation of insulin receptor 
substrate (IRS) proteins that facilitate the docking, apposition, interaction, and activation of other 
downstream effectors. Different IRS propagate the activation of different signal transduction 
pathways such as the metabolic PI3K and CAP/Cbl/TC10 pathways and the mitogenic Ras/MAPK 
pathway. The insulin signalling pathway is subject to an extensive array of inhibitory mechanisms 
that safeguard its physiological dynamic functioning. 
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1.14 Role of Rho-GEFs in Glucose Homeostasis and 
Diabetes 
Rho-GEFs have a key role in the regulation of glucose homeostasis. It was found 
that deficiency of the Rho-GEF Vav3, in mice, results in the development of 
metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and T2DM, but not 
increased adiposity under chow diet. By contrast, Vav3 knockout also protected 
from obesity and metabolic syndrome in mice on high fat diet (HFD) (Menacho-
Márquez et al., 2013). It was shown that depletion of Vav3 resulted in a diet-
dependent abnormal regulation of the sympathetic nervous system, leading to 
enhanced trans-differentiation of white adipose tissue (WAT) into brown adipose 
tissue (BAT) (Menacho-Márquez et al., 2013). In a recent review from the same lab, 
it was reported that Vav2 is also important regulator of insulin signalling in skeletal 
muscle. Mice expressing catalytically inactive Vav2 were reported to exhibit reduced 
skeletal muscle mass and insulin sensitivity resulting in the development of a 
metabolic syndrome-like condition. The inversed phenotype was observed in mice 
expressing a catalytically hyperactive Vav2 (unpublished manuscript, findings 
reported in this review by the authors (Rodríguez-Fdez and Bustelo, 2019)). 
Moreover, experiments in the rat insulinoma cell line (INS-1 832/13) and primary 
rodent islets demonstrated that Vav2 is involved in the glucose-stimulated insulin 
secretion from pancreatic β-cells. Vav2 was found to facilitate glucose-stimulated 
Rac1 activation, thus promoting F-actin depolymerisation and insulin secretion 
(Veluthakal et al., 2015). 
 In addition, the Rac1-GEF Tiam1 was identified as a mediator of metformin-
induced glucose uptake (You et al., 2013). Metformin is a medicine used to treat 
type 2 diabetes, particularly in obese patients, which promotes normal insulin 
responses, decreases liver glucose production and release, and reduces glucose 
absorbance by the intestines. Experiments in the mouse skeletal muscle cell line 
C2C12 showed that Tiam1 is required for metformin-mediated GLUT4 translocation 
to the plasma membrane (You et al., 2013). It was suggested that metformin 
signalling stimulates the formation of an AMPK2/14-3-3/Tiam1 complex that could 
influence Rac1 activation and hence modulate actin cytoskeletal dynamics and 
GLUT4 trafficking (You et al., 2013).  
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 The PDZ-RhoGEF, which specifically activates the RhoA small GTPase was 
also implicated in glucose homeostasis. PDZ-RhoGEF deficiency in mice resulted 
in reduced body weight and fat mass, as well as in increased energy expenditure. 
In addition, depletion of PDZ-RhoGEF protected mice from diet-dependent 
development of obesity and T2DM (Chang et al., 2015). It was proposed that under 
normal dietary conditions, PDZ-RhoGEF supports insulin signalling in WAT through 
the regulation of ROCK-dependent phosphorylation of IRS-1. Under conditions of 
excess nutrients, elevated levels of PDZ-RhoGEF increased signalling to p70S6K 
created an inhibitory feedback loop towards the IRS-1 (Chang et al., 2015). 
1.15 Role of PREX Proteins in Glucose Homeostasis 
and Diabetes  
PREX1 is a modulator of insulin signalling in a range of cell types (Balamatsias et 
al., 2011; Ghalali et al., 2014; Kim et al., 2012; Montero et al., 2013). As has been 
previously stated, the human PREX1 gene is mapped to a genetic locus highly 
associated with type 2 diabetes (Bento et al., 2008). Moreover, SNPs genotyping in 
the PREX1 perigenic region suggested that PREX1 may contribute to the 
susceptibility of obese people to type 2 diabetes (Lewis et al., 2010). However, it 
remains to be seen if these SNPs affect PREX1 expression or function. 
A study in 3T3-L1 adipocytes has demonstrated that the PREX1 protein is 
involved in the insulin-dependent translocation of the glucose transporter GLUT4 to 
the plasma membrane through its Rac-GEF activity (Balamatsias et al., 2011). It 
was shown that the disruption of Prex1-dependent Rac1 activation, by 
overexpression of a PREX1 mutant that lacks its DH domain, results in an inhibition 
of insulin-induced GLUT4 trafficking in 3T3-L1 adipocyte cells. It also negatively 
affected insulin-stimulated glucose uptake by these cells (Balamatsias et al., 2011) 
(Figure 1.15.1).  
PREX1 has also recently been identified as a biomarker of the thermogenic 
potential of human brown adipocytes (Xue et al., 2015). Immortalised pre-
adipocytes were established from human brown and WAT, and were screened by 
microarray profiling for molecular determinants of thermogenic potential. This 
identified that PREX1 expression in preadipocytes correlates with the presence of 
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the brown fat marker UCP1 in differentiated cells. Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR)-mediated knockout of PREX1 in brown 
adipose precursors showed that the GEF had no effect on the ability of 
preadipocytes to differentiate into adipocytes. However, PREX1 deficiency 
significantly decreased the expression of UCP1 and other brown fat markers, as 
well as reducing the basal respiration, proton leak and maximal respiration capacity 
of differentiated adipocytes. Therefore, PREX1 is required for the development of 
the thermogenic potential of brown adipose cells (Xue et al. 2015). The mechanism, 
through which PREX1 regulates gene expression in adipocytes, and its significance 
for the function of BAT in vivo, remain to be investigated. 
The Parsons lab reported that PREX2 also plays an important role in insulin 
signalling. Studies in Prex2 knockout mice have shown that deficiency of Prex2 can 
significantly affect glucose homeostasis and insulin sensitivity in vivo. Upon glucose 
challenge, Prex2 knockout mice - despite having the same baseline glucose levels 
as wild type Prex2 mice - exhibited higher peak and more sustained blood glucose 
levels, suggesting impaired glucose tolerance. Moreover, insulin tolerance tests 
showed that the sustained response of Prex2 knockout mice to insulin injection was 
reduced, suggesting insulin resistance (Hodakoski et al., 2014). Moreover, PIP3 
levels and the activities of several insulin pathway components were suppressed in 
the adipose tissue and liver of Prex2 knockout mice, whereas PTEN activity was 
elevated (Hodakoski et al., 2014) (Figure 1.15.1). Therefore, PREX2 has been 
suggested to be involved in insulin signalling, not through its Rac-GEF activity, but 
by inhibiting PTEN. However, the relative contribution of GEF-dependent and -
independent functions of PREX2 to insulin signalling and glucose homeostasis 
remains to be elucidated. These results seem to be relevant in humans, as analysis 
of PREX2 protein levels in adipocyte tissue from insulin-resistant and insulin-
sensitive humans revealed that insulin-resistant people have lower PREX2 levels 
(Hodakoski et al., 2014). As insulin resistance can develop into type 2 diabetes, it 
seems possible that reduced PREX2 expression may be involved in the 
development of metabolic syndrome, although this remains to be investigated. 
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Figure 1.15.1: PREX proteins in insulin signalling. 
Both PREX1 and PREX2 have been identified as direct binding partners of the two mTOR-
containing protein complexes mTORC1 and mTORC2, which are important effectors of the insulin 
signalling pathway. Moreover, both PREX proteins activate Rac1, and specifically PREX1 has 
been associated with the insulin-dependent translocation of the glucose transporter GLUT4 to the 
plasma membrane of adipocytes. Finally, PREX2 (but not PREX1) was shown to inhibit PTEN and 
therefore contribute to the regulation of PIP3 levels, in a GEF-activity independent manner. The 
inhibition is reciprocal, as PTEN also inhibits the Rac-GEF activity of PREX2. 
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Chapter 2 - Aims and Hypothesis 
 
The importance of PREX proteins in physiological and pathophysiological 
processes such as inflammation, neuronal plasticity, cancer progression and 
metastasis is well established. However, less is known regarding their role in 
metabolic processes. Despite this, there is some evidence to suggest that PREX 
proteins may have a role in insulin signalling and glucose homeostasis. PREX1 was 
shown to regulate the thermogenic capacity of adipocytes, as well as insulin-
stimulated glucose uptake, whereas PREX2 was reported to mediate glucose 
tolerance, possibly through its adaptor function as an inhibitor of the tumour 
suppressor PTEN. 
I therefore aimed to investigate the contribution of PREX proteins to glucose 
homeostasis in vivo by measuring fasting blood glucose levels, glucose tolerance 
and response to insulin challenge in genetically-modified mouse strains (Prex1 
knockout, Prex2 knockout and Prex null mice). I followed up in vivo phenotypic 
observations with ex vivo assessment of insulin signalling in liver, inguinal white 
adipose tissue and skeletal muscle.  
Based on the proposal that the role of PREX2 in glucose homeostasis may 
depend on its adaptor role as an inhibitor of PTEN, rather than its Rac-GEF catalytic 
activity, an additional aim of the project was to assess the significance of the Rac-
GEF activity of PREX1 and PREX2 in glucose homeostasis and insulin signalling. 
To this end, I aimed to generate and evaluate mouse strains with catalytically 
inactive forms of Prex1 or Prex2 (Prex GEF-Dead).   
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Chapter 3 - Materials and Methods 
 
3.1 Molecular Biology Techniques 
3.1.1 Polymerase Chain Reaction (PCR)  
PCR was performed according to guidelines provided by the manufacturer of the 
Pfu DNA polymerase (Promega, M774A). Amplifications were carried out in 50 l 
reaction volumes containing 100 ng template DNA, 0.5 μM forward and reverse 
primers (Sigma), 0.2 mM dNTPs (Bioline), 1 unit Pfu Polymerase in the 
manufacturer’s supplied buffer and, when necessary, 5% DMSO. Reaction 
conditions for standard PCRs were: initial denaturing step at 95oC for 5 min, followed 
by 30 cycles of denaturing at 95oC for 30 s, re-annealing for 30 s at 60oC (or the 
optimal temperature for the primer pair as stated by the manufacturer; Sigma), 
extension at 74C for 2 min/kb of DNA and completion with a final extension at 74oC 
for 5 min. The relevant DNA was isolated by agarose gel electrophoresis (see 
Section 3.1.5), and either the appropriate bands were extracted from the gel and 
purified using QIAquick Gel Extraction kit (Qiagen), or the whole PCR product was 
purified using QIAquick PCR purification kit (Qiagen) according to the 
manufacturer’s instructions. PCR-derived constructs were verified by sequencing 
prior to use (GENEWIZ). 
For the genotyping of the Prex1 knockout, Prex2 knockout and Prex1;Prex2 
double knockout mouse strains, PCR was performed according to guidelines 
provided by the manufacturer of the HotStartTaq DNA polymerase (Qiagen, 
203203). Amplifications were carried out in 20 l reaction volumes containing ~500 
ng template DNA, 0.25 μM forward and reverse primers (Sigma), 0.2 mM dNTPs 
(Bioline) and 2.5 units HotStartTaq DNA polymerase in the manufacturer’s supplied 
buffer. Reaction conditions for standard PCRs were: initial denaturing step at 95oC 
for 15 min, followed by 30 cycles of denaturing at 94oC for 1 min, re-annealing for 
30 s at 64oC, extension at 74C for 1 min and completion with a final extension at 
74oC for 5 min. The relevant DNA was analysed by agarose gel electrophoresis (see 
Section 3.1.5). 
For the genotyping of the newly generated catalytically inactive Prex1 
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E51A/N233A and Prex2 E22A/N204A mouse strains (see Result Sections 4.5.5, 
and 4.5.6), PCR was performed using Pfu DNA polymerase, as described above. 
Reaction conditions for touch-down PCRs were: initial denaturing step at 95oC for 5 
min, followed by 3 cycles of denaturing at 95oC for 30 s, re-annealing for 30 s at 
68oC, extension at 74C for 2 min/kb of DNA, then 3 cycles of denaturing at 95oC 
for 30 s, re-annealing for 30 s at 65oC, extension at 74C for 2 min/kb of DNA, then 
3 cycles of denaturing at 95oC for 30 s, re-annealing for 30 s at 62oC, extension at 
74C for 2 min/kb of DNA, and 35 cycles of denaturing at 95oC for 30 s, re-annealing 
for 30 s at 59oC, extension at 74C for 2 min/kb of DNA and completion with a final 
extension at 74oC for 5 min. The relevant DNA was isolated by agarose gel 
electrophoresis (see Section 3.1.5), and the PCR product was purified using 
QIAquick PCR purification kit (Qiagen) according to the manufacturer’s instructions. 
PCR-product sequence was verified by Sanger sequencing (GENEWIZ). 
3.1.2 Site-directed mutagenesis 
To generate the catalytically inactive human PREX2 E30A/N212A construct, that 
was used for the generation of recombinant proteins, site-directed mutagenesis was 
performed using the Site-Directed Mutagenesis Kit (New England Biolabs, E0554) 
and following the manufacturer’s instructions. Briefly, 1-25 ng of wild type PREX2 
cDNA in the pENTR3C vector was PCR amplified using the Q5 Hot Start High-
Fidelity DNA Polymerase and the primers listed below in Table 3.1. The 
substitutions were created by incorporating the desired nucleotide change in the 
centre of the forward primer, including 19 complementary nucleotides on the 3’ side 
of the mutation. The reverse primer was designed so that the 5’ ends of the two 
primers anneal back-to-back. Then, the PCR product was treated with a provided 
enzyme mix containing a kinase, a ligase and DpnI for circularisation of the PCR 
product and digestion of the template DNA. Finally, the treated mix was used to 
transform supplied high-efficiency NEB 5-alpha Competent E. coli cells. 
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Table 3.1: List of primers used for site-directed mutagenesis of PREX2 cDNA. With bold 
are annotated the mutated nucleotides.  
 
Substitution Forward Primer Reverse primer 
PREX2 Exon 1 
E30A 
CGCGTGTGCGTGCTCAGCG 
CGCTCCAGAAGACCGAGCGG 
CAGGCGAAGCTGCTTCTC 
CAGGTCCTTGGCGCTCTCGGC 
PREX2 Exon 6 
N212A 
GCTGTCTGTTCCAACATA 
GCCGAGGCCAAGAGACAGATG 
TTTCATGGCTTGGAGGG 
CTTCCATCACTGCTGCATAGTC 
 
3.1.3 Analytical restriction digestion of DNA 
Plasmid DNA (200-400 ng) or PCR products were digested by incubation for 1-2 h, 
with 5 units of the appropriate restriction enzyme. The reaction was set up in the 
manufacturer’s recommended buffer, at the recommended temperature and in a 
final volume of 20 μl containing 0.1 mg/ml BSA.  
3.1.4 Preparative restriction digestion of DNA 
Plasmid DNA (5 μg) or PCR products were digested by incubation for 3 h with 5 
units/μg-1 DNA of the appropriate restriction enzyme. The reaction was set up in the 
manufacturer’s recommended buffer at the recommended temperature in a final 
volume of 100 μl containing 0.1 mg/ml BSA. 
3.1.5 Analysis of DNA by agarose gel electrophoresis 
DNA fragments were routinely resolved in TBE (40 mM Tris-borate, 1 mM EDTA) 
agarose gels (1-2% (w/v), Helena Biosciences) stained with ethidium bromide (0.5 
g/ml, BioRad). The size and quantity of DNA was estimated by comparison with 
the DNA marker Hyperladder I or IV (Bioline). When required, the desired molecular 
weight band was cut from the agarose gel using a clean razor blade. The DNA was 
purified from the gel slice using the QIAquick Gel Extraction Kit (Qiagen) according 
to the manufacturer’s instructions. 
3.1.6 Ligation of DNA fragments 
All ligation reactions were carried out in a volume of 10-20 l containing 20-200 ng 
of DNA fragments, 1-2 l of the manufacturer’s 10x ligation buffer and 1-2 l of T4 
DNA ligase (Promega). Typically, 50 ng of vector DNA was ligated with the 
appropriate amount of insert DNA to give a 3:1 molar ratio of insert:vector. The 
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reaction mixture was incubated at 16oC overnight and then stored at -20oC prior to 
DNA introduction into competent E. coli (DH5) cells as described below. 
3.1.7 Expression vectors 
Human PREX1 cDNA constructs in pCMV3(EE) and pCMV3(MYC) vectors for 
mammalian expression were described previously (Barber et al., 2012; Hill et al., 
2005; Welch et al., 1998; Welch et al., 2002), as was the human PREX2 cDNA 
construct in pCMV3(MYC) vector for mammalian expression (Donald et al., 2004). 
3.1.8 Introduction of plasmid DNA into DH5α 
Transformation of subcloning efficiency competent E. coli DH5α (Invitrogen, 18265-
017) was performed using the manufacturer’s protocol. Briefly, an aliquot of 50 μl 
DH5α was thawed on ice and mixed with 1-10 ng of plasmid DNA followed by 30 
min incubation on ice. Cells were heat shocked for 20 s using a water bath at 42°C 
and placed on ice for 2 min. 900 μl of super optimal broth with catabolite repression 
(SOC) (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 
10 mM MgSO4, 10 mM glucose), was added and cells were incubated for 1 h at 
37°C in an orbital shaker at 225 rpm to recover from the transformation. The bacteria 
cells were then spread onto selective Luria-Bertani (LB) (10 g/L tryptone, 5 g/L yeast 
extract, 5 g/L NaCl) agar plates containing antibiotics (100 μg/ml ampicillin or 50 
μg/ml kanamycin, as appropriate) and cultured at 37°C overnight. 
3.1.9 Purification of plasmid DNA 
Single colonies were picked and cultured for the isolation of plasmid DNA. For small 
scale purifications, 5 ml LB containing the appropriate antibiotics (100 μg/ml 
ampicillin, or 50 μg/ml kanamycin) were grown overnight at 37°C in an orbital 
shaker. Plasmid DNA was purified from cultures using the GeneJET miniprep kit 
(Life Technologies, K0503) according to the manufacturer’s instructions. For large-
scale purifications, a 1 ml starter culture was added to 100 ml of LB with the 
appropriate antibiotic and incubated overnight at 37°C in an orbital shaker. Cells 
were pelleted, and plasmid DNA was purified using the plasmid maxiprep plus kit 
with vacuum manifold (Qiagen, 12965) according to the manufacturer’s instructions. 
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3.1.10 Purification of genomic DNA 
Isolation of genomic DNA from tissue culture cells was performed using the Wizard 
Genomic DNA Purification Kit (Promega, A1120) according to the manufacturer’s 
instructions. Briefly, cells were harvested using a 0.25% (w/v) Trypsin 0.53 mM 
EDTA solution, collected into a 1.5 ml micro-centrifuge tube and pelleted by a 10 s 
centrifugation at 16000 x g. The supernatant was removed, and the cell pellet was 
washed with PBS prior to being centrifuged again. PBS was removed, leaving 
behind the cell pellet with residual liquid to resuspend cells by vortexing. Cells were 
then lysed with the provided Nuclei Lysis Solution, treated with RNase Solution and 
incubated at 37oC for 30 min. Afterwards, Protein Precipitation Solution was added, 
and samples were kept on ice for 5 min prior to being centrifuged at 16000 x g for 4 
min to pellet the proteins. DNA precipitation was performed by transferring the 
supernatant to a new tube containing isopropanol, centrifuging at 16000 x g for 1 
min, washing the DNA pellet with 70% ethanol and air-drying it. The dry DNA pellet 
was then rehydrated with nuclease-free water at 65oC for 1 h.  
To isolate genomic DNA from tissue biopsies, ear or tissue biopsies were 
collected in 1.5 ml micro-centrifuge tubes. Tissues were lysed with 500 μl of tissue 
lysis buffer (100 mM Tris-HCl, pH 8.5, 200 mM NaCl, 5 mM EDTA, 0,2% SDS) 
supplemented with 10 mg/ml proteinase K in 10 mM Tris, pH 8.1, 1 mM EDTA, 50% 
glycerol. Samples were then incubated at 55oC for 4 h, and DNA was precipitated 
by adding 350 μl of isopropanol, mixing by inversion and centrifuging at 17000 x g 
for 10 min. The supernatant was removed, and the DNA pellet was washed with 
70% ethanol. Following that, samples were centrifuged again at 17000 x g for 5 min, 
the supernatant was removed, and the DNA pellet was left to air-dry. The dry DNA 
pellet was then rehydrated with 30 μl of TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA) 
at 37oC for 1 h.  
3.1.11 RNA isolation 
To isolate RNA from frozen tissues, less than 50 mg of tissue were used for 
extraction – typically 2 biopsy punches of 2 mm length (KAI Disposable Biopsy 
Punch, BP-20F). Tissue was homogenised in TRI Reagent (ZYMO RESEARCH, 
R2050-1-200), using the TissueLyser II (Qiagen) at a frequency of 300/s for 1.5 min, 
and particulates were removed by centrifugation at 12000 x g for 1 min. RNA 
68 | P a g e  
purification was performed using the Direct-zol RNA MiniPrep (ZYMO RESEARCH, 
R2053) following the manufacturer’s protocol, including the in-column DNase I 
digestion. Purified RNA, eluted in 25 μl of nuclease free water, was stored at -80oC. 
3.1.12 Determination of DNA and RNA purity and quantity 
To determine the quantity and purity of DNA and RNA preparations, the UV 
absorbance at 230, 260 and 280 nm was measured using a NanoDrop ND-100 
Spectrophotometer. The amount of DNA or RNA was determined using the 
absorbance at 260 nm with the appropriate constant for each sample (50 for DNA 
and 40 for RNA). Guanidinium salt and protein contaminations were detected at 230 
and 280 nm, respectively. The ratios of UV absorbance at 260/280 and 260/230 
were used to determine purity of the DNA and were considered acceptable when at 
least 1.85 and 2.15, respectively. 
3.1.13 cDNA synthesis and qPCR 
To quantify the expression levels of PEPCK and G6P, equal amounts of cDNA were 
synthesised using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems, 
4388950) following the manufacturer’s protocol. qPCR was performed using the 
TaqMan Fast Advanced Master Mix according to the manufacturer’s guidelines. The 
reaction was performed using the QuantStudio 12K Flex Real-Time PCR System 
following the manufacturer’s instructions. 
 
3.2 Cell Culture Techniques 
All mammalian cell lines were obtained from ATCC at the beginning of this project. 
For long-term stock preparation, aliquots of the cells were prepared at early 
passages and stored in liquid nitrogen. All mammalian cell lines were used between 
passages 4 and 25.  
3.2.1 Human Liver Hepatocellular Carcinoma cell line 
(HepG2) 
The Human Liver Hepatocellular Carcinoma cell line (HepG2) (ATCC, HB-8065) 
was cultured in cell culture flasks (Nunc) using Dulbecco’s Modified Eagle’s Medium 
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(DMEM) (Invitrogen, 41965-039) supplemented with heat-inactivated Foetal Bovine 
Serum (FBS) (Invitrogen, 10270-106) to a final concentration of 10%. Cells were 
maintained at 37°C in a humidified atmosphere with 5% CO2. HepG2 cells were 
subcultured twice per week, using a 0.25% (w/v) Trypsin-0.53 mM EDTA solution, 
to a subcultivation ratio of 1:4 to 1:6. 
3.2.2 Mouse Embryonic Fibroblast cell line NIH/3T3 
The Mouse Embryonic Fibroblast cell line NIH/3T3 (ATCC, CRL-1658) was cultured 
in cell culture flasks (Nunc) using the ATCC-formulated DMEM, (ATCC, 30-2002) 
supplemented with bovine calf serum (ATCC, 30-2030). Cells were maintained at 
37°C in a humidified atmosphere with 5% CO2. The NIH/3T3 cells were subcultured 
twice per week, using a 0.25% (w/v) Trypsin-0.53 mM EDTA solution, to a 
subcultivation ratio of 1:6 to 1:8. 
3.2.3 Mouse Embryonic Stem cells (ES cells) 
Mouse ES cells used for CRISPR targeting were kindly maintained, frozen and 
stored by Dr Dominik Spensberger at the Babraham Institute Gene Targeting facility. 
The ES cells were maintained in knockout Dulbecco’s Modified Medium (KO-
DMEM) (GIBCO, 10829-018) supplemented with 2 mM GlutaMAX/Glutamate 
(Invitrogen, 35050061), 1x 2-mercaptoethanol (Sigma, M7522), 3 ml 
Penicillin/Streptomycin at final concentration of 50 U/ml (Invitrogen, 15140-122), 
300 μl leukemia inhibitor factor (LIF) at 2000 U/ml (Miltenyi Biotech, 130-095-772), 
and 15% FBS. Gelatin was prepared with 0.1% w/v gelatin (Sigma, 9391) in cell 
culture grade water or 1x PBS and was autoclaved to dissolve and sterilise prior to 
being stored at 4oC. 
3.2.4 Transfection of HepG2 and NIH/3T3 cells with 
expression vectors 
Transfection of both HepG2 and NIH/3T3 cell lines was achieved by JetPEI 
(Polyplus, 101-10N) transfection following the manufacturer’s protocol. Briefly, cells 
were collected by tryptic digest, counted on a hematocytometer, and diluted to the 
required concentration (Table 3.2) in complete medium before being seeded onto 
Nunc tissue-culture grade plastic ware. For immunofluorescence imaging 
experiments, cells were seeded onto 20 mm sterile glass coverslips. The following 
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day, mammalian expression vectors were diluted in sterile NaCl solution (150 mM) 
and vortexed briefly. JetPEI reagent, diluted in sterile NaCl (150 mM), was then 
mixed with the DNA solution before being vortexed again and incubated at room 
temperature for 20 min. Mixtures were added drop-wise onto the pre-seeded cells. 
NIH/3T3 cells were incubated in transfection medium for 24 h prior to experiments, 
while HepG2 were incubated for 48 h. 
Table 3.2: Number of cells, amount of mammalian expression vectors, and volume of  
JetPEI used for transient transfections.  
 
Cell line Plastic-ware 
Cells per 
ml 
Volume 
per well 
Amount of 
expression 
vectors/NaCl 
(150 mM) 
Volume of 
JetPEI/NaCl 
(150 mM) 
HepG2 
6 well plate 5x105 2 ml 3 µg / 100 µl 6 µl / 100 µl 
T75 flask 1.88x106 10 ml 18 µg / 250 µl 36 µl / 250 µl 
NIH/3T3 6 well plate 1x105 2 ml 3 µg / 100 µl 6 µl / 100 µl 
 
 
3.3 Protein Detection Techniques  
3.3.1 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE)  
To separate proteins by size for further Coomassie staining or western-blotting, the 
BioRad Mini Protean II gel electrophoresis system was used to perform SDS-PAGE. 
Gels of 1.5 mm thickness were prepared. The resolving parts were cast first, 
followed by the stacking gels, using 2x buffer stocks. The amounts of acrylamide 
(37.5:1, 30% stock, BioRad) and water used for both the stacking and resolving gels 
and the final concentrations of the resolving gels are listed in the table below (Table 
3.3). Gels were polymerised with 0.1% Tetra-methyl-ethylenediamine (TEMED) 
(BioRad) and 0.05% ammonium persulphate (APS), from a freshly prepared 10% 
stock. Full Range (12-225 kDa) molecular weight markers from GE Healthcare were 
used as standards. Electrophoresis was performed at 120 volts through the stacking 
gel and 180 volts through the resolving gel in 1x running buffer (10x running buffer 
stock: 0.25 M Tris, 1.92 M glycine, 1% SDS). Boiling SDS-PAGE sample buffer 
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(Laemmli buffer, 4x: 0.4 M DTT, 160 mM Tris pH 6.8, 8% SDS, 50% glycerol, 
0.012% bromophenol blue) was added to samples to a final 1.3x concentration, and 
samples were boiled for least 5 min prior to loading. 
 
Table 3.3: The volume of resolving and stacking buffer, bis -acrylamide, water, 10% aps 
and temed required for making up two 1.5 mm thick gels.  
 
 
 
3.3.2 Transfer of proteins onto PVDF membrane 
Following SDS-PAGE, proteins were transferred onto Immobilon-P Polyvinylidene 
fluoride (PVDF) membrane (Millipore) using a standard wet transfer protocol. 
Transfer buffer contained 24 mM Tris, 193 mM glycine and methanol (5% methanol 
for proteins between 120-200 kDa, 10% for all other proteins). Transfers were done 
using a cooling-block in the tank, usually at 100 volts for 120 min, with the mini 
Protean II electrophoresis system, all with constant stirring. 
3.3.3 Detection of proteins by western-blot 
As a standard protocol, following the transfer step, the membrane was blocked for 
1 h in 1x Tris buffered saline (TBS: 20 mM Tris, 0.15 M NaCl, pH 8), 0.05% (v/v) 
Tween-20, 5% non-fat milk powder at room temperature with constant gentle 
shaking. For anti-P-Rex1 6F12 western-blots, an additional 20 min blocking step 
with 0.1% (v/v) BSA in TBS-T was carried out. Primary antibodies were diluted in 
fresh blocking buffer and incubated with the membrane for 1–2 h at room 
temperature (Table 3.4). This was followed by two washes in blocking buffer and 
two additional washes in TBS-T (1x TBS, 0.05% Tween-20) for a total of 30 min 
Separating/Resolving gel Stacking gel 
2x Separation Buffer 
(0.75 M Tris, 0.2% SDS, pH 8.8) 
7.5 ml 
2x Stacking Buffer 
(0.25 M Tris, 0.2% SDS, pH 6.8) 
7.5 ml 
30% Acrylamide 37.5:1 3 ml 30% Acrylamide 37.5:1 2.5 ml 
Water 4.5 ml Water 5 ml 
10% APS 75 μl Bromophenol Blue 35 μl 
TEMED 15 μl 10% APS 75 μl 
  TEMED 15 μl 
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before addition of the secondary antibody (goat anti-mouse IgG-Horseradish 
Peroxidase [HRP] conjugate, BioRad, 1:3000; or goat anti-rabbit IgG Horseradish 
Peroxidase [HRP] conjugate, BioRad, 1:3000, as appropriate) in blocking buffer. 
The incubation was carried out for 1 h and the membrane was again washed twice 
in blocking buffer and twice with TBS-T for a total of 40 min. Proteins were detected 
by Amersham Enhanced Chemiluminescence reagents (ECL or ECL+) according to 
the manufacturer’s instructions and were visualised by exposure to X-ray film (Fuji) 
for an appropriate time and then developed using an X-ray film processor (Xograph 
Imaging Systems). 
 
Table 3.4: Antibodies used for protein detection.  
 
Antibody target Dilution Source Type 
Cross-
reactivity 
Human PREX1 
6F12 
1:30 
Marcus Thelen Laboratory, 
Bellinzona, Switzerland 
(Welch et al., 2005) 
Mouse 
monoclonal 
Human, Mouse 
Human PREX2 1:20000 
Welch Laboratory, 
Cambridge, UK 
(Donald et al., 2008) 
Rabbit 
polyclonal, 
affinity purified 
Human, Mouse 
 
 
3.3.4 Stripping and re-blotting of the membrane 
If required, bound antibodies on western-blotting membranes were stripped off in 
stripping buffer (25 mM glycine, pH 2.0, 1% SDS) for 30 min at room temperature. 
Membranes were then washed in several changes of TBS-T before blocking and re-
probing with a different primary antibody. 
3.3.5 Coomassie-staining of proteins 
To determine the presence of proteins and assess the quantity and purity of protein 
preparations, gels or western-blots were Coomassie stained. Gels were incubated 
in the Coomassie staining solution (0.1% Coomassie brilliant blue R-250, 50% 
methanol, 10% acetic acid) for 1 h, followed by several washes in gel de-staining 
solution (10% methanol, 7% acetic acid). Western-blots were stained with the same 
staining solution for 5 min, followed by several changes of blot de-staining solution 
(50% methanol, 7% acetic acid). 
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3.3.6 Prex1 and Prex2 expression profile analysis 
To assess the expression of Prex1 and Prex2 in different mouse tissues, western-
blotting with antibodies against PREX1 and PREX2 was carried out with whole 
tissue lysate samples from Prex1+/+;Prex2+/+ (wild type), Prex1–/–;Prex2–/– (double 
knockout), Prex1–/– (Prex1 knockout) and Prex2–/– (Prex2 knockout) mice. Brain, 
subcutaneous interscapular brown adipose tissue (intBAT), subcutaneous inguinal 
white adipose tissue (ingWAT), anterior thigh skeletal muscle, and liver were 
retrieved from mice, snap-frozen in liquid N2, and stored at -80oC. For the 
preparation of total lysates frozen tissues (except adipose) were wrapped in cling 
film and homogenised with the use of a hammer. Lysates were prepared with 9 ml/g 
RIPA buffer (30 mM Hepes pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% 
deoxycholate, 0.1% SDS, 5 mM EGTA, 4 mM EDTA, supplemented with 1 mM DTT, 
1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 µg/ml aprotinin and 1 mM PMSF). Lysates 
were sonicated in a Misonix S-3000 sonicator, using the 1/8” probe at 8.5-power 
and with 15 cycles of 1 s on / 1 s off pulses while kept on ice. Finally, samples were 
centrifuged for 5 min at 800 x g and 4oC, the supernatant was collected, and proteins 
from equal volumes of tissue lysates were denatured by the addition of boiling 4x 
SDS-PAGE sample buffer to a final concentration of 1.3x and by boiling for 5 min 
prior to snap freezing in liquid N2. To prepare total lysates from adipose tissue, the 
frozen tissue was homogenised with a hammer and treated with 500 μl of isolation 
medium (50 mM Tris, 150 mM NaCl, 0.2 mM EDTA and protease inhibitors). 500 μl 
of the homogenised adipose tissue were then transferred into a 5 ml polypropylene 
round-bottom tube carrying 1875 μl of chloroform/methanol (1:2) mixture and mixed 
sporadically while being kept on ice for 15 min. Following this, the homogenate was 
diluted with 625 μl water to change the water/chloroform/methanol ratio from 0.8:1:2 
to 1.8:2:2. Then the mixture was centrifuged at 800 x g and 4oC for 5 min, and the 
protein disk between the two phases was collected and resolved with 1 ml of boiling 
1.3x SDS-PAGE sample buffer. Finally, the mixture was incubated at 105oC for 10 
min and mixed regularly to solubilise the proteins. Thereafter, the protein 
concentration among tissue lysates from each condition was evaluated by 
Coomassie staining of protein gels as described above, and lysates were diluted 
appropriately to accomplish equal concentrations among all samples. 
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3.4 Production of Recombinant Proteins from Sf9 cells 
3.4.1 Insect Sf9 cells 
Sf9 (Spodoptera frugiperda) cells were obtained from ThermoFisher, and aliquots 
were stored in liquid nitrogen. Sf9 cells were maintained at 27oC without gassing, in 
suspension at a density of 0.5-2.0 x 106 cells/ml in 500 ml or 1-litre spinner flasks 
(Techne). TNM-FH insect medium (Sigma 1 litre powder aliquots, T1032-1L, 1.75 g 
NaHCO3, 87.5 ml 1M NaOH, pH 6.3, 0.2 μm filtered and stored in the dark) was 
used for routine culture, supplemented with 10% FBS (Invitrogen, 10270-106) and  
1% penicillin/streptomycin solution (P/S) (Invitrogen, 15140-122). Cells were used 
for protein production between 1 and 10 weeks in culture. When required, cells were 
grown as adherent monolayers in tissue culture flasks.  
3.4.2 Lipofection of Sf9 cells 
Escort™ IV is a liposome suspension composed of a polycationic lipid and a neutral, 
non-transfecting lipid compound.  For the lipofection of Sf9 cells, the Escort™ IV 
Transfection Reagent (Sigma-Aldrich, L3287) was used following the 
manufacturer’s protocol. Briefly, 9 x 105 cells were seeded per well into a six-well 
plate, and left in the incubator for an hour to adhere. Baculovirus DNA was diluted 
in serum-free Grace’s insect medium (ThermoFisher Scientific, 11605-045). 
Escort™ IV reagent, also diluted in serum-free Grace’s insect medium, was mixed 
with the DNA solution and incubated at room temperature for 30 min to allow 
complexes to form. After settling, cells were washed twice with serum-free Grace’s 
insect medium, and 1 ml of serum-free Grace’s insect medium was added in each 
well. Mixtures were added drop-wise onto the pre-seeded cells, and plates were 
incubated at 27oC for five hours. Afterwards, transfection medium was removed and 
replaced with complete TMN-FH medium. Plates were incubated for four days at 
27oC to allow for the expansion of viral particles in the cells. After four days, the 
supernatant was removed from the cells, centrifuged at 433 x g for 15 min, and the 
resulting viral suspension was stored at 4oC in the dark (Low-titre supernatant). 
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3.4.3 Amplification of viral particles 
Viral suspensions were amplified twice prior to protein production to produce 
medium- and high-titre supernatant. For the first round of amplification, 0.75 ml of 
low-titre supernatant was used to infect 1.5 x 107 cells in T75 tissue culture flasks 
for 48 hours. At this point, cells were analysed for protein expression. To do this, the 
supernatant was removed from the cells, centrifuged at 433 x g for 15 min and stored 
at 4oC in the dark (medium titre supernatant). The cells were washed with 1 ml of 
Sf9 wash solution (0.7% KCl, 2.66% sucrose, 7 mM NaH2PO4 pH 6.2 RT, 20 mM 
MgCl2), were scraped off (large cell scrapers, Sigma) and were centrifuged at 1500 
x g for 10 min. The supernatant was discarded, and the pellets were snap frozen 
and analysed for protein expression by chemical isolation (see Section 3.4.5). For 
the second round of amplification, 1.2 ml of medium-titre supernatant was used to 
infect 3.5x107 cells in T175 tissue culture flasks for 48 hours, after which time the 
supernatant was removed and centrifuged at 433 x g for 15 min and stored at 4oC 
in the dark (high-titre supernatant). 
3.4.4 Establishing optimal protein production conditions in 
Sf9 cells 
Optimal infection times and viral titres for highest protein production were identified 
for each protein. 75 ml of cells at a density of 1 x 106 cells/ml were put into 250 ml 
spinner flasks and were infected with 0.8% or 2.5% (v/v) of high-titre supernatant. 
15 ml of cells were then harvested on days 0, 1, 2, 3 and 4 post infection, centrifuged 
at 3901 x g for 10 min at RT, and the pellets were snap frozen. Protein production 
was analysed by chemical isolation (see Section 3.4.5). Once optimal infection 
times were established for each protein, 1 litre  of cells at 1 x 106 were put into a 2 
litre spinner flask and were infected with high-titre supernatant at the required 
concentration for the required time. Cells were harvested by centrifugation at 433 x 
g for 30 min at 4oC. The supernatant was discarded, and the cells were resuspended 
in 40 ml of Grace’s insect medium and transferred into a 50 ml falcon tube. A second 
centrifugation followed at 433 x g for 10 min at 4oC, and again the supernatant was 
discarded while the cells were resuspended in Grace’s insect medium, at a volume 
equal to the size of the pellet. The cells were then pipetted drop-wise into liquid 
nitrogen, and the resulting Sf9 cell beads were stored at -80oC, ready for protein 
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purification. 
3.4.5 Small scale chemical isolation from Sf9 cells 
In order to identify the optimal viral infection times and viral titres for optimal protein 
production, small-scale chemical isolation of His-tagged proteins were performed 
using Ni-NTA (nickel-nitrilotriacetic acid) agarose beads (QIAGEN, 30210). Fresh 
or frozen Sf9 cells pellets were vortexed into 1 ml of ice-cold lysis buffer (1% Triton 
X-100, 150 mM NaCl, 5 mM MgCl2, 40 mM Hepes pH 7.5 4oC) until resuspended 
and were incubated for 5 min on ice. Lysates were centrifuged at 13225 x g for 12 
min at 4oC to pellet insoluble material. Ni-NTA Agarose beads, typically 100 μl for 
each sample, were washed 3x in 1 ml water and 3x in 1 ml lysis buffer before 
cytosolic fractions were added to aliquoted agarose beads. These were left to 
immunoprecipitate at 4oC with end-over-end rotation for 60-90 min. Ni-NTA Agarose 
beads were then washed 4x in lysis buffer. Aspirated beads were boiled in 1.3x SDS 
sample buffer before being analysed using 6% SDS-PAGE gel electrophoresis. 
Proteins were visualised by Coomassie staining of the gel. 
3.4.6 Purification of recombinant PREX2 proteins from Sf9 
cells 
His-tagged proteins were purified from Sf9 cells by chemical isolation with Ni-NTA 
Agarose beads. Frozen Sf9 cell beads (the equivalent of approximately 400 ml of 
culture), infected with the appropriate protein-producing baculovirus, were thawed 
on ice. 25 ml of ice-cold lysis buffer (1% PBS, 1% Triton X-100, 25 mM NaF, 20 mM 
β-Glycerophosphate, 1 mM DTT, 0.1 mM PMSF and 10 μg/ml each of antipain, 
pepstatin A, leupeptin, aprotinin) were used to resuspend the pellet, and the solution 
was left on ice for 5 min. The cytosolic fraction was obtained by ultracentrifugation 
(Optima L-100XP ultracentrifuge, rotor T70 Ti) for 1 h at 215577 x g at 4oC. After 
centrifugation, the supernatant was added to 1 ml of packed Ni-NTA Agarose beads 
(pre-washed 3x in water and 3x in lysis buffer) and was left to precipitate with end-
over-end rotation for 90-120 min at 4oC. After precipitation, the beads were washed 
3x in cold wash buffer (2x PBS and 1% Triton X-100) followed by 4 washes in 
wash/elution buffer (1x PBS, 10% glycerol, 1 mM DTT, 0.01% azide and 20 mM 
imidazole). After the final wash, the supernatant was aspirated close to the pellet, 
and the volume of the beads was estimated. To elute the His-tagged proteins from 
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the Ni-NTA Agarose beads, the equivalent volume of wash/elution buffer containing 
600 mM imidazole was added to the beads, and they were incubated on ice for 10 
min. The supernatant was obtained by centrifugation at 800 x g for 1 min at 4oC. 
The Ni-NTA Agarose beads were then eluted with wash/elution buffer containing 
300 mM imidazole, and the supernatants were pooled. A final centrifugation was 
performed to remove any contaminating Ni-NTA Agarose beads. In order to wash 
the PREX2 proteins free of imidazole, PD-10 Desalting Columns (GE Healthcare 
Life Sciences, 52130800) were used according to the manufacturer’s instructions. 
Briefly, PD-10 Desalting Columns, containing Sephadex G-25 resin, were 
equilibrated with equilibration buffer (1x PBS, 10% glycerol, 1 mM DTT, 1 mM 
EGTA, 0.01% azide). Then, a maximal volume of 2.5 ml of sample was added onto 
the column and was left to enter the packed bed completely. The flow-through was 
discarded, collection tubes were placed under the columns, and proteins were 
eluted by adding 3.5 ml elution buffer (1x PBS, 10% glycerol, 1 mM DTT, 0.01% 
azide) through the column. To concentrate the eluted proteins, the Amicon® Ultra-
2 mL Centrifugal Filter (Merck, UCF210024) was used. Following the instructions 
provided by the manufacturer, 2 ml of each sample were added to filter devices and 
spun at 7500 x g in JA14.5 rotor for 20 min, initially. Then, the samples were 
centrifuged further with briefer spins to reduce the volume to approximately 100 μl. 
To further reduce the imidazole concentration, 2 ml of equilibration buffer (1x PBS, 
10% glycerol, 1 mM DTT, 1 mM EGTA, 0.01% azide) were added onto the columns, 
and the samples were concentrated again to 100 μl through centrifugation. Once 
concentrated, the protein was in wash/elution buffer which was supplemented with 
2 mg/ml FAF-BSA and adjusted to contain 50% glycerol (some protein was also 
stored without BSA). The protein was aliquoted, snap frozen in liquid N2 and stored 
at -80oC. Aliquots of all purified proteins were analysed using SDS-PAGE gel 
electrophoresis, and the gels were stained with Coomassie to assess the purity of 
the individual proteins. Proteins used in GEF activity assays were freeze-thawed a 
maximum of three times. 
3.4.7 Rac GEF activity assay for recombinant PREX2 proteins 
This in vitro assay measured the activation (GTP-loading) of recombinant Rac by 
recombinant PREX proteins in the presence of liposomes that either contained the 
PREX activator PIP3 or not. In order to prevent the de-activation of Rac during or 
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after the assay, GTP was presented in the form of the non-hydrolysable analogue 
GTPγS. EDTA, which enables the maximal GTP-loading of Rac, was used as a 
positive control. The final concentrations of assay components were liposomes 
composed of 200 µM each of the lipids phosphatidylcholine (PC), 
phosphatidylserine (PS), and phosphatidylinositol (PI), plus 100 nM EE-Rac1, 50 
nM wild type or GEF-dead His-PREX2 and 5 μM GTPγS, including 1 μCi 
[35S]GTPγS per sample. The final concentration of PIP3 varied as specified for 
each assay and the concentration of EDTA in the positive control was 2 mM.  
The assay was carried out in a volume of 10 μl by incubation for 10 min at 
30οC, followed by the isolation and quantification of GTPγS-loaded Rac. In the 
assay, the liposomes, Rac and GTPγS were combined from 5x stocks (see below, 
2 µl/sample) and PREX proteins added from 2.5x stocks (4 µl/sample). First, 2 μl of 
5x liposomes that either contained or not PIP3 were mixed with 2 μl of 5x stock GDP-
loaded (inactive) EE-Rac1 and incubated on ice for 10 min. Then, 4 μl of 2.5x wild 
type or mutated PREX2 were added, followed by 2 μl of 5x GTPγS. Samples were 
mixed and incubated for 10 min at 30οC. The reaction was stopped by the addition 
of 400 μl ice-cold lysis buffer (1x PBS, 1 mM EGTA, 10 mM MgCl2, 1% Triton X-
100, 0.1 mM GTP). EE-Rac1 was immunoprecipitated using anti-EE antibody 
coupled to prewashed protein G Sepharose beads (‘anti-EE beads’, Onyx 
Pharmaceuticals) by end-over-end rotation for 60 min on ice. The anti-EE beads 
were washed four times with 400 μl of ice-cold lysis buffer. After the last wash, any 
remaining liquid was carefully aspirated and 400 µl of Ultima Gold scintillation fluid 
(PerkinElmer, 6013329) added to the samples and tubes vortexed well. The tubes 
were transferred into scintillation vials (PerkinElmer, 6000292), 5 ml of scintillation 
fluid added, and the [35S]GTPγS-loading of Rac detected by scintillation γ-counting.  
The 5x and 2.5x stocks of all assay components were prepared freshly on 
the day of each assay, as follows: For the preparation of 5x liposomes, a mixture of 
PC, PS and PI (all from Sigma, stored at 12.5 mM each in CHCl3) was dried down 
to form a thin film in a 0.5 ml tube with or without synthetic D,D-Stearoyl-arachidonyl-
PtdIns(3,4,5)P3 (D,D-(S/A)-PIP3), and was then bath sonicated into lipid buffer (20 
mM Hepes pH 7.5 at 4oC, 100 mM NaCl, 1 mM EGTA) to give a concentration of 1 
mM for each lipid (with PIP3 as indicated). For the 5x positive EDTA control, PC, PS 
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and PI were dried down and bath sonicated into lipid buffer supplemented with 10 
mM EDTA. For the preparation of 5x Rac stocks, purified, GDP-loaded, 
recombinant, lipid modified EE-Rac1 (from laboratory stocks, (Hill and Welch, 2006), 
stored at -80°C) was diluted to 500 nM in 20 mM Hepes (pH 7.5 at 4oC), 0.1 M NaCl, 
1 mM EGTA, 5 mM MgCl2, 50 mg/ml FAF BSA and 5 mM DTT. For the preparation 
of 2.5x PREX protein stocks, purified recombinant His-PREX2 or mutated GEF-
dead His-PREX2 (prepared as described in Section 3.4.6, stored at -80°C) were 
diluted to 125 nM in 20 mM Hepes (pH 7.0 at 4oC), 1% betaine, 0.01% Na azide, 
0.5 mM EGTA pH 7.3 RT, 200 mM KCl, 10% ethylene glycol. For the preparation of 
the 5x GTPγS, pH-adjusted GTPγS (in 20 mM Hepes (pH 7.5, 4oC), 0.1 M NaCl; 
stored at -20°C) was diluted to 25 μM in lipid buffer and [35S]GTPγS added to this 
mix to give 1 μCi/2 μl.  
 
3.5 Mouse Strains 
Prex1–/–;Prex2–/– (double knockout, Prex1/2 DKO), Prex1–/– (Prex1 knockout, Prex1 
KO), Prex2–/– (Prex2 knockout, Prex2 KO) and Prex1+/+;Prex2+/+ (wild type, Prex 
WT) mice were generated by the Welch laboratory. The mice were initially on a 
C57Bl6/129Ola mixed genetic background and were previously described (Donald 
et al., 2008; Welch et al., 2005). The mice were group-housed (up to five) in 
individually ventilated cages in the Babraham Small Animal Unit. Mice were kept at 
a 12 h light/12 h dark cycle with dawn/dusk settings. Mice were fed either chow diet 
(CRM (P), SDS, 801722) or 45% high fat diet (RM AFE 45% Fat (P), SDS, 826161) 
ad libitum. Experiments were carried out in accordance with the British Home Office, 
PPL 70-9018, and with the approval of the local Animal Welfare and Ethical Review 
Body.  
To minimise genetic drift, the double knockout and wild type strains were 
crossed with each other and single and double mutant mice were derived from these 
crosses at least once every two years. For this study, recrossing of the Prex1–/–
;Prex2–/– strain with Prex1+/+;Prex2+/+ wild type mice was used to rederive Prex1–/– 
and Prex2–/– single deficient as well as Prex1–/–;Prex2–/– double deficient mouse 
strains immediately prior to the start of the experiments. The Babraham Breading 
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Unit provided C57BL/6J mice for the generation of the PREX catalytically inactive 
mice (Prex1E51A/N233A and Prex2E22A/N204A) as described in Sections 4.5.5, and 4.5.6 
of the results chapter.   
3.5.1 Mouse genotyping 
Mouse genotyping of the Prex1 knockout, Prex2 knockout and Prex1;Prex2 double 
knockout mouse strains was routinely performed in the laboratory by research 
assistant Laraine Crossland. Genomic DNA was isolated from mouse ear or tail 
biopsies as described in Section 3.1.10, and the genotyping was done through PCR 
following the protocol described in Section 3.1.1. The sequences of the primers 
used are detailed in the table 3.5. 
Towards the end of this project, genotyping of these strains was outsourced 
to Transnetyx who developed proprietary real-time PCR protocols using the probes 
detailed in table 3.6. 
 
Table 3.5: List of primer pairs used for the genotyping of genetically modified mouse strains. 
 
Target Forward primer Reverse primer 
PCR product 
size 
Prex1 Knockout 
allele 
GGACCAGAGTTTGA 
CCCCTGAACCTGTGTG 
CCAAATTAAGGGCC 
AGCTCATTCCTCCCAC 
436 bp 
Prex1 Wild Type 
allele 
GACCTGAGGTTTTT 
TTCTGGCCTCCGTGGC 
GAAAGAGGCAGAAG 
CTGGGCACGCCTGGCC 
1 kb 
Prex2 Knockout 
allele 
TCACTGAAGCGG 
GAAGGGACTGGCTGC 
GTTTCAGGTTCAGG 
GGGAGGTGTGGGAGG 
800 bp 
Prex2 Wild Type 
allele 
GATGCACTTTCAAA 
AGGGCCTAGTCCTGCC 
CCCACTGGTCTTGG 
TTAATGATGGGTGTCC 
800 bp 
 
Table 3.6: List of probes used for the genotyping of genetically modified mouse strains from 
Transnetyx. 
 
Target Forward primer Reverse primer Reporter 
Prex1 
Knockout 
allele 
TGTTTTGCCAAGTTC 
TAATTCCATCAGA 
GGGCCCTTAATCCTA 
GACTTTGG 
CTCTAGTGCAATGCCC 
Prex1 Wild 
Type allele 
TGAAACTCTGCAGAA 
ACCTTTATGGT 
ACACCGGCTATGGCA 
TGG 
CCCAGGCCCCAGCATG 
Prex2 
Knockout 
allele 
CCTGCTAGCTCTATA 
AGTTAAGTGGGATA 
CCAAAGGGCAAACCC 
AAAAGG 
ACATCCGGGCACTTTT 
Prex2 Wild 
Type allele 
CCCCTTTTTTCCTGC 
TAGCTCTATA 
CATAGCTTGAGTTTG 
CTTCTTTTATTGCT 
ACTTTTGAATTAGAG 
GAAATAAA 
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For the genotyping of the catalytically inactive Prex1E51A/N233A ES cells, 
genomic DNA was isolated from ES cells as described in Section 3.1.10, and the 
genotyping was done by PCR using the primers listed in the Table 3.7 and following 
the PCR protocol described in Section 3.1.1. 
For the genotyping of the catalytically inactive Prex1E51A/N233A and 
Prex2E22A/N204A mouse strains, genomic DNA was isolated from mouse ear or tail 
biopsies as described in Section 3.1.10, and the genotyping was done through 
Sanger sequencing (GENEWIZ) of PCR products, produced following the protocol 
described in Section 3.1.1. The sequences of the primers used are detailed in the 
Table 3.8. 
Once the Prex2E22A/N204A mouse strain had been established as homozygous 
mice, Transnetyx also developed an assay for their genotyping, as detailed in the 
Table 3.9, and we outsourced their genotyping. 
 
Table 3.7: List of primers used for genotyping of catalytically inactive Prex1 ES cells . 
Annotated with red are the nucleotides that are specific for either the wild type or the 
mutated allele. 
 
Target Forward primer Reverse primer 
PCR 
product 
size 
Prex1 E51A allele 
(1st set) 
GTACTCAACGCCATCCT 
AGG 
TGACTGTGCAATTCGAG
CTG 
279 
Prex1 E51A allele 
(2nd set) 
TGAATGGGTCTTGGCCT
ACA 
GCTCGGTGCCTAGGATG 
GCG 
643 
Prex1 E51 WT allele 
(1st set) 
GTACTCAACGAGATCCT 
GGG 
TGACTGTGCAATTCGAG
CTG 
279 
Prex1 E51 WT allele 
(2nd set) 
TGAATGGGTCTTGGCCT 
ACA 
GCTCGGTGCCCAGGATC 
TCG 
652 
Prex1 N233A allele 
(1st set) 
GCGGAGACCAAGCGACA 
AAT 
AGTTACTGAGGGGAGTT
GGC 
328 
Prex1 N233A allele 
(2nd set) 
CTGGGAAGACTGACACT
CGT 
TTGTCGCTTGGTCTCCG 
CGA 
255 
Prex1 N233 WT allele 
(1st set) 
AATGAGACTAAGAGGCA 
GAT 
AGTTACTGAGGGGAGTT
GGC 
328 
Prex1 N233 WT allele 
(2nd set) 
CTGGGAAGACTGACACT
CGT 
CTGCCTCTTAGTCTCAT 
TGA 
256 
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Table 3.8: List of primers used for genotyping of catalytically inactive Prex1 and Prex2 
mouse strains. 
 
Target Forward Primer Reverse primer 
PCR 
product 
size 
Prex1 Exon 1 
TTCTACAAAGATCCC 
CGCCCAC 
TGACTGTGCAATTCGA 
GCTG 
893 
Prex1 Exon 6 
CTGGGAAGACTGAC 
ACTCGT 
AGTTACTGAGGGGAG 
TTGGC 
566 
Prex2 Exon 1 
GACTGTCCCGTTCTG 
AGTCC 
AATTTGCCCTGGGAG 
ATGGA 
571 
Prex2 Exon 6 
TGCTCACTCATGGAT 
TTGACC 
TCCATCACACATGTC 
TCAGGT 
536 
 
Table 3.9: List of probes used for genotyping of catalytically inactive Prex2 mouse strain by 
Transnetyx. 
 
Target Forward primer Reverse primer Reporter 1 Reporter 2 
Prex2 
Exon 1 
CCGAGCGCGACT
ACGTG 
GACTTGGTGCCG
TGCG 
CACGCTGGAG
TTCCTG 
TACCCTAGAGT
TCCTGGT 
Prex2 
Exon 6 
CTGTACCGGAGC
ACTGGAGATCA 
GCCTGCCACTCT
TCTAAAACTTCCA 
TCTCCATCTGT
CTCTTGG 
TCTCCATTTGC
CGCTTG 
 
3.5.2 In vivo testing of mice 
Cohorts were selected for age- and sex-match between wild type and genetically 
modified mice (Prex1–/–, Prex2–/–, double mutant Prex1–/–;Prex2–/–, or Prex2E22A 
mice), and were additionally weight-matched at the onset of the study. Cohorts were 
followed for one year of their life, from young adult to old age. Glucose tolerance 
tests were performed at 10, 15, 25, 39 and 52 weeks of age. Insulin tolerance tests 
were done at 25 and 43 weeks of age on the same mice, and the mice were also 
tested in metabolic cages at the age of 11 months. At the end of the study, at 12 
months of age, the mice were culled humanely by CO2 inhalation and pithing. The 
carcasses were kept in the -80oC freezer for body composition analysis by EchoMRI. 
3.5.3 Mouse intraperitoneal glucose tolerance test (IPGTT) 
For IPGTT, mice were habituated to being handled by tail marking with permanent 
marker pen, weighing and scruffing for at least two days preceding the experiment. 
On the day of the glucose challenge, the mice were fasted for 6 h starting at 8.30 
AM, water remaining available ad libitum throughout. 15 min prior to glucose 
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injection, the mice were weighed and their baseline blood glucose level tested by 
tail prick and glucometer reading, using the AlphaTRAK 2 blood glucose monitoring 
system (Abbott) with the ‘dog’ code as indicated on the test strips. 2 g/kg of glucose 
(20% glucose at 10 ml/kg) was then given intraperitoneally (i.p.) at time 0. Tail 
bleeds were performed at 15, 30, 45, 60, 75 and 90 min after glucose injection and 
the blood glucose level was determined by glucometer.  
3.5.4 Mouse subcutaneous insulin tolerance test (SCITT) 
For SCITT, the mice were fasted for 4 h on the day of the insulin challenge, starting 
at 8.30 AM, water remaining available ad libitum throughout. 15 min prior to insulin 
injection, the mice were weighed and their baseline blood glucose level were tested 
as described above. 0.75 IU/kg of sterile human recombinant insulin (Actrapid) 
diluted in DPBS (5 ml/kg at 0.15 IU/ml) was then given subcutaneously (s.c.) at time 
0. Tail bleeds were performed at 15, 30, 45, 60, 90, 120 and 180 min after insulin 
injection and blood glucose level was determined by glucometer. In rare cases, 
animals reached dangerously low blood glucose levels of around 2-3 mM. These 
mice were injected intraperitoneally with 100 μl 20% glucose in order to avoid 
hypoglycemic shock and were excluded from the rest of the experiment. During 
experimental optimisation, a lower concentration of insulin (0.5 IU/kg) was tested for 
female mice on HFD, where sterile human recombinant insulin, diluted in DPBS, 
was given subcutaneously (5 ml/kg at 0.10 IU/ml). However, this did not trigger a 
sufficient response, so the higher dose of 0.75 IU/kg was selected for the majority 
of experiments (see supplementary Figure S15).  
3.5.5 Mouse metabolic cages 
To monitor food and water consumption and the production of urine and faeces, 
mice were group-housed in metabolic cages (up to 3 mice/cage), usually at the age 
of 11 months, unless otherwise indicated. Mice were habituated to metabolic cages 
for 1 h on a Friday and for 3 h on the following Monday. Then, mice were housed in 
metabolic cages for 16 h, overnight, for 3 subsequent nights with pre-weighed food 
and water available ad libitum throughout. During daytime, the mice were returned 
into their individually ventilated cages. The remaining food and water, as well as the 
produced urine and faeces, were weighed and recorded for each night. The 
metabolic cages were cleaned and fresh collection tubes were used for each of the 
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3 testing nights.  
3.5.6 Mouse body composition and organ weight 
To analyse the overall body composition of the mice that had undergone metabolic 
assessment, mice were culled after the end of the experiment at 12 months of age, 
and the mouse carcasses kept in the -80oC freezer. The bodies were thawed and 
scanned by EchoMRI to determine the whole body fat and lean mass.  
For organ weighing, young mice (10 week-old males and females), as well 
as middle-aged mice (25 week-old males and 30 week-old females, mostly ex-
breeders) were culled by CO2 and exsanguination, weighed and dissected for organ 
collection. The weights of thirteen organs (brain, intBAT, ingWAT, anterior thigh 
skeletal muscle, pancreas, kidneys, spleen, liver, thymus, heart, lung, salivary 
gland, and when applicable testes) were measured and data were normalised to 
total body weight. 
3.5.7 Ex vivo insulin signalling using mesoscale 
For ex vivo insulin signalling studies, mice were challenged with insulin prior to 
sacrifice and tissue retrieval. For these experiments, mice were fasted for 4 h from 
8.30 AM and tested for their basal blood glucose level by tail prick and glucometer 
reading as described in Section 3.5.4. The mice were subcutaneously injected with 
sterile DPBS at 500 ml/kg or with sterile 0.75 IU/kg human recombinant insulin, 
diluted in DPBS, (5 ml/kg at 0.15 IU/ml). 14 min post injection, the blood glucose 
level was measured again to confirm a response to insulin. At 15 min post injection, 
the mice were sacrificed humanely by cervical dislocation and pithing. Immediately 
thereafter, tissues (liver, anterior thigh skeletal muscle and ingWAT) were collected, 
snap frozen in liquid nitrogen and stored at -80oC. 
Tissue lysates were prepared from less than 50 mg of tissue – typically 2 
biopsy punches of 2 mm length (KAI Disposable Biopsy Punch, BP-20F). Tissue 
was homogenised in Tris lysis buffer (150 mM NaCl, 20 mM Tris, pH 7.5, 1 mM 
EDTA, 1 mM EGTA, 1% Triton-X-100), supplemented with 1% Protease Inhibitor 
Solution, 1% Phosphatase Inhibitor Solution I, 1% Phosphatase Inhibitor Solution II, 
and 0.4% PMSF in DMSO (MSD, R60TX-2), using the TissueLyser II (Qiagen) at a 
frequency of 300/s for 1.5 min. Samples were then incubated on ice for 30 min with 
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frequent vortexing. Finally, samples were centrifuged for 10 min at 1000 x g and 
4oC, and the supernatant was collected and stored at -80oC. For the skeletal muscle 
there was an additional step of tissue homogenisation using the TissueLyser II prior 
to the addition of Tris lysis buffer, and for the adipose tissue there was a delipidation 
step after the centrifugation. Sample concentration was determined using the Pierce 
BCA Protein Assay Kit (ThermoScientific, 23227) following guidelines provided by 
the manufacturer. The Mesoscale Multi-Spot assay system was used to measure 
the phospho-protein and total levels of Akt, p70S6K, and GSK3β (Akt Signaling 
Panel Whole Cell Lysate, K15115D-2, MSD and Akt Signaling (Total Protein) Panel 
Whole Cell Lysates, K15133D, MSD, respectively), following manufacturer’s 
guidelines. Briefly, plates were blocked by the addition of 150 μl/well blocking 
solution and incubation for 1 h with shaking at 700 rpm, RT. After blocking, the plates 
were washed 3 times with 300  μl/well of Tris wash buffer, and 25 μl of sample (liver 
at 2125 μg/ml, skeletal muscle at 1500 μg/ml, ingWAT at 800 μg/ml)  was added per 
well. Plates were incubated at RT for 1 h with shaking at 700 rpm, prior to being 
washed, as previously. Finally, plates were incubated with 25 μl/well of detection 
antibody solution for 1 h at RT with shaking, 700 rpm, they were washed, as 
previously, and 150 μl/well of 1x read buffer T were added directly before imaging 
each plate using the SECTOR Imager. 
3.5.8 ELISA  
For ELISA 14 weeks old mice were fasted for 6 h from 8.30 AM and were 
anaesthetised by rising concentration of CO2 followed by pithing. Whole blood was 
collected by cardiac puncture, taking advantage of the atrial fibrillation and placed 
in EDTA treated Microvette (Microvette CB 300 K2E, SARSTEDT, 16.444.100). 
Samples were centrifuged at RT for 5 min at 2000 x g and the resulting supernatant 
was transferred into a clean polypropylene tube. Samples were centrifuged for a 
second time at RT for 5 min at 2000 x g, the supernatant (plasma) was apportioned 
into 0.5 ml aliquots and stored at -80oC. 
For the quantitative determination of adiponectin, glucagon, and insulin in 
mouse plasma the Mouse Adiponectin ELISA kit (Crystal Chem, 80569), Mercodia 
Glucagon ELISA kit (Mercodia, 10-1281-01), and Ultra Sensitive Mouse Insulin 
ELISA kit (Crystal Chem, 90080) were used, respectively, following manufacturer’s 
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guidelines. 
3.5.9 Bone marrow transplant 
6-8 week old bone marrow recipient mice were γ-irradiated with two doses of 500 
rads (5 Gy) of 137Cs, separated over 3 hours. From this day onwards to 2 weeks, 
their drinking water was supplemented with 2 mg/mL neomycin to minimise chances 
of infections during the critical period of bone marrow reconstitution. On the day after 
the irradiation, bone marrow cells were prepared from 12 week-old donor mice, 
using sterile techniques and solutions throughout. Bone marrow was flushed from 
isolated femurs, tibia and pelvises with PBS-FBS (Dulbecco’s PBS, 10% FBS) using 
a 25G needle, and cells were gently triturated. Cells were counted using a 
haemocytometer and resuspended at 5 × 107 cells/mL in PBS-FBS before passing 
them through a sterile 40 μm cell strainer. One hundred microliter of the cell 
suspension (5 × 106 cells) was then injected intravenously (i.v.) into the irradiated 
recipient mice through the tail vein. The irradiation and i.v. injections were performed 
by senior animal technicians. Animals were housed in individually ventilated caging 
for the next 10 weeks to allow the reconstitution of the hematopoietic system. The 
efficiency of the reconstitution was assessed at the end of the experiments, by 
western blotting of total lysates of cells recovered from the bone marrow for the 
expression of Prex1. 
 
3.6 Generation of GEF-Dead Prex Mouse Strains 
Mouse strains with catalytically inactive versions of Prex1 or Prex2 were generated 
using CRISPR technology by introducing mutations in the genomic DNA which 
result in two amino acid substitutions at critical residues in the catalytic DH domain 
of the mouse Prex1 and Prex2 proteins.  
3.6.1 Single guide RNA (sgRNA) selection and design 
sgRNAs were designed such that they would direct Cas9 nuclease-mediated 
double-strand cleavage to exon 1 and exon 6 of the Prex1 and Prex2 genomic 
sequences, close to the residues of interest. sgRNAs were designed to be 20 
nucleotides long, positioned directly upstream of a requisite 5’-NGG protospacer 
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adjacent motif (PAM) and to not have highly homologous sites elsewhere in the 
mouse genome, to reduce the risk of off-target cleavage. Off-target potential was 
assessed and scored using several CRISPR sgRNA bioinformatic design tools, 
including the software provided by the Feng Zhang laboratory (http://crispr.mit.edu/), 
the Broad Institute (http://www.broadinstitute.org/rnai/public/ 
analysis-tools/sgrna-design), and the E-CRISPR (http://www.e-crisp.org/E-
CRISP/). Three sgRNAs were selected for each target based on their score in these 
web-based tools, their position relevant to the region in which we aimed to introduce 
the point mutation and the DNA strand they were targeting. To clone the guide 
sequence into the sgRNA expression plasmid, two oligonucleotides of the following 
form were synthesized, with the 5’-NGG motif not being included in the 20-nt guide 
sequence: 
5’ – CACCGNNNNNNNNNNNNNNNNNNN     – 3’ 
3’ –           CNNNNNNNNNNNNNNNNNNNCAAA – 5’ 
Since a 5’ guanine is required for transcription from the U6 promoter that is used to 
express the sgRNAs, any sgRNAs that lacked this feature were extended in the 5’ 
direction by the addition of a single guanine. The sequences of the guide RNAs 
designed are detailed in the results Table 4.4. 
3.6.2 Guide-it sgRNA in vitro transcription and screening 
system 
sgRNAs were produced and the assessment of their targeting efficiency in vitro 
done using the Guide-it kit (Clontech, 631439), following the manufacturer’s 
protocol. Briefly, DNA template that contained the sgRNA encoding sequence under 
the control of a T7 promoter was generated by a PCR reaction according to 
guidelines provided by the manufacturer. 100 ng of sgRNA-encoding template was 
then transcribed in vitro to create the sgRNA, using the T7 polymerase and 
transcription buffer provided. A cleavage template for screening the sgRNAs was 
also created by amplifying a ~2 kb fragment of mouse genomic DNA, containing the 
target sequence in an asymmetric position that produces two cleavage fragments 
of unequal size – primers are listed in Table 4.5. Thereafter, the DNA template was 
cleaved in vitro using a sgRNA in combination with the Guide-it Recombinant Cas9 
Nuclease in the manufacturer’s recommended buffer. The reaction was incubated 
at 37oC for 1 h and then stopped by a 10 min incubation at 70oC. Finally, the whole 
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reaction volume was analysed on a 1% TBE agarose gel. 
3.6.3 Surveyor assay 
To assess the ability of sgRNAs to guide the Cas9 nuclease to the right genomic 
site within cells, the Surveyor Assay was performed on DNA extracts of NIH/3T3 
cells transfected with sgRNA-expressing pSpCas9(BB)-2A-GFP plasmid. The 
Surveyor Assay was performed using the IDT Surveyor Mutation Detection Kit 
following the manufacturer’s instructions. Briefly, touch-down PCR amplicons of the 
DNA regions of interest from mutant and wild type cells were prepared using Pfu 
polymerase as described in Section 3.1.1 and the primers listed in Table 4.5. Equal 
amounts of mutant and wild type DNA were mixed and hybridized to form 
hetero/homoduplexes. The hetero/homoduplex formation was performed by heating 
the mixture at 95oC for 10 min and then letting it cool down to 25oC by 2.5oC/min. 
Wild type DNA underwent the same procedure to serve as homoduplex negative 
control. The annealed test hetero/homoduplex and reference homoduplex mixtures 
were digested with Surveyor Nuclease S following the manufacturer’s protocol. The 
reaction was incubated at 42oC for 1 h and then analysed on a 1% TBE agarose 
gel. 
3.6.4 Single stranded DNA (ssDNA) repair template design  
To promote homology-directed repair (HDR), ssDNA repair templates were 
designed such that they were around 200 bp long and, apart from the desired point 
mutation, carried at least one silent mutation, which created restriction digest site 
for screening purposes. When possible, silent mutations that destroyed the PAM 
sides were also introduced. The sequences of the ssDNA designed are detailed in 
the Table 4.6. The repair templates were ordered from Dharmacon as PAGE-
purified Ultramer ssDNA. 
3.6.5 Mouse strain generation by HDR-mediated gene 
targeting of mouse ES cells  
To generate knock-in mouse ES cell clones, Freestyle MAX reagent (Thermofisher, 
16447100) was used following the manufacturer’s instructions. ES cells (15 × 105 
cells), maintained as described in Section 3.2.3, were transfected with 500 ng 
sgRNA targeting Prex1 E51A in the pSpCas9(BB)-2A-GFP (PX458) vector, 500 ng 
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of sgRNA targeting Prex1 N233A in the pCas-Guide-EF1a-CD4 vector, 200 ng of 
donor ssDNA for Prex1 E51A, and 200 ng of donor ssDNA for Prex1 N233A. The 
sequences of the guide RNAs designed are detailed in the results Table 4.4, while 
the sequences of the ssDNA designed are detailed in the Table 4.6. The cells were 
cultured for 10 days prior to being trypsinised and diluted to single cells. Expanded 
colonies were then split into two 96-well plates. One plate of ES cells was frozen at 
-80°C, and another plate was used to prepare genomic DNA for PCR screening and 
confirmation by Sanger sequencing. Positive colonies were taken forward by Dr 
Dominik Spensberger to the Babraham Small Animal Unit for implantation into 
mouse White-C57BL/6J blastocysts. Mice were screened for chimerism by coat 
colour, and biopsies of promising chimeras were screened as described in Section 
3.5.1. Targeted chimeras were bred with wild type C57BL/6J mice and all offspring 
were genotyped to test for germline transmission. 
3.6.6 Mouse strain generation by zygote microinjection  
In order to generate Prex2E22A mice, Dr Dominik Spensberger performed zygote 
microinjection. Briefly, the microinjection solution consisted of annealed crRNA (20 
ng/μl; IDT), tracrRNA (20 ng/μl; Dharmacon), Cas9 mRNA (50 ng/μl; Dharmacon) 
and ssDNA donor (15 ng/μl; Dharmacon), which were suspended in nuclease-free 
water. The sequences of the guide RNAs designed are detailed in the results Table 
4.4, while the sequences of the ssDNA designed are detailed in the Table 4.6. The 
injection solution was microinjected into the pronucleus of C57BL/6J mouse 
zygotes. All pups were genotyped as described in Section 3.5.1, and heterozygous 
Prex2E22A/+ mice were bred together to generate homozygous Prex2E22A/E22A 
animals. Once this strain was established, females were super-ovulated for zygote 
production, and were re-targeted by a further round of pronuclear injections to target 
the second site, Prex2N204A. Prex2E22A/E22A;N204A/+ mice were bred together to 
generate homozygous double knock-in Prex2E22A/E22A;N204A/N204A mice. 
 
3.7 Statistical Analysis 
Results are given as mean ± standard error of the mean (SEM). For the analysis of 
IPGTT and SCITT, data were normalised by subtracting the basal blood glucose 
90 | P a g e  
level – as measured 15 min before the injection – of each individual mouse from the 
blood glucose level measured at each time point. The total glucose response was 
calculated as the area under the curve (AUC) of the normalised data. For 
comparison between two groups, unpaired Student’s t-test was used, whereas for 
comparison among multiple groups, ordinary one-way ANOVA followed by post-hoc 
tests with Tukey’s multiple comparisons correction. Longitudinally observed 
parameters in different groups were compared by 2-way ANOVA with repeated 
measures followed by post-hoc tests with Sidak multiple comparisons correction. 
Parameters with values p<0.05 were considered to differ significantly. 
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Chapter 4 - Results 
 
4.1 Expression of endogenous Prex1 and Prex2 in 
insulin-responsive mouse tissues 
To begin the study of the roles of endogenous Prex1 and Prex2 in glucose 
metabolism, the expression levels of these proteins in insulin-responsive tissues 
needed to be assessed. The main insulin-sensitive tissues are the liver, adipose 
tissue and skeletal muscle. Furthermore, as the brain is the overall controller of 
metabolic processes, brain samples were also included.  
Published data from our lab showed that both Prex proteins are expressed in 
brain and, at lower levels, in liver. Here, brain, liver, skeletal muscle, subcutaneous 
inguinal and visceral epididymal (gonadal) white adipose tissue as well as 
interscapular brown adipose tissue (intBAT) from Prex1+/+;Prex2+/+ (Prex WT), 
Prex1–/– (Prex1 KO), Prex2–/– (Prex2 KO) and Prex1–/–;Prex2–/– (Prex DKO) were 
tested by western-blotting for the endogenous expression levels of the Prex 
proteins. Total tissue lysates from each genotype were blotted with the 6F12 mouse 
monoclonal antibody against PREX1. Total protein extracts from HepG2 cells 
transiently overexpressing PREX2 or PREX1, as described in Section 3.2.4, were 
used as controls. As shown in Figure 4.1.1A, clear Prex1 bands were detected in 
brain and liver tissue extracts, but skeletal muscle showed no expression of Prex1 
protein. Prex1 was also detected in the subcutaneous inguinal and visceral 
epididymal (gonadal) white adipose tissue as well as in inBAT. The same 
membranes were also blotted with rabbit polyclonal antibody against PREX2. Prex2 
protein was found to be expressed at low but detectable levels in total brain but not 
in liver. Like Prex1, Prex2 was undetectable in skeletal muscle, but unlike Prex1, its 
expression in adipose tissue was restricted to intBAT (Figure 4.1.1B). After blotting 
for both PREX proteins the membranes were stained with coomassie to confirm 
even protein loading (Figure 4.1.1C). No global up-regulation of Prex2 was seen in 
Prex1-deficient insulin-sensitive tissues, and vice versa, suggesting that Prex 
proteins do not compensate for the loss of the other isoform on a gross protein level 
scale. 
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Taken together, the results indicate that Prex proteins are expressed in all 
major insulin sensitive tissues except skeletal muscle, and therefore could 
potentially play a role in glucose homeostasis in vivo. 
 
 
 
 
Figure 4.1.1: Expression of endogenous Prex1 and Prex2 in insulin-responsive 
mouse tissues.  
(A,B) Brain, liver, skeletal muscle, white adipose tissues (WAT) and brown adipose tissue (BAT) 
were collected from Prex1
+/+
;Prex2
+/+
 wild type (WT), Prex1
–/–
;Prex2
–/– 
(DKO), Prex1
–/–
 (P1 KO) 
and Prex2
–/– 
(P2 KO) mice. Total lysates were prepared at 2% w/v and western-blotted for (A) 
Prex1 and (B) Prex2. Total lysates from HepG2 cells overexpressing either PREX1 (PREX1 OE) 
or PREX2 (PREX2 OE) were used as positive and negative controls, respectively. (C) Coomassie 
stain of blots to show that equal amounts of lysate were loaded per lane. Representative blots 
from 3 preparations are shown. 
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4.2 Metabolic phenotype of Prex1 KO mice 
To understand the role of Prex1 in glucose metabolism in vivo, the metabolic 
phenotype of Prex1–/– (Prex1 KO) mice was studied. Briefly, the mice were tested 
for fasting blood glucose levels, response to glucose tolerance test and response to 
insulin tolerance test, throughout ageing. Glucose tolerance tests (IPGTT) were 
performed at 10 and 15 weeks, and at 6, 9 and 12 months of age by i.p. 
administration of 2 g/kg glucose (20% glucose at 10 ml/kg) after 6 h of fasting, unless 
otherwise indicated. Insulin sensitivity tests (SCITT) tests were done at 5 and 10 
months of age by s.c. administration of 0.75 IU/kg of human recombinant insulin at 
0.15 IU/ml after 4 h of fasting, unless otherwise indicated. Both sexes were tested, 
and two diets were compared, normal chow diet and 45% HFD. In addition, mice 
were assessed for body weight throughout ageing, tested in metabolic cages at 11 
months of age, and their body composition was analysed post mortem at one year. 
Prex1 KO and Prex1+/+;Prex2+/+ (Prex WT) mice of same age and sex were tested 
in parallel under the same conditions for direct comparison.  
4.2.1 Male Prex1 KO mice on chow diet show lower fasting 
blood glucose levels and better glucose tolerance than 
Prex WT mice 
Two independent cohorts, set up almost a year apart, were used to characterise the 
metabolic phenotype of male Prex1 KO mice on chow diet. The Prex WT mice in 
these cohorts responded as expected throughout ageing (see Supplemental Data, 
Section 6), except for an elevated basal blood glucose level at 10 weeks of age, 14 
mM instead of the 12 mM average for Prex WT mice. 
As seen in Figures 4.2.1A and 4.2.2A, the fasting blood glucose level was 
around 11 mM in Prex1 KO males and remained stable throughout ageing, contrary 
to Prex WT males whose blood glucose steadily rose within the year, as expected 
from our analysis of multiple Prex WT cohorts shown in Section 6.1. During IPGTT  
(2 g/kg), the blood glucose levels of Prex1 KO mice peaked lower, at 21-24 mM,  
compared to Prex WT males, 15 min after the glucose challenge, and also 
decreased back to basal level faster and more rapidly (Figure 4.2.1A). Moreover, 
Prex1 KO males did not exhibit the mild glucose intolerance observed in Prex WT 
mice from the age of 6 months onwards (Figure 4.2.1B). Overall, Prex1 KO had 
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better glucose tolerance than Prex WT males throughout ageing (Figures 4.2.1C 
and 4.2.1B), despite gaining weight at a comparable rate and having similar body 
composition (Figure 4.2.2C-D). Therefore, Prex1 KO males show lower fasting 
blood glucose and better glucose clearance compared to Prex WT controls. 
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Figure 4.2.1: Male Prex1 KO mice on chow diet show lower fasting blood glucose 
levels and better glucose tolerance than Prex WT mice. 
Male Prex1
–/–
 (Prex1 KO, red) and Prex1
+/+
;Prex2
+/+
 (Prex WT, blue) mice on chow diet were 
subjected to i.p. glucose tolerance test (IPGTT) at the ages of 10 and 15 weeks, 6, 9 and 12 
months. Food was withdrawn 6 h prior to i.p. injection of 20% glucose at 10 ml/kg (final 
concentration 2 g/kg). Blood glucose levels were tested by tail bleed 15 min prior to the i.p. injection 
to determine the basal fasted blood glucose levels, and every 15 min after the glucose injection 
for 90 min, as indicated, to assess the response to glucose challenge.(A) Blood glucose 
concentration during IPGTT. (B) Blood glucose levels during IPGTT, normalised by subtracting 
the basal blood glucose level. (C) Total glucose response (AUC of normalised data). Data are 
pooled from 2 independent cohorts (Prex WT n=10; Prex1 KO n=10), and are presented as mean 
± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple comparisons correction was 
used to compare genotypes during IPGTT. Unpaired Student’s t-test was used to analyse the total 
glucose response. 
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Figure 4.2.2: The low fasting blood glucose levels and improved glucose tolerance 
of male Prex1 KO mice on chow diet persist throughout ageing.  
The fasting blood glucose levels, response to glucose challenge, and body weight of the male 
Prex1 KO (red) and Prex WT (blue) mice from Figure 4.2.1 are expressed as a function of age. 
(A) Fasting blood glucose levels; data from column A in Figure 4.2.1. (B) Response to IPGTT; 
normalised data from columns B and C in Figure 4.2.1. (C) Body weight, measured after 6 and 4 
h fasting, prior to glucose and insulin challenges, respectively. (D) Body composition at 1 year of 
age. The mice in (A-C) were culled at 1 year of age and the cadavers were scanned by Echo MRI 
for lean mass and body fat. Data are pooled from 2 independent cohorts (Prex WT n=10; Prex1 
KO n=10) and presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s 
multiple comparisons correction was used to compare genotypes during ageing. Unpaired 
Student’s t-test was used to analyse the body composition. 
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Upon insulin challenge, the blood glucose levels of Prex1 KO males dropped 
to their lowest level at 45 min post injection, showing a drop of 5 mM, and returned 
to around 10 mM at 180 min (Figure 4.2.3A,C), similarly to the Prex WT controls. 
At 10 months of age however, Prex1 KO males showed a reduced response to 
insulin challenge compared to their Prex WT counterparts (Figure 4.2.3E-H). The 
fasting blood glucose levels were significantly lower in the Prex1 KO than the Prex 
WT males (Figure 4.2.3E-F), and their response to insulin was smaller and shorter-
lasting (Figure 4.2.3G). In Prex1 KO males, the glucose levels dropped only by 3 
mM, instead of the 5 mM seen in Prex WT, and returned to basal levels at 120 min 
instead of persisting for the duration of the test (Figure 4.2.3G). This would suggest 
that Prex1 KO mice became insulin resistant at old age. However, Figure 4.2.3E 
shows that this may be consequence of the reduced fasting blood glucose level of 
these mice. In absolute terms, the blood glucose level of the Prex1 KO mice actually 
dropped lower than that of Prex WT mice in response to the insulin challenge and 
in both genotypes glucose returned to around 10 mM at 150 min. It is difficult, 
therefore, to conclude whether the ageing Prex1 KO males are truly insulin resistant 
or if their lower fasting blood glucose levels mean they simply need to respond less 
to insulin in order to maintain a similar level of glucose homeostasis. In any event, 
their response to insulin is less at 10 months of age and this is an effect of ageing, 
as the Prex1 KO males responded normally to the insulin challenge at 5 months of 
age. 
To begin to investigate the cause of the lower fasting blood glucose level and 
improved glucose tolerance, the mice were housed in metabolic cages at 12 weeks 
and 11 months of age. In both ages, the water and food consumption as well as the 
urine and faeces production of Prex1 KO male mice were normal (Figure 4.2.4A-
H). The only parameter that showed a tendency towards differences between 
genotypes was the water consumption, which was slightly increased in Prex1 KO 
males, although this did not reach statistical significance. 
In summary, Prex1 KO males on chow diet show lower fasting blood glucose 
levels and improved glucose homeostasis compared to Prex WT mice throughout 
ageing, and apparently, they become insulin-resistant in old age. 
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Figure 4.2.3: Prex1 KO male mice on chow diet show apparent insulin resistance 
in old age.  
The male Prex1 KO (red) and Prex WT (blue) mice on chow diet shown in Figure 4.2.1 were 
subjected to s.c. insulin tolerance test (SCITT) at the ages of (A-D) 5 and (E-H) 10 months. Food 
was withdrawn 4 h prior to s.c. injection of 0.75 IU/kg of human recombinant insulin at 0.15 IU/ml. 
Blood glucose levels were tested by tail bleed 15 min prior to the s.c. injection to determine basal 
blood glucose levels, as well as after the insulin injection at 15, 30, 45, 60, 90,120 and 180 min to 
assess the response to insulin. (A,E) Blood glucose concentration during SCITT. (B,F) Fasting 
blood glucose levels after 4 h fasting. (C,G) Blood glucose levels during SCITT, normalised by 
subtracting the fasting blood glucose level from each mouse individually. (D,H) Total insulin 
response (AUC of normalised data). Data are pooled from 2 independent cohorts (Prex WT n=10; 
Prex1 KO n=10) and are presented as mean ± SEM. 2-way ANOVA with repeated measures and 
Sidak’s multiple comparisons correction was used to compare genotypes during SCITT. Unpaired 
Student’s t-test was used to analyse the basal blood glucose levels and total insulin response. 
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Figure 4.2.4: Male Prex1 KO mice on chow diet perform normally in metabolic 
cages.  
Male Prex1 KO (red) and Prex WT (blue) mice were habituated to metabolic cages, as detailed in 
Materials and Methods, weighed and group-housed (up to 3) in metabolic cages overnight for 16 
h on 3 subsequent nights with food and water provided ad libitum. Their (A,E) water consumption, 
(B,F) food consumption, (C,G) urine production, and (D,H) faeces production were measured after 
each night and were normalised to the combined body weights of the mice housed in each cage. 
(A-D) Data are pooled from 2 independent cohorts of 12 week-old males (WT n=9; Prex1 KO n=9). 
(E-H) Data pooled from 2 independent cohorts of male Prex1 KO and Prex WT mice in Figure 
4.2.1 at 11 months of age (Prex WT n=10; Prex1 KO n=10). Data are presented as the mean ± 
SEM of each night (n=3), with unpaired Student’s t-test for comparison between genotypes. 
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4.2.2 Male Prex1 KO mice on HFD have low fasting blood 
glucose levels, but a normal glucose tolerance 
Next, male Prex1 KO mice were introduced to 45% HFD, after a “reference” glucose 
challenge at 10 weeks of age, and remained on this HFD throughout their life. Data 
here are pooled from two independent cohorts, set up almost 5 months apart. The 
Prex WT control mice in these cohorts responded as expected throughout ageing. 
As shown in Figure 4.2.5A, Prex1 KO male mice on HFD maintained their 
lower fasting blood glucose levels up to the age of 6 months. Similarly to Prex WT 
mice, HFD caused a rapid onset of glucose intolerance in Prex1 deficient mice 
(Figure 4.2.5A). During glucose tolerance tests (performed as for mice on chow 
diet) , the blood glucose levels of HFD-fed Prex1 mice kept increasing beyond the 
15 min time point, reaching 42 mM at 60 min, and remaining around 40 mM within 
the 90 min of the test. Normalisation of the glucose response showed that Prex1 KO 
mice had slightly worse glucose tolerance than the Prex WT mice after only one 
month of HFD (Figure 4.2.5B-C). As one month of HFD was sufficient to render the 
mice of both genotypes severely glucose intolerant, we reduced the dosage of 
glucose in IPGTTs at later ages to one quarter of the original dose (0.5 g/kg, data in 
ochre box). As well as preventing mice from going into hyperglycaemic shock, it was 
reasoned that submaximal doses of glucose might unravel subtle differences 
between the genotypes. The graphs within the ochre box show that, under these 
conditions, glucose only triggered a mild response (Figure 4.2.5C). Although it still 
took longer for blood glucose levels to return to normal (Figure 4.2.5B), there was 
no difference between the genotypes. Hence, in contrast to mice on chow diet, 
Prex1 KO males on HFD were not protected from developing glucose intolerance. 
The effects of ageing are summarised in Figure 4.2.6. As mentioned above, 
the HFD induced an increase in the fasting blood glucose levels of male Prex1 KO 
mice. However, this increase was not as sharp as for their Prex WT counterparts, 
meaning that the fasting blood glucose levels of the Prex1 KO males remained lower 
than those of the Prex WT controls until 9 months of age (Figure 4.2.6A). On the 
other hand, the response to glucose challenge in Prex1 KO mice on HFD was 
slightly worse at 15 weeks of age that that or WT controls, but comparable to the 
response of Prex WT males at all other ages tested (Figure 4.2.6B). 
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Figure 4.2.5: Male Prex1 KO mice on HFD have low fasting blood glucose levels, 
but exhibit a normal response to glucose challenge. 
The fasting blood glucose levels and response to IPGTT were measured in male Prex1 KO (red) 
and Prex WT (blue) mice on 45% HFD at the ages of 10 and 15 weeks, 6, 9 and 12 months, as 
described in the legend to Figure 4.2.1. Glucose was injected at 2 g/kg at 10 and 15 weeks of 
age, and at 0.5 g/kg at later ages (ochre box). (A) Blood glucose concentration during IPGTT. (B) 
Blood glucose levels during IPGTT, normalised by subtracting the basal blood glucose level. (C) 
Total glucose response (AUC of normalised data). Data are pooled from 2 independent cohorts 
(Prex WT n=10; Prex1 KO n=10), and are presented as mean ± SEM. 2-way ANOVA with repeated 
measures and Sidak’s multiple comparisons correction was used to compare genotypes during 
IPGTT. Unpaired Student’s t-test was used to analyse the total glucose response. 
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Figure 4.2.6: Prex1 KO males on HFD are not protected from developing glucose 
intolerance.  
The fasting blood glucose levels, response to glucose challenge, and body weight of the male 
Prex1 KO (red) and Prex WT (blue) mice on HFD from Figure 4.2.5 are expressed as a function 
of age. Note that the dose of glucose was reduced from 2 g/kg to 0.5 g/kg from the age of 6 months 
onwards (data in ochre box). In faded red are represented the Prex1 KO male mice on chow diet 
from Figure 4.2.1 for visual comparison, but no statistical analysis was performed, as the animals 
were not directly compared experimentally. (A) Fasting blood glucose levels; data from column A 
in Figure 4.2.5. (B) Response to IPGTT; normalised data from columns B and C in Figure 4.2.5. 
(C) Body weight, measured after 6 and 4 h fasting, prior to glucose and insulin challenges, 
respectively. (D) Body composition at 1 year of age. The mice in (A-C) were culled at 1 year of 
age and the cadavers were scanned by Echo MRI for lean mass and body fat. Data are pooled 
from 2 independent cohorts (Prex WT n=10; Prex1 KO n=10), and are presented as mean ± SEM. 
2-way ANOVA with repeated measures and Sidak’s multiple comparisons correction was used to 
compare genotypes during ageing. Unpaired Student’s t-test was used to analyse the body 
composition. 
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Both at 5 and 10 months of age, the response of male Prex1 KO mice on 
HFD to insulin challenge was similar to that of Prex WT mice (Figure 4.2.7A-D, E-
H), despite differences in their basal blood glucose levels (Figure 4.2.7B, F). 
Interestingly the response of both genotypes to insulin was greater in mice on HFD 
compared to chow diet. Moreover, the insulin response of HFD-fed mice was 
reduced at 10 months compared to 5 months of age in a similar manner for both 
genotypes (Figure 4.2.7D, H), indicating that HFD did render Prex1 KO males 
insulin intolerant with age, but to a similar extent  to Prex WT mice. 
The mice from both genotypes gained weight in a similar way, and their body 
composition at one year of age was identical (Figure 4.2.6C-D). Finally, no 
difference was found in their water and food consumption or urine and faeces 
production in the metabolic cages (Figure 4.2.8A-D).  
In summary, Prex1 deficiency did not prevent mice on HFD from becoming 
glucose intolerant, although it helped maintain low fasting blood glucose levels, and 
neither did it affect their insulin sensitivity. Hence, the absence of Prex1 improves 
glucose tolerance, but only during healthy ageing and not in mice with metabolic 
syndrome. 
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Figure 4.2.7: Male Prex1 KO mice on HFD show a normal response to insulin 
challenge. 
The fasting blood glucose levels and response to SCITT were measured in the male Prex1 KO 
(red) and Prex WT (blue) mice on 45% HFD from Figure 4.2.5 at the ages of (A-D) 5 and (E-H) 
10 months, as described in the legend to Figure 4.2.3. (A,E) Blood glucose concentration during 
SCITT. (B,F) Fasting blood glucose levels. (C,G) Blood glucose levels during SCITT, normalised 
by subtracting the fasting basal blood glucose level from each mouse individually. (D,H) Total 
insulin response (AUC of normalised data). Data are pooled from 2 independent cohorts (Prex WT 
n=10; Prex1 KO n=10) and are presented as mean ± SEM. 2-way ANOVA with repeated measures 
and Sidak’s multiple comparisons correction was used to compare genotypes during SCITT. 
Unpaired Student’s t-test was used to analyse the basal blood glucose level and total insulin 
response. 
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Figure 4.2.8: Male Prex1 KO mice performed normally in metabolic cages. 
The male Prex1 KO (red) and Prex WT (blue) mice from Figure 4.2.5 were habituated to metabolic 
cages at 11 months of age, as detailed in Materials and Methods, weighed and group-housed (up 
to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water provided 
ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and (D) 
faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are pooled from 2 independent cohorts (Prex WT 
n=10; Prex1 KO n=10). Data are presented as the mean ± SEM of each night (n=3), and unpaired 
Student’s t-test was used for the comparison between the genotypes. 
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4.2.3 Female Prex1 KO mice on chow diet show similar 
glucose response to Prex WT mice throughout ageing 
Similar to males, Prex1 KO females had lower fasting blood glucose levels than 
Prex WT females, throughout ageing (Figures 4.2.9A and 4.2.10A). However, this 
phenotype of females was not as pronounced as that of males, presumably because 
females have lower fasting glucose levels than males anyway. It is worth mentioning 
that the Prex WT females in this cohort had slightly higher fasting blood glucose 
levels compared to most other Prex WT females tested under the same conditions 
(see Supplementary Data, Section 3). Regarding the response to glucose 
challenge, Prex1 KO females also showed a trend towards improved glucose 
tolerance compared to Prex WT controls (Figure 4.2.9B-C). However, this did not 
persist at all tested ages and was not statistically significant, unlike in males, 
presumably again because the glucose tolerance of females is better than that of 
males (Figure 4.2.10B). The response of Prex1 KO females to insulin challenge, at 
10 months of age, was identical to that of their Prex WT controls (Figure 4.2.11A-
E). 
The rate of body weight gain and the body composition of Prex1 KO females 
were also identical to that of Prex WT female mice (Figure 4.2.10C, D). Interestingly, 
the Prex1 deficient females had a tendency to increased water consumption, and 
produced significantly more urine compared to their Prex WT counterparts at 11 
months of age (Figure 4.2.12A, C), whereas food consumption and faeces 
production, were similar between the groups (Figure 4.2.12B, D).  
Overall, therefore, there was a sex dependence in the metabolic phenotype 
of Prex1 KO mice. Only Prex1 KO males showed significantly lower basal blood 
glucose levels and improved glucose tolerance throughout ageing compared to Prex 
WT controls. However, females showed a similar trend. It should be kept in mind 
that only one cohort of Prex1 KO females was tested, and bigger n-numbers would 
be required to further investigate the extent and possible causes of this sex 
dependency. 
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Figure 4.2.9: Female Prex1 KO mice on chow diet show a normal response to 
glucose challenge. 
The fasting blood glucose levels and response to IPGTT were measured in female Prex1 KO (red) 
and Prex WT (blue) mice on chow diet, as described in the legend to Figure 4.2.1. Only data from 
15 weeks and 9 months of age are shown, for brevity, although mice of all ages up to one year 
were tested. (A) Blood glucose concentration during IPGTT. (B) Blood glucose levels during 
IPGTT, normalised by subtracting the basal blood glucose level. (C) Total glucose response (AUC 
of normalised data). Data are from 1 cohort (Prex WT n=4; Prex1 KO n=3) and presented as mean 
± SEM. 2-way ANOVA with repeated measure and Sidak’s multiple comparisons correction was 
used to compare genotypes during IPGTT. Unpaired Student’s t-test was used to analyse the total 
glucose response. 
 
108 | P a g e  
 
 
 
 
Figure 4.2.10: Prex1 KO females on chow diet show a tendency for improved 
glucose tolerance during ageing, although the phenotype is milder than in males. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the female 
Prex1 KO (red) and Prex WT (blue) mice in Figure 4.2.9 are expressed as a function of age. (A) 
Fasting blood glucose levels; data from column A in Figure 4.2.9. (B) Response to IPGTT; 
normalised data from columns B and C in Figure 4.2.9. (C) Body weight, measured after 6 and 4 
h fasting, prior to glucose and insulin challenges, respectively. (D) Body composition at 1 year of 
age. The mice in (A-C) were culled at 1 year of age and the cadavers were scanned by Echo MRI 
for lean mass and body fat. Data are from 1 cohort (Prex WT n=4; Prex1 KO n=3) and presented 
as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple comparisons 
correction was used to compare genotypes during ageing. Unpaired Student’s t-test was used to 
analyse the body composition. 
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Figure 4.2.11: Female Prex1 KO mice on chow diet show a normal response to 
insulin challenge. 
The fasting blood glucose levels and response to SCITT were measured in the female Prex1 KO 
(red) and Prex WT (blue) mice from Figure 4.2.9 on chow diet at 10 months of age, as described 
in the legend to Figure 4.2.3. (A) Blood glucose concentration during SCITT. (B) Fasting blood 
glucose levels. (C) Blood glucose levels during SCITT, normalised by subtracting the fasting basal 
blood glucose level from each mouse individually. (D) Total insulin response (AUC of normalised 
data). Data from 1 cohort (Prex WT n=4; Prex1 KO n=3) and presented as mean ± SEM. 2-way 
ANOVA with repeated measures and Sidak’s multiple comparisons correction was used to 
compare genotypes during SCITT. Unpaired Student’s t-test was used to analyse the fasting basal 
blood glucose levels and total insulin response. 
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Figure 4.2.12: Female Prex1 KO mice produce more urine than Prex WT mice. 
The female Prex1 KO (red) and Prex WT (blue) mice in Figure 4.2.9 were habituated to metabolic 
cages at 11 months of age, as detailed in Materials and Methods, weighed and group-housed (up 
to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water provided 
ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and (D) 
faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. (A-D) Data are from 1 cohort (Prex WT n=4; Prex1 KO 
n=3) and presented as the mean ± SEM of each night (n=3). Unpaired Student’s t-test was used 
for comparison between genotypes. 
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4.2.4 Female Prex1 KO mice on HFD exhibit improved 
glucose tolerance compared to Prex WT mice at 6 
months of age 
Having seen that diet affected the metabolic phenotype of Prex1 KO males, Prex1 
KO females were also introduced to 45% HFD. Throughout ageing, HFD did not 
affect the fasting blood glucose levels of Prex1 KO females or Prex WT controls 
(Figures 4.2.13A and 4.2.14A). Yet, HFD rapidly induced a worse response to 
glucose challenge in both genotypes. At 15 weeks, there was no difference between 
the genotypes in their response to glucose challenge. However, interestingly, at 6 
months, when the glucose intolerance of Prex WT females worsened yet further, the 
Prex1 KO mice showed significantly better glucose tolerance, maintaining the level 
of response seen at 15 weeks’ time point. Nevertheless, at 9 months the glucose 
tolerance of Prex1 KO females worsened and became comparable again to that of 
Prex WT mice (Figures 4.2.13B-C and 4.2.14B). For the 12-month time point, 
therefore, a lowered dose of glucose was used during the IPGTT, in order to reveal 
any subtle protection that might be afforded by the Prex1 deficiency, and this is 
indeed what was observed. This protection from glucose intolerance was seen 
despite both genotypes starting from identical body weight and gaining weight at the 
same rate throughout ageing (Figure 4.2.14C). Hence, Prex1 deficiency affords 
some protection from glucose intolerance to female mice on HFD. This was in 
contrast to Prex1 KO males, who showed improved glucose tolerance only on chow 
diet, but not on HFD. 
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Figure 4.2.13: Female Prex1 KO mice on HFD are less glucose intolerant than Prex 
WT mice at 6 months of age.  
The fasting blood glucose levels and response to IPGTT were measured in female Prex1 KO (red) 
and Prex WT (blue) mice on 45% HFD at the ages of 10 and 15 weeks, 6, 9 and 12 months, as 
described in the legend to Figure 4.2.1. The ochre box denotes glucose challenge at the reduced 
dose of 1 g/kg instead of 2 g/kg (A) Blood glucose concentration during IPGTT. (B) Blood glucose 
levels during IPGTT, normalised by subtracting the basal blood glucose level. (C) Total glucose 
response (AUC of normalised data). Data are pooled from 3 independent cohorts (Prex WT n=12; 
Prex1 KO n=14), and are presented as mean ± SEM. 2-way ANOVA with repeated measures and 
Sidak’s multiple comparisons correction was used to compare genotypes during IPGTT. Unpaired 
Student’s t-test was used to analyse the total glucose response. 
 P a g e  | 113 
 
 
 
Figure 4.2.14: Female Prex1 KO mice show some protection from HFD-induced 
glucose intolerance.  
The fasting blood glucose levels, response to glucose challenge, and body weight of the female 
Prex1 KO (red) and Prex WT (blue) mice on 45% HFD from Figure 4.2.13 are expressed as a 
function of age. In faded red are represented the female Prex1 KO mice on chow diet from Figure 
4.2.9 for visual comparison, but no statistical analysis was performed, as these animals were not 
directly compared experimentally. (A) Response to IPGTT; normalised data from columns B and 
C in Figure 4.2.13. (B) Fasting blood glucose levels; data from column A in Figure 4.2.13. The 
ochre box denotes glucose challenge at the reduced dose of 1 g/kg instead of 2 g/kg. (C) Body 
weight, measured after 6 and 4 h fasting, prior to glucose and insulin challenges, respectively. (D) 
Body composition at 1 year of age. The mice in (A-C) were culled at 1 year of age and the cadavers 
were scanned by Echo MRI for lean mass and body fat. Data are pooled from 3 independent 
cohorts (Prex WT n=12; Prex1 KO n=14), and are presented as mean ± SEM. 2-way ANOVA with 
repeated measures and Sidak’s multiple comparisons correction was used to compare genotypes 
during ageing. Unpaired Student’s t-test was used to analyse the body composition. 
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Due to the increased response of HFD-fed males to insulin (compared to 
mice on chow diet), it was expected that females might also be more sensitive to 
insulin. In order to avoid causing hypoglycaemic shock, considering the low basal 
blood glucose levels of HFD-fed females, the females were therefore challenged 
with a lower dose of insulin (0.5 IU/kg compared to the 0.75 IU/kg routinely used) at 
the 5 months time point. Figure 4.2.15A-E shows that the glucose levels of Prex1 
KO females dropped by 6 mM after 45 min, to 5 mM. Under these conditions, a 
smaller drop by 4 mM was observed in the Prex WT mice, before steadily returning 
to ~8 mM at 120 min and remaining there until the end of the test. This was seen 
despite normal fasting blood glucose levels (Figure 4.2.15D). However, this 
increased insulin sensitivity was subtle, and overall the response to insulin was not 
significantly different in Prex1 KO females than WT controls (Figure 4.2.15B-C). 
Using the normal insulin dose (0.75 IU/kg) for the 10 months challenge (Figure 
4.2.15F-J), the Prex1 KO females were again found to be slightly more sensitive to 
insulin compare to Prex WT controls, in a similar way to what was observed at 5 
months, but again this did not reach statistical significance. 
Housing of females on HFD in metabolic cages at the age of 11 months did 
not reveal any significant differences in their water and food consumption or urine 
and faeces production (Figure 4.2.16A-D). However, interestingly, the post mortem 
body composition analysis at the age of one year revealed that Prex1 KO females 
had slightly less fat percentage compared to Prex WT mice (Figure 4.2.14D). This 
reduced fat level might be a consequence of the improved glucose tolerance; 
perhaps an increased glucose metabolism throughout the life-course meant that 
less fat deposits needed to be laid down to store excess energy.  
Overall, it can be concluded that Prex1 deficiency protects females on HFD 
from glucose intolerance to some degree, and that it also affords a tendency towards 
increased sensitivity to insulin. Hence, it affords the mice some metabolic 
advantage. 
To summarise the metabolic phenotype of Prex1 deficient mice overall (see 
Table 4.1), Prex1 deficiency results in low fasting blood glucose levels in males and 
in improved glucose tolerance both in males on chow diet and in females on HFD. 
Hence, Prex1 deficiency affords improved glucose homeostasis to mice. This 
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phenotype was diet dependent, as Prex1 KO males showed improved glucose 
tolerance only on chow diet throughout ageing, but were not protected from HFD-
diet induced glucose intolerance. This was despite lower fasting blood glucose 
levels in Prex1 KO than Prex WT mice on both diets, suggesting that low fasting 
glucose levels are either not causally related or insufficient to afford the protection 
against glucose intolerance. Moreover, the metabolic phenotype of Prex1 KO mice 
also showed sex-dependence. Prex1 KO females on chow diet showed a tendency 
to improved glucose tolerance throughout ageing, but this phenotype was not as 
strong as in males. This could possibly be a reflection of the fact that females had 
much better glucose tolerance than males anyway, so the Prex1 KO made relatively 
less of a difference in females. However, intriguingly, Prex1 deficient females on 
HFD exhibited significantly improved glucose tolerance compared to Prex WT 
controls, although this was obvious only at 6 months of age, and seen at later ages 
merely when the dose of glucose in challenges was reduced. Hence, Prex1 
deficiency affords some protection from glucose intolerance in females but not 
males on HFD. Perhaps this sex difference is again a reflection of the fact that WT 
females on HFD were less glucose intolerant than males, so the mild protection 
afforded by Prex1 deficiency became more evident in the females. On both chow 
and HFD, Prex1 KO females had normal fasting blood glucose levels, throughout 
ageing, which again suggests that the improved glucose tolerance of these mice is 
uncoupled mechanistically from their fasting blood glucose levels. During insulin 
challenge, Prex1 deficient males showed an accelerated recovery phase, 
suggesting that Prex1 deficiency might alter the counter-regulatory response to 
hypoglycaemia.  
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Figure 4.2.15: Female Prex1 KO mice on HFD show a normal response to insulin 
challenge. 
The female Prex1 KO (red) and Prex WT (blue) mice on 45% HFD from Figure 4.2.13 were 
subjected to SCITT at the ages of (A-D) 5 and (E-H) 10 months, as described in the legend to 
Figure 4.2.3. At 5 months mice were injected with 0.5 IU/kg of human recombinant insulin whereas 
at 10 months with 0.75 IU/kg (A,E) Blood glucose concentration during SCITT. (B,F) Fasting blood 
glucose levels. (C,G) Blood glucose levels during SCITT, normalised by subtracting the fasting 
basal blood glucose level from each mouse individually. (D,H) Total insulin response (AUC of 
normalised data). Data are pooled from 3 independent cohorts (Prex WT n=12; Prex1 KO n=14) 
and are presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple 
comparisons correction was used to compare genotypes during SCITT. Unpaired Student’s t-test 
was used to analyse the basal blood glucose level and total insulin response. 
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Figure 4.2.16: Female Prex1 KO mice perform normally in metabolic cages.  
The female Prex1 KO (red) and Prex WT (blue) mice from Figure 4.2.13 were habituated to 
metabolic cages at the age of 11 months, as detailed in Materials and Methods, weighed and 
group-housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food 
and water provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine 
production, and (D) faeces production were measured after each night and were normalised to the 
combined body weights of the mice housed in each cage. Data pooled from 3 independent cohorts 
(Prex WT n=12; Prex1 KO n=14) and are presented as the mean ± SEM of each night (n=3). 
Unpaired Student’s t-test was used for the comparison between the genotypes. 
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Table 4.1: Summary table of metabolic phenotype of Prex1 KO mice on chow or high fat 
diet. Bold font was used to annotate findings that reached statistical significance in most time points 
tested, while bold and italic font was used to indicate strong trends  that show statistical significance 
in only one or two time points tested.  
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4.2.5 Ex vivo characterisation of Prex1 KO metabolic 
phenotype 
In order to begin to understand the possible mechanism for the metabolic phenotype 
of Prex1 KO mice, mice from all genotypes were dissected and the weight of their 
organs at young adult (10 weeks old) and middle age (24 weeks old for males, 30 
weeks old for females) were compared. 
Figure 4.2.17 shows that the liver of Prex1 KO mice was consistently smaller 
than of Prex WT across all groups tested. Young Prex1 KO males also had smaller 
inguinal WAT (ingWAT), skeletal muscle and testes compared to Prex WT controls, 
which persisted tendentially to 24 weeks of age but only the liver and ingWAT 
reached statistical significance in these middle-aged mice. Young Prex2 KO mice 
also had smaller ingWAT and skeletal muscle than Prex WT mice but larger kidneys 
and livers. Both male and female Prex1/2 DKO mice had smaller livers compared 
to the Prex WT controls, to a similar level as seen in Prex1 KO. Overall, the reduced 
liver size in Prex1 KO and Prex1/2 DKO mice was the most consistent difference in 
both sexes and ages. 
Organ weight of animals on HFD was not systematically measured. However, 
in light of the findings presented above, the liver and intBAT of some HFD-fed mice 
were weighed, after their cadavers had been screened by the Echo MRI at 1 year 
of age. Under these conditions, only the Prex1/2 DKO males, but not Prex1 KO 
males were found to have smaller liver, and no difference was observed in the 
weight of the intBAT (Figure 4.2.18). It should be noted, however, that the condition 
of the cadavers at this stage was less than ideal, as they had been thawed for more 
than a day, so these results should be interpreted with caution. 
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Figure 4.2.17: Prex1 KO mice have smaller livers. 
Prex WT, Prex1 KO, Prex2 KO and Prex1/2 DKO male and female mice (symbol colours as 
indicated in the chart legend) were culled by CO2 asphyxiation followed by severance of the 
femoral artery at the ages indicated and were dissected for organ collection. The weights of 
thirteen organs (brain, interscapular brown adipose, inguinal white adipose, skeletal muscle, 
pancreas, kidneys, spleen, liver, thymus, heart, lung, salivary gland, and when applicable testes) 
were measured, and data were normalised by total body weight. Data are presented as mean ± 
SEM. 2-way ANOVA with Sidak’s multiple comparisons correction was used to compare the 
genotypes. (10 week-old males : Prex WT n=10, Prex1 KO n=10, Prex2 KO n=10 and Prex1/2 
DKO n=9; 10 week-old females : Prex WT n=14, Prex1 KO n=12, Prex2 KO n=11 and Prex1/2 
DKO n=4; 24 week-old males old: Prex WT n=8, Prex1 KO n=6, Prex2 KO n=6 and Prex1/2 DKO 
n=5; 30 week-old females  old: Prex WT n=10, Prex1 KO n=12, Prex2 KO n=11 and Prex1/2 DKO 
n=10) 
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Figure 4.2.18: Male Prex1/2 DKO mice on HFD have smaller livers at 1 year of age. 
Prex WT, Prex1 KO, Prex2 KO and Prex1/2 DKO male and female mice on HFD (symbol colours 
as indicated in the chart legend) were dissected for organ collection at 1 year of age, after their 
cadavers had been thawed and scanned by Echo MRI. The weights of two organs (liver and 
interscapular brown adipose) were measured, and data were normalised to total body weight 
before dissection. Data are presented as mean ± SEM. 2-way ANOVA with Sidak’s multiple 
comparisons correction was used to compare the genotypes. (1 year-old males at: Prex WT n=18, 
Prex1 KO n=11, Prex2 KO n=5 and Prex1/2 DKO n=4; 1 year-old females: Prex WT n=13, Prex2 
KO n=8 and Prex1/2 DKO n=5). 
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Following up on the tissue size differences observed in younger Prex1 KO 
mice, the freshly dissected liver, skeletal muscle, ingWAT and intBAT of 10 week-
old males were fixed in formalin and sent to Abbey Veterinary Services for 
preparation of standard H&E sections which were analysed by pathologist Dr Cheryl 
Scudamore. The histological analysis revealed that glycogen storage was reduced 
in Prex1 KO livers compared to Prex WT control livers, while increased eosinophilia 
was found in Prex1 KO intBAT (Figure 4.2.19). No obvious morphological changes 
between the two genotypes were observed in skeletal muscle and ingWAT. Given 
that I had identified sex difference in the low fasting blood glucose levels of Prex1 
KO mice, which were only observed in males but not females, as well as in the 
improved glucose tolerance, which was more pronounced in males than females, at 
least on chow diet, tissues from female Prex1 KO and Prex WT mice were also sent 
for analysis. The histological analysis failed to uncover any morphological changes 
in the tissues of Prex1 KO females, despite these females having reduced liver size, 
just like their male counterparts. By correlation, these results suggest that reduced 
liver glycogen storage and/or BAT eosinophilia could be linked to the low fasting 
blood glucose or improved glucose tolerance of male Prex1 KO mice. 
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Figure 4.2.19: Prex1 KO mice have reduced glycogen storage in the liver and 
eosinophilia in the brown adipose tissue.  
Haematoxylin-eosin staining of formalin-fixed (A) liver and (C) interscapular brown adipose tissue 
from 10 week-old Prex WT (blue) and Prex1 KO (red) mice on chow diet was performed and 
analysed by professional pathologists at Abbey Veterinary Services. Images shown are 
representative of three mice per group. (B, D) Findings in the tissues were scored by the 
pathologist using a non-linear semi-quantitative grading system from 0 to 5, where 0 = no 
significant change and 5 = whole organ or tissue affected. (B) Grading of clear cytoplasm in liver 
cells, consistent with glycogen storage. (D) Grading of eosinophilia in brow adipose tissue. Data 
are from 1 cohort (WT n=3; Prex1 KO n=3) and are presented as mean ± SEM. 
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In order to explore the possibility of low fasting blood glucose levels in Prex1 
KO males being a result of altered insulin signalling, this pathway was investigated 
in 10 week-old Prex1 KO and Prex WT males on chow diet by ex vivo analysis. The 
mice were injected s.c. with either DPBS or insulin at 0.75 IU/kg, culled 15 min 
thereafter by cervical dislocation (with pithing as secondary method), and ingWAT, 
skeletal muscle, and liver were collected and snap-frozen in liquid nitrogen within 2 
min of the animal’s death. Total tissue lysates were prepared in the presence of 1% 
TX100, protease inhibitors and phosphatase inhibitors. Mesoscale analysis was 
performed on these total lysates for the phosphorylated and total levels of the insulin 
pathway components Akt, p70S6K and GSK3β. The activity of these enzymes 
(judged by the phosphorylation status of regulatory sites) increased with insulin 
treatment, as expected, in the Prex WT tissues. Insulin stimulation increased the 
levels of phospho-Akt most, in all tissues, whereas phospho-p70S6K was mainly 
increased in the ingWAT and phospho-GSK3β in the liver. However, no differences 
were found in the insulin pathway activity between Prex1 KO and control tissues 
(Figure 4.2.20), except for an apparent increase in GSK3β activity in insulin-treated 
Prex1 KO ingWAT that was not observed in Prex WT tissue. Dissection of the 
possible origin of this signal showed that the phospho-GSK3β level in these samples 
was normal, but total GSK3β levels had significantly decreased, leading to a relative 
increase in phosphorylated GSK3β per amount of total protein expressed. It is not 
impossible, but unlikely, that the total level of GSK3β should have declined within 
15 min of insulin stimulation specifically in Prex1 KO tissue. Hence, this result must 
be interpreted with caution until it can be confirmed by repeats of the experiment. 
Overall, therefore, it seems that Prex1 deficiency has no obvious effects on the 
insulin pathway activity under the conditions tested.  
The liver samples from insulin- and control-treated animals were also used 
for mRNA extraction, and the expression levels of Pepck and G6p were analysed 
by qPCR as a measure of the hepatic reaction to insulin stimulation. Although Pepck 
levels were slightly increased in the mock-treated Prex1 KO mice compared to the 
Prex WT controls, this did not reach statistical significance. Moreover, no difference 
was observed in the Pepck levels after insulin stimulation between the two 
genotypes (Figure 4.2.21). Hence, Prex1 KO has no obvious effects on the 
expression levels of these two liver enzymes, but more experiments would be 
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needed to investigate the possibility of a constitutive increase in Pepck levels. 
Another avenue explored were the plasma levels of hormones relevant to 
glucose homeostasis. To this end, the levels of adiponectin, glucagon, and insulin 
were measured in the plasma of fasted 14 week-old Prex1 KO and Prex WT males. 
Surprisingly, adiponectin was found to be significantly reduced in the Prex1 KO 
mice, although glucagon and insulin levels were normal (Figure 4.2.22). This was 
surprising given that low adiponectin levels are usually associated with poor rather 
than good glucose tolerance. 
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Figure 4.2.20: Insulin signalling is apparently unaffected in Prex1 KO liver, skeletal 
muscle and white adipose tissue. 
10 week-old male Prex WT (blue) and Prex1 KO (red) mice on chow diet were fasted 4 h prior to 
s.c. injection of either DPBS or insulin at 0.75 IU/kg. Blood glucose levels were tested by tail bleed 
15 min prior to the s.c. injection to determine basal blood glucose levels, as well as 14 min after 
the insulin injection to assess the response to insulin. At 15 min, mice were culled and tissues – 
inguinal white adipose tissue, skeletal muscle and liver – were collected and snap-frozen in liquid 
nitrogen within 2 min. Total lysates were prepared and samples were tested for regulatory 
phosphorylation and total levels of Akt, p70S6K and GSK3β using mesoscale multiplex plates. 
Data are pooled form 3 independent cohorts (Prex WT DPBS n=5; Prex WT Insulin n=5; Prex1 
KO DPBS n=5; Prex1 KO Insulin n=6), and are presented as mean ± SEM of the phosphorylated 
protein divided by the total level of that protein for each sample. Statistical analysis was done by 
2-way ANOVA with Sidak’s multiple comparisons correction. 
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Figure 4.2.21: Prex1 KO males show a normal hepatic reaction to insulin challenge. 
A) Pepck and (B) G6p transcripts were analysed by qPCR of RNA from the livers of same insulin- 
or mock-treated Prex WT (blue) and Prex1 KO (red) mice as in Figure 4.2.20. Transcript levels 
were normalized to the housekeeping gene b2M. Data are pooled form 3 independent cohorts 
(Prex WT DPBS n=5; Prex WT Insulin n=5; Prex1 KO DPBS n=5; Prex1 KO Insulin n=6), and are 
presented as mean ± SEM. Statistical analysis was done by 2-way ANOVA  with Sidak’s multiple 
comparisons correction. 
 
 
 
 
 
 
Figure 4.2.22: Prex1 KO males have reduced plasma levels of adiponectin levels 
under fasting conditions. 
14 week-old male Prex WT (blue) and Prex1 KO (red) mice on chow diet were fasted for 6 h prior 
to the collection of peripheral blood and preparation of blood plasma. The plasma levels of (A) 
adiponectin, (B) glucagon and (C) insulin were quantified by ELISA. Data are pooled from 2 
independent cohorts (Prex WT n=9; Prex1 KO n=9). Statistical analysis was done by unpaired 
Student’s t-test. 
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Finally, given that Prex1 is widely expressed in cells of the hematopoietic 
system and known to mediate neutrophil-, macrophage-, and platelet-dependent 
inflammatory responses (Pantarelli and Welch, 2018; Pitchford et al., 2017) 
combined with the fact that inflammation is a key player in metabolic syndrome 
(Saltiel and Olefsky, 2017), we wanted to investigate a possible contribution of the 
immune system to the phenotype of low fasting blood glucose levels and improved 
glucose tolerance observed in Prex1 KO mice. Therefore, 7 week-old mice were 
lethally irradiated, and their hematopoietic system was reconstituted with bone 
marrow cells from 12 week-old donor mice that were either Prex WT or Prex1 KO. 
After bone marrow transplantation, the mice were kept on chow diet for 10 weeks in 
order to let their haematopoietic system reconstitute with that of the donor mice, and 
then they were subjected to IPGTT. Figure 4.2.23A-C shows that Prex1 KO males 
with a Prex1 KO hematopoietic system had improved glucose tolerance compared 
to irradiated Prex WT with either a Prex WT- or Prex1 KO-derived hematopoietic 
system. Hence, the improved glucose tolerance of Prex1 KO mice persisted through 
the bone marrow transplantation process. However, at that stage, a Prex1 KO 
haematopoietic system was insufficient to afford improved glucose tolerance to mice 
that were otherwise wild type. Moreover, this was seen despite the fact that the Prex 
WT mice, which had undergone bone marrow transplantation, had lower fasting 
blood glucose levels than wild type mice have usually. This might be taken as a 
further indication that the improved glucose tolerance of Prex1 KO mice is not a 
direct consequence of their low fasting blood glucose levels (Figure 4.2.23D). It is 
also worth noting that, on the day of the experiment, all tested mice had comparable 
weight (Figure 4.2.23E). 
Importantly, the glucose tolerance of the same mice was tested again 10 
weeks later, at 20 weeks after the bone marrow transplant. At that age, Prex WT 
mice with Prex WT hematopoietic system had developed considerable glucose 
intolerance, whereas the Prex1 KO mice with Prex1 KO hematopoietic system had 
maintained their significantly improved glucose tolerance. Surprisingly however, the 
Prex WT mice that had been reconstituted with a Prex1 KO hematopoietic system 
also exhibited improved glucose tolerance (Figure 4.2.23F-H). 
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It is worth pointing out that, at this time point, the Prex WT controls had again 
somewhat lower basal blood glucose than other WT groups (Figure 4.2.23I), and 
all mice gained weight at comparable rates (Figure 4.2.23J), hence it is unlikely that 
fasting blood glucose levels or body weight had any crucial influence on the 
observed improved glucose tolerance. 
Overall, the results from the bone marrow transplantation experiment show 
that a Prex1 KO hematopoietic system is sufficient to protect otherwise wild type 
mice from developing age-related glucose intolerance, provided that the 
haematopoietic system is given ample time to establish itself. 
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Figure 4.2.23: Hematopoietic cells contribute to the metabolic phenotype observed 
in Prex1 KO mice. 
7 week-old Prex WT or Prex1 KO recipient mice were lethally irradiated and their hematopoietic 
system reconstituted with bone marrow from 12 week-old Prex WT or Prex1 KO donor mice, as 
indicated (symbol colours as indicated in the chart legend). Irradiated mice were kept on chow diet 
and their water was supplemented with neomycin (2 mg/ml) for 2 weeks post irradiation. At (A-E) 
10 weeks and (F-J) 20 weeks after the bone marrow transplantation, mice were subjected to 
IPGTT, as described in the legend to Figure 4.2.1. (A,F) Blood glucose concentration during 
IPGTT. (B,G) Blood glucose levels during IPGTT, normalised by subtracting the fasting basal 
blood glucose level from each mouse individually. (C,H) Total glucose response (AUC of 
normalised data). (D,I) Fasting blood glucose levels. (E,J) Total body weight as measured after 6 
h fasting. Data are from 1 cohort (Prex1 KO bone marrow transplanted into Prex WT mice n=9; 
Prex WT bone marrow transplanted into Prex WT mice n=3; Prex1 KO bone marrow transplanted 
into Prex1 KO mice n=3) and are presented as mean ± SEM. 2-way ANOVA with repeated 
measures and Sidak’s multiple comparisons correction was used to compare genotypes during 
IPGTT. 1-way ANOVA was used to analyse the total glucose response, basal blood glucose level 
and total body weight. 
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4.3 Metabolic phenotype of Prex2 KO mice 
In order to understand the role of Prex2 in glucose metabolism in vivo, the metabolic 
phenotype of Prex2–/– (Prex2 KO) mice was studied, as previously described for the 
Prex1 KO mice. Prex2 KO and Prex WT mice of same age and sex were tested in 
parallel under the same conditions for direct comparison.  
4.3.1 Male Prex2 KO mice on chow diet show similar fasting 
blood glucose levels and glucose tolerance to Prex WT 
mice 
As can be seen from the representative graphs in Figure 4.3.1 (which only show 
the 15-week and 9-month time points, for brevity), Prex2 KO males on chow diet 
had normal basal blood glucose levels and response to glucose challenge 
compared to Prex WT mice at both ages. The overview of all time-points tested 
showed that Prex2 KO males had identical basal blood glucose levels to the Prex 
WT controls throughout ageing (Figure 4.3.2A). In contrast, the response to glucose 
challenge fluctuated with age between the two genotypes. It started similar at 10 
weeks, but then the Prex2 KO mice had slightly better glucose tolerance then Prex 
WT controls at 15 weeks and 6 months of age and worse at one year of age (Figure 
4.3.2B). Overall, although the total glucose response of the Prex2 KO males showed 
a tendency to improved glucose tolerance in young age and worse in old age, it did 
not differ significantly from the response of control males. The fluctuations in the 
response to glucose challenge could be a reflection of the uneven weight gain of the 
Prex2 KO cohorts throughout the ageing process, which was significantly different 
from WT at those ages (15 weeks and 1 year, Figure 4.3.2C), where the largest 
differences in glucose tolerance were observed. The body composition of the mice 
at one year of age was normal (Figure 4.3.2D). 
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Figure 4.3.1: Male Prex2 KO mice on chow diet show similar fasting blood glucose 
levels and glucose tolerance to Prex WT mice. 
The fasting blood glucose levels and response to IPGTT were measured in male Prex2–/– (Prex2 
KO, green) and Prex WT (blue) mice on chow diet, as described in the legend to Figure 4.2.1. 
Only data from 15 weeks and 9 months of age are shown for brevity, although mice of all ages up 
to one year were tested. (A) Blood glucose concentration during IPGTT. (B) Blood glucose levels 
during IPGTT, normalised by subtracting the basal blood glucose level. (C) Total glucose response 
(AUC of normalised data). Data are pooled from 2 independent cohorts (Prex WT n=9; Prex2 KO 
n=9), and are presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s 
multiple comparisons correction was used to compare genotypes during IPGTT. Unpaired 
Student’s t-test was used to analyse the total glucose response. 
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Figure 4.3.2: Male Prex2 KO mice on chow diet overall have a normal response to 
glucose challenge, with some age-related fluctuations. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the male 
Prex2 KO (green) and Prex WT (blue) mice in Figure 4.3.1 are expressed as a function of age. 
(A) Fasting blood glucose levels; data from column A in Figure 4.3.1. (B) Response to IPGTT; 
normalised data from columns B and C in Figure 4.3.1. (C) Body weight, measured after 6 and 4 
h fasting, prior to glucose and insulin challenges, respectively. (D) Body composition at 1 year of 
age. The mice in (A-C) were culled at 1 year of age and the cadavers were scanned by Echo MRI 
for lean mass and body fat. Data are pooled from 2 independent cohorts (Prex WT n=9; Prex2 KO 
n=9), and are presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s 
multiple comparisons correction was used to compare genotypes during ageing. Unpaired 
Student’s t-test was used to analyse the body composition. 
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Upon insulin challenge in 5 month-old mice, the blood glucose levels of Prex2 
KO males dropped to their lowest level at 45 min post injection, by 5 mM, and 
returned to around 8 mM at 120 min (Figure 4.3.3A,C), similar to the response of 
the Prex WT controls. At 10 months however, Prex2 KO males showed increased 
insulin sensitivity compared to their Prex WT counterparts (Figure 4.3.3G-H), as 
their response to insulin was the same as at the young age (5 mM drop in blood 
glucose). In contrast, the Prex WT controls had developed insulin resistance, as 
their glucose levels only dropped by 3 mM, and returned to basal levels within 120 
min (Figure 4.3.3G) Yet, the fasting blood glucose level of Prex2 KO mice was 
higher, and the absolute level of blood glucose, at the peak of the response, was 
similar between genotypes. As discussed previously for Prex1 KO mice, where a 
similar effect was observed, it seems possible that the counter-regulatory 
mechanisms to insulin were elicited more weakly in Prex WT than Prex2 KO mice 
in order to achieve similar homeostasis (Figure 4.3.3E-F).  
It is worth pointing out that the Prex WT males in this cohort had lower basal 
glucose levels, a smaller response to glucose challenge from the age of 15 weeks 
onwards, and a reduced response to insulin at the age of 10 months compared to 
most male Prex WT cohorts on chow diet (see Supplementary Data, Section 1). 
Hence, there is a possibility that Prex2 KO deficiency actually leads to somewhat 
improved glucose tolerance and insulin sensitivity. In any event, it is clear that Prex2 
KO mice on chow diet are not glucose intolerant or insulin resistant. 
To complete the assessment of the metabolic phenotype of Prex2 KO males, 
the same cohort of mice was tested in the metabolic cages at 11 months of age, 
and no difference was found between Prex2 KO and Prex WT mice (Figure 4.3.4F-
I). Interestingly, a separate cohort of 12 week-old mice was also tested in the 
metabolic cages, and these young Prex2 KO males showed significantly reduced 
water and food consumption, as well as reduced urine production, compared to Prex 
WT controls (Figure 4.3.4B-E) despite being heavier (Figure 4.3.4A).  It may be 
useful to repeat the latter experiment with a different cohort of young mice for 
confirmation. 
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Figure 4.3.3: Prex2 KO male mice on chow diet show an apparent increase in 
insulin sensitivity in old age. 
The fasting blood glucose levels and response to SCITT were measured in the male Prex2 KO 
(green) and Prex WT (blue) mice on chow diet from Figure 4.3.1 at the ages of (A-D) 5 and (E-H) 
10 months, as described in the legend to Figure 4.2.3. (A,E) Blood glucose concentration during 
SCITT. (B,F) Fasting blood glucose levels. (C,G) Blood glucose levels during SCITT, normalised 
by subtracting the fasting basal blood glucose level from each mouse individually. (D,H) Total 
insulin response (AUC of normalised data). Data are pooled from 2 independent cohorts (Prex WT 
n=9; Prex1 KO n=9) and are presented as mean ± SEM. 2-way ANOVA with repeated measures 
and Sidak’s multiple comparisons correction was used to compare genotypes during SCITT. 
Unpaired Student’s t-test was used to analyse the basal blood glucose level and total insulin 
response. 
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Figure 4.3.4: Young, but not old, male Prex2 KO mice are less active in metabolic 
cages than Prex WT mice. 
Male Prex2 KO (green) and Prex2 WT (blue) mice were habituated to metabolic cages at the age 
of 12 weeks (A-E) and 11 months (F-I) as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (B,F) water consumption, (C,G) food consumption, (D,H) urine 
production, and (E,I) faeces production were measured after each night and were normalised to 
the combined body weights of the mice housed in each cage. (A) Body weight of 12 weeks old 
males on chow diet. (A-E) Data are from 1 cohort of 12 week-old males on chow diet (Prex WT 
n=6; Prex2 KO n=6). (F-I) Data are pooled from the 2 independent cohorts of male Prex2 KO and 
Prex WT mice on chow diet in Figure 4.3.1, tested at the age of 11 months (Prex WT n=9; Prex2 
KO n=9). Data are presented as the mean ± SEM of each night (n=3), and unpaired Student’s t-
test was used for the comparison between genotypes. 
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4.3.2 Male Prex2 KO mice on HFD have lower fasting blood 
glucose levels but worse glucose tolerance than Prex 
WT mice 
Prex2 KO males were introduced to 45% HFD at 10 weeks of age. As shown in 
Figure 4.3.5A, although they had similar basal blood glucose levels to their Prex 
WT counterparts at 10 weeks, they then maintained lower fasted blood glucose 
levels up to 9 months of age. However, Prex2 deficiency was not enough to protect 
them from glucose intolerance. Similarly to Prex WT, HFD caused a rapid onset of 
glucose intolerance in Prex2 KO males (Figure 4.3.5A). During glucose challenge, 
the blood glucose levels kept increasing beyond the 15 min time point, reaching 41 
mM at 30 min and remaining around 40 mM within the 90 min of the test. 
Normalisation of the glucose response revealed that Prex2 KO mice had slightly 
worse glucose tolerance than Prex WT mice throughout ageing (Figure 4.3.5B-C). 
As described before, the dosage of glucose in IPGTTs was reduced from 6 months 
onwards to one quarter of the original dose (0.5 g/kg, data in ochre box). The graphs 
within the ochre box show that, under these conditions, glucose triggered a milder 
response in both genotypes (Figure 4.3.5C), but it still took longer for blood glucose 
levels to return to normal (Figure 4.3.5B), and importantly Prex2 KO males were 
more glucose intolerant under these conditions than the WT controls. 
The effects of ageing are summarised in Figure 4.3.6. As mentioned above, 
the HFD-induced increase in fasting blood glucose levels was delayed in male Prex2 
KO mice, remaining significantly lower than in Prex WT controls until the age of 9 
months (Figure 4.3.6A). Furthermore, the glucose tolerance of Prex2 KO mice on 
HFD was worse than that of Prex WT males at most ages, and this reached 
significance at the age of 9 months (Figure 4.3.6B). 
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Figure 4.3.5: Male Prex2 KO mice on HFD show reduced glucose tolerance. 
The fasting blood glucose levels and response to IPGTT were measured in male Prex2 KO (green) 
and Prex WT (blue) mice on 45% HFD at the ages of 10 and 15 weeks, 6, 9 and 12 months, as 
described in the legend to Figure 4.2.1. (A) Blood glucose concentration during IPGTT. The dose 
of glucose used in the IPGTT was 2 g/kg at the ages of 10 and 15 weeks, and 0.5 g/kg thereafter 
(data in ochre box) (B) Blood glucose levels during IPGTT, normalised by subtracting the basal 
blood glucose level. (C) Total glucose response (AUC of normalised data). Data are pooled from 
1-2 independent cohorts with 4-5 mice per genotype each, and are presented as mean ± SEM. 2-
way ANOVA with repeated measures and Sidak’s multiple comparisons correction was used to 
compare genotypes during IPGTT. Unpaired Student’s t-test was used to analyse the total glucose 
response. 
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Figure 4.3.6: Male Prex2 KO mice on HFD weigh less and have lower fasting blood 
glucose levels than WTs, but are glucose intolerant throughout most of their lives.  
The fasting blood glucose levels, response to glucose challenge, and body weight of the male 
Prex2 KO (green) and Prex WT (blue) mice in Figure 4.3.5 are expressed as a function of age. 
Note that the dose of glucose was reduced from 2 g/kg to 0.5 g/kg from the age of 6 months 
onwards (data in ochre box). In pale green are represented the Prex2 KO male mice on chow diet 
from Figure 4.3.1 for comparison, but these mice were not included in the statistical analysis as 
they were not directly compared experimentally. (A) Fasting blood glucose levels; data from 
column A in Figure 4.3.5. (B) Response to IPGTT; normalised data from columns B and C in 
Figure 4.3.5. (C) Body weight, measured after 6 and 4 h fasting, prior to glucose and insulin 
challenges, respectively. Data are pooled from 1-2 independent cohorts with 4-5 mice per 
genotype each, and are presented as mean ± SEM. 2-way ANOVA with repeated measures and 
Sidak’s multiple comparisons correction was used to compare genotypes during ageing. (D) Body 
composition at 1 year of age. The mice in (A-C) were culled at 1 year of age and the cadavers 
were scanned by Echo MRI for lean mass and body fat. Data from 1 cohort (Prex WT n=5; Prex1 
KO n=5) and presented as mean ± SEM. Unpaired Student’s t-test was used to analyse the body 
composition. 
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At 5 months of age, the overall response of Prex2 KO males on HFD to insulin 
challenge was similar to that of Prex WT mice. Although they had an accelerated 
counter-regulatory response, meaning their blood glucose returned towards fasting 
levels slightly more rapidly (Figure 4.3.7A-D). In contrast, at 10 months of age, 
Prex2 KO males demonstrated a pronounced reduction in insulin sensitivity. Their 
total response to insulin being half that of Prex WT mice (Figure 4.3.7 E-H), 
indicating that Prex2 KO males on HFD develop age-related insulin resistance which 
is more severe than in Prex WT mice.  
Although the two genotypes had identical body weight at the onset of the 
study, Prex2 KO males gained weight more slowly and were significantly lighter than 
Prex WT mice from 6 months of age onwards (Figure 4.3.6C). Surprisingly, the body 
composition analysis, at 1 year, revealed that Prex2 KO males on HFD had 
increased body fat percentage compared to the heavier Prex WT controls (Figure 
4.3.6D). Their lower body weight would argue against their having worse glucose 
tolerance than WTs, but the increased body fat of Prex2 KO males on HFD could 
be a contributing factor to their glucose intolerant and insulin resistant phenotype. 
Finally, no difference was found in the water and food consumption, or urine and 
faeces production of Prex2 KO mice on HFD in metabolic cages (Figure 4.3.8A-D). 
To summarise the metabolic phenotype of Prex2 KO males, Prex2 deficiency 
did not obviously affect the fasting blood glucose levels, glucose tolerance or insulin 
sensitivity of mice on chow diet, in contrast to an earlier report by the Parsons lab 
(Hodakoski et al., 2014). Importantly, however, Prex2 deficiency rendered mice on 
HFD glucose intolerant and insulin resistant in old age. 
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Figure 4.3.7: Male Prex2 KO mice on HFD become insulin resistant in old age. 
The fasting blood glucose levels and response to SCITT were measured in the male Prex2 KO 
(green) and Prex WT (blue) mice on 45% HFD from Figure 4.3.5 at the age of (A-D) 5 and (E-H) 
10 months, as described in the legend to Figure 4.2.3. (A,E) Blood glucose concentration during 
SCITT. (B,F) Fasting blood glucose levels. (C,G) Blood glucose levels during SCITT, normalised 
by subtracting the fasting basal blood glucose level from each mouse individually. (D,H) Total 
insulin response (AUC of normalised data). Data are pooled from 2 independent (Prex WT n=8; 
Prex2 KO n=9), and are presented as mean ± SEM. 2-way ANOVA with repeated measures and 
Sidak’s multiple comparisons correction was used to compare genotypes during SCITT. Unpaired 
Student’s t-test was used to analyse the basal blood glucose level and total insulin response. 
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Figure 4.3.8: Male Prex2 KO mice perform normally in metabolic cages.  
The male Prex2 KO (green) and Prex WT (blue) mice from Figure 4.3.5 were habituated to 
metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and 
(D) faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are from 1 cohort (Prex WT n=5; Prex1 KO n=5). 
Data are presented as the mean ± SEM of each night (n=3), and unpaired Student’s t-test was 
used for the comparison between genotypes. 
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4.3.3 Ageing female Prex2 KO mice on HFD show age-related 
fluctuations in their glucose tolerance  
To investigate sex differences, the metabolic phenotype of female Prex2 KO mice 
was also tested. As can be seen from the representative graphs in Figure 4.3.9, 
and the ageing overview graphs in Figure 4.3.10, Prex2 females had normal fasting 
blood glucose levels (Figures 4.3.9A and 4.3.10A) and a normal response to 
glucose challenge throughout ageing (Figure 4.3.10B). However, there was an 
interesting tendency for improved glucose tolerance at young age, and worse 
glucose tolerance at old age, similar to what was previously observed in the male 
Prex2 KO mice. However, neither the improved glucose tolerance at young age (up 
to 6 months) nor the reduced glucose tolerance at old age reached statistical 
significance. Furthermore, the apparently improved glucose tolerance at young age 
(up to 6 months) could be a reflection of the fact that the Prex WT controls in this 
cohort had a bigger glucose response than expected for Prex WT females (see 
Supplemental Data in Section 6). In addition, Prex2 KO females had normal 
responses to insulin both at 5 months and at 10 months of age (Figure 4.3.11A-B). 
Despite Prex2 KO females being slightly heavier than their Prex WT 
counterparts, mice of both genotypes gained weight at a similar rate, and the body 
composition at one year of age was comparable between the two genotypes (Figure 
4.3.10C-D). Furthermore, housing of the same mice in metabolic cages at 11 
months of age did not reveal any differences either in their water and food intake or 
urine and faeces excretion (Figure 4.3.12A-D). 
 Hence, overall Prex2 deficiency did not have any significant effects on the 
metabolic phenotype of female mice on chow diet, although it did induce an 
interesting tendency to improved glucose tolerance in the young and worsened 
glucose tolerance in the old female mice. 
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Figure 4.3.9: Female Prex2 KO mice on chow diet show similar fasting blood 
glucose levels and glucose tolerance to Prex WT mice. 
The fasting blood glucose levels and response to IPGTT were measured in female Prex2 KO 
(green) and Prex WT (blue) mice on chow diet, as described in the legend to Figure 4.2.1. Only 
data from 15 weeks and 9 months of age are shown, for brevity, although mice of all ages up to 
one year were tested. (A) Blood glucose concentration during IPGTT. (B) Blood glucose levels 
during IPGTT, normalised by subtracting the basal blood glucose level. (C) Total glucose response 
(AUC of normalised data). Data are from 1 cohort (Prex WT n=5; Prex2 KO n=5), and are 
presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple 
comparisons correction was used to compare genotypes during IPGTT. Unpaired Student’s t-test 
was used to analyse the total glucose response. 
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Figure 4.3.10: Female Prex2 KO mice on chow diet overall have a normal response 
to glucose challenge, with some age-related fluctuations. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the female 
Prex2 KO (green) and Prex WT (blue) mice in Figure 4.3.9 are expressed as a function of age. 
(A) Fasting blood glucose levels; data from column A in Figure 4.3.9. (B) Response to IPGTT; 
normalised data from columns B and C in Figure 4.3.9. (C) Body weight, measured after 6 and 4 
h fasting, prior to glucose and insulin challenges, respectively. (D) Body composition at 1 year of 
age. The mice in (A-C) were culled at 1 year of age and the cadavers were scanned by Echo MRI 
for lean mass and body fat. Data are from 1 cohort (Prex WT n=5; Prex2 KO n=5), and are 
presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple 
comparisons correction was used to compare genotypes during ageing. Unpaired Student’s t-test 
was used to analyse the body composition. 
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Figure 4.3.11: Female Prex2 KO mice on chow diet show a normal response to 
insulin challenge. 
The fasting blood glucose levels and response to SCITT were measured in the female Prex2 KO 
(green) and Prex WT (blue) mice from Figure 4.3.9 on chow diet at the ages of 5 and 10 months, 
as described in the legend to Figure 4.2.3. (A) Blood glucose concentration during SCITT. (B) 
Fasting blood glucose levels. Data are from 1 cohort (Prex WT n=5; Prex2 KO n=5), and are 
presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple 
comparisons correction was used to compare genotypes during SCITT. Unpaired Student’s t-test 
was used to analyse the basal blood glucose levels. 
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Figure 4.3.12: Female Prex2 KO mice performed normally in metabolic cages.  
The female Prex2 KO (green) and Prex WT (blue) mice from Figure 4.3.9 were habituated to 
metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and 
(D) faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are from 1 cohort (Prex WT n=5; Prex1 KO n=5) 
and are presented as the mean ± SEM of each night (n=3). Unpaired Student’s t-test was used for 
comparison between genotypes. 
 
Despite the lack of effect of Prex2 deficiency on the metabolic phenotype of 
female mice on chow diet, we were still interested in investigating whether 
introduction of the mice to HFD could unveil a role of Prex2 in glucose homeostasis, 
especially considering that a diet-dependent phenotype was seen in Prex2 KO 
males. To this end, Prex2 KO and Prex WT control female mice were fed HFD from 
10 weeks of age until the end of the experiment at 1 year. Under these conditions, 
the fasting blood glucose levels of Prex2 KO mice remained identical to those of 
Prex WT controls (Figure 4.3.13A and Figure 4.3.14A). Interestingly, at 15 weeks 
and 6 months, when Prex WT mice started becoming glucose intolerant, the Prex2 
KO females demonstrated a tendency to improved glucose clearance during IPGTT 
(Figure 4.3.13A-C), which was reversed to poorer glucose tolerance at later ages 
(Figure 4.3.13A-C and Figure 4.3.14B). This repeated the pattern of age-related 
effects on glucose tolerance that was previously observed in both male and female 
Prex2 KO mice on chow diet. The insulin sensitivity of Prex2-deficient females on 
HFD was normal (Figure 4.3.15A-D).  
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A possible reason for the apparent age-related switch from improved to 
worsened glucose tolerance could be that the Prex2 KO females on HFD were 
significantly heavier than the Prex WT controls from 9 months onwards (Figure 
4.3.14C). Figure 4.3.16 shows furthermore that Prex2 KO females also produced 
less faeces and urine than the Prex WT controls, although no significant difference 
was detected in their water and food intake, which might imply that these mice 
converted more energy into fat. Indeed, this was confirmed at 1 year of age by body 
composition analysis, when Prex2 KO females were found to have a higher body fat 
percentage (Figure 4.3.14D). Hence, whereas Prex2 KO males on HFD showed 
multiple signs of metabolic syndrome in their old age, the females put on more 
weight (and body fat) than WT controls, but did not develop metabolic syndrome. 
In summary, Prex2 KO females did not show significant abnormalities in their 
glucose and insulin responses, except for a tendency to improved glucose tolerance 
at young age and worsened glucose intolerance at older age, both on chow and 
HFD. 
Taken together, the results on the metabolic phenotype of Prex2 KO mice 
show that ageing male Prex2 KO mice on HFD develop significant glucose 
intolerance and insulin resistance. Ageing Prex2 KO males on chow diet, as well as 
Prex2 KO females on chow or HFD, also show a tendency to worsened glucose 
tolerance in old age, in spite of better glucose tolerance at young age and either 
normal or increased insulin sensitivity (Table 4.2).  
Compared to Prex1 KO mice (Section 4.2), Prex2 KO mice showed almost 
the opposite metabolic phenotype. Where Prex1 deficiency improved glucose 
tolerance overall, Prex2 deficiency worsened it. Furthermore, only Prex2 deficiency 
but not Prex1 deficiency induced insulin resistance (Table 4.2).  
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Figure 4.3.13: Female Prex2 KO mice on HFD show a tendency to age-dependent 
changes in glucose tolerance. 
The fasting blood glucose levels and response to IPGTT were measured in female Prex2 KO 
(green) and Prex WT (blue) mice on 45% HFD at the ages of 10 and 15 weeks, 6, 9 and 12 months, 
as described in the legend to Figure 4.2.1. The ochre box denotes glucose challenge at the 
reduced dose of 1 g/kg instead of 2 g/kg. (A) Blood glucose concentration during IPGTT. (B) Blood 
glucose levels during IPGTT, normalised by subtracting the basal blood glucose level. (C) Total 
glucose response (AUC of normalised data). Data are pooled from 3 independent cohorts (Prex 
WT n=13; Prex2 KO n=15), and are presented as mean ± SEM. 2-way ANOVA with repeated 
measures and Sidak’s multiple comparisons correction was used to compare genotypes during 
IPGTT. Unpaired Student’s t-test was used to analyse the total glucose response. 
152 | P a g e  
 
 
 
 
Figure 4.3.14: Ageing female Prex2 KO mice on HFD overall show normal glucose 
tolerance, with some age-related fluctuation. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the female 
Prex2 KO (green) and Prex WT (blue) mice on 45% HFD from Figure 4.3.13 are expressed as a 
function of age. In pale green are represented the Prex2 KO female mice on chow diet from Figure 
4.3.9 for visual comparison, but were not included in the statistical analysis, as these animals were 
not directly compared experimentally. (A) Fasting blood glucose levels; data from column A in 
Figure 4.3.13. (B) Response to IPGTT; normalised data from columns B and C in Figure 4.3.13. 
(C) Body weight, measured after 6 and 4 h fasting, prior to glucose and insulin challenges, 
respectively. (D) Body composition at 1 year of age. The mice in (A-C) were culled at 1 year of 
age and the cadavers were scanned by Echo MRI for lean mass and body fat. Data are pooled 
from 3 independent cohorts (Prex WT n=13; Prex2 KO n=15), and are presented as mean ± SEM. 
2-way ANOVA with repeated measures and Sidak’s multiple comparisons correction was used to 
compare genotypes during ageing. Unpaired Student’s t-test was used to analyse the body 
composition. 
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Figure 4.3.15: Female Prex2 KO mice on HFD show a normal response to insulin 
challenge. 
The fasting blood glucose levels and response to SCITT were measured in the female Prex2 KO 
(green) and Prex WT (blue) mice on 45% HFD from Figure 4.3.13 at the age of 5 and 10 months, 
as described in the legend to Figure 4.2.3. (A) Blood glucose concentration during SCITT. (B) 
Fasting blood glucose levels. Data from 1 cohort (Prex WT n=5; Prex2 KO n=5), and are presented 
as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple comparisons 
correction was used to compare genotypes during SCITT. Unpaired Student’s t-test was used to 
analyse the basal blood glucose levels. 
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Figure 4.3.16: Female Prex2 KO mice on HFD produce less urine than Prex WT 
mice.  
The female Prex2 KO (green) and Prex WT (blue) mice from Figure 4.3.13 were habituated to 
metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and 
(D) faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are pooled from 3 independent cohorts (Prex WT 
n=13; Prex2 KO n=15), and are presented as the mean ± SEM of each night (n=3). Unpaired 
Student’s t-test was used for the comparison between the genotypes. 
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Table 4.2: Summary table of metabolic phenotype of Prex1 KO, and Prex2 KO mice on 
chow or high fat diet. Bold font was used to annotate findings that reached statistical significance 
in most time points tested, while bold and italic font was used to indicate strong trends  that show 
statistical significance in only one or two time points tested.  
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4.4 Metabolic phenotype of Prex1/2 DKO mice 
Given that Prex1 and Prex2 deficiencies had almost opposing effects on the 
metabolic phenotype of mice, we wanted to explore how the absence of both Prex 
proteins would affect mouse glucose homeostasis. Therefore Prex1–/–;Prex2–/– 
(Prex1/2 DKO) mice were studied, as described previously for the single KO mice. 
Prex1/2 DKO and Prex WT mice of same age and sex were tested in parallel under 
the same conditions for direct comparison.  
4.4.1 Male Prex1/2 DKO mice on chow diet have normal 
homeostasis throughout ageing 
Prex1/2 DKO males on chow diet had similar fasting blood glucose levels to Prex 
WT controls throughout ageing, with a tendency to lower levels than controls in old 
age (Figures 4.4.1A and 4.4.2A). Moreover, although the two genotypes had an 
identical glucose response at most ages, the Prex1/2 DKO appeared to have better 
glucose tolerance at 6 months (Figures 4.4.1B-C and 4.4.2B). This is more 
reminiscent of the Prex1 KO phenotype than the Prex2 KO phenotype, although it 
was less pronounced. Furthermore, it should be pointed out that the Prex WT 
controls tested here in parallel had an overall bigger response to glucose challenge 
than average Prex WT males, and therefore it is possible that the increased glucose 
tolerance at 6 months of age might not stand if further cohorts were tested. 
Upon insulin challenge, the blood glucose levels of Prex1/2 DKO males 
dropped to their lowest level at 45 min post injection and returned to around 8 mM 
at 120 min, similar to their Prex WT controls, and as typical for these conditions 
(Figure 4.4.3A). However, as seen previously in Prex1 KO males, this was 
confounded by the fact that the fasting blood glucose levels of Prex1/2 DKO males 
were slightly lower than that of Prex WT controls. Normalisation of the data revealed 
that the blood glucose of Prex1/2 DKO mice dropped by 3 mM, contrary to the Prex 
WT controls whose glucose levels dropped by 5 mM (Figure 4.4.3B-D). As 
discussed for the single KO mice above, it is suspected that the different levels of 
fasting blood glucose cause homeostatic mechanisms to be engaged to a different 
extent in order to achieve similar glucose homeostasis overall. At 10 months of age, 
the Prex1/2 DKO males showed a slightly increased and longer-lived response to 
insulin compared to the Prex WT mice, but not significantly so, which again 
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suggested that the insulin sensitivity of Prex1/2 DKO mice on chow diet is normal 
(Figure 4.4.3E-H). 
Prex1/2 KO mice were leaner than their Prex WT counterparts throughout 
ageing, and from 10 months this reached statistical significance (Figure 4.4.2C), 
although there was no difference in the body composition between Prex1/2 DKO 
and Prex WT mice at 1 year (Figure 4.4.2D). What is more, no difference was found 
in the water and food intake or the urine and faeces production between Prex1/2 
DKO males and controls when they were housed in metabolic cages at 11 months 
of age (Figure 4.4.4A-D). 
Overall, it seems that on chow diet, deficiency in both Prex proteins causes 
a phenotype that is similar to the Prex1 KO phenotype, but milder. As the phenotype 
of the DKO mice is not worse than either of the single KOs’, there is no obvious 
redundancy between the Prex proteins in the control of glucose homeostasis under 
chow diet conditions. Furthermore, as the phenotype of the DKO mice is milder than 
that of Prex1 KO mice, it can be hypothesised that currently unidentified regulators 
of glucose homeostasis compensate for the absence of both Prex proteins, which is 
not required when only one Prex protein is deleted. 
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Figure 4.4.1: Male Prex1/2 DKO mice on chow diet show similar fasting blood 
glucose levels and glucose tolerance to Prex WT mice. 
The fasting blood glucose levels and response to IPGTT were measured in male Prex1–/–;Prex2–
/– (Prex1/2 DKO, orange) and Prex WT (blue) mice on chow diet, as described in the legend to 
Figure 4.2.1. Only data from 15 weeks and 9 months of age are shown, for brevity, although mice 
of all ages up to one year were tested. (A) Blood glucose concentration during IPGTT. (B) Blood 
glucose levels during IPGTT, normalised by subtracting the basal blood glucose level. (C) Total 
glucose response (AUC of normalised data). Data are pooled from 2-3 independent cohorts with 
4-5 mice per genotype, and are presented as mean ± SEM. 2-way ANOVA with repeated 
measures and Sidak’s multiple comparisons correction was used to compare genotypes during 
IPGTT. Unpaired Student’s t-test was used to analyse the total glucose response. 
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Figure 4.4.2: Old male Prex1/2 DKO mice on chow diet have a tendency to low 
fasting blood glucose levels and middle-aged mice appear to have somewhat 
improved glucose tolerance. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the male 
Prex1/2 DKO (orange) and Prex WT (blue) mice in Figure 4.4.1 are expressed as a function of 
age. (A) Fasting blood glucose levels; data from column A in Figure 4.4.1. (B) Response to 
glucose challenge (IPGTT); normalised data from columns B and C in Figure 4.4.1. (C) Body 
weight, measured after 6 and 4 h fasting, prior to glucose and insulin challenges, respectively. 
Data are pooled from 2-3 independent cohorts with 4-5 mice per genotype, and are presented as 
mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple comparisons correction 
was used to compare genotypes during ageing. (D) Body composition at 1 year of age. The mice 
in (A-C) were culled at 1 year of age and the cadavers were scanned by Echo MRI for lean mass 
and body fat. Data are pooled from 2 independent cohorts (Prex WT n=9; Prex1/2 DKO n=9) and 
presented as mean ± SEM. Unpaired Student’s t-test was used to analyse the body composition. 
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Figure 4.4.3: Male Prex1/2 DKO mice on chow diet apparently show a reduced 
response to insulin challenge in middle age. 
The fasting blood glucose levels and response to SCITT were measured in the male Prex1/2 DKO 
(orange) and Prex WT (blue) mice on chow diet from Figure 4.4.1 at the ages of (A-D) 5 and (E-
H) 10 months, as described in the legend to Figure 4.2.3. (A,E) Blood glucose concentration 
during SCIT. (B,F) Fasting blood glucose levels. (C,G) Blood glucose levels during SCITT, 
normalised by subtracting the fasting basal blood glucose level from each mouse individually. 
(D,H) Total insulin response (AUC of normalised data). Data are pooled from 2 independent 
cohorts (Prex WT n=9; Prex1/2 DKO n=9), and are presented as mean ± SEM. 2-way ANOVA 
with repeated measures and Sidak’s multiple comparisons correction was used to compare 
genotypes during SCIT. Unpaired Student’s t-test was used to analyse the basal blood glucose 
level and total insulin response. 
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Figure 4.4.4: Male Prex1/2 DKO mice perform normally in metabolic cages. 
The male Prex1/2 DKO (orange) and Prex WT (blue) mice in Figure 4.4.1 were habituated to 
metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and 
(D) faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. (A-D) Data are pooled from 2 independent cohorts (WT 
n=9; Prex1/2 DKO n=9) and presented as the mean ± SEM of each night (n=3). Unpaired Student’s 
t-test for comparison between genotypes. 
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To test for the effect of diet, Prex1/2 DKO males were introduced to 45% HFD 
at the age of 10 weeks. As seen before in Prex1 KO and Prex2 KO males, Prex1/2 
DKO males on HFD had lower basal blood glucose levels than Prex WT controls 
(Figures 4.4.5A and 4.4.6A). Surprisingly though, HFD only induced an increase in 
the fasting blood glucose levels of Prex WT controls, whereas Prex1/2 DKO mice 
maintained their fasting blood glucose at a level comparable to that of their chow 
diet-fed counterparts (Figure 4.4.6A). In spite of this protection, HFD rendered the 
mice glucose intolerant over time, to the same extent as in Prex WT controls 
(Figures 4.4.5B-C and 4.4.6B). Again, this was more reminiscent of the Prex1 KO 
than the Prex2 KO phenotype, as Prex1 KO males also showed an improved 
glucose tolerance on chow diet that was lost on HFD. 
Both at 5 and 10 months of age, insulin challenge caused the blood glucose 
of male Prex1/2 DKO on HFD to drop to levels similar to that in Prex WT controls 
(Figure 4.4.7A, E). However, as seen previously with other cohorts, likely due to 
their lower fasting blood glucose levels (Figure 4.4.7B, F), the overall response was 
smaller in Prex1/2 DKO males compared to Prex WT mice (Figure 4.4.7C-D, G-H). 
Moreover, the insulin response of HFD-fed mice was reduced at 10 months 
compared to 5 months of age, for both genotypes (Figure 4.4.7D, H), indicating that 
HFD rendered Prex1/2 DKO males insulin resistant with age in a similar manner to 
Prex WT mice. It should be kept in mind though that the Prex WT males here 
responded to insulin a little stronger than expected from the analysis of multiple 
cohorts (see Supplementary Data, Section 2). 
 Unlike Prex1/2 DKO mice on chow diet, which gained weight more slowly 
than WT controls, mice from both genotypes gained weight in an identical way on 
HFD. Surprisingly, however, the Prex1/2 DKO males had higher fat percentage 
compare to the controls at their post mortem examination (Figure 4.4.6C-D), 
similarly to what was previously observed with Prex2 KO males on HFD. Finally, no 
difference was found in the water and food consumption or urine and faeces 
production of Prex1/2 DKO males on HFD housed in the metabolic cages (Figure 
4.4.8A-D).  
In conclusion, similarly to Prex single knockout strains, Prex1/2 double 
deficiency helped males on HFD  maintain low fasting blood glucose levels , but did 
164 | P a g e  
not prevent them from becoming glucose intolerant, nor did it affect their insulin 
sensitivity. 
 
 
 
 
 
 
Figure 4.4.5: Male Prex1/2 DKO mice on HFD show similar glucose tolerance to 
Prex WT mice. 
The fasting blood glucose levels and response to IPGTT were measured in male Prex1/2 DKO 
(orange) and Prex WT (blue) mice on 45% HFD at the ages, as described in the legend to Figure 
4.2.1. Only data from 15 weeks and 9 months of age are shown for brevity, although mice of all 
ages up to one year were tested. (A) Blood glucose concentration during IPGTT. The dose of 
glucose used in the IPGTT was 2 g/kg at the ages of 10 and 15 weeks, and 0.5 g/kg thereafter 
(data in ochre box). (B) Blood glucose levels during IPGTT, normalised by subtracting the basal 
blood glucose level. (C) Total glucose response (AUC of normalised data). Data from 1 cohort 
(Prex WT n=4; Prex1/2 DKO n=5) and are presented as mean ± SEM. 2-way ANOVA with 
repeated measures and Sidak’s multiple comparisons correction was used to compare genotypes 
during IPGTT. Unpaired Student’s t-test was used to analyse the total glucose response. 
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Figure 4.4.6: Male Prex1/2 DKO mice on HFD have low fasting blood glucose levels 
but a normal response to glucose challenge throughout ageing. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the male 
Prex1/2 DKO (orange) and Prex WT (blue) mice in Figure 4.4.5 are expressed as a function of 
age. Note that the dose of glucose was reduced from 2 g/kg to 0.5 g/kg from the age of 6 months 
onwards (data in ochre box). In faded orange are represented the Prex1/2 DKO male mice on 
chow diet from Figure 4.4.1 for visual comparison, but these mice were not included in the 
statistical analysis as they were not directly compared experimentally. (A) Fasting blood glucose 
levels; data from column A in Figure 4.4.5. (B) Response to IPGTT; normalised data from columns 
B and C in Figure 4.4.5. (C) Body weight, measured after 6 and 4 h fasting, prior to glucose and 
insulin challenges, respectively. (D) Body composition at 1 year of age. The mice in (A-C) were 
culled at 1 year of age and the cadavers were scanned by Echo MRI for lean mass and body fat. 
Data are from 1 cohort (Prex WT n=4; Prex1/2 DKO n=5) and presented as mean ± SEM. 2-way 
ANOVA with repeated measures and Sidak’s multiple comparisons correction was used to 
compare genotypes during ageing. Unpaired Student’s t-test was used to analyse the body 
composition. 
 
166 | P a g e  
 
 
Figure 4.4.7: Male Prex1/2 DKO mice on HFD show apparent insulin resistance 
throughout ageing. 
The fasting blood glucose levels and response to SCITT were measured in the male Prex1/2 DKO 
(orange) and Prex WT (blue) mice on 45% HFD from Figure 4.4.5 at the age of (A-D) 5 and (E-
H) 10 months, as described in the legend to Figure 4.2.3. (A,E) Blood glucose concentration 
during SCITT. (B,F) Fasting blood glucose levels. (C,G) Blood glucose levels during SCITT, 
normalised by subtracting the fasting basal blood glucose level from each mouse individually. 
(D,H) Total insulin response (AUC of normalised data). Data from 1 cohort (Prex WT n=4; Prex1/2 
DKO n=5) and presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s 
multiple comparisons correction was used to compare genotypes during SCITT. Unpaired 
Student’s t-test was used to analyse the basal blood glucose level and total insulin response. 
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Figure 4.4.8: Male Prex1/2 DKO mice perform normally in metabolic cages. 
The male Prex1/2 DKO (orange) and Prex WT (blue) mice from Figure 4.4.5 were habituated to 
metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and 
(D) faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are from 1 cohort (Prex WT n=4; Prex1/2 DKO 
n=5) and are presented as the mean ± SEM of each night (n=3). Unpaired Student’s t-test for 
comparison between genotypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
168 | P a g e  
4.4.2 Female Prex1/2 DKO mice have a tendency to worsened 
glucose response throughout ageing 
Lastly, the metabolic phenotype of the Prex1/2 DKO females on chow and HFD was 
investigated. The representative graphs in Figure 4.4.9 and the ageing overview 
graphs in Figure 4.4.10 show that Prex1/2 DKO females on chow diet had identical 
fasting blood glucose levels to the Prex WT controls (Figures 4.4.9A and 4.4.10A). 
Moreover, Prex1/2 deficiency did not alter significantly the response to glucose 
challenge in females on chow diet, although there was a tendency to worse glucose 
tolerance (Figures 4.4.9B-C and 4.4.10A). Similarly, Prex1/2 DKO females on chow 
diet had normal insulin responses both at 5 months and at 10 months’ time points, 
except for a slightly altered counter-regulatory response in old age (Figure 4.4.11 
A-B). Finally, Prex1/2 DKO and Prex WT females on chow diet gained weight at a 
comparable rate and had similar body composition at one year of age (Figure 
4.4.10C-D), despite Prex1/2 DKO consuming less water and food and producing 
less urine and faeces (Figure 4.4.12 C-D). Overall, therefore, the absence of both 
Prex proteins did not have any significant effect on the metabolic phenotype of 
female mice on chow diet. 
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Figure 4.4.9: Female Prex1/2 DKO mice on chow diet show similar fasting blood 
glucose levels but a tendency towards worsened glucose tolerance compared to 
Prex WT mice. 
The fasting blood glucose levels and response to IPGTT were measured in female Prex1/2 DKO 
(orange) and Prex WT (blue) mice on chow diet, as described in the legend to Figure 4.2.1. Only 
data from 15 weeks and 9 months of age are shown, for brevity, although mice of all ages up to 
one year were tested. (A) Blood glucose concentration during IPGTT. (B) Blood glucose levels 
during IPGTT, normalised by subtracting the basal blood glucose level. (C) Total glucose response 
(AUC of normalised data). Data are pooled from 2 independent cohorts (Prex WT n=9; Prex1/2 
DKO n=8) and presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s 
multiple comparisons correction was used to compare genotypes during IPGTT. Unpaired 
Student’s t-test was used to analyse the total glucose response. 
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Figure 4.4.10: Female Prex1/2 DKO mice on chow diet have a tendency to worsened 
glucose tolerance throughout ageing. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the female 
Prex1/2 DKO (orange) and Prex WT (blue) mice in Figure 4.4.9 are expressed as a function of 
age. (A) Fasting blood glucose levels; data from column A in Figure 4.4.9. (B) Response to IPGTT; 
normalised data from columns B and C in Figure 4.4.9. (C) Body weight, measured after 6 and 4 
h fasting, prior to glucose and insulin challenges, respectively. (D) Body composition at 1 year of 
age. The mice in (A-C) were culled at 1 year of age and the cadavers were scanned by Echo MRI 
for lean mass and body fat. Data are pooled from 2 independent cohorts (WT n=9; Prex1/2 DKO 
n=8) and are presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s 
multiple comparisons correction was used to compare genotypes during ageing. Unpaired 
Student’s t-test was used to analyse the body composition. 
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Figure 4.4.11: Female Prex1/2 DKO mice on chow diet show an altered late-phase 
response to insulin challenge in old age. 
The fasting blood glucose levels and response to SCITT were measured in female Prex1/2 DKO 
(orange) and Prex WT (blue) mice from Figure 4.4.9 on chow diet at the ages of 5 and 10 months, 
as described in the legend to Figure 4.2.3. (A) Blood glucose concentration during SCITT. (B) 
Fasting blood glucose levels. Data are pooled from 2 independent cohorts (Prex WT n=9; Prex1/2 
DKO n=8) and are presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s 
multiple comparisons correction was used to compare genotypes during SCITT. Unpaired 
Student’s t-test was used to analyse the basal blood glucose levels. 
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Figure 4.4.12: Female Prex1/2 DKO mice consume less water and food and produce 
less urine and faeces compared to Prex WT mice in metabolic cages. 
The female Prex1/2 DKO (orange) and Prex WT (blue) mice from Figure 4.4.9 were habituated to 
metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and 
(D) faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are pooled from 2 independent cohorts (Prex WT 
n=9; Prex1/2 DKO n=8) and are presented as the mean ± SEM of each night (n=3). Unpaired 
Student’s t-test was used for comparison between genotypes. 
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On HFD, the basal blood glucose levels of Prex1/2 DKO females did not 
change compared to Prex WT controls, similarly to what had been seen in Prex1/2 
DKO males (Figures 4.4.13A and 4.4.14A). However, from 15 weeks of age, after 
just one month on HFD, Prex1/2 DKO females demonstrated reduced glucose 
clearance during IPGTT, compared to Prex WT mice, and this glucose intolerance 
persisted until the age of one year (Figures 4.4.13B-C and 4.4.14B). This 
phenotype was contrary to what was previously seen with the Prex1 and Prex2 KO 
females on HFD, which had shown either improved glucose tolerance (Prex1 KO) 
or, at most, a tendency to worsened glucose tolerance in old age (Prex2 KO). This 
would suggest that the two Prex proteins can compensate, or even over-
compensate, for each other to provide glucose tolerance in female mice on HFD, 
and this redundancy is lost when both proteins are deleted. This was a sex-specific 
phenotype, as Prex1/2 DKO males on HFD showed normal glucose tolerance.  
The insulin sensitivity of the Prex1/2 deficient females on HFD was normal 
overall, except for the exaggerated counter-regulatory response in both middle-
aged and old animals (Figure 4.4.15A-B). A similar phenotype had also been seen 
in old females on chow diet.  
Finally, the Prex1/2 DKO and the Prex WT females gained weight at a 
comparable rate and had similar body composition at one year of age (Figure 
4.4.14C-D). Moreover, as can be seen in Figure 4.4.16, Prex1/2 DKO females also 
had normal water and food intake as well as urine and faeces production.  
Taken together these data suggest that, in the absence of both Prex proteins, 
females on HFD are glucose intolerant, unlike Prex WT females or females with 
Prex single KO under the same conditions. 
To summarise this section (see also Table 4.3), deficiency of both Prex1 and 
Prex2 in chow diet fed males has no major effects, except causing a tendency to 
improved glucose tolerance in middle-aged animals. On HFD, Prex1/2 DKO males 
showed low fasting blood glucose levels throughout ageing, but normal glucose 
tolerance. Their apparent insulin resistance is likely to be a reflection of their low 
fasting blood glucose levels, rather than true insulin resistance, as normal absolute 
levels of blood glucose are achieved upon insulin challenge. In contrast to the 
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Prex1/2 DKO males and to singlePrex1 or Prex2 KO females, Prex1/2 DKO females 
showed a tendency to reduced glucose tolerance on chow diet and actual glucose 
intolerance on HFD. This phenotype of the DKO mice overall shows that there is 
sex- and diet-dependent redundancy between Prex proteins in the control of glucose 
tolerance (in females on HFD), as well as compensation from other regulators of 
glucose homeostasis that engages when both Prex proteins are deleted. 
 
 
 
 
 
 
Figure 4.4.13: Female Prex1/2 DKO mice on HFD show normal fasting blood 
glucose levels but a trend to reduced glucose tolerance. 
The fasting blood glucose levels and response to IPGTT were measured in female Prex1/2 DKO 
(orange) and Prex WT (blue) mice on 45% HFD, as described in the legend to Figure 4.2.1. Only 
data from 15 weeks and 9 months of age are shown, for brevity, although mice of all ages up to 
one year were tested. The ochre box denotes glucose challenge at the reduced dose of 1 g/kg 
instead of 2 g/kg. (A) Blood glucose concentration during IPGTT. (B) Blood glucose levels during 
IPGTT, normalised by subtracting the basal blood glucose level. (C) Total glucose response (AUC 
of normalised data). Data are from 1 cohort (Prex WT n=5; Prex1/2 DKO n=5) and are presented 
as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple comparisons 
correction was used to compare genotypes during IPGTT. Unpaired Student’s t-test was used to 
analyse the total glucose response. 
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Figure 4.4.14: Middle-aged female Prex1/2 DKO mice on HFD are glucose intolerant. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the female 
Prex1/2 DKO (orange) and Prex WT (blue) mice on 45% HFD from Figure 4.4.13 are expressed 
as a function of age. The ochre box denotes glucose challenge at the reduced dose of 1 g/kg 
instead of 2 g/kg. In faded orange are represented the Prex1/2 DKO female mice on chow diet 
from Figure 4.4.9 for visual comparison, but were not included in the statistical analysis, as these 
animals were not directly compared experimentally. (A) Fasting blood glucose levels; data from 
column A in Figure 4.4.13. (B) Response to IPGTT; normalised data from columns B and C in 
Figure 4.4.13. (C) Body weight, measured after 6 and 4 h fasting, prior to glucose and insulin 
challenges, respectively. (D) Body composition at 1 year of age. The mice in (A-C) were culled at 
1 year of age and the cadavers were scanned by Echo MRI for lean mass and body fat. Data are 
from 1 cohort (Prex WT n=5; Prex1/2 DKO n=5) and are presented as mean ± SEM. 2-way ANOVA 
with repeated measures and Sidak’s multiple comparisons correction was used to compare 
genotypes during ageing. Unpaired Student’s t-test was used to analyse the body composition. 
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Figure 4.4.15: Female Prex1/2 DKO mice on HFD show normal fasting blood 
glucose levels but an altered late-phase response to insulin challenge. 
The fasting blood glucose levels and response to SCITT were measured in the female Prex1/2 
DKO (orange) and Prex WT (blue) mice on 45% HFD from Figure 4.4.13 at the ages of 5 and 10 
months, as described in the legend to Figure 4.2.3. (A) Blood glucose concentration during SCITT. 
(B) Fasting blood glucose levels. Data are from 1 cohort (Prex WT n=5; Prex1/2 DKO n=5) and 
are presented as mean ± SEM. Unpaired Student’s t-test was used to analyse the total glucose 
response. 
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Figure 4.4.16: Female Prex1/2 DKO mice perform normally in metabolic cages.  
The female Prex1/2 DKO (orange) and Prex WT (blue) mice from Figure 4.4.13 were habituated 
to metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and 
(D) faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are from 1 cohort (Prex WT n=5; Prex1/2 DKO 
n=5) and are presented as the mean ± SEM of each night (n=3). Unpaired Student’s t-test was 
used for comparison between genotypes. 
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Table 4.3: Summary table of metabolic phenotype of Prex1 KO, Prex2 KO, and Prex1/2 
DKO mice on chow or high fat diet.  Bold font was used to annotate findings that reached 
statistical significance in most time points tested, while bold and italic font was used to indicate 
strong trends that show statistical significance in only one or two time points tested.  
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4.5 Adaptor functions of PREX proteins in glucose 
homeostasis and insulin signalling 
In order to study functions of PREX proteins that are independent of their catalytic 
Rac-GEF activity, I generated and studied GEF-dead proteins and mice. 
Recombinant protein was generated to confirm catalytic inactivity in vitro. 
Mammalian expression constructs were used for overexpression of GEF-dead 
proteins and analysis of their effects on the insulin signalling pathway. GEF-dead 
mouse strains were generated to test glucose homeostasis in the same manner as 
previously in the KO mice. Recombinant WT PREX1 and GEF-dead PREX1 
proteins, as well as constructs for the expression of WT PREX1, WT PREX2 and 
GEF-dead PREX1 in mammalian cells were already available in the laboratory, but 
all other tools were generated in the frame of this PhD. 
4.5.1 Design of human recombinant catalytically inactive 
PREX2 
To generate catalytically inactive PREX2 protein, residues whose mutation would 
render the human PREX2 protein catalytically inactive were identified based on the 
literature. Mutation of the residues Glu56 and Asn238 within the catalytic DH domain 
of human PREX1 was previously shown to render the protein GEF-Dead both in 
vitro and in cells (Hill et al., 2005). Similarly, mutation of the Leu334 and Lys335 
residues within the catalytic DH domain of the mouse GEF protein Vav1 resulted in 
inactivation of its GEF activity (Saveliev et al., 2009). Furthermore, these mutations 
in both GEFs had been reported to not affect the normal folding of the proteins, or 
their interaction with other proteins (Figure 4.5.1A). I annotated these target 
residues on the crystal structural of the DH domain of the Rac-GEF protein Tiam1 
in complex with Rac1 (Figure 4.5.1B), which confirmed that all these amino acids 
present their side chains towards Rac1, hence their mutation was expected to 
specifically disrupt the Rac-GEF activity.  
As presented in Figure 4.5.1C, alignment of the amino acid sequence of the 
Rac-GEFs Tiam1, Prex1 and Prex2 showed that the equivalent to Vav1 residue 
Leu334 was not conserved throughout Rac-GEFs. Therefore, it was decided to 
mutate the PREX2 residues that are equivalent to those in GEF-Dead PREX1 for 
the generation of catalytically inactive PREX2. These residues are Glu30 and Asn212.  
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Figure 4.5.1: Strategy for the generation of atalytically inactive human PREX2 
protein and catalytically inactive Prex1 and Prex2 mice. 
(A) Graphical representation of PREX protein binding partners and intended point mutations in 
their DH domain. (B) Crystal structure of the DH domain of mouse GEF protein Tiam1 in complex 
with Rac1, with the equivalent residues highlighted in red that are known to produce GEF-dead 
PREX1 and Vav1 proteins when mutated to alanine. The two outer residues have been mutated 
in PREX1, the middle ones in Vav1 (Provided by Simon R. Andrews, Babraham Bioinformatics 
Facility). (C) Alignment of the mouse Tiam1 and the human PREX1 and PREX2 protein 
sequences. Black highlights annotate the equivalent residues of PREX1 Glu56 and Asn238 and 
Vav1 Leu334 and Lys335   that were reported to render PREX1 and Vav1 GEF-Dead (alignment 
provided by Simon R. Andrews). 
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4.5.2 Production and characterisation of catalytically inactive 
human PREX2 protein 
To confirm that the mutation of Glu30 and Asn212 in the catalytic DH domain of 
PREX2 indeed rendered the protein catalytically inactive, recombinant human 
PREX2-E30A/N212A protein was produced and purified from Sf9 cells. 
Recombinant human wild type PREX2 (PREX2 WT) was produced at the same time 
as a control (Figure 4.5.2A-B). The purified proteins were tested in a liposome-
based in vitro Rac-GEF activity assay, using human recombinant EE-Rac1-GDP as 
substrate, with increasing doses of PIP3 as stimulus, and EDTA as a positive control. 
Rac-GEF activity was measured as the PREX2-stimulated 35S-GTPγS loading of 
EE-Rac1. This confirmed that the introduction of mutations E30A and N212A into 
the DH domain of PREX2 inhibited it from acting as a PIP3-regulated Rac-GEF 
(Figure 4.5.2C). Its basal (PIP3-independent) Rac-GEF activity was also lower than 
that of the WT protein, hardly detectable over the no-GEF basal control that 
contained only EE-Rac1. Hence, the mutations chosen were effective at rendering 
PREX2 protein catalytically inactive. 
4.5.3 Overexpression of GEF-dead PREX1 and GEF-dead 
PREX2 in HepG2 cells increases insulin pathway 
activity to a similar extent as overexpression of the 
wild type proteins. 
To assess the importance of the Rac-GEF activity of PREX proteins in insulin 
signalling, an expression vector for the overexpression of human Glu30 → Ala30 ; 
Asn212 → Ala212 catalytically inactive PREX2 in mammalian cells was also 
generated. Expression constructs for catalytically inactive PREX1 as well as wild 
type PREX1 and PREX2 were already available in the lab and were used in parallel. 
HepG2 human liver carcinoma cells were transfected to overexpress wild type (WT) 
PREX1 or PREX2 or catalytically inactive PREX1 E56A/N238A or PREX2 
E30A/N212A proteins, and mock-transfected cells with vector only constructs (v.o. 
control) were tested in parallel. The cells were serum-starved for 8 h in serum-free 
medium containing 0.1% BSA, prior to stimulation with 25 nM insulin for various 
lengths of time. Total cell lysates were prepared and analysed by western blot for 
the phosphorylation of Akt on the mTORC2 target site S473 that confers full 
activation, as a measure of insulin pathway activity, by western blot. As shown in 
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Figure 4.5.3A, overexpression of either wild type PREX1 or PREX1 E56A/N238A 
in insulin-stimulated HepG2 human liver cells caused increased Akt 
phosphorylation. Similar results were obtained upon overexpression of wild type 
PREX2 or PREX2 E30A/N212A (Figure 4.5.3B). The level of Akt phosphorylation 
on S473 increased in a time-dependent manner in cells that expressed either WT 
or GEF-dead PREX proteins, from 10 s of insulin stimulation onwards, and it 
remained elevated until the longest time-point tested, 2 hours. Under the same 
conditions, vector-control treated cells responded to insulin stimulation at a much 
lower level. The extent of Akt phosphorylation was very similar between wild type 
and GEF-dead PREX proteins, at comparable levels of overexpression. 
Quantification by ImageJ densitometric analysis confirmed that our observation 
reached statistical significance between v.o. control and PREX expressing cells, and 
that there was no statistically significant difference between WT and GEF-dead 
proteins, except that fewer time points reached significance with the PREX2 GEF-
dead protein than the equivalent PREX2 WT protein (Figure 4.5.3C-D). These 
results suggest that both PREX proteins can promote insulin signalling not only 
through their Rac-GEF activity, but also in a GEF-activity independent manner as 
adaptor proteins, at least in this overexpression system. 
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Figure 4.5.2: Generation of purified human recombinant catalytically inactive EE-
PREX2E30A/N212A protein in Sf9 cells. 
(A) Sequencing trace of human EE-PREX2E30A/N212A DNA construct, assembled with Gap4 
software, showing the mutated residues in red boxes. This construct was used for lentivirus 
production, transduction of Sf9 insect cells, and expression of human recombinant catalytically 
inactive EE-PREX2E30A/N212A protein. Human recombinant wild type EE-PREX2 (blue bars) and 
mutated EE-PREX2E30A/N212A (red bars) were produced in Sf9 cells and purified to >90% purity 
using anti-EE antibody coupled protein A sepharose as detailed in Materials and Methods. (B) 
Protein gel of the purified protein. (C) The purified proteins were tested in a liposome-based in 
vitro GEF activity assay, using EE-Rac1-GDP as substrate and increasing doses of PIP3 as 
stimulus, together with either Sf9 cell derived purified recombinant PREX2 protein, either WT or 
GEF-dead, as indicated. 35S-GTPγS loading of EE-Rac1 was measured to determine Rac-GEF 
activity. EDTA was used as a positive control. Data are pooled from 3 independent experiments  
and presented at mean ± SEM. 
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Figure 4.5.3: Overexpression of wild type and GEF-dead PREX1 or PREX2 in HepG2 
cells increases AKT activity to a similar level in response to insulin stimulation. 
HepG2 human liver carcinoma cells were transfected to overexpress WT PREX, or catalytically 
inactive PREX (PREX1 E56A/N238A, PREX2 E30A/N212A), or mock-transfected with vector only 
(v.o. control), and were serum-starved for 8 h in serum-free medium containing 0.1% BSA, prior 
to stimulation with 25 nM insulin for the indicated periods of time. Total cell lysates were western 
blotted for active Akt (phospho-S473). (A,B) Representative Western blots, (C,D) overexpression 
controls western blotted for EE tag and (E,F) quantification by ImageJ densitometric analysis of 
HepG2 with (A,E) PREX1 or PREX1 E56A/N238A, (B,F) PREX2 or PREX2 E30A/N212A. Data 
are mean ± SEM of 3-6 independent experiments, normalized to the v.o. 0-time point. Statistics 
are 2-way ANOVA repeated measures and Dunnett’s multiple comparisons correction. 
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4.5.4 Targeting strategy of catalytically inactive Prex mouse 
strains 
On the basis of my data that showed the effects of overexpressed human GEF-dead 
PREX1 E56A/N238A and PREX2 E30A/N212A on insulin signalling in HepG2 cells, 
together with the literature on the adaptor function of PREX2 as an inhibitor of PTEN, 
led me to generate knock-in mice. In these mice, point mutations were introduced 
in the genomic loci that turn wild type Prex1 and Prex2 into catalytically inactive 
Prex1 or Prex2 proteins, with the aim of studying adaptor functions of the Prex 
proteins in glucose homeostasis in vivo. 
To generate catalytically inactive Prex1 and Prex2 mouse strains, the 
equivalent residues in the murine DH domain to those described above for the work 
in the HepG2 cell line and with human recombinant protein were targeted and 
mutated to alanine in the mouse genome. For mouse Prex1, these residues are 
Glu51 and Asn233, and for mouse Prex2 they are Glu22 and Asn204. Within the mouse 
genomic sequence, the two target residues in each gene are located ~ 90 kb apart, 
too far apart to be targeted through a single homologous recombination event, and 
too close to enable the generation of mice by crossing strains with a single mutation. 
Therefore, CRISPR technology was selected to be used. The principle of CRISPR 
technology is to design single guide RNAs (sgRNAs) that direct the Streptococcus 
pyogenes-derived wild type Cas9 nuclease to introduce a double-strand cleavage 
at a specific sequence within the genome and thus enable genome editing (Qi et al., 
2013; Ran et al., 2013a; Ran et al., 2013b) (Figure 4.5.4).  
For this project, the following targeting plans were considered. The first was 
to employ wild type Cas9, which mediates site-specific double-strand DNA brakes 
3 bp 5’ of the PAM sequence, to target both exons of Prex1 or Prex2 at the same 
time, using two different repair templates. However, there were concerns about off-
target effects and losing parts of the genomic sequence due to the introduction of 
double-strand brakes. Therefore, the alternative of using the Cas9D10A (Cas9 
nickase), which cleaves only one DNA strand, was considered. Cas9D10A allows 
increased specificity when loci are targeted by paired Cas9 complexes designed to 
generate adjacent DNA nicks. The thought was that each locus would be targeted 
with a pair of Cas9D10A and the relevant repair template for the introduction of the 
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desired mutation. The drawbacks of this approach were the amount of components 
that needed to be microinjected into the zygote and the remaining fear of losing 
parts of the genomic sequence. A third option was to introduce one Cas9 nickase 
for each target locus, one aiming at the transcribed strand and one aiming at the 
non-transcribing strand, which would decrease the zygote loading and keep the 
genome stable. However, there were concerns about the efficiency with which the 
repair template would be incorporated. Taking everything into consideration, it was 
decided to opt for the first strategy, but the sgRNAs were selected in a way that 
would keep viable the third option as well. 
 
 
 
Figure 4.5.4: Principle of CRISPR-Cas9 gene editing technology 
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Type II system 
consists of the Cas9 nuclease from S. pyogenes (green) and the Guide RNA (blue), comprising a 
scaffold which binds to the Cas9 nuclease and a 20-nt guide sequence which pairs with the DNA 
target, directly upstream of a requisite 5′-NGG adjacent motif (PAM; yellow). Cas9 mediates a 
DSB ∼3bp upstream of the PAM (red arrows). The double-strand brakes can be repaired either 
through the error-prone non-homologous end joining (NHEJ) mechanism which results in random 
indel mutations or through the homology directed (HD) repair by the introduction of a repair 
template (Ran et al., 2013b). (Diagram adapted from (transOMIC technologies, 2012)).  
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4.5.4.1 Design of the single guide RNAs 
Having decided on a targeting strategy, the next step was to design sgRNAs 
for Prex1 and Prex2. The genomic sequences of interest were analysed by web-
based bioinformatic tools developed to identify suitable target sites and 
computationally predict off-target sites for each target. I chose the following 
databases: the Feng Zhang laboratory’s CRISPR Design Tool, the Broad Institute’s 
sgRNA Designer, and E-CRISPR. The intended target sites that were identified by 
all softwares as most specific were further evaluated as suitable sgRNAs for each 
specific genomic site to be targeted. The sgRNAs were selected to be into close 
proximity with the targeted residues which would enable the design of a smaller 
repair template. Moreover, sgRNAs for both DNA strands were selected to be tested 
for their efficiency (Table 4.4). 
Table 4.4: sgRNA sequences tested for each intended point mutation in the mouse prex1 
and prex2 genes. In green are annotated the requisite PAM sequences, which are not part of the 
sgRNA sequences themselves. 
 
Mutation on Prex1 Exon 1, nt265-267, GAG -> GCG 
Name sgRNA Oligo Sequence Target Strand 
mwt 1.1 GTGCGTACTCAACGAGATCC-TGG sense 
mwt 1.2 GGGCACCGAGCGCGACTACG-TGG sense 
mwt 1.3 GCGTTGAGTACGCACAGACGG-AGG antisense 
Mutation on Prex1 Exon 6, nt92590-92592, AAT -> GCT 
Name sgRNA Oligo Sequence Target Strand 
mmt 1B.2 GCAATGAGACTAAGAGGCAGA-TGG sense 
mwt 1.5 GCCAACATCAATGAGACTAAG-AGG sense 
mwt 1.6 GTTGGAGCAGACAGTCTTCA-TGG antisense 
Mutation on Prex2 Exon 1, nt392-394, GAG -> GCG 
Name sgRNA Oligo Sequence Target Strand 
mmt 2A.1 GCGCTGAGCACGCACACGCGC-AGG antisense 
mmt 2B.1 GAAGACCGAGCGCGACTACG-TGG sense 
mwt 2.3 GCGCGACTACGTGGGCACGC-TGG sense 
Mutation on Prex2 Exon 6, nt96342-96344, AAT -> GCG 
Name sgRNA Oligo Sequence Target Strand 
mwt 2.4 GCGTGTGTTCCAACATTAATG-AGG sense 
mmt 2A.2 GTTGGAACACACGGCTTTCA-TGG antisense 
mmt 2B.2 GTAATGAGGCCAAGAGACAGA-TGG sense 
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4.5.4.2 In Vitro assessment of sgRNA efficiency 
To assess the efficiency with which the designed sgRNAs guided the Cas9 nuclease 
to cleave at the right site in the Prex1 and Prex2 genomic sequence, the Guide-it 
sgRNA In vitro Transcription and Screening System was used initially. In this 
system, an sgRNA construct was produced by in vitro transcription, and it was 
subsequently used in combination with recombinant Cas9 nuclease in vitro to cleave 
PCR amplified Prex1 or Prex2 genomic target sequences, respectively (Table 4.5). 
DNA template and sgRNA provided by the kit manufacturer were used as positive 
controls, whereas negative controls were PCR amplified target sequences digested 
with recombinant Cas9 only, without any sgRNA.   
After the in vitro cleavage reaction, the DNA products were resolved by gel 
electrophoresis. As can be seen in Figure 4.5.5A, all the designed sgRNAs 
managed to guide the Cas9 nuclease correctly to the intended Prex1 or Prex2 target 
sequence, and facilitated the introduction of a double-strand brake. For each target 
site, the upper band (labelled as Band A; Figure 4.5.5A) was the un-cleaved DNA 
sequence, whereas the two bands below, labelled Band B, where the cleavage 
products. Given that the produced DNA fragments were of the predicted size, it was 
concluded that the sgRNAs had indeed guided the Cas9 nuclease to the intended 
target sites. However, the presence of remaining un-cleaved DNA template also 
demonstrated that the sgRNAs resulted in a partial rather than total digest of the 
targeted sequence. In order to evaluate the efficiency of the sgRNAs therefore, lane 
profile analysis of the gel images was performed using Image Lab Software to 
quantify the band densities (Figure 4.5.5B). The efficiency of each sgRNA for each 
locus was defined as the percentage of un-cleaved template. The sgRNA that left 
the lowest percentage of un-cleaved targeting template was considered to be the 
best for that locus (Figure 4.5.5B). 
For exon 1 of Prex1, the most efficient sgRNA was Mwt 1.2, with 26.4% of 
un-cleaved DNA template left, while for exon 6, Mmt 1B.2 (7.3%) was the best. 
Regarding the targeting of Prex2, the most efficient sgRNA for exon 1 was Mmt 2B.1 
with only 9.7% of un-cleaved DNA template left, and for exon 6 Mmt 2B.2 (12.1%). 
In addition to the best sgRNA for each locus, the second best was also selected for 
further assessing of their efficiency in the NIH/3T3 mouse cell line. The selected 
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sgRNAs were the following: for the targeting of Prex1 exon 1 - sgRNAs Mwt 1.1 and 
Mwt 1.2; for the targeting of Prex1 exon 6 - sgRNAs Mmt 1B.2 and Mwt 1.6; for the 
targeting of Prex2 exon1 - sgRNAs Mmt 2A.1 and Mmt 2B.1; and finally for the 
targeting of Prex2 exon6 - sgRNAs Mwt 2.4 and Mmt 2B.2. 
 
Table 4.5: List of primer pairs used for the amplification of ~2 kb DNA fragments containing 
the region of interest to be tasted in the guide-it sgRNA in vitro transcription and screening 
system and the surveyor assay. 
 
 
# 
gRNA 
Target 
Forward 
Primer 
Reverse 
Primer 
Product 
size 
gRNA 
Tested 
Distance 
from F 
primer 
Distance 
from R 
primer 
1 
Prex1 
Exon1 
TGAATGGGTCT 
TGGCCTACA 
AAAACCGCAGT 
CAACCTAGC 
1916 
mwt 1.1 627 1289 
mwt 1.2 649 1268 
mwt 1.3 607 1309 
2 
Prex1 
Exon6 
GGCACCCACAG 
AACGAATTA 
CAATGCCCCTT 
CCAAAGTCC 
1978 
mwt 1.5 617 1362 
mwt 1.6 587 1391 
mmt1B.2 623 1355 
3 
Prex2 
Exon1 
GGTCAGTGGTG 
TGGTTGTTT 
CCACCAAGTCC 
AGCTCAAAT 
2151 
mmt2A.1 677 1474 
mwt 2.1 719 1432 
mwt 2.3 727 1424 
4 
Prex2 
Exon6 
TCAGTTTTGAA 
ATTGTGGTGCA 
GCTGAGGGACA 
TTCAAGACC 
2039 
mwt 2.4 494 1545 
mmt2A.2 473 1566 
mmt2B.2 509 1530 
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Figure 4.5.5: In Vitro and Surveyor DNA cleavage assays revealed the efficiency of 
sgRNAs and Cas9 nuclease for the generation of catalytically inactive Prex1 and 
Prex2 mice. 
(A) PCR fragment of Prex1 or Prex2 mouse genomic sequence containing the sgRNA target sites 
were incubated with candidate sgRNAs and recombinant Cas9 nuclease and cleavage products 
resolved by gel electrophoresis. As a positive control (+ Control), a 2kb control fragment and 
control sgRNA were used as provided with the kit. As negative controls (– Control), DNA fragments 
were incubated with Cas9 in absence of sgRNA. (B) Image Lab Software was used to quantify the 
efficiency of the sgRNAs. In each lane, band A denotes the un-cleaved DNA template, and bands 
B and C the cleaved products. The quantity of un-cleaved DNA template remaining in band A was 
used to determine the cleavage efficiency of each sgRNA (low un-cleaved DNA template = high 
sgRNA efficiency). (C) DNA was extracted from NIH/3T3 cells transfected with pSpCas9(BB)-2A-
GFP plasmid expressing sgRNA for exon 1 and exon 6 of Prex1 and Prex2, respectively. The 
sgRNA target sites were PCR amplified from genomic DNA extracted from wild type and 
transfected cells. The PCR product of the mutated cells was combined with equal amounts of the 
corresponding PCR product from wild type cells, and the Surveyor Nuclease was used to cleave 
the mismatched sites. The cleavage products were resolved by gel electrophoresis. 
Homoduplexes from wild type DNA fragments were used as negative controls (– control). (D) 
Quantification of sgRNA efficiency as in (B). Cleavage products present in the negative control 
were considered to be due to the exonuclease activity of the Surveyor Nuclease, and were not 
taken into consideration. 
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4.5.4.3 Assessment of sgRNA efficiency in cells 
To assess if the sgRNAs could perform as well in cells as they did in the in vitro 
system, the NIH/3T3 mouse cell line was chosen as the test system, and a Surveyor 
Assay was used that is based on the ability of Surveyor Nuclease to introduce 
double-strand brakes on the 3’-side of mismatched sites. For these experiments, 
NIH/3T3 cells were co-transfected with an sgRNA-expressing pSpCas9(BB)-2A-
GFP plasmid and a puromycin-expressing plasmid. GFP fluorescence was used as 
a rough indicator of transfection efficiency. Puromycin resistance was used for 
antibiotic selection. After recovery, the cells were harvested and lysed for DNA 
extraction. Thereafter, the relevant genomic regions of Prex1 and Prex2 were 
amplified by PCR, and the DNA PCR products of wild type and transfected cells 
were mixed in equal quantities to enable heteroduplex formation. The 
heteroduplexes were then treated with Surveyor Nuclease. As a negative control, 
homoduplexes of wild type DNA samples were used. 
As can be seen in Figure 4.5.5C, the Surveyor Nuclease treatment led to the 
cleavage of the heteroduplex DNA molecules into two smaller molecules, labelled 
Band B and Band C, respectively. Besides these products, there remained un-
cleaved wild type or mutant homoduplexes (top bands: Band A), indicating that the 
cleavage sides were specific for mismatched DNA sequences, as desired. 
Furthermore, there were also some digestion products in the negative controls, likely 
due to the exonucleolytic activity of the Surveyor Nuclease. Although these bands 
were considered to be background, they were included in the lane profiling used for 
the quantification of the sgRNAs efficiency in order to provide conservative 
estimates of cleavage efficiency (Figure 4.5.5D). As with the previous in vitro 
analysis step, the efficiency of each sgRNA for each genomic locus was again 
defined as the percentage of un-cleaved template. The sgRNA that left the lowest 
percentage of un-cleaved targeting template was considered the best for that locus.  
The results obtained by the Surveyor Assay reinforced our conclusion from 
the in vitro assay that the designed sgRNAs were of sufficiently high efficacy and 
specificity, and confirmed furthermore that they work in cells as well as in vitro. This 
result allowed progression to the next step in the targeting process, the design of 
appropriate repair template DNAs that carry the desired point mutations. 
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4.5.4.4 Design of the single-stranded DNA repair template 
In order to introduce the desired point mutations in the Prex1 or Prex2 mouse 
genome by HDR, ssDNA donor oligo nucleotides were designed for each targeted 
genomic site. Following recommendation from the Head of our Gene Targeting 
Facility, Dr Dominik Spensberger, the repair templates were designed to be around 
~200 nt long and have symmetric homology arms of at least 90 nt. Apart from the 
desired point mutation, the possibility of having additional “silent” point mutations 
that would destroy the PAM site and/or significantly change the sequence of the 
sgRNA was also explored. This was necessary in order to avoid Cas9 cleavage of 
the HDR-edited sites. Finally, to facilitate detection of successful targeting by PCR-
based detection assay, silent nucleotide changes that would create restriction 
enzyme sites without affecting the amino acid sequence of the proteins were 
introduced (Figure 4.5.6). 
Therefore, the final selection of the sgRNAs was done on the basis that it 
enabled the repair template to meet all the aforementioned criteria. The sequence 
of the designed templates is shown in Table 4.6 
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Table 4.6: ssDNA repair template sequence designed for each intended point 
mutation in the mouse Prex1 and Prex2 genes. In bold red are annotated the desired 
point mutations, whereas in plain red are highlighted the silent mutations. T he nucleotide 
changes in Prex1 exon 1 will result in the E51A mutation and exon 6 in N233A. The 
equivalent changes in Prex2 will result in the E22A and N204A mutations, respectively  
 
Mutation on Prex1 Exon 1, nt265-267, GAG -> GCG 
Name ssDNA Oligo Sequence 
P1M1 
GGTGCGCATCCCGATGCTCGCGGCCCCGTCTCCGGGCCGTGCGCGGCC
GCCCGCGACTCGGAGCGCCAGCTGCGCCTCCGTCTGTGCGTACTCAACG
CCATCCTAGGCACCGAGCGCGACTACGTGGGCACCTTGCGTTTCCTGCA
GTCGGTGAGCTCCCGCCACCTGTGGCCGGCCGGCCCGCGTTGCGCTTTT
GTC 
Mutation on Prex1 Exon 6, nt92590-92592, AAT -> GCT 
Name ssDNA Oligo Sequence 
P1M2 
ACTAGGAGTTGGCCAAGAGGACCCCCGGCAAGCACCCTGACCACACCGC
GGTACAGAGTGCCCTGCAGGCCATGAAGACTGTCTGCTCCAACATCGCG
GAGACCAAGCGACAAATGGAGAAGCTGGAGGCCCTGGAGCAGCTGCAGT
CTCACATTGAAGGCTGGGAGGTGCGTGGTCAGGGTCCTCTGCTGAGGGG
GCT 
Mutation on Prex2 Exon 1, nt392-394, GAG -> GCG 
Name ssDNA Oligo Sequence 
P2M1 
CTTGCCCCCAGCTCCGCGCCCCGCCGGCCACCATGAGCGACGAAAGCG
CCAGGGAAGTAGACAAGCAGCTTCGCCTGCGCGTGTGCGTGCTCAGCGC
TCTTCAGAAGACCGAGCGCGACTACGTGGGTACCCTAGAGTTCCTGGTGT
CGGTGAGTAGCCGGCCCCGCGCACGGCACCAAGTCTGGAGCATTGTCTG
C 
Mutation on Prex2 Exon 6, nt96342-96344, AAT -> GCG 
Name ssDNA Oligo Sequence 
P2M2 
TCTCCACAGGAATTACTGAAGCGGACTCCACGGAGACATAGTGACTACAC
AGCAGTGATGGAAGCACTCCAAGCCATGAAAGCCGTGTGTTCCAATATTG
CTGAGGCCAAGCGGCAAATGGAGAAACTGGAAGTTTTAGAAGAGTGGCA
GGCACACATTGAAGGCTGGGAGGTACGTGTCCTTTGCTCAGCTCTT 
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Figure 4.5.6: Design of DNA repair templates. 
Part of the DNA repair templates used for the introduction of point mutations in Prex1 (A) exon 1 
and (B) exon 6, and Prex2 (C) exon 1 and (D) exon 6. The top line represents the wild type 
sequence whereas the bottom line shows the sequence of the repair template. In red boxes are 
annotated the nucleotide changes introduced to render the protein catalytically inactive. In green 
boxes are highlighted the silent mutations introduced to create restriction enzyme sites and/or 
change the sgRNA sequence. Blue arrows show the unique restriction enzyme sites which could 
help in genotyping. The nucleotide changes in Prex1 exon 1 will result in the E51A mutation and 
exon 6 in N233A. The equivalent changes in Prex2 will result in the E22A and N204A mutations, 
respectively. 
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4.5.5 Generation of catalytically inactive Prex1 mouse strain 
Once the CRISPR targeting components were designed and validated, the materials 
were given to Dr Dominik Spensberger from the Babraham gene Targeting Facility 
for injection into mouse zygotes. However, given that CRISPR zygote injections had 
not been performed previously at the Babraham Institute, it was decided to perform 
ES cell targeting in parallel as a backup strategy. For this approach, Dr Spensberger 
targeted White C57BL/6J ES cells (black-6 background cells with mutations in fur 
colour genes that produce white-coated animals), using the same strategy and 
materials. 
The genotyping methods considered so far included PCR amplification of the 
two Prex1 loci of interest, analysis by gel electrophoresis, purification of the PCR 
products and either analytical restriction enzyme digest or Sanger sequencing. Due 
to the large number of ES clones that resulted from the targeting for the two Prex1 
mutations, it was concluded that the aforementioned approach would not be cost- 
and time-effective for a big scale screening. Hence, primers specific for the desired 
mutations were designed and validated in order to develop a PCR-only based 
screening (see Materials and Methods Table 3.7).  
Through this method, out of two 96 well plates, one ES clone was found to 
be positive for mutation E51A in exon 1 of Prex1, and this ES cell clone was 
retargeted for mutation N233A on exon 6. After the second round of targeting, out 
of two 96 well plates, one ES clone was found to be positive for mutation N233A on 
exon 6 by PCR. This finding was further confirmed by Sanger sequencing which 
showed that this ES colony was positive for both mutations in Prex1 (Figure 4.5.7A). 
This ES colony was used for injection into mouse C57BL/6J blastocysts. The 
blastocysts were then transferred into the ovaries of pseudopregnant C57BL/6J 
recipients and chimeric pups were born. The coat colour was used to estimate the 
contribution of targeted ES cells to the chimeric mice. Mice with agouti coats (Figure 
4.5.7B) were genotyped by PCR to assess the extent of incorporation of the two 
Prex1 mutations. Mice that were found to be heterozygous for the mutations were 
set up for breeding with wild type C57BL/6J mice. From this breeding, germline 
transmission was achieved, but only one mouse that was heterozygous for mutation 
on exon 6 of Prex1 but wild type for E51A was born (Figure 4.5.7C). (Presumably, 
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this mouse was only mutated for N233A because the ES cell clone was not properly 
clonal after the initial E51A targeting event). In any event, the resulting heterozygous 
Prex1E51A/+ mouse unfortunately died without giving birth to any heterozygous pups, 
and this first targeting attempt was therefore unsuccessful in establishing the mouse 
strain. 
In our second attempt to generate mice with catalytically inactive Prex1, Dr 
Spensberger used the same targeting strategy but microinjected the material into 
zygotes instead of transfecting it into ES cells. Microinjected zygotes were then 
implanted into female recipients, and all resulting pups were genotyped by PCR and 
Sanger sequencing. Dr Spensberger trialled several options, and found the 
simultaneous injection of the targeting material for both mutations to be 
unfavourable, whereas targeting of E51A alone was successful and produced one 
heterozygous Prex1E51A/+ animal. Unfortunately, this heterozugous female died 
while giving birth to her first litter, and all her pups perished, so this second attempt 
at generating a GEF-dead Prex1 mouse strain also failed. Further attempts are 
currently ongoing. 
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Figure 4.5.7: Generation of catalytically inactive Prex1 mouse strain. 
(A) Positively targeted ES cells. One sgRNA for each mutation was cloned into the pCas-Guide-
EF1a-CD4 vector. The CRISPR plasmids were transfected into mouse ES cells. To determine the 
overall editing efficiency of the CRISPR, DNA was extracted from the pool of transfected cells and 
pools containing recombinant alleles identified via PCR screening. To obtain monoclonal genome-
edited colonies, positive pools were plated onto a P100 cell culture plate to form single-cell 
colonies. The individual ES cell clones were subjected to a second round of PCR screening to 
identify the clones containing the desired knock-in allele and positive clones were also confirmed 
by Sanger sequencing. Positively targeted ES cells were injected into C57BL/6J blastocysts to 
produce chimeras. (B) Representative images of positive and negative chimeric mice. (C) 
Germline transmission. 
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4.5.6 Generation of catalytically inactive Prex2 mouse strain 
The experience from targeting the Prex1 strain allowed Dr Spensberger to optimise 
the protocol for direct zygote injection, and he used this for the generation of the 
catalytically inactive Prex2 mouse strain. Initially, mice positive for the mutation on 
exon 1 of Prex2 (E22A) were generated and bred together until the mutation was 
established at homozygous state. Zygotes from these homozygous mice were then 
re-targeted for the second mutation on exon 6 (N204A) (Figure 4.5.8). In this 
manner, both the Prex2E22A/E22A and the Prex2E22A/E22A; N204A/N204A strains were 
established successfully. These homozygous strains were called Prex2 E22A and 
Prex2 E22A/N204A, for brevity. The homozygous mice were born at the expected 
Mendelian rate, were fertile, bred well and appeared healthy. 
 
 
 
 
Figure 4.5.8: Generation of catalytically inactive Prex2 mouse strain. 
Genomic sequence from the homozygous Prex2 E22A/N204A mouse. Prex2 (A) exon 1 and (B) 
exon 6. The top line (black) represents the wild type sequence whereas the bottom line (red) shows 
the sequence of the repair template. In bold and underlined red and in red boxes are annotated 
the nucleotide changes introduced to render the protein catalytically inactive. In purple are the 
silent point mutations introduced to create restriction enzyme sites and/or change the sgRNA 
sequence. In underlined black is the sgRNA sequence whereas in underlined green is the PAM 
sequence. 
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4.5.7 Metabolic phenotype characterisation of Prex2 E22A 
mice 
According to the literature, introduction of just one of the intended mutations in the 
DH domain of Prex2 should be sufficient to render the protein catalytically inactive 
(Lucato et al., 2015). Therefore, the Prex2E22A/E22A (Prex2 E22A) mouse strain was 
used to investigate the importance of the Rac-GEF activity in glucose homeostasis 
while the Prex2E22A/N204A strain was still being bred to homozygosity. The metabolic 
phenotype of Prex2 E22A mice was studied in the same manner as described 
previously for the Prex KO mice. Wild type C57BL/6J (C57BL/6J WT) mice of same 
age and sex were tested in parallel under the same conditions for direct comparison.  
4.5.7.1 Metabolic phenotype of male Prex2 E22A mice on chow diet 
Figures 4.5.9A and 4.5.10A show that, on chow diet, Prex2 E22A males had lower 
fasting blood glucose levels compared to controls throughout ageing. What is more, 
from 15 weeks of age onwards, the Prex2 E22A mice also had a significantly 
improved response to IPGTT (Figures 4.5.9C and 4.5.10B). Although their glucose 
levels peaked at 15 min post glucose injection, similarly to their C57BL/6J WT 
counterparts, their blood glucose levels decreased faster than in WT controls, and 
were almost back to basal levels at 90 min (Figure 4.5.9A-B). In contrast, C57BL/6J 
WT males showed signs of glucose intolerance from 15 weeks of age onwards. This 
was despite both genotypes having similar body weight, which increased at a 
comparable rate during ageing (Figure 4.5.10C). This increased glucose tolerance 
in Prex2 E22A mice was a striking effect, and proves that Prex2 has adaptor 
functions in the control of glucose homeostasis. Furthermore, the phenotype of 
these mice is stronger and different to the phenotype previously observed in the 
Prex2 KO males, which showed at best a tendency to improved glucose tolerance 
at young age and to glucose intolerance in old age. Hence, in the Prex2 KO mouse, 
another regulator of glucose homeostasis is likely to compensate for the loss of 
Prex2, which does not do in the Prex2 E22A mouse, as the Prex2 protein is still 
expressed in these mice to fulfil important adaptor roles.  
To assess insulin sensitivity, Prex2 E22A mice were challenged with 0.75 
IU/kg human insulin as described previously. At 5 months of age, the overall insulin 
response was slightly reduced in the Prex2 E22A mice compared to the C57BL/6J 
 P a g e  | 201 
WT controls (Figure 4.5.11A, D). The blood glucose levels of Prex2 E22A males 
dropped to their lowest level at 45 min post injection, showing a drop of 5 mM from 
basal, and returned to around 8 mM at 120 min  (Figure 4.5.11A, C), contrary to the 
6.5 mM drop observed in the C57BL/6J WT males. However, as discussed for the 
various Prex KO strains above, this observation could be due to an altered counter-
regulatory response to critically low blood glucose levels at the peak of the 
response, as a result of the low fasting blood glucose levels (Figure 4.5.11B). At 10 
months of age, the Prex2 E22A males showed a longer lasting response to insulin 
compared to their WT counterparts (Figure 4.5.11E, G). Although both genotypes 
had become somewhat insulin resistant at that age (their blood glucose levels 
having dropped by only 3.5 mM), the WT males showed a sharp rise back to the 
basal glucose levels at 120 min, while the Prex2 E22A followed a more steady 
increase (Figure 4.5.11G). 
Interestingly, from the housing of mice in the metabolic cages it was 
observed, that Prex2 E22A mice produce more urine, compared to their C57BL/6J 
WT counterparts, despite their average water intake being almost identical. The food 
consumption and faeces production were similar between the two genotypes 
(Figure 4.5.12). 
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Figure 4.5.9: Male Prex2 E22A mice on chow diet show lower fasting blood glucose 
levels and better glucose tolerance than C57BL/6J WT mice.  
The fasting blood glucose levels and response to IPGTT were measured in male Prex2 E22A/E22A 
(Prex2 E22A, yellow) and C57BL/6J WT (grey) mice on chow diet at the ages of 10 and 15 weeks, 
6, and 12 months, as described in the legend to Figure 4.2.1. (A) Blood glucose concentration 
during IPGTT. (B) Blood glucose levels during IPGTT, normalised by subtracting the basal blood 
glucose level. (C) Total glucose response (AUC of normalised data). Data are from 1 cohort 
(C57BL/6J WT n=4; Prex2 E22A n=5), and presented as mean ± SEM. 2-way ANOVA with 
repeated measures and Sidak’s multiple comparisons correction was used to compare genotypes 
during IPGTT. Unpaired Student’s t-test was used to analyse the total glucose response. 
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Figure 4.5.10: The low fasting blood glucose levels and improved glucose 
tolerance of male Prex2 E22A mice on chow diet persist throughout ageing. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the male 
Prex2 E22A (yellow) and C57BL/6J WT (grey) mice from Figure 4.5.9 are expressed as a function 
of age. (A) Fasting blood glucose levels; data from column A in Figure 4.5.9. (B) Response to 
IPGTT; normalised data from columns B and C in Figure 4.5.9. (C) Body weight, measured after 
6 and 4 h fasting, prior to glucose and insulin challenges, respectively. Data are from 1 cohort 
(C57BL/6J WT n=4; Prex2 E22A n=5), and are presented as mean ± SEM. 2-way ANOVA with 
repeated measures and Sidak’s multiple comparisons correction was used to compare genotypes 
during ageing. 
 
204 | P a g e  
 
 
Figure 4.5.11: Male Prex2 E22A mice on chow diet show an altered response to 
insulin challenge compared to C57BL/6J WT mice. 
The fasting blood glucose levels and response to SCITT were measured in male Prex2 E22A 
(yellow) and C57BL/6J WT (grey) mice on chow diet from Figure 4.5.9 at the ages of (A-D) 5 and  
(E-H) 10 months, as described in the legend to Figure 4.2.3. (A,E) Blood glucose concentration 
during SCITT. (B,F) Fasting blood glucose levels. (C,G) Blood glucose levels during SCITT, 
normalised by subtracting the fasting basal blood glucose level from each mouse individually. 
(D,H) Total insulin response (AUC of normalised data). Data are from 1 cohort (C57BL/6J WT n=4; 
Prex2 E22A n=5), and are presented as mean ± SEM. 2-way ANOVA with repeated measures 
and Sidak’s multiple comparisons correction was used to compare genotypes during SCITT. 
Unpaired Student’s t-test was used to analyse the basal blood glucose levels and total insulin 
response. 
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Figure 4.5.12: Male Prex2 E22A mice have increased urine production.  
The male Prex2 E22A (yellow) and C57BL/6J WT (grey) mice from Figure 4.5.9 were habituated 
to metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed and group-
housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with food and water 
provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine production, and 
(D) faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are from 1 cohort (C57BL/6J WT n=4; Prex2 E22A 
n=5), and are presented as the mean ± SEM of each night (n=3). Unpaired Student’s t-test was 
used for the comparison between the genotypes. 
 
 
 
4.5.7.2 Metabolic phenotype of male Prex2 E22A mice on HFD 
To test the effects of diet on the metabolic phenotype of the Prex2 E22A mice, males 
were introduced to 45% HFD at the age of 10 weeks, after their “baseline” glucose 
challenge. As shown in Figures 4.5.13A and 4.5.14A, male Prex2 E22A mice on 
HFD maintained low fasting blood glucose levels throughout ageing, similarly to 
what was observed previously in the Prex2 KO males on HFD. Surprisingly though, 
the Prex2 E22A mice also maintained their improved glucose tolerance throughout 
ageing (Figures 4.5.132B-C and 4.5.14B). Both the Prex2 E22A and their 
C57BL/6J WT controls developed some glucose intolerance due to the HFD. Figure 
4.5.13B shows that it became difficult for mice to clear the glucose from their blood 
stream after glucose challenge, even though the dosage was reduced from 6 
months onwards (to 0.5 g/kg, data in ochre box), similarly to what was previously 
observed in the Prex2 KO mice. However, the blood glucose levels in the Prex2 
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E22A males did not rise nearly as much as in the C57BL/6J WT controls and 
returned back to basal within the time frame of the experiment (Figure 4.5.13B). 
Again, this phenotype was more striking and distinct from that of Prex2 KO mice, 
which had been glucose intolerant under the same conditions. Hence, it seems that 
the Rac-GEF activity of Prex2 limits glucose tolerance, both on chow and HFD. 
 
Both at 5 and 10 months of age, the insulin response of Prex2 E22A males 
on HFD was similar to that of C57BL/6J WT mice, despite their lower basal blood 
glucose levels (Figure 4.5.15A-D, E-H), which suggests that Prex2 does not have 
important adaptor functions in insulin sensitivity. This was again very different to the 
phenotype of the Prex2 KO mice on HFD, which were insulin resistant in old age. 
Hence, it seems that the Rac-GEF activity of Prex2 plays a role in maintaining the 
insulin sensitivity of old mice. 
 
Although the two genotypes started from identical body weight, the Prex2 
E22A mice gained weight at a slightly slower rate than the C57BL/6J WT mice 
(Figure 4.4.14C). Consequently, the body composition analysis, at 1 year, revealed 
that Prex2 E22A males on HFD had lower fat percentage compared to the heavier 
C57BL/6J WT controls (Figure 4.4.14D). This difference in the body fat percentage 
could be, at least in part, the reason for the improved glucose tolerance seen in 
Prex2 E22A mice. Finally, no difference was found in their water and food 
consumption or urine and faeces production in the metabolic cages (Figure 
4.5.16A-D).  
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Figure 4.5.13: Male Prex2 E22A mice on HFD show lower fasting blood glucose 
levels and better glucose tolerance than C57BL/6J WT mice. 
The fasting blood glucose levels and response to IPGTT were measured in male Prex2 E22A 
(yellow) and C57BL/6J WT (blue) mice on chow diet at the ages of 10 weeks, 6, 9, and 12 months, 
as described in the legend to Figure 4.2.1. Glucose was injected at 2 g/kg at 10 weeks of age, 
and at 0.5 g/kg at later ages (ochre box). (A) Blood glucose concentration during IPGTT. (B) Blood 
glucose levels during IPGTT, normalised by subtracting the basal blood glucose level. (C) Total 
glucose response (AUC of normalised data). Data are pooled from 2 independent cohorts 
(C57BL/6J WT n=10; Prex2 E22A n=9), and are presented as mean ± SEM. 2-way ANOVA with 
repeated measures and Sidak’s multiple comparisons correction was used to compare genotypes 
during IPGTT. Unpaired Student’s t-test was used to analyse the total glucose response. 
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Figure 4.5.14: The low fasting blood glucose levels and improved glucose 
tolerance of male Prex2 E22A mice on HFD persist throughout ageing.  
The fasting blood glucose levels, response to glucose challenge, and body weight of the male 
Prex2 E22A (yellow) and C57BL/6J WT (grey) mice on HFD from Figure 4.5.13 are expressed as 
a function of age. In faded yellow are represented the Prex1 KO male mice on chow diet from 
Figure 4.5.9 for visual comparison, but no statistical analysis was performed, as the animals were 
not directly compared experimentally. (A) Fasting blood glucose levels; data from column A in 
Figure 4.5.13. (B) Response to IPGTT; normalised data from columns B and C in Figure 4.5.13. 
(C) Body weight, measured after 6 and 4 h fasting, prior to glucose and insulin challenges, 
respectively. (D) Body composition at 1 year of age. The mice in (A-C) were culled at 1 year of 
age and the cadavers were scanned by Echo MRI for lean mass and body fat. Data are pooled 
from 2 independent cohorts (C57BL/6J WT n=10; Prex2 E22A n=9), and are presented as mean 
± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple comparisons correction was 
used to compare genotypes during ageing. Unpaired Student’s t-test was used to analyse the body 
composition. 
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Figure 4.5.15: Male Prex2 E22A mice on HFD show a normal response to insulin 
challenge throughout ageing. 
The fasting blood glucose levels and response to SCITT were measured in male Prex2 E22A 
(yellow) and C57BL/6J WT (grey) mice on 45% HFD from Figure 4.5.13 at the ages of (A-D) 5 
and (E-H) 10 months, as described in the legend to Figure 4.2.3. (A,E) Blood glucose 
concentration during SCITT. (B,F) Fasting blood glucose levels. (C,G) Blood glucose levels during 
SCITT, normalised by subtracting the fasting basal blood glucose level from each mouse 
individually. (D,H) Total insulin response (AUC of normalised data). Data are pooled from 2 
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independent cohorts (C57BL/6J WT n=10; Prex2 E22A n=9), and are presented as mean ± SEM. 
2-way ANOVA with repeated measures and Sidak’s multiple comparisons correction was used to 
compare genotypes during SCITT. Unpaired Student’s t-test was used to analyse the basal blood 
glucose level and total insulin response. 
 
 
 
 
Figure 4.5.16: Male Prex2 E22A mice on HFD perform normally in metabolic cages.  
The male Prex2 E22A (yellow) and C57BL/6J WT (blue) mice on 45% HFD from Figure 4.5.13 
were habituated to metabolic cages at 11 months of age as detailed in Materials and Methods, 
weighed and group-housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights 
with food and water provided ad libitum. Their (A) water consumption, (B) food consumption, (C) 
urine production, and (D) faeces production were measured after each night and were normalised 
to the combined body weights of the mice housed in each cage. Data are pooled from 2 
independent cohorts (C57BL/6J WT n=10; Prex2 E22A n=9), and are presented as the mean ± 
SEM of each night (n=3). Unpaired Student’s t-test was used for the comparison between the 
genotypes. 
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4.5.7.3 Metabolic phenotype of female Prex2 E22A mice  
To investigate sex differences in Prex2 E22A mice, females were also tested on 
HFD. As can be seen in Figure 4.5.17A and in the ageing overview graphs in Figure 
4.4.18A, Prex2 E22A females had lower fasting blood glucose levels than C57BL/6J 
WT controls. However, contrary to their male counterparts, they did not exhibit 
improved glucose tolerance (Figures 4.5.17B-C and 4.45.18B). Moreover, Prex2 
E22A females were found to have normal insulin responses both at 5 months’ and 
at 10 months’ time point (Figure 4.5.19A-B). Females of both genotypes also 
gained weight at a similar rate (Figure 4.5.18C) and had identical body composition 
(Figure 4.5.18D). Housing of the mice in metabolic cages at 11 months of age also 
did not reveal any differences to the controls (Figure 4.4.20A-D). Hence, the 
phenotype of the Prex2 E22A mice is highly sex-dependent, more so than the 
phenotypes previously observed in the various Prex KO strains. As the phenotype 
is seen in the males but not the females, it seems likely that male sex hormones 
play a role in the underlying mechanism. It must be noted, however, the results of 
the Prex2 E22A females are from a single cohort, so they need to be confirmed in 
the future through at least a second, independent cohort, and females need also to 
be tested on chow diet. 
Having seen previously in the Prex deficient mice that there were differences 
in the weight of some of their organs, 10 week-old and 1 year-old male Prex2 E22A 
mice on chow diet were dissected and organ weight was compared to C57BL/6J 
WT controls of the same sex and age. Interestingly, Prex2 E22A males had smaller 
livers compared to their C57BL/6J WT counterparts at both ages tested, similar to 
what was previously found in the Prex1 KO mice (Figure 4.5.21A-B). Moreover, the 
liver was found to be significantly smaller in 1 year-old HFD-fed males compared to 
controls (Figure 4.5.21C). Finally, 1 year-old females on HFD were found to have 
smaller intBAT than their C57BL/6J counterparts (Figure 4.5.21D). These data 
highlight the liver as a possible key organ for further study, at least in males, in order 
to unravel the molecular mechanism underlying the improved glucose tolerance of 
Prex2 E22A mice. 
212 | P a g e  
 
 
 
Figure 4.5.17: Female Prex2 E22A mice on HFD have low fasting blood glucose 
levels, but normal glucose tolerance. 
The fasting blood glucose levels and response to IPGTT were measured in female Prex2 E22A 
(yellow) and C57BL/6J WT (grey) mice on 45% HFD at the ages of 10 weeks, 6, 9, and 12 months, 
as described in the legend to Figure 4.2.1. The ochre box denotes glucose challenge at the 
reduced dose of 1 g/kg instead of 2 g/kg. (A) Blood glucose concentration during IPGTT. (B) Blood 
glucose levels during IPGTT, normalised by subtracting the basal blood glucose level. (C) Total 
glucose response (AUC of normalised data). Data are from 1 cohort (C57BL/6J WT n=5; Prex2 
E22A n=5), and are presented as mean ± SEM. 2-way ANOVA with repeated measures and 
Sidak’s multiple comparisons correction was used to compare genotypes during IPGTT. Unpaired 
Student’s t-test was used to analyse the total glucose response. 
 
 P a g e  | 213 
 
 
 
Figure 4.5.18: Female Prex2 E22A mice on HFD have normal glucose tolerance 
throughout ageing. 
The fasting blood glucose levels, response to glucose challenge, and body weight of the female 
Prex2 E22A (yellow) and C57BL/6J WT (grey) mice on 455 HFD from Figure 4.5.17 are expressed 
as a function of age. (A) Fasting blood glucose levels; data from column A in Figure 4.5.17. (B) 
Response to IPGTT; normalised data from columns B and C in Figure 4.5.17. (C) Body weight, 
measured after 6 and 4 h fasting, prior to glucose and insulin challenges, respectively. (D) Body 
composition at 1 year of age. The mice in (A-C) were culled at 1 year of age and the cadavers 
were scanned by Echo MRI for lean mass and body fat. Data are from 1 cohort (C57BL/6J WT 
n=5; Prex2 E22A n=5), and are presented as mean ± SEM. 2-way ANOVA with repeated 
measures and Sidak’s multiple comparisons correction was used to compare genotypes during 
ageing. Unpaired Student’s t-test was used to analyse the body composition. 
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Figure 4.5.19: Female Prex2 E22A mice on HFD show similar fasting blood glucose 
levels and insulin response to C57BL/6J WT mice. 
The fasting blood glucose levels and response to SCITT were measured in female Prex2 E22A 
(yellow) and C57BL/6J WT (grey) mice on 45% HFD from Figure 4.5.17 at the ages of 5 and 10 
months, as described in the legend to Figure 4.2.3. (A) Blood glucose concentration during SCITT. 
(B) Fasting blood glucose levels. Data are from 1 cohort (C57BL/6J WT n=5; Prex2 E22A n=5), 
and are presented as mean ± SEM. 2-way ANOVA with repeated measures and Sidak’s multiple 
comparisons correction was used to compare genotypes during SCITT. Unpaired Student’s t-test 
was used to analyse the basal blood glucose level. 
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Figure 4.5.20: Female Prex2 E22A mice perform similarly to C57BL/6J WT mice in 
metabolic cages.  
The female Prex2 E22A (yellow) and C57BL/6J WT (grey) mice from Figure 4.5.17 were 
habituated to metabolic cages at 11 months of age, as detailed in Materials and Methods, weighed 
and group-housed (up to 3) in metabolic cages overnight for 16 h on 3 subsequent nights with 
food and water provided ad libitum. Their (A) water consumption, (B) food consumption, (C) urine 
production, and (D) faeces production were measured after each night and were normalised to the 
combined body weights of the mice housed in each cage. Data are from 1 cohort (C57BL/6J WT 
n=5; Prex2 E22A n=5) and are presented as the mean ± SEM of each night (n=3). Unpaired 
Student’s t-test was used for the comparison between the genotypes. 
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Figure 4.5.21: Male Prex2 E22A mice have smaller livers. 
Male Prex2 E22A (yellow) and C57BL/6J WT (grey) mice on chow diet were culled by CO
2
 
asphyxiation followed by severance of the femoral artery and were dissected for organ collection 
at the ages (A) 10 weeks and (B) 1 year old. The weights of thirteen organs (brain, interscapular 
brown adipose, inguinal white adipose, skeletal muscle, pancreas, kidneys, spleen, liver, thymus, 
heart, lung, salivary gland, and testes) were measured and data were normalised by total body 
weight after culling. Data are presented as mean ± SEM. Statistics are 2-way ANOVA with Sidak’s 
multiple comparisons correction. Prex2 E22A (yellow) and C57BL/6J WT (grey) (C) male and (D) 
female mice on 45% HFD were dissected for organ collection at 1 year of age, after their cadavers 
had been thawed and scanned by Echo MRI. The weights of two organs (liver and brown adipose) 
were measured and data were normalised to total body weight before dissection. Data are 
presented as mean ± SEM. Unpaired Student’s t-test was used for the comparison between the 
genotypes. (A) Data from 2 cohorts (C57BL/6J WT n=11, and Prex2 E22A n=11). (B) Data from 1 
cohort (C57BL/6J WT n=5, and Prex2 E22A n=6). (C) Data are from 2 cohorts (C57BL/6J WT 
n=10, and Prex2 E22A n=8). (D) Data from 1 cohort (C57BL/6J WT n=4, and Prex2 E22A n=5). 
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Table 4.7: Summary table of metabolic phenotype of Prex2 KO and Prex2 E22A mice on chow or 
high fat diet. Bold font was used to annotate findings that reached statistical significance in most time 
points tested. 
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Chapter 5 - Discussion 
 
PREX proteins have been identified as instrumental contributors in many 
physiological and pathological processes such as inflammation, neuronal plasticity, 
cancer progression and metastasis. However, their importance in metabolic 
processes has only recently started to emerge. The main objectives of this project 
were to determine the functional roles of PREX proteins in glucose homeostasis and 
development of metabolic syndrome as well as to assess the importance of their 
Rac-GEF activity in these processes.  
 To briefly summarise the main findings of my project: Prex deficiency in mice 
has isoform-, sex-, diet-, age- and catalytic activity-dependent effects on glucose 
homeostasis. Prex1 KO caused low fasting blood glucose and improved glucose 
clearance in males on chow diet throughout ageing, whereas Prex1 KO males on 
HFD showed only low fasting blood glucose. In females Prex1 deficiency improved 
glucose tolerance in middle-aged mice on HFD. Bone marrow transplantation 
suggested that Prex1 contributes to the regulation of glucose homeostasis largely 
through the haematopoietic system. Prex2 KO also caused low fasting blood 
glucose, but unlike Prex1 KO, produced glucose intolerance and age-related insulin 
resistance in males on HFD. In females, Prex2 deficiency was associated with a 
tendency to improved glucose clearance in young age that worsened in old age. 
Hence, both Prex1 and Prex2 play significant roles in glucose homeostasis, but 
have nearly opposite effects, especially regarding glucose tolerance. Prex1/2 DKO 
males showed a phenotype that resembled Prex1 KO mice, although milder, on both 
chow and HFD. Instead, Prex1/2 DKO females displayed an overall worse 
phenotype than their single KO counterparts. These results suggest some 
redundancy between Prex Rac-GEFs in glucose homeostasis as well as 
compensation by other Rac-GEFs. Overexpression of catalytically inactive mutants 
of Prex1 and Prex2 in HepG2 cells revealed that both proteins can mediate insulin 
signalling in a Rac-GEF activity independent manner, and hence GEF-dead mice 
were generated to investigate the adaptor functions of Prex proteins in glucose 
homeostasis. Prex2 E22A GEF-dead mice had low fasting blood glucose levels, and 
males showed much improved glucose tolerance throughout ageing, both on chow 
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and HFD. Hence, Prex2 regulates glucose homeostasis both through its Rac-GEF 
activity and through adaptor functions; its Rac-GEF activity limits glucose 
homeostasis, whereas its adaptor functions improve it. My data suggest that it may 
be beneficial to develop inhibitors of Prex Rac-GEF activity for the treatment of 
hyperglycemia and glucose intolerance. 
5.1 Prex expression in insulin-sensitive tissues 
I began by investigating Prex1 and Prex2 expression in insulin-sensitive mouse 
tissues through western blotting of total lysates. Prex1 was strongly expressed in 
brain, at lower level in the liver, in white (inguinal and epididymal) and in brown 
adipose tissue, but there was no expression in skeletal muscle. These findings 
confirm and extend previous studies which showed that Prex1 is expressed in brain, 
thymus, spleen, lung, bone marrow and peripheral blood leukocytes, but absent 
from skeletal muscle on both the protein and mRNA level (Welch et al., 2002). Prex1 
protein expression in liver and adipose tissue had not been reported before, but low 
levels of Prex1 mRNA had previously been observed (Uhlén et al., 2015; Welch et 
al., 2002). 
Prex2 was expressed at low levels in brain and intBAT, but not detected in 
skeletal muscle, liver and white adipose tissue depots tested in this study. Prex2 
expression in brain (cerebellum) and liver was previously reported, but these studies 
used immunoprecipitation to concentrate the protein prior to blotting, suggesting that 
Prex2 levels in brain and liver are low overall (Donald et al., 2004; Hodakoski et al., 
2014). In addition, PREX2 expression was previously detected in human white 
adipose tissue, both on the mRNA (Uhlén et al., 2015) and protein (Hodakoski et 
al., 2014) level, but the protein was described as a low molecular weight form of 
PREX2 that could be a proteolytic fragment (Hodakoski et al., 2014). It is well known 
that while Prex2 mRNA is expressed in multiple mouse tissues, the protein is not as 
widely expressed (Donald et al., 2004). Although the mechanism through which 
Prex2 protein is suppressed in these cases is still unknown, the apparent lack of 
Prex2 in white adipose tissue in my study could either be real or be a limitation of 
the sensitivity of our antibody. This might be investigated further by 
immunoprecipitation before blotting, but as Prex2 was readily detectable in intBAT, 
its level in white adipose tissue will be low at best. 
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In this study, the expression of Prex proteins was not evaluated in pancreas. 
However, we have unpublished results from MSc student Anna Roberts, whom I 
tutored, which suggest that both Prex1 and Prex2 are expressed in mouse pancreas 
(data not shown). Moreover, expression of PREX2, was previously reported in 
human pancreatic epithelial cell line (Uhlén et al., 2015; Yang et al., 2016). 
Therefore, Prex1 and Prex2 are expressed in all major organs that control 
glucose homeostasis, with the notable exception of the skeletal muscle. This lack of 
expression in skeletal muscle is surprising in light of my findings that several mouse 
strains in this study have improved glucose clearance, especially considering that 
skeletal muscle is the tissue that accounts for the majority of glucose uptake from 
the blood. It is of course entirely possible that Prex proteins affect glucose uptake 
by skeletal muscle without being expressed in that tissue.  
This study only superficially investigated the possibility that a single knockout 
would lead to a deregulation of the other Prex protein, and no obvious compensatory 
upregulation was found. However, given that Prex1/2 DKO males have phenotype 
that resembles that observed with the Prex1 KO males, whereas Prex1/2 DKO 
females showed worse phenotype than both single KO females. It would be of 
interest to evaluate more systematically how knockout of one Prex protein affects 
the expression levels of the other, for example in sub-sections of tissues and within 
cell types,  as well as to assess whether there are sex differences. 
5.2 Role of Prex1 in glucose homeostasis 
 Once it was established that PREX proteins are indeed present in insulin 
sensitive organs, the aim was to investigate their role in glucose homeostasis in 
vivo. It was expected that Prex1-deficient mice would have reduced glucose 
tolerance. This hypothesis was based upon considerable body of evidence showing 
that Prex1 mediates insulin signalling in a range of cell types (Dillon et al., 2014), 
that Rac1 is involved in the insulin-stimulated translocation of GLUT4 transporter to 
the plasma membrane (JeBailey et al., 2004; Sylow et al., 2014; Takenaka et al., 
2019), that PREX1 is modulating this process in adipocytes (Balamatsias et al., 
2011), and that PREX1 knockout in brown adipocytes reduces their thermogenic 
capacity (Xue et al., 2015). From these findings, it was predicted that Prex1 KO 
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would lead to reduced glucose uptake by white adipocytes and reduced energy 
usage by brown adipocytes, and thus to elevated blood glucose levels and impaired 
glucose clearance in vivo. In contrast, male Prex1 KO mice on chow diet exhibited 
reduced fasting blood glucose levels which persisted throughout ageing and 
improved glucose tolerance from 15 weeks of age onwards. These observations 
were not due to obvious differences in the total body weight or body composition, 
as both Prex1 KO mice and their Prex WT counterparts put on weight at a similar 
rate and had identical lean and fat mass percentages.  
The fact that the Prex1 KO phenotype differed so profoundly from the 
hypothesis formed on the basis of studies performed in cell lines highlights the 
importance of investigating in vivo the physiological relevance of observations made 
in vitro. Inter-organ crosstalk and the activation of compensatory mechanisms for 
the maintenance of systemic homeostasis cannot be taken into account when 
working in cell lines. In addition, some of the in vitro work, for example the 
experiments suggesting that PREX1 mediates GLUT4 translocation to the plasma 
membrane in 3T3-L1 adipocytes (Balamatsias et al., 2011), were done using 
overexpression systems. Therefore, some of these observations could be due to 
overexpression side effects like activation and overloading of specific biological 
pathways over other, promiscuous interactions, or disruption of regulation (Moriya, 
2015). 
 One consideration when interpreting the fasting blood glucose levels is the 
stress of the mice during handling and sampling. The low fasting blood glucose 
levels observed in the Prex1 KO mice and several other strains used in this study 
could reflect that these mice were less stressed than their WT counterparts. All mice 
were handled repeatedly in the days before any procedure, in order to familiarise 
them with the process and reduce the stress level to a certain extent. Moreover, at 
least two blood samples were taken from each mouse, both to measure fasting 
blood glucose and to assess the response to glucose or insulin challenge, and the 
lower reading was used for plotting the response curve. In addition to these efforts 
to keep stress levels low, it could be of interest to also determine basal blood 
glucose levels by measuring glycated haemoglobin (HbA1c) (Carson et al., 2010; 
Sacks, 2011). HbA1c is formed by the non-enzymatic attachment of glucose to 
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haemoglobin and is considered to reflect a longer-term glycaemic status than 
measurement of fasting blood glucose levels by glucometer. Similarly, it would be 
of interest to test the levels of stress hormones, such as adrenaline, cortisol, and 
norepinephrine, in the plasma of Prex1 KO mice and other strains with low fasting 
blood glucose. 
As outlined in the introduction, skeletal muscle is the main organ for glucose 
clearance from the blood stream and the insulin-regulated GLUT4 transporter is the 
main mechanism for glucose clearance by uptake into cells, both in skeletal muscle 
and adipose tissue. Hence, one of the attempts I made to find a mechanism for the 
increased glucose clearance in Prex1 KO mice was to analyse skeletal muscle and 
adipose tissue isolated from 10-week old male Prex1 KO and Prex WT animals, 15 
min after s.c. insulin stimulation or mock treatment, for total Glut4 levels (data not 
shown). No difference was detected between the genotypes, which suggests it is 
unlikely that Prex1 KO caused an overall change in Glut4 levels. However, it would 
be beneficial to follow further the expression pattern of Glut4 by alternative methods, 
like qPCR. Moreover, I made a first attempt at fractionating dissociated skeletal 
muscle and ingWAT cells (from the experiment described here-above, using a 
commercially available kit Mem-PER Plus, 89842), in order to determine whether 
Prex1 KO affects the insulin-stimulated membrane translocation of Glut4 into the 
plasma membrane enriched fraction. However, that experimental protocol needs to 
be optimised further before conclusions can be drawn. Such ex vivo investigation of 
Glut4 trafficking will be useful to determine whether the Prex1 KO phenotype is due 
to aberrant presence of Glut4 transporter in the plasma membrane. Considering 
that, many mouse strains showed low fasting blood glucose levels, it could be worth 
to extend this line of work to other glucose transporters like the insulin-independent 
Glut1, Glut2, and Glut3.  
Another approach that I trialled in order to determine the mechanisms that 
underlie the low fasting blood glucose and increased glucose clearance in Prex1 
KO mice was a glucose uptake experiment performed using heavy glucose 
combined with NMR analysis, in collaboration with Professor Jules Griffin  from the 
University of Cambridge Biochemistry Department (data not shown). In this 
experiment, skeletal muscle, ingWAT and liver were rapidly isolated from 15 week-
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old male Prex1 KO and Prex WT mice 30 min after the i.p. injection of heavy [U-
13C6]D-glucose, and tissue lysates were examined by NMR for [U-13C6]-containing 
metabolites. Unfortunately, [U-13C6]-metabolites were undetectable in skeletal 
muscle and ingWAT. [U-13C6]-lactate was discovered in the liver, but without any 
significant differences between genotypes, suggesting that glucose metabolism in 
the liver of Prex1 KO animals may be normal, although this would need to be 
corroborated by more work. The likely reason for the low levels of [U-13C6] 
metabolite recovery is that the mice were injected with 0.15 g/kg of glucose rather 
than the 2 g/kg that I routinely used during glucose challenges. This dose was 
obviously insufficient to unravel differences in the relative contribution of various 
organs to glucose uptake between the genotypes. Due to time restrictions, the 
protocol could not be optimised further within the frame of this study. Adaptation of 
the route of administration or a different time for tissue collection would be 
appropriate factors to try in future experiments. Finally, injection of 2-Deoxy-D-
glucose could be a better option, since it is phosphorylated by hexokinase to 2-DG-
P but cannot be further metabolized in the glycolytic pathway, and therefore 
accumulates in cells and is more readily detectable. I trialled an i.p. challenge with 
a fluorescent variant of 2-Deoxy-D-glucose in Prex WT and Prex1 KO mice, followed 
by flow cytometric analysis of cell suspensions from isolated tissues, but no 
fluorescence was detected within cells under the conditions tested. 
Another possible explanation for the phenotype observed could be enhanced 
energy expenditure, for example by increased locomotor activity or production of 
heat. Locomotor activity is unlikely to be the cause, as it is well documented that 
Prex1 KO mice have normal locomotor activity (Donald et al., 2008; Li et al., 2015). 
Moreover, housing of the mice in metabolic cages did not reveal any significant 
differences in water and food intake or urine and faeces production. It is however 
possible that the urine of Prex1 KO mice contains more glucose, which remains to 
be tested. Increased heat production is an interesting option, in view of PREX1 
having been identified as a biomarker for BAT thermogenic capacity (Xue et al., 
2015). The study showed that knockout of PREX1 in human brown adipose 
precursor cells significantly decreased the expression of the thermogenicity marker 
UCP1, as well as the basal respiration, proton leak and maximal respiration capacity 
of differentiated adipocytes (Xue et al., 2015). On the basis of this study, one would 
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predict that Prex1 KO mice have lower thermogenicity, lower energy expenditure 
and therefore increased blood glucose levels and reduced glucose clearance, rather 
than the low blood glucose and increased glucose clearance we observed. In 
addition to this, I found that Prex1 KO males have eosinophilia in intBAT, and 
according to the recent literature, this is indicative of beige-to-brown remodelling, as 
an attempt to increase the thermogenicity of adipose tissue (Lee and Tontonoz, 
2014; Villarroya et al., 2018). In view of these results, one could speculate that 
brown adipose mass would increase due to accumulation of unused fat. However, 
no difference was found between the weights of intBAT obtained from Prex1 KO or 
Prex WT mice. It would be of interest to investigate the Ucp1 levels in the BAT and 
the body temperature of the mice in order to evaluate the effects of Prex1 deficiency 
on thermogenicity in vivo. Moreover, ex vivo Seahorse analysis of oxygen 
consumption rate and extracellular acidification rate in primary adipose cells could 
further interrogate the effect of Prex1 deficiency on the cellular metabolic function 
of these cells. Such Seahorse analysis was attempted in collaboration with Dr Chris 
Church at AstraZeneca, using isolated adipose cells from the white and brown 
adipose tissue of Prex WT and various Prex deficient strains, which had been 
cultured and differentiated in vitro. I obtained preliminary data on Prex1/2 DKO mice 
which suggested some changes in energy expenditure (data not shown), but it was 
concluded that these changes likely reflected differences in the level of 
differentiation into mature adipocytes achieved in this experiment, rather than true 
defects in thermogenicity. More optimisation of this protocol would be required to 
investigate thermogenicity further. If Prex1 deficiency was indeed found to impair 
the Ucp1 mediated heat-generating system, this in turn could force the utilisation of 
other, less efficient and metabolically costly thermogenic mechanisms such as the 
glycerol phosphate cycle (Newsholme and Stanley, 1987). Employment of such 
alternative mechanisms, due to reduced BAT thermogenic capacity, could be a 
possible explanation for the reduced fasting blood glucose levels observed in Prex1 
KO mice. However, it seems overall unlikely that Ucp1-dependent mechanisms are 
grossly affected by the Prex1 KO, as a main phenotypical characteristic of UCP1 
deficient mice is their resistance to developing diet-induced obesity (Liu et al., 2003). 
In contrast, the rate of body weight gain between Prex1 KO and Prex WT male mice 
on HFD was indistinguishable. 
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Measurement of the weight of individual organs revealed that Prex1 KO mice 
had smaller ingWAT compared to their Prex WT counterparts. However, histological 
analysis of this tissue did not reveal any differences, other than size, between Prex 
deficient mice and controls. Several studies have demonstrated that visceral white 
fat produces adverse metabolic effects, whereas increased subcutaneous adipose 
tissue is associated with improved insulin sensitivity and lower metabolic risk (Kwon 
et al., 2017; Neeland et al., 2013; Rosen and Spiegelman, 2014). Accordingly, fat 
distribution rather than the total fat mass seem to be important for homeostasis (Fox 
et al., 2007; Kim et al., 2011b; Tchkonia et al., 2013). Therefore, it would be 
important to investigate other white adipose tissue depots such as the gonadal, 
epicardial, retroperitoneal, peri-renal, omental, and mesenteric fat, in order to better 
understand the relative contribution of white adipose tissue to the metabolic 
phenotype observed of Prex1 KO mice. 
In addition to reduced ingWAT mass, Prex1 deficient mice also had smaller 
livers. Histology and gene expression analysis revealed furthermore that their livers 
exhibit reduced glycogen storage and slightly increased Pepck expression (it should 
be noted that organ weight measurement and histological analysis were performed 
in fed mice whereas Pepck levels were assessed in 4 h-fasted mice). The trend 
towards increased Pepck could point to increased de novo glucose synthesis in the 
liver, maybe due to impaired hepatic glycogenolysis and as an attempt to counteract 
the low fasting blood glucose levels. More experiments are required to determine 
the significance of this trend, but if it stands, an evaluation of gluconeogenesis in 
Prex1 KO mice could be of interest. The reduced glycogen storage might account 
for the decreased liver size. It could also indicate that the low fasting blood glucose 
levels observed in Prex1 KO mice were a cause or consequence of the limited liver 
glycogen availability. However, at this point it is worth keeping in mind that Prex1 
KO females also had reduced liver size but did not exhibit reduced glycogen storage 
(data not shown), and only showed a trend to reduced fasting blood glucose and 
improved glucose homeostasis on chow diet. Therefore, impaired glycogen 
accumulation is unlikely to be the only cause of reduced liver size. Systematic 
monitoring of blood glucose levels and histological analysis during fasting might help 
to elucidate whether low blood glucose levels correlate with hepatic glycogen stores. 
Such assessment would also help explain the improved glucose tolerance observed 
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in Prex1 KO mice. It has been shown that prolonged periods of fasting results in 
glycogen depletion-enhanced insulin-stimulated glucose utilisation in mice (Ayala et 
al., 2006; Heijboer et al., 2005). Therefore, it could be hypothesised that the 6-hour 
fasting to which mice were subjected to prior to glucose challenges induced a 
metabolic state of enhanced insulin sensitivity. Histological analysis of skeletal 
muscle, another major site of glycogen storage, revealed no difference between 
genotypes, suggesting that reduced hepatic glycogen storage does not elicit 
compensatory accumulation of glycogen in skeletal muscle. Together with the 
results from the heavy glucose tracking experiment discussed above, which had 
revealed no obvious differences in hepatic glucose metabolism, these findings could 
lead one to speculate that Prex1 deficiency reduces glycogen synthesis in the liver. 
One other possibility to assess the contribution of Prex1 expression in different 
tissues to the metabolic phenotype would be to make tissue-specific KO mice, for 
example using liver or adipose tissue specific deletion. However, for this, floxed 
Prex1 mice would first need to be generated. 
Prex1 KO males had reduced fasting plasma levels of the insulin-sensitising 
hormone adiponectin. This was surprising because low adiponectin levels are 
heavily associated with adverse metabolic phenotype in mice and humans (Dridi 
and Taouis, 2009; Kadowaki and Yamauchi, 2005). A possible explanation for this 
finding, given the reduced fasting blood glucose levels in Prex1 KO mice, could be 
that less adiponectin signalling is required for the maintenance of homeostasis. 
Leptin is another important insulin-sensitising hormone; it could be of significance 
to determine its levels in Prex1 deficient mice. Interestingly the fasting plasma levels 
of glucagon and insulin levels were no different between genotypes. A bigger n-
number would greatly benefit this set of experiments. Moreover, it could be useful 
to assess the levels of these hormones under fed conditions as well as during 
glucose challenge. 
The immune system has recently emerged to be a key player in the 
maintenance of glucose homeostasis (Zmora et al., 2017). The development of 
metabolic syndrome is intricately entwined with chronic inflammation, and is now 
widely regarded as an inflammatory disease. For example, increased numbers and 
activity of pro-inflammatory tissue macrophages contribute to the development of 
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insulin resistance (Zmora et al., 2017). As Prex1 is widely expressed in cells of the 
hematopoietic system, contributing to the regulation of neutrophil-, macrophage-, 
and platelet-dependent inflammatory responses (Hornigold et al., 2018), the 
possible contribution of the immune system to the metabolic phenotype of Prex1 KO 
mice was investigated. Bone marrow transplantation surprisingly revealed that a 
Prex1 KO hematopoietic system is sufficient to protect otherwise wild type mice from 
developing age-related glucose intolerance. Hence, the increased glucose 
tolerance observed in Prex1 KO mice seems to be largely conferred by Prex1 
deficiency in the haematopoietic system. Given that Prex1 is known to be required 
for inflammatory responses, this could be due to a reduction in inflammation in the 
Prex1 KO mice. It would be useful to investigate the expression of different 
inflammatory cytokines in plasma and further explore leukocyte tissue infiltrates by 
histology, especially in view of the increased eosinophilia observed in intBAT. It 
would also be interesting to trial a long-term treatment of Prex WT and Prex1 KO 
mice with non-steroid anti-inflammatory veterinary medicines, in order to assess if 
reduction in inflammation would have a larger effect on the glucose tolerance of 
Prex1 KO and Prex WT mice. 
Another interesting finding of the bone marrow transplant experiment was 
that it uncoupled the low fasting blood glucose from improved glucose tolerance. 
Beforehand, several of the Prex deficient mouse strains showed low fasting blood 
glucose without having altered glucose tolerance, but in the bone marrow transplant 
experiment all animals had similar levels of fasting blood glucose levels, yet the 
mice with Prex1 KO hematopoietic systems had better glucose tolerance. This 
indicates that the improved glucose tolerance is not a consequence of low fasting 
blood glucose levels, and therefore the two observations probably have different 
aetiologies. Given that there is no obvious correlation between fasting blood glucose 
levels and glucose tolerance, these observations are likely due to deregulation of 
different pathways in different organs/tissues. 
One interesting feature of the Prex1 KO mouse phenotype was the diet 
dependence. HFD induces obesity, insulin resistance and glucose tolerance, in mice 
as well as humans. Prex1 KO mice on HFD retained their lower fasting blood 
glucose levels throughout ageing, but not their improved glucose tolerance which 
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showed that their phenotype is diet-dependent. This was seen despite the fact that 
the diet did not induce any differences in the total body weight gain rate or body 
composition between Prex1 KO and Prex WT mice. The fact that the improved 
glucose tolerance was seen on chow but was lost on HFD (at least in males) 
suggests that Prex1 KO is beneficial for males during healthy ageing, but not robust 
enough to protect them from developing diet-induced metabolic syndrome. It is also 
possible, that another Rac-GEF compensates for the loss of Prex1 in a diet 
dependent manner. This could be investigated in the future through expression 
analysis, as discussed above, with the additional comparison of tissues from mice 
on HFD with mice on chow diet. 
Loss of insulin sensitivity is a key factor in the development of age-related 
and diet-induced metabolic syndrome. Prex1 deficient mice on chow diet had a 
normal response to insulin challenge when middle-aged (5 months), but an altered 
response at old age (10 months). Although they did respond to insulin, their blood 
glucose levels did not drop as much, percent-wise, as in Prex WT mice, and returned 
to fasting levels within 2 hours after the insulin challenge, contrary to control mice 
whose blood glucose levels remained low. One obvious interpretation of this finding 
could be that Prex1 KO males developed insulin resistance with age. Although this 
might be true, it is worth considering that they did exhibit some response to insulin 
in the first phase of the challenge. The most significant deviation from the response 
of Prex WT mice was from 30 min after the insulin injection onwards. Given that 
insulin has a half-life of ~10 min in the blood stream, it is generally accepted that 
glucose excursions at later time points mostly depend on the counter-regulatory 
response to hypoglycaemia rather than direct effects of insulin (Alquier and Poitout, 
2018; Hughey et al., 2014). This indicates that Prex1 deficiency might affect mainly 
counter-regulatory responses to low blood glucose levels and not insulin sensitivity. 
It could also be speculated that their low fasting blood glucose levels made these 
mice more capable to maintain glucose homeostasis by shifting the glycaemic 
threshold to higher glucose concentrations. Hence, counter-regulatory responses 
would be triggered more easily in Prex1 KO mice during insulin challenge. In the 
literature, counter-regulatory mechanisms to hypoglycaemia were reported to be 
initiated at elevated plasma glucose concentrations in subjects with T2DM (Burge 
et al., 2001; Cryer et al., 2003), which is not the case in the Prex1 KO mice. To 
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investigate this further, it would be of interest to follow the plasma levels of insulin, 
as well as of counter-regulatory factors such as glucagon, epinephrine, and 
norepinephrine during insulin challenge. 
Another interesting aspect of the Prex1 KO mouse phenotype was its sex-
dependence. Differences in the metabolic phenotypes of males and females are 
well documented in the literature (Mauvais-Jarvis et al., 2013; Reynolds et al., 
2019). In the present study, comparison of wild type males and females showed the 
expected sex-differences, with lower fasting blood glucose as well as better glucose 
tolerance and insulin sensitivity in females than in males and thus overall better 
glucose homeostasis in females. The metabolic phenotype of both female and male 
Prex1 KO mice was tested in order to investigate the role of Prex1 in these sex 
differences. Females on chow diet had a tendency to low fasting blood glucose 
levels and improved glucose tolerance during ageing, but normal responses to 
insulin challenge. This result showed that there is indeed a sex-dependency of the 
Prex1 KO phenotype, with the phenotype of the females being milder than that of 
Prex1 KO males on chow diet. One could speculate that the phenotype of the 
females was milder because females had much better glucose homeostasis than 
males, and hence less protection was required. Interestingly, when the female Prex1 
KO mice were introduced to HFD, they showed markedly improved glucose 
tolerance at 6 months of age, consistently across all three individually tested 
cohorts, and a tendency for improved glucose tolerance also at one year. This 
phenotype was not seen in males, so was again sex-dependent, but this time 
stronger in females than males. The HFD induced a stronger decline in glucose 
tolerance in males than females, even in wild type mice, and hence it is conceivable 
that the increase in glucose tolerance afforded by the Prex1 deficiency was too small 
to have an effect in males but sufficient to protect females from diet-induced glucose 
intolerance to some extent. I tried to address this possibility by titrating down the 
dose of glucose used when challenging mice on HFD, but this, while successful in 
females, failed to reveal a difference in the males. 
The sex-dependency of the Prex1 KO phenotype seems likely to be due to 
sex hormones. Sex hormones affect a multitude of factors in the mouse, including 
size; muscle mass, stress levels and aggression, and all of these factors are known 
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to affect glucose homeostasis. The finding that Prex1 deficient females on HFD 
showed improved glucose tolerance particularly at 6 months of age is intriguing, as 
6 months is the end of the reproductive age for females. Therefore, the improved 
glucose tolerance at that age could be associated with hormonal changes during 
menopause. Hormone treatment and/or gonadectomy could be employed to try and 
unravel the relevant contribution of sex hormones to the metabolic phenotype 
observed in Prex1 KO mice.  
5.3 Role of Prex2 KO in glucose tolerance and insulin 
sensitivity 
As described in the introduction, Prex2 has also been implicated in insulin 
signalling and metabolic syndrome. The Parsons lab described their Prex2–/– male 
mice to have reduced glucose tolerance and develop insulin resistance at young 
age (6-8 weeks old), on chow diet (Hodakoski et al., 2014). Moreover, the PREX2 
protein was found to be down-regulated in the adipose tissue of insulin-resistant 
human patients (Hodakoski et al., 2014). Surprisingly, the Prex2 KO mouse findings 
were not reproduced in this study. Our male Prex2 KO mice were found to have an 
overall normal metabolic phenotype when on chow diet, with normal fasting blood 
glucose levels, overall normal glucose tolerance despite some age-related 
fluctuations, and if at all, somewhat improved insulin sensitivity in old age. This 
controversy between the report by the Parsons lab and my own findings could be a 
result of differences in many aspects of the experimental protocol. First, the two 
Prex2 KO mouse strains were produced independently by the two laboratories and 
different targeting strategies had been used. As both strains are on a C57BL/6 
genetic background, it seemed unlikely that background plays a role. However, the 
number of times that mice were backcrossed could be different, and even the 
C57BL/6 strain is known to be highly divergent between institutions and thus not 
necessarily comparable. To account for this possibility, I compared our usual Prex2 
KO mice (and Prex WT controls) that had been backcrossed five times to C57BL/6J 
background with Prex2 KO mice from the same strain that had been backcrossed 
more than 10 times to C57BL/6J (and C57BL/6J controls). The phenotype of normal 
fasting blood glucose levels and glucose tolerance was the same, both at the age 
tested by the Parsons lab (6 weeks) and at the age that we usually tested our mice 
(10 weeks) (data not shown). In addition to the mouse strains, experimental 
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conditions were slightly different, although the same dosage of glucose and insulin 
was applied. The Parsons lab they performed overnight starvation prior to glucose 
tolerance test, and insulin challenge at fed state. In contrast, in this study, a 6- or 4-
hour fasting was performed prior to glucose and insulin tolerance tests, respectively. 
Such differences in the level of fasting are likely to affect the subsequent responses 
to glucose and insulin challenges (Andrikopoulos et al., 2008). Here, a 6-hour fasting 
period was selected, as it most closely resembles the human response to overnight 
starvation. Prolonged starvation in the mouse results in body weight loss and 
considerable metabolic stress, which promotes insulin-stimulated glucose 
utilisation. This is in contrast to the situation in humans, where prolonged fasting 
impairs insulin-mediated glucose transport (Alquier and Poitout, 2018). Moreover, 
the time of the day that the experiments are performed and the housing temperature 
have been reported to modify the metabolic phenotype of mice (Ayala et al., 2010). 
Another consideration was the dose in relation to the body weight. In the present 
study, the Prex2 KO mice put on weight more slowly during ageing than their Prex 
WT counterparts, and the dosage of both glucose and insulin was adjusted to total 
body weight rather than lean mass, as recommended (McGuinness et al., 2009). 
However, the body composition analysis at the end of the experiment showed that 
the lean mass percentage was comparable between the genotypes. Therefore, the 
doses used should not have been disproportionally larger for the Prex WT mice, 
which could have resulted in misleading results. Hence, categorically Prex2 KO 
mice on chow diet do not develop glucose intolerance and insulin resistance in our 
hands. 
When the Prex2 KO males were introduced to HFD, they maintained their 
low fasting blood glucose levels throughout ageing, indicating that Prex2 KO mice 
are protected from diet-induced hyperglycaemia. However, this was not enough to 
protect them from developing diet-induced glucose intolerance and insulin 
resistance worse than their Prex WT counterparts. Prex2 KO mice on HFD showed 
a tendency to reduced glucose tolerance throughout their lifetime, and significant 
glucose intolerance at 9 months of age. In addition, middle-aged Prex2 KO males 
on HFD showed an exaggerated counter-regulatory response to insulin challenge 
and significant insulin resistance in old age. Interestingly, although the Prex2 KO 
mice tested in this study put on less body weight during ageing than the Prex WT 
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controls, they had increased fat mass percentage. Thereby, it is conceivable that 
the reduced glucose tolerance and insulin sensitivity could be due to these animals 
being dosed with disproportionally large amounts of glucose, when standardised to 
their lean mass. However, as previously discussed for mice on chow diet, the 
difference in lean mass was less than 10%, so the dosage would not have differed 
significantly when calculated to lean mass, and can therefore be discounted. 
Importantly, unlike the phenotype of Prex2 KO mice on chow diet, that of  
Prex2 KO males on HFD resembles closely the findings reported by the Parsons 
lab for their Prex2 KO mice on chow diet (Hodakoski et al., 2014). Therefore, it 
appears that, overall, the phenotype of these mice is robust enough to be 
reproduced in independent mouse strains and by different labs, although certainly 
not under comparable experimental conditions. It would be interesting to determine 
the PIP3/PIP2 levels in insulin sensitive tissues of Prex2 KO mice on HFD, in order 
to investigate whether the glucose intolerance and insulin resistance seen here are 
associated with increased Pten activity. Such de-inhibited Pten activity would 
presumably lead to reduced PIP3 levels, and thus reduced insulin signalling and 
glucose clearance, which might eventually result in the glucose intolerance and 
insulin resistance observed in these mice. However, the mechanism is probably not 
that straightforward. In fact, it seems unlikely that the loss of Prex2-mediated Pten 
inhibition in the Prex2 KO is the only mechanism underlying the observed 
phenotype, as two-fold increase of Pten expression levels has been reported to 
result in improved insulin sensitivity and protection from diet-dependent metabolic 
defects (Ortega-Molina et al., 2012), the opposite phenotype to what was expected. 
Important mechanistic insight into the origins of the metabolic phenotype was 
gained through the study of Prex2 catalytically-inactive mice, which evaluated the 
relative contribution of Prex2 Rac-GEF activity and Prex2 adaptor functions to 
glucose homeostasis. This is going to be discussed in Section 5.7. 
In contrast to Prex1 KO mice, young male Prex2 KO mice exhibited increased 
liver and kidney size, as well as reduced ingWAT, and skeletal muscle size. 
Nevertheless, these findings did not persist into middle age; and their significance 
is presently unclear. Furthermore, histological analysis of the liver, ingWAT, and 
skeletal muscle in 10-week old Prex2 KO mice did not reveal any differences (data 
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not shown). 
As previously with the Prex1 KO mice, it would be of interest to test the 
distribution of white adipose tissue, as increased subcutaneous adipose tissue 
might account for the maintenance of low fasting blood glucose levels in Prex2 KO 
males on HFD. Overall, a similar analysis of the underlying mechanisms would be 
useful, as were previously proposed for the Prex1 KO mouse strain, with the 
exception of the bone marrow transplantation, as Prex2 is not thought to be 
expressed in the haematopoietic system. 
Like Prex1 KO mice, there was a sex-dependence on the Prex2 KO 
phenotype. On chow diet, both Prex2 KO males and females showed normal fasting 
blood glucose levels throughout ageing, and overall normal glucose tolerance, with 
some age-related fluctuations, as well as normal insulin sensitivity. However, where 
Prex2 KO males on HFD were glucose intolerant and insulin resistant, females were 
not. As proposed previously for Prex1 KO mice, gonadectomy and/or hormone 
treatment could be performed to analyse the causes of this observed sex difference 
in Prex2 KO mice. 
5.4 Glucose homeostasis in Prex1/2 DKO mice 
Male Prex1/2 DKO mice on chow diet showed low fasting blood glucose 
levels in old age, followed by somewhat improved glucose tolerance, and apparent 
insulin resistance in middle-age. Thus, their phenotype overall resembled that of 
Prex1 KO males, although it was not as strong. The fact that, in males, the double 
KO did not exacerbate the phenotype of either single KO suggests that in the 
absence of both Prex proteins, another Rac-GEF (or glucose homeostasis 
mechanism) compensates to some extent.  
Prex1/2 DKO mice on HFD had low fasting blood glucose levels, similarly to 
what was observed in both single knockout strains, but their glucose tolerance was 
similar to that of Prex WT mice. Moreover, Prex1/2 DKO males on HFD exhibited 
altered insulin responses compared to Prex WT controls and had increased fat mass 
percentage, as it was seen with the Prex2 KO mice under the same conditions. 
However, similarly to what was discussed previously for the single KO mice, the 
apparent insulin resistance of Prex1/2 DKO mice could be a reflection of the 
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difference in fasting blood glucose levels rather than true insulin resistance. 
More importantly, there was a definite sex-difference in Prex1/2 DKO mice. 
Whereas the phenotype of Prex1/2 DKO males overall was no worse than that of 
single KO strains, Prex1/2 DKO females were worse than their single KO 
counterparts on both diets. This implies that there is significant redundancy between 
Prex proteins specifically in females, which is an astonishing finding. Having 
repeatedly seen sexual dimorphism in the metabolic phenotype of Prex knockout 
mice, it seems that these sex-dependent differences even affect the signalling 
pathways through which the Prex proteins signal, largely non-redundant pathways 
in males and some redundant signalling in females. Therefore, it seems likely that 
gonadal hormones impact Prex signalling in a much more profound manner than 
could have been expected from studying the single KO strains alone. 
Overall, the results obtained from Prex1/2 DKO males appear to resemble 
more the Prex1 KO phenotype on both diets, despite the single knockouts 
demonstrating almost opposing phenotypes on HFD. Instead, the results obtained 
from Prex1/2 DKO females were worse than the phenotype of the single KO mice. 
This demonstrates that the roles of Prex1 and Prex2 in glucose homeostasis are not 
simply interchangeable, except in some situations specifically in females, as 
discussed here above; it seems likely that this overall low redundancy triggers 
different compensatory responses. The most obvious difference is that the two Prex 
proteins show distinct tissue distribution; and even within organs where both 
proteins are expressed they might be present in different cell types. As discussed 
above, one major difference on the cellular level is that hematopoietic Prex1 was 
shown to be involved in regulating glucose tolerance, whereas Prex2 is not 
expressed in the haematopoietic system. On a molecular level, only Prex2 interacts 
with Pten and contributes to the regulation of PIP3 levels, therefore modulating 
PI3K/Akt downstream signalling through at least one mechanism in which Prex1 is 
not involved. 
It would be interesting to investigate which Rac-GEF, if any, compensates for 
the loss of Prex1 and Prex2 in male double KO mice, to produce a phenotype that 
is weaker than in the single KOs. As Vav and Tiam1 Rac-GEFs have previously 
been implicated in glucose homeostasis, they might be obvious candidates. This 
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could be tested in the future by expression analysis, searching for upregulation of 
Rac-GEFs on the mRNA or protein level in insulin-sensitive Prex1/2 DKO tissues. 
One could also measure Rac activity in DKO compared to single KO tissues, either 
by Pak-CRIB pull down assay, or better yet, by in vivo or ex vivo FLIM-Fret analysis 
using the Rac activity reporter strain that is already available in our laboratory. This 
may help elucidate if Rac activity levels are reduced in single KO tissues but rescued 
by upregulation of another Rac-GEF in double KO tissues. Finally, one could also 
employ genetic means, through the generation and testing of mice deficient in 
multiple Rac-GEFs, although this would likely have complex consequences for 
multiple organ systems. 
5.5 Roles of Prex proteins in insulin signalling 
As described in the introduction, both PREX1 and PREX2 are known to mediate IR 
signalling, although most of that literature is on PREX2. In this study, I investigated 
the role of Prex1 in insulin signalling ex vivo, and I tested the roles of both Prex 
proteins, and of their catalytic activities, in insulin signalling in an overexpression 
system in HepG2 cells. 
The literature that previously investigated the role of PREX1 in IR signalling 
had shown that PREX1 knockdown in breast cancer cells reduces IGF-1 stimulated 
IR signalling to Rac1 (Dillon et al., 2014; Montero et al., 2013), and knockdown in 
ovarian cancer cells reduces the IGF-1 stimulated activation of both the mTORC2 
substrate Akt-S473 and Rac1 (Kim et al., 2012). Surprisingly, high levels of Prex1 
expression in human breast cancer are associated with decreased 
PI3K/Akt/mTOR/GSK3 pathway activity markers, possibly through a negative 
feedback loop where PI3K inhibits PREX1 expression. However, PREX1 
overexpression in breast cancer cell lines enhanced the IGF-1 stimulated activating 
phosphorylation of the IGF-1R/IR, Akt (T308 and S473) and MEK via Rac, 
suggesting that PREX1 acts both downstream and upstream of PI3K to create a 
positive feedback loop (Dillon et al., 2014).  
In the present study, I used Mesoscale analysis to evaluate insulin pathway 
activity in the liver, skeletal muscle and ingWAT of mock- and insulin-treated Prex1 
KO and Prex WT mice. While I could readily detect the insulin-stimulated activation 
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of Akt in all tissues, of p70S6K in ingWAT and of GSK3β and in liver, there were no 
obvious differences between the genotypes under the conditions tested. One 
possible difference was an insulin-dependent increase in GSK3β activity in the 
ingWAT of Prex1 KO mice, but this was due to an apparent decrease in total GSK3β 
levels, which needs to be confirmed by further experiments. Considering that these 
ex vivo results were derived from a small n-number of mice and without much 
protocol optimisation, it is possible that the experimental parameters were not ideal 
for insulin pathway interrogation. For instance, a time course or dose response 
would give better insight into the pathway activation profile, but the scope for such 
optimisation is necessarily limited for ex vivo experiments. It seems likely that further 
optimisation would reveal a role for Prex1 in insulin signalling also in vivo, 
considering the importance seen in vitro.   
Within the insulin signalling pathway, the importance of the interaction of 
Prex1 with mTOR is particularly intriguing. As described in the introduction, it was 
shown that both PREX1 and PREX2 bind directly to mTOR, and thus both mTOR 
complexes, mTORC1 and mTORC2. Furthermore, Prex1 knockdown was shown to 
reduce activation of the mTORC1 substrate p70S6K, although so far only studied in 
response to amino acid stimulation and not insulin (Hernandez-Negrete et al., 2007). 
The findings discussed above, which showed that Prex1 knockdown reduced the 
IGF-1 stimulated phosphorylation of the mTORC2 substrate Akt-S473 (Kim et al., 
2012), suggest that Prex1 is able to mediate IR signalling through mTOR, although 
it is currently unknown whether any of this occurs through the direct interaction of 
Prex1 with mTOR. Hence, it could be of importance to work further towards 
understanding the significance of this interaction for the insulin signalling pathway.  
In order to assess the importance of PREX Rac-GEF activity in insulin 
signalling, the generation of a catalytically inactive mutant of PREX2 was first 
required. For this purpose two residues, Glu30 and Asn212 within the PREX2 DH 
catalytic domain were mutated to alanine. Purified recombinant human 
PREX2E30A/N212A protein was produced, and tested in a liposome-based in vitro Rac-
GEF activity assay, which confirmed that the E30A and N212A mutations 
successfully inhibited both the basal and PIP3-stimulated Rac-GEF activity of 
PREX2. This was in line with recent analysis of the crystal structure of PREX1 in 
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complex with Rac1, which demonstrated that the equivalent residues to both of 
these are important for the PREX1:Rac1 interaction (Lucato et al., 2015). Moreover, 
the mutation of the equivalent residues in PREX1 to alanine rendered the PREX1 
protein GEF-dead both in vitro and in cells without affecting its normal folding (Hill 
et al., 2005; Welch, 2015). 
Overexpression of either wild type or catalytically inactive PREX1 and 
PREX2 in HepG2 cells resulted in increased Akt activity in response to insulin 
stimulation. These data suggest that both PREX proteins can mediate insulin 
signalling not only through their Rac-GEF activity, but also as adaptor proteins, at 
least in this overexpression system. In regards to PREX2, a GEF-independent role 
was to be expected, based upon the studies by the Parsons lab, which had shown 
that Prex2 binding inhibits Pten activity in a GEF-independent manner (Hodakoski 
et al., 2014). The Parsons lab had furthermore suggested that Prex2 KO might affect 
the insulin pathway activity also in vivo through relief of inhibition of Pten by Prex2 
(Hodakoski et al., 2014). In contrast to Prex2, the GEF-activity independent role of 
PREX1 in insulin signalling came as a surprise. The only other GEF-independent 
role of PREX1 is in the regulation of agonist-induced GPCR trafficking, which was 
recently discovered in our lab and is as yet unpublished. Unlike PREX2, PREX1 
does not interact with PTEN, and therefore it would be very interesting to investigate 
in the future through which adaptor function PREX1 regulates the insulin signalling 
pathway. It is possible that the interaction of PREX1 and PREX2 with mTOR is 
important in this regard. 
5.6 Generation of catalytically inactive Prex mouse 
strains 
On the basis of my in vitro results which suggested that both PREX1 and PREX2 
have adaptor functions in insulin signaling, combined with the phenotypes of the 
Prex KO mice, it was considered useful to generate catalytically inactive Prex mouse 
strains. To achieve this goal, I targeted residues in the mouse genome that are 
equivalent to those in the human recombinant catalytically inactive PREX1 and 
PREX2 proteins, namely Glu51 and Asn233 for Prex1, and Glu22 and Asn204 for 
Prex2. The relevant nucleotides are located on exon 1 and exon 6, respectively, of 
each Prex gene, and in the mouse genome these exons are around 90 kb apart in 
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both genes. Hence, traditional gene targeting by homologous recombination would 
have been impossible, as this distance is too large for a single targeting vector yet 
too small for crossover to occur and allow crossing of single-mutant strains. 
Therefore, a CRISPR targeting approach was designed instead. The principle of 
CRISPR technology is to design sgRNAs that direct the Cas9 nuclease to cleave a 
specific sequence, and in the case of knock-in mice, introduce a repair template that 
encodes for the desired mutation.  
The selected strategy was to target both exons 1 and 6 of the Prex1 or Prex2 
genes at the same time, using wild type Cas9 and a repair template for each site to 
introduce the desired mutations. Although there were concerns regarding off-target 
effects due to Cas9-mediated un-specific double-strand brakes, the alternative of 
employing a pair of Cas9D10A nickases for higher specificity was rejected as it 
would have increased the amount of components needed to be microinjected into 
the zygote and reduce targeting efficiency. Moreover, it had been reported in the 
literature that off-target effects are rare in mouse zygotes microinjected with Cas9 
mRNA, possibly due to the transient nature of the expression of Cas9 protein from 
mRNA compared to the relatively extended expression from a plasmid in cell line 
transfection experiments (Singh et al., 2015). Another concern regarding the 
simultaneous targeting of both exons with the wild-type Cas9 nuclease was the 
theoretical potential for deletion of parts of the genomic sequence. However, it was 
previously seen that two Cas9-mediated cleavage events ~700 bp apart in the 
mouse genome resulted in detrimental deletions only in 35% of the obtained mice 
(Yang et al., 2013). It was concluded that the risk of losing part or the whole 90 kb 
genomic sequence between the cut sites in the Prex genes was considerably lower.  
The sgRNAs were designed using online available databases for each 
targeting locus and were all tested for their targeting efficiency in vitro. However, 
there was scepticism on how efficient these sgRNAs would be in cells. Therefore, 
the sgRNAs were also assessed for their efficiency in the NIH/3T3 mouse cell line 
using SURVEYOR nuclease assay. Comparable results were obtained with both 
methods, which confirmed that for future projects the in vitro assessment would 
likely be sufficient. Another important component of the CRISPR approach, when 
introducing point mutations, was the design of ssDNA that acts as a repair template, 
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promoting HDR. This repair template was designed in a way that it would not only 
introduce the desired point mutations, but also silent mutations that generated 
unique restriction sites, providing an efficient and robust screening method. In the 
end, I did not utilise these restriction sites in my genotyping, but rather developed a 
PCR protocol with primers specific for the mutated or the wild type sequence, as 
this method was deemed less time-consuming. However, that PCR protocol yielded 
many false positive results, so to be absolutely certain of the genotype, I resorted to 
Sanger sequencing of the PCR products, which was the most time consuming but 
yielded incontrovertible results.  
Although catalytically inactive Prex1 mouse strain was not established within 
the time of this project, there were two successful targeting events that yielded one 
heterozygous Prex1 GEF-dead female each; both survived into adulthood but died 
before they could give birth to heterozygous pups. This should be regarded as very 
unfortunate rather than related to any detrimental effects of the genotype on 
breeding or viability, as the phenotype would not be expected to be severer than 
that of the Prex1 KO mouse, and thus further targeting efforts are currently ongoing. 
In contrast, the catalytically inactive Prex2 mouse strain was successfully 
established. As Dr Spensberger had learned that microinjection of too much 
targeting material into zygotes was detrimental, initially mice positive for the 
mutation on exon 1 of Prex2 were generated and bred together until the mutation 
was homozygous (E22A). Zygotes from these homozygous mice were subsequently 
retargeted for mutation N204A on exon 6 (N204A).  
5.7 Metabolic phenotype of the GEF-dead Prex2 E22A 
mouse 
While the re-targeting of the Prex2E22A/E22A (Prex2 E22A) mouse strain to 
Prex2E22A/E22A;N204A/N204A was ongoing, I decided to investigate the metabolic 
phenotype of the Prex2 E22A mouse. This strain was considered to be a “nearly 
GEF-dead” mouse, based on the documented low level of GEF-activity that 
remained in the equivalent human PREX1 G56A protein (Lucato et al., 2015). Glu56 
of PREX1 forms high-density hydrogen bonds with residues within the switch 1 of 
Rac1, whereas Asn 238 (the equivalent of N204 in mouse Prex2) forms hydrogen 
bonds with residues in switch 2. Mutation of either of these residues alone was 
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sufficient to reduce the level of Rac1 binding and GDP-exchange activity of PREX1 
in vitro to maximally 5% of residual activity (Lucato et al., 2015). Given the high 
homology between the Prex1 and Prex2 DH domains, it was concluded that this 
finding would extend to Prex2, and the Prex2E22A/E22A mouse would show a similar 
>95% loss of GEF activity, although formal verification is outstanding.  
Prex2E22A/E22A (Prex2 E22A) males on chow diet had lower fasting blood 
glucose levels than controls throughout ageing, and exhibited improved glucose 
tolerance from 15 weeks of age onwards, despite an overall normal response to 
insulin challenge. Prex2 E22A males on HFD retained both their low fasting blood 
glucose levels and their improved glucose tolerance throughout ageing. Female 
Prex2 E22A mice also demonstrated reduced fasting blood glucose levels on HFD, 
but their glucose response was normal throughout ageing. Therefore, the phenotype 
of the Prex2 E22A mouse resembled much more that of Prex1 KO than Prex2 KO 
mice, except it was more pronounced and less diet-dependent, but just as sex-
dependent. Overall, the Prex2 E22A mouse showed much improved glucose 
homeostasis. These results demonstrate that Prex2 has important Rac-GEF activity 
independent functions in the control of blood glucose levels.  
In contrast to the Prex2 E22A mouse, the Prex2 KO mice had an overall 
normal metabolic phenotype on chow diet, but reduced glucose tolerance and age-
related insulin resistance on HFD. Hence, the absence of Prex2 protein and the 
absence of Prex2 catalytic activity affect glucose homeostasis in almost opposite 
ways, with the GEF activity apparently limiting glucose tolerance and the adaptor 
functions promoting it. One mechanism that is lost in the Prex2 KO mouse that is 
likely intact in the Prex2 E22A mouse is the inhibition of Pten, although this needs 
to be corroborated by measurements of PIP3 levels. Additional differences in 
phenotype between Prex2 KO and E22A mice could be due to compensatory 
mechanisms (such as upregulation of other GEFs) being triggered in the absence 
of the Prex2 protein that are not triggered when the protein is expressed but 
catalytically inactive. In that case, one might presume that the adverse metabolic 
phenotype of the Prex2 KO mouse is in fact a ‘side-effect’ of such compensatory 
mechanisms. 
Due to time-limitations, I could obtain body composition data for Prex2 E22A 
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mice only on HFD, which showed that they had reduced fat percentage compared 
to their WT counterparts. Moreover, both at 10 weeks and 1 year of age, Prex2 
E22A mice had significantly smaller livers compared to their WT counterparts, on 
both chow diet and HFD, in contrast to young Prex2 KO mice, which had larger livers 
than controls. The reduced liver size suggests that the liver might be an important 
contributor to the observed phenotype in Prex2 E22A mice. Therefore, it would be 
of interest to measure the PIP3/PIP2 levels and Rac activity particularly in the liver 
(as well as other insulin sensitive tissues) of the Prex2 E22A mouse, and to 
interrogate the insulin signalling pathway in these tissues to determine whether the 
metabolic phenotype of Prex2 KO and Prex2 E22A mice are related to the 
Prex2/Pten interaction.  
5.8 Comparison of the Prex mouse to other Rac-GEF 
and PI3K mutant strains 
We need to consider how the metabolic phenotypes of Prex mice compare to those 
of related mouse strains, namely mice deficient in other Rho-GEFs or in the Prex 
regulator PI3K. 
Like Prex proteins, PDZ-RhoGEF is a GEF that signals downstream of 
GPCRs, as it is regulated by the Gα subunits of heterotrimeric G proteins. Moreover, 
like Prex proteins, PDZ-RhoGEF regulates metabolism, specifically by governing 
susceptibility to diet-induced obesity and type 2 diabetes. PDZ-RhoGEF deficiency 
resulted in reduced body weight and fat mass as well as increased energy 
expenditure on chow-fed mice (Chang et al., 2015). Similarly, Prex1 deficiency 
resulted in reduced adipose tissue mass at both young and middle age. However, 
Prex1 KO mice were not significantly thinner than their Prex WT counterparts, and 
the percentage of fat mass was normal. Likewise, although Prex2 KO mice on chow 
diet were lighter than the Prex WT control mice, they had normal body composition. 
Therefore, it seems unlikely that there is any redundancy between Prex proteins and 
PDZ-RhoGEF in glucose homeostasis. This is unsurprising, as PDZ-Rho-GEF is a 
Rho-specific GEF, and not a Rac-GEF. 
Vav-family GEFs, which activate Rac, and possibly also Cdc42 and RhoA in 
vivo, are also important regulators of metabolism. Vav3 deficient mice on chow diet 
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developed metabolic syndrome, NAFLD, and T2DM without increased adiposity 
(Menacho-Márquez et al., 2013), whereas, Prex deficiency either improved the 
metabolic phenotype of mice (Prex1 KO and Prex2 E22A) or had no significant 
effect (Prex2 KO). Moreover, mice expressing catalytically inactive Vav2 exhibit 
reduced skeletal muscle mass and insulin sensitivity, resulting in metabolic 
syndrome (Rodríguez-Fdez and Bustelo, 2019), whereas neither Prex1 nor Prex2 
significantly affected the insulin sensitivity of mice on chow diet. As discussed 
before, the apparent insulin resistance observed under some conditions was 
probably due to low fasting blood glucose levels or altered counter-regulatory 
responses. 
Both PDZ-RhoGEF and Vav3 depletion protected mice from diet-dependent 
development of obesity and metabolic syndrome (Chang et al., 2015; Menacho-
Márquez et al., 2013). In the present study, Prex1 and Prex2 single knockout males 
on HFD were not protected from diet-induced obesity and glucose intolerance, 
despite their low fasting blood glucose levels. Only HFD-fed Prex2 E22A males 
showed reduced body weight and fat mass, as well as low fasting blood glucose 
levels and improved glucose tolerance. Therefore, it seems unlikely that Vav3 and 
Prex1 or Prex2 have redundant functions in metabolism, which was perhaps again 
unsurprising, because vav proteins are regulated by tyrosine phosphorylation and 
mostly signal downstream of different receptors to Prex. However, we previously 
demonstrated redundancy between Prex1 and Vav1 in neutrophils, and between 
Prex1 and either Vav1 or Vav3 in platelets (Pantarelli and Welch, 2018), so it would 
makes sense to explore possibility of redundancy with Vav in metabolism in the 
future. 
Overall, Prex deficiency or GEF-activity deficiency revealed roles in glucose 
homeostasis that are both comparable, to an extent, and non-redundant to those of 
other Rho-GEFs, highlighting the complexity and crucial importance of tight Rho-
GTPase regulation by multiple GEFs. 
As Prex proteins mediate insulin signalling, we should consider the Prex KO 
phenotypes in relation to other mouse strains related to the insulin/PI3K signalling 
pathway. Systemic insulin receptor knockout in mice led to slightly reduced prenatal 
growth, as well as neonatal diabetic ketoacidosis due to hyperglycaemia and 
244 | P a g e  
hyperinsulinemia, ultimately resulting in early postnatal death (Accili et al., 1996; 
Joshi et al., 1996). In contrast, adipose tissue specific knockout of the insulin 
receptor surprisingly protected against diet- and age-related metabolic syndrome, 
despite glucose intolerance and insulin resistance at young age (Friesen et al., 
2016). Analysis of whole-body IRS KO mice revealed that from the IRS tested, IRS1 
and IRS2 are more relevant in insulin signalling-mediated glucose homeostasis. 
Knockout of IRS1 resulted in insulin resistance with compensatory IRS2-dependent 
hyperinsulinemia and β cell hyperplasia, which afforded normal glucose tolerance 
(Araki et al., 1994; Tamemoto et al., 1994). Instead, IRS2 deficiency was associated 
with peripheral insulin resistance but impaired compensatory insulin secretion, 
which led to hyperglycaemia and development of T2DM (Kubota et al., 2000; 
Withers et al., 1998). Considering the differences in phenotype, it seems unlikely 
that the effects of Prex KO on glucose homeostasis derive from altered IRS function. 
For example, the fasting insulin and glucagon levels of Prex1 KO mice were normal, 
whereas pancreatic function was strongly affected in the IRS KO mice. However, 
given that PREX1 overexpression in breast cancer cell lines enhanced the IGF-1 
stimulated activation of the IGF-1R and IR (Dillon et al., 2014), it would be interesting 
to evaluate the phosphorylation state of IR in Prex1 KO mice upon insulin 
stimulation. 
Insulin signalling downstream of IRS1 and IRS2, promotes the activation of 
the PI3K/Akt pathway. As described in the introduction, Class IA PI3Ks are 
heterodimeric molecules composed of p85 regulatory and p110 catalytic subunits. 
Knockout of Pik3r1, which codes for the p85α, p55α, and p50α isoforms of the 
regulatory subunit, resulted in perinatal death associated with liver necrosis (Fruman 
et al., 2000). Interestingly, these mice showed hypoglycaemia and improved 
glucose clearance, similarly to the Prex1 KO and Prex2 E22A mice here. Moreover, 
like Prex1 KO, Pik3r1 deficiency did not reduce Akt activation in liver and skeletal 
muscle, and neither did it affect Glut1 and Glut4 expression in skeletal muscle 
(Fruman et al., 2000). However, contrary to Prex1 KO, Pik3r1 KO mice showed 
reduced insulin levels, both in fasting and fed state. Knockout of the p85α isoform 
specifically also led to hypoglycaemia and increased insulin sensitivity in mice, as 
well as upregulation of p55α and p50α which promoted insulin-mediated PIP3 
generation and Glut4 translocation to the plasma membrane in p85α KO mice 
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(Terauchi et al., 1999). Moreover, mutations in the C-terminal SH2 domain of human 
PIK3R1 have been associated with insulin resistance, reduced subcutaneous fat in 
humans (Huang-Doran et al., 2016). 
 Systemic deficiency of the catalytic p110α or p110β subunits of PI3K is 
embryonic lethal. However, expression of a kinase-dead p110α knock-in 
(p110αD933A/WT) at heterozygous state resulted in hyperphagia, increased adiposity, 
glucose intolerance, hyperinsulinemia, and insulin resistance (Foukas et al., 2006). 
Interestingly, p110αD933A/WT mice displayed an impaired insulin response that 
resembles the response of 10 months old Prex1 KO male mice (reduced glucose 
drop in the initial phase of the insulin challenge followed by quick recovery back to 
basal levels during the later phase). Nevertheless, p110αD933A/WT mice had normal 
glucose levels (Foukas et al., 2006). Intriguingly, ageing p110αD933A/WT mice were 
protected from age-related fat accumulation and demonstrated improved insulin 
sensitivity and glucose tolerance (Foukas et al., 2013). In contrast, male Prex2 KO 
mice showed apparent increased insulin sensitivity in old age, but both male and 
female Prex2 KO mice exhibited a tendency to improved glucose tolerance in young 
age, which worsened in old age. More recently, adipose tissue specific inactivation 
of p110α was reported to result in increased β-adrenergic signalling which promoted 
glucose uptake by BAT, and these mice maintained normal glucose homeostasis 
despite age-related insulin resistance (Araiz et al., 2019). 
Overall, therefore, there is no obvious straightforward correlation between 
the phenotypes of mice with deficiencies in the insulin/PI3K signalling pathway and 
mice with Prex deficiency, suggesting that the effects in the Prex deficient mice 
derive from a complex combination of mechanisms, that may include but are not 
restricted to the insulin/PI3K signalling pathway. 
5.9 Conclusion and Future Perspective 
In conclusion, this study demonstrated that both Prex1 and Prex2 proteins have 
important and unexpected physiological roles in the regulation of glucose 
homeostasis. Prex1 deficiency helps maintain low glucose levels and protects from 
age-related glucose intolerance. Although the mechanisms through which Prex1 
controls glucose homeostasis are still unclear, bone marrow transplant experiments 
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indicated this could be through the regulation of inflammation. Prex2 deficiency 
resulted in glucose intolerance in mice on HFD, whereas catalytically-inactive Prex2 
mice had improved glucose tolerance both on chow and high fat diet. These data 
suggested that Prex2 regulates glucose homeostasis both through its Rac-GEF 
activity and through adaptor functions, with its Rac-GEF activity limiting glucose 
homeostasis and its adaptor functions promoting it. Following on from my work, the 
Prex1-GEF-Dead mouse will show the Rac-GEF activity or the adaptor functions of 
Prex1 regulate glucose homeostasis, and the Prex2 E22A/N204A mouse will show 
if total inhibition of Prex2 Rac-GEF activity would afford even more benefit than 
Prex2 E22A. 
My work suggests that the development of therapeutics to target PREX1 and 
PREX2 may be a new avenue for the treatment hyperglycaemia and glucose 
intolerance associated with metabolic syndrome. For PREX1, work on the Prex1-
GEF-Dead mouse will reveal whether drugs should target protein stability or Rac-
GEF activity, and for PREX2, my results suggest that targeting the Rac-GEF activity 
should be beneficial, whereas targeting stability would be detrimental. Depending 
on the phenotypes of the Prex1-GEF-Dead and Prex2 E22A/N204A mice, it may be 
useful to generate and evaluate crosses that are GEF-dead for both Prex proteins. 
This would elucidate whether prospective PREX inhibitors would need to be isoform 
specific. In any event, more investigation is required to identify the molecular 
mechanism through which PREX proteins regulate glucose homeostasis, in order 
to facilitate the design of PREX-directed therapeutic approaches. 
Although the selective targeting of PREX catalytic activity has proven 
challenging, as for other GEFs, the recent reports of the PREX1 crystal structure 
(Cash et al., 2016; Lucato et al., 2015) may facilitate the design of small molecule 
inhibitors. Drugs that target the level and/or stability of PREX1 could include 
epigenetic regulators (e.g. micro-RNAs), as PREX1 protein levels are known to be 
controlled by these processes. The development of such drugs is being trialled for 
other types proteins, but has not yet reached the clinic, usually due to lack of efficacy 
and specificity. Examples of small molecule inhibitors that affect the catalytic activity 
of other GEFs with high efficacy and specificity do exist, although mainly as 
laboratory tools and only for GEFs that activate quite distantly related GTPases, 
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such as the Arf-GEF inhibitor Brefeldin A (Cherfils and Zeghouf, 2013). 
Nevertheless, efforts are currently ongoing worldwide, both in academia and in 
industry, to target the activity of GEFs and small GTPases, such as the Ras-GEF 
SOS and K-Ras in human cancers (Evelyn et al., 2014; Simanshu et al., 2017). 
Therefore, it seems likely that the development of PREX Rac-GEF inhibitors for the 
treatment of hyperglycemia and glucose intolerance should be feasible in the future. 
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Appendix A - Supplementary Material 
 
Metabolic phenotype of Prex Wild Type mice 
In order to better illustrate the metabolic phenotype of genetically modified mice, the 
responses of wild type mice are described here, using combined data from all 
cohorts of  Prex1+/+;Prex2+/+ (Prex WT) mice that were tested throughout this PhD 
project. In summary, the mice were tested for fasting blood glucose levels, response 
to glucose tolerance test and response to insulin tolerance test, throughout ageing. 
Glucose tolerance tests were performed at 10 and 15 weeks, and at 6, 9 and 12 
months of age. Insulin tolerance tests were done at 5 and 10 months of age. Both 
sexes were tested, and two diets were compared, normal chow diet and high fat 
(45%) diet. In addition, mice were assessed for body weight throughout ageing, 
tested in metabolic cages at 11 months of age, and their body composition was 
analysed post mortem at one year. 
1. Metabolic phenotype of male Prex WT mice on chow diet 
First, we will consider the responses of male Prex WT mice on chow diet. As seen 
in Figures S1A and S2A, the blood glucose levels in young males was 12 mM after 
6 h of fasting, and rose steadily to 15 mM at one year of age, as expected (Reynolds 
et al., 2019). During glucose tolerance tests by i.p. administration of 2 g/kg glucose 
(20% glucose at 10 ml/kg), the blood glucose level reached a maximum of 25-30 
mM at 15 min post injection and gradually returned towards basal level to around 
15 mM after 90 min (Figure S1B). Normalisation of the glucose response by 
subtracting the basal blood glucose level for each mouse showed that glucose 
challenge triggers an average increase of blood glucose levels by 15 mM (Figure 
S1C). Both raw and normalised data showed that the glucose response of mice 
changed from the age of 6 months onwards, as their blood glucose levels remained 
elevated up to 30 min post injection rather than declining after 15 min as at younger 
age. The area under the curve of the normalised data was used to assess the total 
response to glucose challenge (dots represent individual mice) (Figure S1D). 
Overall, despite the increase in basal blood glucose level from 12 to 15 mM during 
ageing (Figure S2A), the total response to glucose challenge did not change 
significantly with age, although it fluctuated somewhat between 50 and 70 units 
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(Figure S2B). As expected, the mice gained weight in a steady way throughout 
ageing, starting from 26 g at 10 weeks and reaching 35 g at one year (Figure S2C). 
For insulin tolerance tests, the mice were starved for 4 h prior to being 
challenged by s.c. administration of 0.75 IU/kg of human recombinant insulin at 0.15 
IU/ml. As shown in Figure S3A, both at 5 and at 10 months the blood glucose level 
dropped from 13 to 7 mM at 45 min post injection and then returned gradually to 
around 10 mM, remaining at that level throughout the 3 h of testing (Figure S3B). 
Normalisation of glucose levels by subtracting the basal blood glucose level for each 
mouse showed that insulin challenge triggered an average decrease of blood 
glucose levels by 5 mM (Figure S3C). A small decrease was observed in the total 
insulin response between 5 and 10 months of age, from 25 to 20 units (Figure S3D), 
indicating that the mice developed a mild insulin resistance due to ageing. However, 
this decrease in insulin sensitivity did not reach statistical significance. 
To further investigate the metabolic phenotype of Prex WT males, the mice 
were introduced to metabolic cages at 11 months of age. After habituation, the mice 
were group-housed in metabolic cages overnight for 16 h on 3 subsequent nights. 
Food and water were provided ad libitum. Prex WT males consumed on average 78 
mg of water and 71 mg of food per gram of body weight per night, and they produced 
34 mg of urine and 28 mg of faeces per gram of body weight per night (Figure S4A-
D). 
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Figure S1: Fasting blood glucose level and response to glucose challenge 
of male Prex WT mice on chow diet. 
Male Prex1
+/+
;Prex2
+/+
 (Prex WT) mice on chow diet were subjected to i.p. glucose tolerance test 
(IPGTT) at the ages of 10 and 15 weeks, 6, 9 and 12 months. Food was withdrawn 6 h prior to i.p. 
injection of 20% glucose at 10 ml/kg (final concentration 2 g/kg). Blood glucose levels were tested 
by tail bleed 15 min prior to the i.p. injection to determine the basal fasted blood glucose levels, 
and every 15 min after the glucose injection for 90 min, as indicated, to assess the response to 
glucose challenge. Data are pooled from 18 independent cohorts with 2-6 animals each, and 
presented as mean ± SEM. (A) Fasting blood glucose levels. (B) Blood glucose concentration 
during IPGTT. (C) Blood glucose levels during IPGTT, normalised by subtracting the basal blood 
glucose level from each mouse individually. (D) Total glucose response calculated as AUC of 
normalised data.  
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Figure S2: Effects of ageing on the response to glucose challenge, fasting blood 
glucose levels, and body weight of male Prex WT mice on chow diet. 
The fasting blood glucose level, response to glucose challenge, and body weight of the male Prex 
WT mice in Figure S1 are expressed as a function of age. Data are pooled from 18 independent 
cohorts with 2-6 animals each, and are presented as mean ± SEM. (A) Fasting blood glucose 
levels; data from column A in Figure S1. (B) Response to IPGTT; normalised data from column D 
in Figure S1. (C) Total body weight, measured after 6 and 4 h fasting, prior to glucose and insulin 
challenges, respectively. 
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Figure S3: Response of male Prex WT mice on chow diet to insulin challenge at 5 
months and 10 months of age. 
The male Prex WT mice on chow diet shown in Figure S1 were subjected to s.c. insulin tolerance 
test (SCITT) at the ages of 5 and 10 months. Food was withdrawn 4 h prior to s.c. injection of 0.75 
IU/kg of human recombinant insulin at 0.15 IU/ml. Blood glucose levels were tested by tail bleed 
15 min prior to the s.c. injection to determine basal blood glucose levels, as well as after the insulin 
injection at 15, 30, 45, 60, 90,120 and 180 min to assess the response to insulin. Data are pooled 
from 6 independent cohorts with 4-5 animals each, and are presented as mean ± SEM. (A) Fasting 
basal blood glucose levels. (B) Blood glucose levels during SCITT. (C) Glucose levels during 
SCITT, normalised by subtracting the fasting basal blood glucose level from each mouse 
individually. (D) Total insulin response, calculated as AUC of normalised data. 
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Figure S4: Male Prex WT mice water and food consumption as well as urine and 
faeces production in metabolic cages. 
The male Prex WT mice from Figure S1 were habituated to metabolic cages at 11 months of age 
as detailed in Materials and Methods, weighed and group-housed (up to 3) in metabolic cages 
overnight for 16 h on 3 subsequent nights with food and water provided ad libitum. Their (A,E) 
water consumption, (B,F) food consumption, (C,G) urine production, and (D,H) faeces production 
were measured after each night and were normalised to the combined body weights of the mice 
housed in each cage. Data are pooled from 6 independent cohorts with 4-5 animals each, and are 
presented as the mean ± SEM of each night (n=3).  
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2. Metabolic phenotype of male Prex WT mice on HFD 
To investigate the effect of diet on glucose metabolism, male Prex WT mice were 
introduced to 45% HFD, after a “reference” glucose challenge at 10 weeks of age, 
and remained on this HFD throughout their life. 
Figure S5A compares the basal blood glucose levels of mice on HFD (dark 
blue) to mice on chow diet (light blue). Overall, mice on HFD had elevated basal 
blood glucose levels, reaching 15 mM at 15 weeks, after only one month of HFD, 
compared to 12 mM for chow diet, and rising further to 18 mM, to diabetic level, at 
6 months. IPGTT in 15-week old mice (that had been on HFD for one month) was 
performed under the same conditions as for mice on chow diet. This showed that 
the HFD had caused a rapid onset of glucose intolerance (Figure S5B). The blood 
glucose levels of HFD-fed mice kept increasing beyond the 15 min time point, 
reaching a dangerous level of 40 mM at 45 min and remaining above 30 mM within 
the 90 min of the test. These mice had to remain under observation for up to 2.5 h 
to ensure their blood glucose levels returned to 20 mM or below. Normalisation of 
the glucose response by subtracting the basal blood glucose level for each mouse 
showed that glucose challenge triggered an increase of blood glucose levels by 25 
mM, 1.7 times more than for mice on chow diet (Figure S5C-D). As it was apparent 
that one month of HFD was sufficient to render the mice severely glucose intolerant, 
we reduced the dosage of glucose in IPGTTs at later ages to 0.5 g/kg (20% glucose 
at 2.5 ml/kg), one quarter of the original dose (data in ochre box), in order to prevent 
mice from going into hyperglycaemic shock. Under these conditions, blood glucose 
levels did not rise as much, but the duration of the response to IPGTT was similar 
to the test at 15-weeks, as it took again longer for blood glucose levels to return to 
normal. 
The effects of ageing are summarised in Figure S6. As mentioned above, 
the HFD induced a rapid increase in fasting blood glucose levels. However, 
curiously, these basal blood glucose levels of HFD-fed mice improved again after 
the age of 6 months and were comparable to that of chow-fed mice (15 mM) by one 
year (Figure S6A). Due to the different amount of glucose used for IPGTTs, no 
direct comparison can be drawn regarding the total glucose response of HFD- and 
chow-fed mice, apart from the 15 weeks time point. Interestingly, just like for fasting 
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blood glucose levels, an improvement was also observed in the response of HFD-
fed mice to IPGTT after the age of 6 months (Figure S6B). 
Insulin tolerance tests showed that HFD also had complex effects on insulin 
sensitivity. Indeed, at 5 months of age, the insulin tolerance of mice on HFD was 
better than that of chow-fed mice. Although the diet had increased their fasting blood 
glucose level from 12 to 18 mM (Figure S7A), during insulin challenge (s.c. insulin 
at 0.75 IU/kg) blood glucose levels dropped to 8.5 mM at 45 min (Figure S7B). 
Normalising for basal blood glucose level showed that insulin challenge caused a 
drop by 8.5 mM in mice on HFD compared to 5 mM for mice on chow (Figure S7C). 
However, at 10 months of age, when basal blood glucose levels were similar 
between diets, the insulin response was also comparable. Hence, the insulin 
response of HFD-fed mice was lower at 10 months than at 5 months of age (Figure 
S7D), indicating that HFD rendered mice insulin intolerant with age, as expected. 
Finally, also as expected, mice on HFD gained weight at a much higher rate 
than chow-fed mice, weighing roughly twice as much from the age of 9 months 
(Figure S6C). However, while housed in the metabolic cages, mice on HFD 
consumed half as much water and almost three times less food than their chow diet-
fed counterparts (Figure S8A-B), and consequently also their urine and faeces 
production was decreased (Figure S8C-D). 
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Figure S5: Fasting blood glucose level and response to glucose challenge of male 
Prex WT mice on HFD.  
Male Prex WT mice on 45% HFD (dark blue) were subjected to IPGTT at the ages of 10 and 15 
weeks, 6, 9 and 12 months. Food was withdrawn 6 h prior to i.p. injection of 20% glucose at 10 
ml/kg (final concentration 2 g/kg) at 10 and 15 weeks old and at 2.5 ml/kg (final concentration 
0.5g/kg) at 6, 9 and 12 months old - data in ochre box. Blood glucose levels were tested by tail 
bleed 15 min prior to the i.p. injection to determine the basal fasted blood glucose levels, and every 
15 min after the glucose injection for 90 min, to assess the response to glucose challenge. Data 
are pooled from 4 independent cohorts with 4-5 animals each, and presented as mean ± SEM. In 
light blue are represented the male mice on chow diet from Figure S1 for visual comparison, but 
no statistical analysis was performed, as these animals were not directly compared experimentally. 
(A) Fasting blood glucose levels. (B) Blood glucose concentration during IPGTT. (C) Blood 
glucose levels during IPGTT, normalised by subtracting the basal blood glucose level from each 
mouse individually. (D) Total glucose response calculated as AUC of normalised data. 
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Figure S6: Effects of ageing on the fasting blood glucose levels, response to 
glucose challenge, and body weight of male Prex WT mice on HFD. 
The fasting blood glucose level, response to glucose challenge, and body weight of the HFD-fed 
male Prex WT mice in Figure S5 are expressed as a function of age (dark blue). Data are pooled 
from 4 independent cohorts with 4-5 animals each, and are presented as mean ± SEM. Note that 
the dose of glucose was reduced from 2 g/kg to 0.5 g/kg from the age of 6 months onwards (data 
in ochre box). In light blue are represented the male mice on chow diet from Figure S2 for visual 
comparison, but no statistical analysis was performed, as these animals were not directly 
compared experimentally. (A) Fasting blood glucose levels; data from column A in Figure S5. (B) 
Response to IPGTT; normalised data from column D in Figure S5. Note that IPGTT was done 
with 2 g/kg at 10 and 15 weeks, but with 0.5 g/kg at later ages (ochre box). (C) Total body weight, 
measured after 6 and 4 h fasting, prior to glucose and insulin challenges, respectively. 
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Figure S7: Response of male Prex WT mice on HFD to insulin challenge at 5 and 
10 months of age.  
The male Prex WT mice on 45% HFD shown in Figure S5 were subjected to SCITT at the ages 
of 5 and 10 months (dark blue). Food was withdrawn 4 h prior to s.c. injection of 0.75 IU/kg of 
human recombinant insulin at 0.15 IU/ml. Blood glucose levels were tested by tail bleed 15 min 
prior to the s.c. injection to determine basal blood glucose levels, as well as after the insulin 
injection at 15, 30, 45, 60, 90,120 and 180 min to assess the response to insulin. Data are pooled 
from 6 independent cohorts with 4-5 animals each, and are presented as mean ± SEM. In light 
blue are represented the male mice on chow diet from Figure S3 for visual comparison, but no 
statistical analysis was performed, as these animals were not directly compared experimentally. 
(A) Fasting basal blood glucose levels. (B) Blood glucose levels during SCITT. (C) Glucose levels 
during SCITT, normalised by subtracting the fasting basal blood glucose level from each mouse 
individually. (D) Total insulin response, calculated as AUC of normalised data.  
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Figure S8: HFD-fed male Prex WT mice water and food consumption as well as 
urine and faeces production in metabolic cages.  
The male Prex WT mice on HFD from Figure S5 (dark blue) were habituated to metabolic cages 
at 11 months of age, as detailed in Materials and Methods, weighed and group-housed (up to 3) 
in metabolic cages overnight for 16 h on 3 subsequent nights with food and water provided ad 
libitum. In light blue are represented the male mice on chow diet from Figure S4 for visual 
comparison, but no statistical analysis was performed, as these animals were not directly 
compared experimentally. Their (A) water consumption, (B) food consumption, (C) urine 
production, and (D) faeces production were measured after each night and were normalised to the 
combined body weights of the mice housed in each cage. Data are pooled from 6 independent 
cohorts with 4-5 animals each, and are presented as the mean ± SEM of each night (n=3). 
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3. Metabolic phenotype of female Prex WT mice on chow diet 
After investigating males, I wanted to explore the possibility of sex differences. To 
this end, female Prex WT mice were tested on both chow and HFD, in a similar 
manner to the males. Again, data displayed are from all cohorts that were tested 
throughout this PhD project, comparing females (dark blue) with males (light blue). 
As shown in Figures S9A and S10A, females had lower fasting blood 
glucose levels than males throughout ageing, around 10 mM at 10 weeks and 11 
mM at one year, compared to 12-15 mM for males. During IPGTT (2 g/kg), blood 
glucose levels peaked at 20 mM 15 min after challenge in females and then 
decreased rapidly back to basal levels, at all ages tested, contrary to the higher 
maximal level and steadier decline seen in males (Figure S9B). During ageing, the 
total response of females to glucose challenge fluctuated somewhat, but did not 
change significantly (Figure S10B). Overall, therefore, females had better glucose 
tolerance than males throughout ageing (Figure S9C, D). 
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Figure S9: Fasting blood glucose level and response to glucose challenge of 
female Prex WT mice on chow diet. 
Female Prex WT mice on chow diet (dark blue) were subjected to IPGTT at the ages of 10 and 15 
weeks, 6, 9 and 12 months. Food was withdrawn 6 h prior to i.p. injection of 20% glucose at 10 
ml/kg (final concentration 2 g/kg). Blood glucose levels were tested by tail bleed 15 min prior to 
the i.p. injection to determine the basal fasted blood glucose levels, and every 15 min after the 
glucose injection for 90 min, as indicated, to assess the response to glucose challenge. Data are 
pooled from 4 independent cohorts with 4-5 animals each, and presented as mean ± SEM. In light 
blue are represented the male mice on chow diet from Figure S1 for visual comparison, but no 
statistical analysis was performed, as the animals were not directly compared experimentally. (A) 
Fasting blood glucose levels. (B) Blood glucose concentration during IPGTT. (C) Blood glucose 
levels during IPGTT, normalised by subtracting the basal blood glucose level from each mouse 
individually. (D) Total glucose response calculated as AUC of normalised data. 
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Figure S10: Effects of ageing on the fasting blood glucose levels, response to 
glucose challenge, and body weight of female Prex WT mice on chow diet.  
The fasting blood glucose level, response to glucose challenge, and body weight of the female 
Prex WT mice in Figure S9 (dark blue) are expressed as a function of age. Data are pooled from 
4 independent cohorts with 4-5 animals each, and are presented as mean ± SEM. In light blue are 
represented the male mice on chow diet from Figure S2 for visual comparison, but no statistical 
analysis was performed, as the animals were not directly compared experimentally. A) Fasting 
blood glucose levels; data from column A in Figure S9. (B) Response to IPGTT; normalised data 
from column D in Figure S9. (C) Total body weight, measured after 6 and 4 h fasting, prior to 
glucose and insulin challenges, respectively. 
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Upon insulin challenge, females demonstrated a slightly bigger response to 
insulin than the males. At 5 months of age, similarly to males, their blood glucose 
level dropped to its lowest level at 45 min post injection and returned to around 10 
mM at 180 min (Figure S11B). However, the amplitude of the response was larger, 
as glucose levels dropped by 7 mM in females compared to 5 mM in males (Figure 
S11C). Interestingly, females retained similar insulin sensitivity at 10 months (30 
units), unlike males which showed a slight reduction in their response, suggesting 
that females on chow diet do not develop age-related insulin resistance. In addition, 
the response to insulin was longer-lasting in females than males (Figure S11D). 
 
 
 
 
 
 
Figure S11: Response of female Prex WT mice on chow diet to insulin challenge.  
The female Prex WT mice on chow diet shown in Figure S9 (dark blue) were subjected to SCITT 
at the ages of 5 and 10 months. Food was withdrawn 4 h prior to s.c. injection of 0.75 IU/kg of 
human recombinant insulin at 0.15 IU/ml. Blood glucose levels were tested by tail bleed 15 min 
prior to the s.c. injection to determine basal blood glucose levels, as well as after the insulin 
injection at 15, 30, 45, 60, 90,120 and 180 min to assess the response to insulin. Data are pooled 
from 4 independent cohorts with 4-5 animals each, and are presented as mean ± SEM. In light 
blue are represented the male mice on chow diet from Figure S3 for visual comparison, but no 
statistical analysis was performed, as these animals were not directly compared experimentally. 
(A) Fasting basal blood glucose levels. (B) Blood glucose levels during SCITT. (C) Glucose levels 
during SCITT, normalised by subtracting the fasting basal blood glucose level from each mouse 
individually. (D) Total insulin response, calculated as AUC of normalised data. 
Finally, Prex WT females gained weight steadily throughout their lives, from 
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18 g at 10 weeks to 27 g at one year, but remained much lighter throughout than 
their male counterparts, as expected (Figure S10C). Hence, it was surprising to see 
from their housing in metabolic cages that they had higher water and food intake 
than the males at the same age. They consumed 0.1 g of water and 0.1 g of food 
per g of mouse per night, and they produced 0.04 g of urine and 0.04 g of faeces 
per g of mouse per night (Figure S12A-D). 
 
 
 
 
 
 
Figure S12: Female Prex WT mice water and food consumption as well as urine and 
faeces production in metabolic cages.  
The female Prex WT mice in Figure S9 (dark blue) were habituated to metabolic cages at 11 
months of age, as detailed in Materials and Methods, weighed and group-housed (up to 3) in 
metabolic cages overnight for 16 h on 3 subsequent nights with food and water provided ad libitum. 
In light blue are represented the male mice on chow diet from Figure S4 for visual comparison, 
but no statistical analysis was performed, as these animals were not directly compared 
experimentally. Their (A) water consumption, (B) food consumption, (C) urine production, and (D) 
faeces production were measured after each night and were normalised to the combined body 
weights of the mice housed in each cage. Data are pooled from 6 independent cohorts with 4-5 
animals each, and are presented as the mean ± SEM of each night (n=3). 
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4. Metabolic phenotype of female Prex WT mice on HFD 
Finally, Prex WT females were introduced to HFD after the 10-week glucose 
challenge. To elucidate the effect of diet, data for females on HFD (dark blue) are 
compared to those for females on chow diet (light blue). 
Figure S13A shows that there was a slight increase in basal blood glucose 
level due to HFD, from 10 to 12 mM, but not as big as for the males (Figure S6A). 
In contrast, diet had a more striking effect on glucose tolerance (Figure S13B, C).  
At 15 weeks of age, IPGTT caused an increase in the glucose levels of females on 
HFD to 27 mM at 15 min post glucose injection and glucose levels remained high 
up to 30 min before returning to basal levels at 90 min. At 6 and 9 months, glucose 
challenge caused a similarly rapid increase, but glucose levels kept rising, reaching 
a high of 30 mM after 45 min, then declined, but did not return to baseline. Because 
the females showed worryingly high levels of blood glucose during IPGTT at 9 
months of age, we reduced the dose at the 12 months test for some cohorts to half, 
1 g/Kg. As previously seen in males, this milder dose reduced the amplitude of the 
response, but the slow return towards basal levels that is typical for glucose 
intolerance remained (Figure S13B-D). Altogether, the fasting blood glucose levels 
of females did not change significantly during ageing due to diet (Figure S14A), but 
the glucose tolerance of females on HFD was much worse than that of chow-fed 
females (Figure S14B).  
Due to the increased response of females to IPGTT compared to males, we 
feared that females might also be more sensitive to insulin. In order to avoid causing 
hypoglycaemic shock, we therefore initially challenged some cohorts of females with 
a lower dose of insulin (0.5 IU/kg compared to 0.75 IU/kg for males). However, there 
was no significant drop in glucose levels under these conditions (Figure S15A-D).  
In contrast, insulin challenge at the standard dose of 0.75 IU/kg caused blood 
glucose levels in 5-month old females on HFD to drop lower than in females on chow 
diet, reaching a low of 4 mM after 45 min before steadily returning to ~10 mM at 120 
min and remaining there until the end of the test (Figure S15B-D). At 10 months of 
age, the insulin sensitivity of HFD fed mice was similar to that of females on chow 
diet, and their response to insulin was longer-lasting, with blood glucose levels 
remaining below 10 mM throughout. Hence, as previously seen in males, HFD 
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caused an increase in insulin sensitivity in both sexes, which we had not expected. 
However, in males, this improved insulin sensitivity did not persist into old age, 
whereas it did in females. This resulted in similar blood glucose levels upon insulin 
challenge despite increased fasting blood sugar levels in female mice on HFD, 
indicating the existence of robust homeostatic mechanisms of regulation that were 
not overcome by the HFD. 
As expected, females on HFD also gained more weight throughout their 
lifetime than females on chow diet; however, the effect was not as large as in males, 
where the difference had been two-fold (Figure S14C). Similarly to the males 
though, females on HFD consumed less water and food and produced less urine 
and faeces compared to their chow-fed counterparts (Figure S16A-D). 
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Figure S13: Fasting blood glucose level and response to glucose challenge of 
female Prex WT mice on HFD. 
Female Prex WT mice on 45% HFD (dark blue) were subjected to IPGTT at the ages of 10 and 
15 weeks, 6, 9 and 12 months old. Food was withdrawn 6 h prior to i.p. injection of 20% glucose 
at 10 ml/kg (final concentration 2 g/kg) at 10, 15 weeks, 6, and 9 months old and at 1 g/kg (20% 
glucose at 5 ml/kg) at 9 and 12 months old – data in ochre box. Blood glucose levels were tested 
by tail bleed 15 min prior to the i.p. injection to determine the basal fasted blood glucose levels, 
and every 15 min after the glucose injection for 90 min, to assess the response to glucose 
challenge. Data are pooled from 7 independent cohorts with 4-5 animals each, and presented as 
mean ± SEM. In light blue are represented the female mice on chow diet from Figure S9 for visual 
comparison, but no statistical analysis was performed, as these animals were not directly 
compared experimentally. (A) Fasting blood glucose levels. (B) Blood glucose concentration 
during IPGTT. (C) Blood glucose levels during IPGTT, normalised by subtracting the basal blood 
glucose level from each mouse individually. (D) Total glucose response calculated as AUC of 
normalised data. 
 P a g e  | 293 
 
 
 
 
Figure S14: Effects of ageing on the fasting blood glucose levels, response to 
glucose challenge, and body weight of female Prex WT mice on HFD.  
The fasting blood glucose level, response to glucose challenge, and body weight of the female 
Prex WT mice on HFD from Figure S13 (dark blue) are expressed as a function of age. Data are 
pooled from 7 independent cohorts with 4-5 animals each, and are presented as mean ± SEM. 
Note that the dose of glucose was reduced from 2 g/kg to 0.5 g/kg from the age of 6 months 
onwards (data in ochre box). In light blue are represented the female mice on chow diet from 
Figure S10 for visual comparison, but no statistical analysis was performed, as these animals 
were not directly compared experimentally. (A) Response to IPGTT; normalised data from 
columns B and C in Figure S13. (B) Fasting blood glucose levels; data from column D in Figure 
S13. Note that IPGTT was done with 2 g/kg at 10 and 15 weeks as well as 6 and 9 months, but 
with 1 g/kg at later ages (ochre box). (C) Total body weight, measured after 6 and 4 h fasting, prior 
to glucose and insulin challenges, respectively. 
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Figure S15: Response of female Prex WT mice on HFD to insulin challenge at 5 
months and 10 months of age. 
The female Prex WT mice on 45% HFD shown in Figure S13 (dark blue) were subjected to SCITT 
at the ages of 5 and 10 months. Food was withdrawn 4 h prior to s.c. injection of 0.15 IU/ml of 
human recombinant insulin at 0.5 IU/kg (data in green box) or 0.75 IU/kg, as indicated in the figure. 
Blood glucose levels were tested by tail bleed 15 min prior to the s.c. injection to determine basal 
blood glucose levels, as well as after the insulin injection at 15, 30, 45, 60, 90,120 and 180 min to 
assess the response to insulin. Data are pooled from 7 independent cohorts with 4-5 animals each, 
and are presented as mean ± SEM. In light blue are represented the female mice on chow diet 
from Figure S11 for visual comparison, but no statistical analysis was performed, as these animals 
were not directly compared experimentally. (A) Fasting basal blood glucose levels. (B) Blood 
glucose levels during SCITT. (C) Glucose levels during SCITT, normalised by subtracting the 
fasting basal blood glucose level from each mouse individually. (D) Total insulin response, 
calculated as AUC of normalised data. 
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Figure S16: HFD-fed female Prex WT mice water and food consumption as well as 
urine and faeces production in metabolic cages.  
The female Prex WT mice on HFD in Figure S13 (dark blue) were habituated to metabolic cages 
at 11 months of age, as detailed in Materials and Methods, weighed and group-housed (up to 3) 
in metabolic cages overnight for 16 h on 3 subsequent nights with food and water provided ad 
libitum. In light blue are represented the female mice on chow diet from Figure S12 for visual 
comparison, but no statistical analysis was performed, as these animals were not directly 
compared experimentally. Their (A) water consumption, (B) food consumption, (C) urine 
production, and (D) faeces production were measured after each night and were normalised to the 
combined body weights of the mice housed in each cage. Data are pooled from 7 independent 
cohorts with 4-5 animals each, and are presented as the mean ± SEM on each night (n=3).  
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